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Abstract 
Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia, and 
despite recent introduction of targeted therapies, remains incurable. An important 
hallmark of CLL is severe immune deficiency, including the failure to mount effective 
anti-tumour immune responses. This can partly be explained by insufficient antigen 
presentation, but also by the existence of complex CLL-induced T-cell defects. Based 
on the cancer immuno-editing hypothesis that the immune system not only protects a 
host against tumour formation but can also be compromised to actively provide a pro-
tumour microenvironment, modulating cancer-induced T-cell defects could restore the 
full anti-tumour response and result in more durable clinical responses. 
The immune checkpoint molecules PD-1 (expressed on activated immune effector 
cells) and PD-L1 (expressed on antigen-presenting and microenvironmental cells 
including tumour cells) have emerged as important mediators of T-cell suppression. 
Several studies suggest that PD-L1/PD-1 inhibitory signalling in CLL might be 
overcome by the immune modulatory drug lenalidomide. Furthermore, directly targeting 
PDL-1/PD-1 interactions produces significant responses in solid cancers. However, 
similar studies are notably absent in CLL, and the effect of PDL-1/PD-1 blockade on 
restoring cancer-induced immune dysfunction is not understood.  
Transgenic Eμ-TCL1 mice have been extensively validated as an adequate preclinical 
model of aggressive human CLL, and our group showed their suitability to mirror T-cell 
defects observed in human CLL. Using the Eμ-TCL1 model, this dissertation project 
substantially extends our previous characterization of CLL-induced T-cell dysfunction 
and evaluates the functional impact of PD-L1/PD-1 inhibitory signalling both in parallel 
with disease development and in different microenvironments.  
The findings to be described here demonstrate that developing CLL is associated with 
specific T-cell subset alterations, phenotypic changes, and functional defects that are 
very similar in peripheral blood and secondary lymphoid organs. In addition to PD-L1, 
PD-L2 is identified as a potential mediator of inhibitory signalling in CLL. CD8+ T cells 
in leukaemic mice are characterised as a functionally heterogeneous population, in 
which subsets of cells are able to exert effector functions despite PD-1 expression. In 
vivo lenalidomide treatment repairs selected phenotypic alterations and immune 
synapse formation, and a PD-L1 IgG blocking antibody effectively controls disease and 
reverses global T-cell defects even in cells expressing PD-1. In sum, this work provides 
a strong rationale to explore PD-L1/PD-1 targeting in CLL clinical trials, potentially in 
combination with novel agents. 
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1 Background 
1.1 Chronic lymphocytic leukaemia  
1.1.1 Epidemiology and clinical features of the disease 
Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia in Western 
countries with an age-adjusted incidence rate of about 5 cases per 100,000 men and 
women per year1, 2. With a median age at diagnosis of 72 years, CLL is predominantly 
a disease of the elderly, although ⅓ of patients are diagnosed at or below 65 years of 
age. CLL is characterised by the progressive accumulation of mature B lymphocytes 
within blood, bone marrow, lymph nodes and spleen, leading to lymphocytosis, 
lymphadenopathy and organomegaly. The diagnosis is based on the combination of 
lymphocyte morphology and the presence of at least 5,000 circulating clonal 
CD19+CD20+IgM+IgD+ B lymphocytes/µL blood persisting for more than three 
months; additional characteristics of the CLL immunophenotype are the expression of 
CD5, CD23, and kappa or lambda light chain restriction3, 4. The findings of less than 
5,000 circulating clonal B lymphocytes/µL in the absence of palpable lymphadenopathy 
fulfil the criteria for a diagnosis of monoclonal B-cell lymphocytosis (MBL), whereas 
those patients with lymphadenopathy fulfil the criteria for a diagnosis of small 
lymphocytic lymphoma (SLL)5. Although all cases of CLL appear to be preceded by 
MBL, the majority of individuals with MBL have a low risk of developing a 
haematological malignancy, largely depending on the number of monoclonal B 
lymphocytes detected6, 7. As CLL proceeds, constitutional symptoms and occasionally 
extranodal infiltrates are observed. Another CLL hallmark is immune suppression and 
deficiency, a feature which will be further discussed in Chapter 1.1.4. Clinical features 
are generally highly variable, and while many patients are asymptomatic and never 
require any treatment, the features and course of disease can be very aggressive in 
specific subgroups of patients.  
 
1.1.2 Clinical staging and prognosis 
To identify patients with poorer risk disease, several staging and prognosis systems 
have been developed. Clinically, the two most established prognostic staging systems 
are the Rai8 and Binet9 classifications, which are based on physical examination and 
blood counts (see Table 1). Patients with low-risk disease (i.e. Rai stage 0, Binet stage 
A) generally have a median survival of up to 17 years. This is significantly shortened in 
patients with intermediate-risk (i.e. Rai stage I or II, Binet stage B) and high-risk 
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disease (i.e. Rai stage III or IV, Binet stage C) to 5 to 8 years and to less than 2 years, 
respectively.  
 
Rai Staging System 
stage simplified 3-Stage System clinical features 
0 low risk lymphocytosis in blood and bone marrow only 
I 
intermediate risk 
lymphocytosis + lymphadenopathy 
II lymphocytosis + splenomegaly/hepatomegaly 
III 
high risk 
lymphocytosis + anaemia 
IV lymphocytosis + thrombocytopenia 
Binet Staging System 
group  clinical features 
A 
< 3 involved lymph node areas, no anaemia or  
thrombocytopenia 
B 
≥ 3 involved lymph node areas, no anaemia or 
thrombocytopenia 
C 
haemoglobin <10g/dl and/or platelets <100,000/μl ± 
lymphadenopathy/ organomegaly 
Table 1: Overview of parameters included into the Rai and Binet staging systems. 
 
With the improved understanding of disease biology and mechanisms of pathogenesis, 
a variety of additional prognostic factors have emerged over the last 10 to 15 years. 
These include patient-related characteristics (e.g. age, performance status and co-
morbidities) and disease-related biomarkers. However, only a few biomarkers have 
been prospectively validated. These include immunoglobulin heavy chain variable 
region (IgVH) gene mutation analysis10, 11, CD3810 and ZAP-70 expression12, and 
cytogenetic abnormalities determined by fluorescence in situ hybridisation (FISH)13. 
Among the latter, deletion of the chromosome region 17p13.1 (del17p) is of high 
prognostic importance, as patients with this abnormality typically require therapy within 
one year of diagnosis and have a median overall survival (OS) of just 32 months due to 
poor response to standard immunochemotherapy13. However, selected retrospective 
data indicate that a minority of patients with del17p might experience an indolent 
course despite the mutation14. The general lack of chemosensitivity in this subset is 
biologically explained by the absence of the tumour suppressor protein TP53, the locus 
for which is located on the short arm of chromosome 1715. This deletion is often 
accompanied by inactivating mutations of the second allele of TP53, leading to a 
complete loss of TP53 function16, 17. Other cytogenetic abnormalities commonly 
observed in CLL include deletion of 11q22.3 (del11q), trisomy of chromosome 12, and 
deletion of 13q14 (del13q) as the sole abnormality13; median survival times for patients 
in these groups were found to be 79, 114, 111, and 133 months, respectively. 
Potentially critical genes within the affected regions of these chromosomes include 
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DLEU2/mir15a/miR15-1 for del13q18, NOTCH1 for trisomy 1219, and RDX and ATM for 
del11q20. More recently, SF3B1, BIRC3 and MYD88 have been identified to be 
recurrently mutated in CLL21-23, and several retrospective studies indicate that these 
mutations appear to be enriched in cohorts of patients with high-risk characteristics and 
poor response to conventional therapy24-26.  
As many prognostic markers were identified and validated in small, retrospective, and 
heterogeneously treated cohorts of patients, efforts are now being focused on 
combining individual markers into a more accurate and powerful prognostic score. 
Rossi and colleagues integrated mutational and cytogenetic data from 1,274 CLL 
patients to identify four hierarchical subgroups27. These included high-risk patients with 
TP53 and/or BIRC3 abnormalities with a 10-year survival of 29%; intermediate-risk 
patients with NOTCH1 and/or SF3B1 mutations and/or del11q (10-year survival 37%); 
low-risk patients with trisomy 12 or normal cytogenetics (10-year survival 57%); and 
very low-risk patients with del13q as a sole abnormality (10-year survival 69.3%). A 
recent study developed a more clinically applicable comprehensive prognostic index for 
OS combining disease stage, biological markers, and patient-related factors from 1,948 
CLL patients participating in phase III trials of the German CLL Study Group 
(GCLLSG)28. Using multivariate modelling, they identified 8 factors as being 
independently associated with inferior survival from study entry. These included del17p 
and del11q, elevated serum thymidine kinase and β2 microglobulin, unmutated IgVH, 
ECOG performance status greater than 0, male gender and age over 60 years. While 
such sophisticated and comprehensive prognostic scores contribute significantly to 
increasing the predictive value of currently available biomarkers, their day-to-day 
application in clinical practise is still limited by the lack of availability of specialized 
assays and laboratories, as well as economic constraints.  
 
1.1.3 Current treatment options and unmet needs 
As there is no reliable curative approach, the decision to begin treatment of CLL is 
based on the development of symptoms and disease activity29, 30. Factors guiding the 
choice of treatment include physical fitness, the presence of comorbidities, and 
validated biological prognostic factors such as IgVH mutation status and cytogenetic 
abnormalities. In young patients without significant comorbidities, 
immunochemotherapy approaches (chemotherapy plus a monoclonal antibody) are 
typically used as front-line treatment. The current standard is fludarabine, 
cyclophosphamide and the anti-CD20 antibody rituximab (FCR)31, 32. While this regimen 
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leads to high overall response rates (ORR) and a long progression-free survival (PFS), 
it is unsuitable for certain subgroups of patients including those with TP53 
abnormalities13, 33, 34 and elderly patients with comorbidities who are typically unable to 
tolerate toxicities associated with FCR35. In the latter, chlorambucil is a widely accepted 
therapeutic option, and the combination with rituximab is generally well tolerated and 
improves PFS36, 37. Another option is the combination of rituximab with bendamustine 
(BR); a Phase II trial by the GCLLSG found an ORR of 88%, which translated into an 
event free survival (EFS) of almost 34 months. This combination produced only very 
moderate toxicities, making it particularly suitable for elderly CLL patients38. A direct 
comparison between FCR and BR is currently being conducted in an ongoing Phase III 
trial. A recently published pivotal Phase III trial by the GCLLSG showed that the type 2 
anti-CD20 antibody obinutuzumab (GA101) was superior to rituximab when each was 
combined with chlorambucil39. Another anti-CD20 monoclonal antibody is the fully 
humanized agent ofatumumab, which shows high efficacy in untreated and 
relapsed/refractory patients, and even in patients pre-treated with rituximab40-42. A 
recently published direct preclinical in vitro and in vivo comparison of obinutuzumab 
with rituximab and ofatumumab demonstrated that obinutuzumab was superior to 
rituximab and ofatumumab in the induction of direct cell death and antibody-dependent 
cellular cytotoxicity (ADCC), showed slower internalization rate upon binding to CD20, 
and induced superior in vivo anti-tumour efficacy, but was 10 to 1,000 times less potent 
in mediating complement-dependent cytotoxicity (CDC)43.  
To capitalize on the success of rituximab, a variety of monoclonal antibodies is 
currently being tested in preclinical studies, for example against receptor tyrosine 
kinase-like orphan receptor 1 (ROR-1)44 or CD4445, or has been introduced to the 
treatment of CLL. Among those, the anti-CD52 monoclonal antibody alemtuzumab and 
combinations of this with chlorambucil, high-dose corticosteroids, rituximab, and FCR 
appeared to be able to overcome the negative impact of TP53 abnormalities in the first-
line treatment setting (both in terms of its predictive value and its effect on the 
response to treatment)46-49. However, alemtuzumab-containing approaches are 
associated with severe haematological and non-haematological toxicities and infectious 
complications, making them unsuitable for the majority of CLL patients. In the relapsed 
setting, the management of patients with TP53 abnormalities is even more challenging. 
Several clinical studies demonstrated that FCR and combinations with high-dose 
corticosteroids, alemtuzumab or alternative regimens consisting of rituximab, 
oxaliplatin, cytarabine and fludarabine (OFAR) have only limited and short-term 
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efficacy and are associated with high toxicity rates50-56. Thus, identifying new strategies 
for the del17p and TP53 mutated CLL patient subsets remains especially urgent.  
A great deal of work has therefore been focused on identifying agents that can provide 
anti-tumour activity in the absence of functional p53. These efforts led to the 
development of the cyclin dependent kinase (CDK) inhibitor flavopiridol and the 
second-generation CDK inhibitor dinaciclib. In several studies flavopiridol has 
demonstrated potent clinical activity even in the highest risk CLL subsets, and has 
provided benefit to patients lacking other options57, 58. However, due to its rapid 
induction of tumour cell death, this agent carries the risk of acute tumour lysis 
syndrome that can be fatal without proper monitoring and intervention. To reduce this 
risk, CDK inhibitors have been combined with cytoreductive therapies. In a recently 
published phase I study, the combination of flavopiridol with cyclophosphamide and 
rituximab was tolerable and active in high-risk CLL patients, and tumour lysis syndrome 
was not observed59, 60. Regardless, concerns persist, and widespread clinical 
application of CDK inhibitors in CLL appears unlikely at this time.  
After many years without a significant clinical breakthrough, CLL researchers have 
recently been able to capitalize on laboratory data showing the importance of B-cell 
receptor (BCR) signalling in CLL tumour cell survival and proliferation. BCR activation 
is a central stimulus in CLL cells, and promotes their survival by activating multiple 
downstream kinases such as Bruton’s tyrosine kinase (BTK), spleen tyrosine kinase 
(Syk), ZAP-70, Src family kinases, and phosphatidylinositol 3-kinase (PI3K)61, 62. These 
events drive the expression of pro-survival molecules, in part via activation of 
transcription factors such as NF-κB. An overview of BCR signalling pathways and 
targets is provided in Figure 1.  
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Figure 1: BCR signalling pathway and targets for molecular inhibitors: Engagement of the 
BCR by antigen induces phosphorylation of immune receptor tyrosine-based activation motifs 
(ITAMs) within the cytoplasmic domains of immunoglobulins, which is primarily mediated by the 
Src family kinase Lyn. This results in the recruitment and activation of the tyrosine kinase Syk. 
Activated Syk forms a membrane-associated complex with other tyrosine kinases such as Lyn 
and BTK, and adapter molecules such as B-cell linker protein (BLNK). This complex mediates 
the activation of downstream signalling pathways such as PI3K and phospholipase Cγ2 
(PLCγ2). PI3K generates the second messenger phosphatidylinositol-3,4,5-triphosphate (PIP3), 
which recruits molecules such as Akt. PLCγ activation leads to the release of intracellular 
calcium and subsequent activation of protein kinase C (PKC). These events lead in turn to 
activation of mitogen activated protein kinases (MAPKs) including extracellular signal regulated 
kinase (ERK), c-JUN NH2-terminal kinase (JNK) and p38 MAPK. Activation of PKC also 
increases expression of the transcription factor NFĸB, while the rise in intracellular calcium 
causes activation of nuclear factor of activated T cells (NFAT). Figure taken from Hallek 201363. 
 
Recent clinical studies convincingly show that agents inhibiting BCR signalling are well 
tolerated and very active, even in patients with relapsed and fludarabine-refractory CLL 
and/or those with TP53 abnormalities. To date, the most clinically successful BCR 
pathway inhibitor is the BTK inhibitor ibrutinib. In addition to blocking BCR-associated 
anti-apoptosis pathways, ibrutinib interferes with BCR- and chemokine-mediated 
homing and retention of CLL cells in the protective lymph node and bone marrow 
microenvironments64-66. In a phase I/II study of ibrutinib in 85 heavily pre-treated 
patients with relapsed or refractory CLL, the ORR was 71%, with a PFS of 75% and an 
OS of 83% at 26 months. Importantly, these responses were independent of the 
presence of del17p67. Ibrutinib monotherapy is also very well tolerated and effective in 
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treatment-naive elderly CLL patients, producing an ORR of 71% in this population68. To 
validate these early encouraging results, a randomized phase III study of 391 
relapsed/refractory CLL patients demonstrated that ibrutinib significantly improved 
ORR (42.6% vs. 4.1%, P<0.001) as well as PFS and OS compared to ofatumumab 
monotherapy, and was able to overcome the adverse effect of del17p69. 
Idelalisib (formerly known as GS-1101 and CAL-101) is an inhibitor of the PI3K 
regulatory subunit p110δ that is involved in CLL cell survival, clonal expansion and 
retention in lymphoid tissues70, 71. In a phase I study of 54 heavily pre-treated patients 
with relapsed/refractory CLL, including patients with del17p, 81% achieved nodal 
responses with an ORR of 72% and a very acceptable safety profile72. A phase III trial 
was then initiated on 220 patients with relapsed CLL that compared idelalisib in 
combination with rituximab to rituximab plus placebo73. Due to overwhelming 
improvement in efficacy in the idelalisib arm, the study was interrupted after the first 
interim analysis. The ORR was 81% and 13% for the idelalisib combination and the 
rituximab monotherapy, respectively; at 12 months, OS was 92% versus 80%, and PFS 
93% versus 46%, respectively.  
The BCL-2 family of proteins controls apoptosis by modulating mitochondrial stability. A 
delicate balance of anti-apoptotic (e.g. BCL-2, BCL-XL, MCL-1) and pro-apoptotic (e.g. 
BAD, BAX, NOXA) family members is essential to normal immune system function. In 
many tumour types including CLL, this balance is disrupted to aberrantly promote cell 
survival. BCL-2 antagonists such as navitoclax (previously ABT-263) and GDC-0199 
(previously ABT-199) have been developed to restore apoptosis by interfering with 
BCL-2 protein-protein interactions, thus blocking its mitochondria-stabilizing activity. In 
a phase I study of navitoclax in 29 patients with relapsed/refractory CLL, lymphocytosis 
was reduced by more than 50% in 19 of 21 patients with baseline lymphocytosis, and 
partial response (PR) or disease stabilization was achieved in almost half of the 
patients, including those with del17p74. The newer agent GDC-0199 is even more 
promising, as it is more specific for BCL-2 and lacks the platelet-depleting activity of 
navitoclax. 
Lenalidomide is an especially unusual drug in CLL due to its ability to modulate 
immune responses75. A derivative of thalidomide, lenalidomide was recently found to 
interact with cereblon, a component of a multiprotein E3 ubiquitin ligase complex. This 
interaction alters the proteasomal degradation of certain proteins, including the 
transcription factors IKZF-1 and 376. However, lenalidomide has very little direct 
cytotoxic activity against CLL cells, and appears to work primarily by enhancing anti-
tumour immunity in effector cells, suggesting pleiotropic effects on immune cells77-81. 
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Several clinical trials have demonstrated that lenalidomide, both as a single agent and 
in combination with rituximab or corticosteroids, has activity in untreated and 
relapsed/refractory CLL, including in patients with del17p82-90. However, lenalidomide 
occasionally produces serious toxicities including immune-mediated tumour flare 
reactions, impeding its clinical development78, 91. 
Combinations of all of these agents are currently being investigated in randomized and 
non-randomized clinical trials with immunochemotherapy and with other novel agents. 
While early results are encouraging, especially in the combination setting, it is yet to be 
seen if these will translate into long-lasting remissions and disease control. Further 
emphasizing the inadequacy of monotherapy even with effective targeted agents, 
recent reports show that a subset of patients develop resistance to ibrutinib therapy 
due to mutations within BCR pathway components, and similar resistance mechanisms 
to other substances are likely to arise as well92.  
The only curative treatment option in CLL to date is allogeneic haematopoietic stem 
cell transplantation (HSCT). HSCT takes advantage of the graft-versus-leukaemia 
(GvL) effect mediated by differentiated transplanted immune effector cells, which are 
able to mount an anti-tumour immune response and induce long-lasting clinical 
remission93. Additional observations supporting GvL activity in CLL include decreased 
relapse rates in patients who develop graft versus host disease (GvHD)94, 95, and 
increased relapse rates in recipients of T-cell depleted allografts96. However, HSCT is 
only applicable to a minority of CLL patients, as patients are typically of advanced age 
at presentation. In addition, it is associated with significant treatment related mortality 
and morbidity, largely due to chronic graft versus host disease (cGvHD)24, 97-99. 
Internationally accepted guidelines suggest that HSCT is indicated in patients who are 
fit enough, have a suitable matched donor, have 17p deletion or TP53 mutations, or 
relapsed quickly after chemo-immunotherapy100. As described above, several new 
agents are in clinical trials or have recently been approved for CLL that demonstrate 
impressive and durable responses in high-risk patients who might be candidates for 
transplant. Thus, HSCT must always be considered in view of other, potentially less 
toxic therapies that could be offered. The choice of HSCT versus a novel agent is one 
that must be gauged on a patient-by-patient basis, and this will change as data mature 
on the use of these novel agents in CLL101. 
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1.1.4 Immune dysfunctions in CLL 
As introduced in Chapter 1.1.1, immune dysfunction is a major hallmark of CLL. This 
can be related both to the disease and to the treatments administered. Clinical 
manifestations include severe and recurrent infections, hypogammaglobulinaemia, 
autoimmune anaemia and thrombocytopenia, and poor responses to vaccination102. 
Infectious complications pose an enormous challenge in the management of CLL 
patients, and retrospective analyses indicate they are the main cause of increased 
morbidity and mortality, accounting for up to 50% of CLL-related deaths103-105. Disease-
related immune suppression is significantly aggravated by treatment with steroids and 
immunochemotherapy; in fact, a main risk factor for infectious complications in CLL 
patients is the number of previous chemotherapeutic regimens106, 107.  
Several quantitative and qualitative immune defects have been described in CLL to 
date, which include both humoral and cellular immunity. Early data implied that an 
impaired complement system might be involved in the pathophysiology of CLL and its 
associated immune defects108. Complement plays a crucial role in the control of some 
bacterial infections, as opsonisation with complement is necessary for clearance by 
neutrophils. Although CLL patients appear to have normal concentrations of 
complement factors, a defect in C3b binding to certain bacteria has been reported108. In 
another study, reduced activity of the classical complement pathway predicted 
shortened survival109. 
Cellular immune defects are observed in nearly all immune subsets. Among B cells, the 
most clinically apparent defect is hypogammaglobulinaemia, the severity of which 
tends to increase with the duration and stage of disease110-112. It has been proposed 
that hypogammaglobulinaemia might be the result of IL-4 mediated abnormal 
CD30/CD30L interactions, leading to impaired isotype switching and increased 
sensitivity of normal B cells to FasL-mediated cell death113. Early studies indicate that 
clonal CLL cells have a limited ability to present antigen to T cells114, 115, largely due to 
an inadequate costimulatory capacity116, 117, leading to the failure of T-cell responses. A 
wide range of immune defects have been described in the T-cell compartment itself. 
Several studies demonstrated that despite reduced relative numbers of CD3+, CD4+ 
and CD8+ T cells because of the relative expansion of CLL cells in lymphocytes, 
absolute T-cell numbers are actually increased in CLL patients, and this increase 
correlates with disease stage118-125. This increase in CD3+ T cells was found to be 
primarily due to a relative expansion of CD3+CD8+ T cells over CD3+CD4+ T cells, 
leading to a reduction of the typical CD4+/CD8+ ratio. It is hypothesized that this might 
be attributed to the higher sensitivity of CD4+ T-cell subtypes to CLL-induced Fas-
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mediated cell death126. Another potential explanation for the “loss” of CD4+ T cells in 
the blood is migration into secondary lymphoid organs towards CLL-secreted 
cytokines. An early study by Pizzolo et al. described that CD4+ T cells are the 
predominant subtype in the bone marrow of CLL patients127. This accumulation might 
be chemokine-mediated, as activated CD40L+CD4+ T cells in bone marrow and lymph 
nodes express CCR4, the receptor for the CLL cell-released chemokine CCL22, and 
are predominantly found in proliferation centres of secondary lymphoid organs (so-
called pseudofollicles), a hallmark histopathology finding in CLL describing the 
microanatomical tissue sites where CLL proliferation occurs128, 129. Chemo-attracted 
CD40L+CD4+ T cells are therefore likely to provide pro-survival and costimulatory 
signals to CLL cells, leading to the progressive accumulation of malignant cells. 
Another study linked CD38 expression by CLL cells to interactions with CD4+ T cells 
within pseudofollicles and found that CD38 expression was higher in tissues that 
contain pseudofollicles and was subject to dynamic changes in response to contact 
with activated CD4+ T cells130. Peripheral blood CD4+ cell subsets were later described 
to be skewed towards central memory (CM) and effector memory (EM) cells, which 
was more pronounced in patients with unmutated IgVH compared to mutated IgVH 
status and correlated with shorter treatment-free survival, but not CD38 expression or 
cytogenetic risk groups131. Interestingly, CD4+ memory cells were superior to CD4+ 
naive cells in protecting CLL cells from apoptosis, probably via IL-4 secretion, 
indicating that even outside of pseudofollicles, CLL survival is promoted by CD4+ T 
cells.  
Among CD8+ T cells, subsets were also found to be skewed towards CCR7- effector 
cells compared to healthy controls132-135. Recently, multidimensional scaling (principal 
coordinates analysis) was applied to form a T-cell score integrating 24 circulating T-cell 
subsets to describe the evolution of T-cell phenotypes from MBL to advanced stage 
CLL136. Distinct T-cell scores were found for different stages of CLL development, even 
at the MBL stage, and changes were apparent during disease progression and after 
treatment. This important finding highlights the dynamic alterations of T-cell 
phenotypes as a response to the presence of disease. Consequently, these T-cell 
scores were also of prognostic value; patients with higher scores had significantly 
shorter time to treatment compared to those with low T-cell scores, and scores also 
correlated with established prognostic markers such as IgVH status and cytogenetic 
aberrations. Changes in the score were mainly driven by specific T-cell subsets such 
as CD4+CD25hi regulatory T-cells (TRegs), CD3+CD56+ NKT cells and γδ T cells, 
although terminally differentiated TEMRA CD8+ subsets at the expense of effector-
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memory subsets were confirmed to contribute to high T-cell scores in patients with 
advanced disease.  
In addition to CD4+ and CD8+ subset characteristics, a number of alterations in the 
surface expression of T-cell activation markers have been reported. These include 
increased expression of CD57, CD69, HLA-DR, killer immunoglobulin-like receptors 
(KIRs) and CD94, and decreased expression of CD62L and CD28137-139. CD57+ T cells 
especially appear to represent clonal or oligoclonal populations, probably as a result of 
chronic activation by CLL-associated antigens140-142. Another major factor influencing 
lymphoid subsets in healthy individuals is CMV infection143. Indeed, expanded 
populations of CMV-specific CD4+ and CD8+ T cells have been reported in CMV+ CLL 
patients144-146. Work from our group demonstrated that CD8+ T cells from CMV+ CLL 
patients appeared shifted towards a TEMRA phenotype, while CMV- patients 
predominantly exhibit an EM phenotype (as described above)133. In line with previous 
observations, a similar shift was also observed in CMV+ healthy controls, indicating 
that altered CD8+ subset composition was unrelated to CMV serostatus. Chronic T-cell 
activation has been extensively studied in patients with viral infections, where chronic 
antigenic stimulation leads to failed T-cell immune responses and the ongoing 
replication of virus-specific effector T cells. This is associated with a number of 
progressive phenotypic and functional T-cell changes, such as a hierarchical loss of 
effector CD8+ T-cell function and the expression of inhibitory surface receptors such as 
PD-1 and CTLA-4, which has been termed T-cell exhaustion147. Our group 
demonstrated that T cells from CLL patients actually carry features of T-cell 
exhaustion, such as an increased surface expression of CD244, CD160, and PD-1, 
especially in the expanded population of effector T cells133. In addition, CD8+ T cells 
exhibited proliferative and cytotoxic functional defects, but had an increased production 
of IFN-γ, TNF-α and TBET, and normal IL-2 production. Similar to T-cell subsets, 
impaired T-cell function was unrelated to CMV serostatus. This was also explored from 
a slightly different angle by Kater’s group, who found that although global T-cell defects 
indeed occur in CLL patients, CMV-specific antiviral T-cell responses appear to be 
uncompromised148. 
Overall, these findings highlight the range of functional T-cell defects and imply a high 
degree of heterogeneity of the T-cell population in CLL. In addition, they expand the 
previous notion of cytokine production by T cells in CLL, which was based on a 
dichotomous Th-1 versus Th-2 cytokine skewing. Impaired or aberrant classical Th1 
and Th2 cytokine production, i.e. IFN-γ and IL-2 (Th-1 response), and IL-4, IL-5 and IL-
10 (Th-2 response) and their correlation with clinical course and outcome have been 
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investigated in several clinical and translational studies149-151. Some studies suggested 
that T cells in CLL were skewed towards Th-2 responses, with an increase in IL-4 and 
IL-6 producing T-cell subsets152-155. Both IL-4 and IL-6 have been demonstrated to 
induce CLL cell proliferation and to protect CLL cells from apoptosis in vitro, probably 
via an increase of BCL-2 expression156 as well as enhanced STAT6 levels and 
phosphorylation157. In addition, IL-6 serum levels, along with IL-10, are increased in 
CLL patients and correlate with OS149. Similar to IL-4 and IL-6, IL-10 has anti-apoptotic 
properties in vitro158. In contrast, significant evidence demonstrates that IFN-γ, TNF-α, 
and IL-2 are upregulated in CLL T cells and correlate with disease stage159-164. These 
cytokines have also been demonstrated to induce CLL cell proliferation and to protect 
CLL cells from apoptosis in vitro165, 166. The biological situation is likely to be much 
more complex, and cytokines certainly exert their functions in a dynamic network rather 
than against or from single cells. To account for this complexity, groups of cytokines 
and chemokines have been analysed within the context of networks167. Three clusters 
of highly correlated but differentially expressed cytokines were identified. These 
included cytokines that had previously been implied in CLL, but also new molecules 
relevant to CLL biology such as CCL17, CXCL11, IL-5 and IL-17. However, these were 
evaluated in serum, and not attributed to specific T-cell subsets, therefore also 
accounting for cytokines/chemokines released by CLL and/or other cells. Considering 
the increasing evidence of the complexity of networks of cytokines and chemokines 
between CLL cells and the microenvironment168, determining cytokine secretion by 
specific cell subsets and under in vitro stimulation conditions might therefore no longer 
be sufficient. Indeed, CLL cells were recently described to bear functional and 
phenotypic resemblance to IL-10-producing regulatory B10 cells169. Another study 
found IL-10 secretion by B cells to be linked to surface CD5 expression, controlled by 
transcription factors STAT3 and NFAT2, suggesting a CD5-triggered autocrine 
feedback mechanism to maintain protective cytokine production170.  
A major effort of our group has been to investigate the underlying molecular 
mechanisms of T-cell dysfunction in CLL patients171. We demonstrated that both CD4+ 
and CD8+ T cells from patients with CLL show multiple differentially expressed genes 
when compared to these cells from age-matched healthy donors, indicating that global 
T-cell defects occur on a molecular level. Deregulated genes were enriched in 
pathways of T-cell proliferation, differentiation, vesicle trafficking, and actin 
cytoskeleton formation and included cdc42, PIK4CB, RAB35 and ARPC1B, all of which 
are key regulators of the formation and stabilisation of the immune synapse. Most 
importantly, very similar alterations in gene expression could be induced in normal 
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allogeneic T cells after direct contact with CLL cells in co-culture, indicating that the 
presence of the malignant CLL cell drives the observed T-cell changes. The global 
nature of molecular T-cell defects was confirmed by Di Ianni et al., who demonstrated 
that peripheral blood T cells from CLL patients showed deregulated genes involved 
mainly in cell differentiation, proliferation, survival, apoptosis, cytoskeleton formation, 
vesicle trafficking and T-cell activation172. A recently published study demonstrated by 
gene expression profiling and subsequent gene enrichment analysis that differentially 
expressed genes in CD3+ T cells from CLL patients were enriched in the signature of 
publicly available combined CD8+ EM/CM T cells135.   
Subsequently, our group demonstrated the inappropriate functional response of T cells 
to antigen presenting cells (APCs) due to their inability to effectively regulate actin 
remodelling and to recruit key cytoskeletal signalling molecules such as Lck, Cdc42, 
WASp, filamin-A and dynamin-2, using immune synapse formation assays and 
confocal microscopy77. Consistent with our gene expression studies, these defects 
could be induced in normal allogeneic T cells by co-culturing them in direct cell-cell 
contact with CLL cells. More recently, impaired actin remodelling was found to be 
mediated by activation of the Rho GTPases RhoA, CdC42, and Rac179, which also led 
to impaired LFA-1 mediated T-cell adhesion and migration81.  
Several groups have highlighted the importance of other T-cell subsets as components 
of the CLL microenvironment, such as CD4+CXCR5+ circulating follicular helper T cells 
(Tfh) and IL-17 producing Th17 cells. Tfh cells of a Tfh-th2 and a Tfh-th17 phenotype 
were significantly increased in the peripheral blood of CLL patients compared to 
healthy controls, especially in patients with advanced stage disease173. Moreover, 
higher Th17 and IL-17A values were associated with less advanced clinical stage of 
CLL, and also inversely correlated with numbers of TRegs174, 175. An increase in TRegs 
is implicated in advanced stage disease and correlates with shorter time to 
treatment136, 176, 177. This expansion can be explained by a combination of increased 
formation, facilitated by CD27-CD70 interactions in lymph node proliferation centres, 
and decreased sensitivity to drug-induced apoptosis because of a shifted Noxa:BCL-2 
balance178. In addition, both CD4+ and CD8+ T cells in CLL aberrantly express surface 
and cytoplasmic CTLA4 (CD152)179, which is an essential marker to define TRegs and 
plays an important functional role in limiting T-cell immune responses180, 181.  
Another immune subset with functional and numerical alterations in CLL, especially in 
advanced disease, is natural killer (NK) cells. In earlier work, NK cells were reported to 
have a reduced ability to lyse leukaemia cell lines because of a lack of cytoplasmic 
granules182, 183. This could be restored by IL-2, which also resulted in increased 
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granularity of the large granular lymphocyte subset184. In contrast, a more recent 
publication indicated that peripheral NK cells from CLL patients maintain partial 
functionality and are able to degranulate and exert ADCC, although some variability 
was observed185. Proposed mechanisms by which CLL cells impair NK cell function 
include inhibition via soluble factors186, 187 and cell surface receptors HLA-G188 or 4-1BB 
ligand189. In patients with early stage CLL and in those with mutated IgVH, higher NK-
cell numbers are observed, with a higher NK:CLL cell ratio being predictive of longer 
time to treatment190. Moreover, numbers of CD3+CD16+CD56+ NKT cells appear to be 
important in CLL, as a reduction in numbers was associated with disease progression 
and a higher risk of death191.  
Aberrant numbers and functional defects are also observed in plasmacytoid dendritic 
cells, which were recently found to have markedly reduced IFN-α production via 
decreased expression of FMS-like tyrosine kinase 3 receptor (Flt3) and Toll-like 
receptor 9 (TLR9), as well as in granulocytes, which exhibited impaired phagocytic and 
bactericidal function, migration and chemotaxis through lysozyme and 
myeloperoxidase deficiencies and altered secretion of TNF-superfamily proteins192-195.  
Several studies have focused on monocytes and macrophages in CLL. A recently 
published study found an increased absolute number of monocytes in CLL patients 
compared to healthy controls, which were skewed towards non-classical Tie-2-
expressing monocytes196. Gene expression analysis performed in this study revealed 
an altered composition and deregulation of genes involved in phagocytosis and 
inflammation, such as RAP1GAP, tubulins and CDC42EP3, which resulted functionally 
in inhibited proliferation of T cells in contact with CLL monocytes. Healthy donor 
monocytes increased migration and up-regulated CD16, RAP1GAP, IL-10, IL-8 and 
MMP9 while down-regulating PTGR2 in response to leukemic cells or conditioned 
media. The clinical relevance of peripheral absolute monocyte count (AMC) has been 
demonstrated by the finding that patients with low AMC had a shorter time to treatment 
and evidence of immune dysregulation leading to increased mortality197. In addition, 
patients with high AMC also had a shorter time to treatment compared to intermediate 
AMC patients. In another study on 29 patients with previously untreated early to 
intermediate stage CLL prior to therapy with alemtuzumab, rituximab and G-CSF, 
monocytes were found to have decreased expression of HLA-DR and CD86, 
suggesting decreased antigen-presenting capacity and reduced immune stimulatory 
capacity198. Higher HLA-DRlo/neg monocyte levels were associated with shorter time to 
disease progression, while the number of total monocytes did not influence time to 
progression. This was further extended in a recently published study by Jitschin et 
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al.199. The authors found significantly increased levels of circulating CD14+HLA-DRlo 
cells which express myeloid markers such as CD11c, CD13, CD33, adhesion 
molecules CD11b and CD62L, and receptors associated with promotion and activation 
of myeloid cells such as TNF-receptor type 2/CD120b, and showed phenotypic and 
functional features linking them the myeloid-derived suppressor cells (MDSCs), a 
heterogeneous population that shares certain characteristics including an aberrant 
myeloid phenotype and the ability to suppress T cells.  
Proposed mechanisms by which CLL cells polarize monocytes/macrophages and affect 
their function include the production and release of soluble factors. One such example 
is macrophage migration inhibitory factor (MIF), a proinflammatory and 
immunoregulatory chemokine; patients with advanced stage CLL show a trend toward 
higher MIF levels compared with patients with early-stage CLL200. A second example is 
extracellular nicotinamide phosphoribosyltransferase (eNAMPT), a rate-limiting enzyme 
in NAD biosynthesis with cytokine/adipokine-like properties201. Furthermore, MDSCs 
were found to exert immune regulatory functions on T cells via indoleamine 2,3-
dioxygenase (IDO)199. Early in vitro evidence for a tumour-supporting role of monocytes 
was based on the observation that peripheral blood monocytes from CLL patients could 
be differentiated ex vivo into nurse-like cells (NLC), which protect CLL cells from 
spontaneous or drug-induced apoptosis through multiple interactions regulated by 
soluble or cell-surface molecules such as CXCL12, CXCL13, BAFF, APRIL, CD31, 
plexin-B1 and activation of the BCR signalling cascade168, 202, 203. Gene expression 
analyses suggested that NLC bear resemblance to tumour-associated macrophages 
(TAMs)204, 205, which are alternatively activated M2 macrophages with IL-10highIL-12low 
cytokine secretion, poor antigen-presenting capacity, immunosuppressive effects and 
pro-angiogenic properties. In vivo, a population of CD68+CD14+ cells resembling 
TAMs/NLC can be found in the spleen and lymphoid tissues of CLL patients206, 207.  
 
1.2 Murine models of CLL 
1.2.1 Eμ-TCL1 mouse model 
1.2.1.1 Generation and disease characteristics 
T-cell leukaemia/lymphoma protein (TCL1) expression in humans is restricted to 
subsets of immature cells within the T and B lymphoid lineage (i.e. pre-B cells, 
immature IgM expressing B cells, early triple negative T-cell progenitors), while it 
functions as an oncogene in leukaemic cells carrying a t(14;14)(q11;q32) translocation 
or an inv(14)(q11;q32) inversion208. TCL1 is located on chromosome 14q32.1 and 
Fabienne McClanahan                                                                                                 Background 
Page 40 of 258 
 
consists of the TCL1A (HGNC ID 11648)209 and the TCL1B (HGNC ID 11649) genes210, 
211. The Eμ-TCL1 (hereafter abbreviated to TCL1) mouse model, one of the most 
established preclinical models for CLL using immune competent mice, was derived by 
placing the entire human TCL1 coding region under the control of a mouse IgVH 
promoter and a IgH-μ enhancer212, which results in specific expression of TCL1 in 
immature and mature B cells213. Originally, two TCL1+/wt founders on the B6C3 
background were obtained and further bred to study the expression of TCL1 and the 
course and characteristics of disease in transgenic TCL1+/wt offspring compared to non-
transgenic litter-mates. At 6 month of age, transgenic mice exhibited an expanded 
B220low+/IgM+ population in the peripheral blood. This population co-expressed CD5 
and Mac-1/CD11b, was also present in bone marrow, peritoneal cavity and spleen, and 
expanded with age (see Table 2). Non-transgenic controls showed a normal 
distribution of B-cell populations, and peripheral T-cell subsets were comparable 
between transgenic mice and controls. After 13 to 18 months, 100% of transgenic mice 
became visibly ill with hepatosplenomegaly, lymphadenopathy and high white blood 
cell (WBC) counts, all of which are hallmarks of human CLL. At the endpoint, spleen 
weights ranged from 1.5 to 2.3 g (normal spleen weight .07 ± .01 g), and the WBC 
count was 1.8x108 per µL of blood (normal value ~2.8x106).  
 
 % IgM+CD5+ B cells 
age bone marrow peritoneal cavity spleen 
2 months 1 45 4 
4 months 2 46 9 
8 months 43 74 69 
control: WT 4 months >1 20 1 
Table 2: Development of expanded IgM+CD5+ B-cell population over time and in different 
organs in TCL1 mice. Adapted from Bichi et al.212; Abbreviations: WT = wild type. 
 
Despite a 100% penetrance, the long latency of TCL1-driven leukaemia is an obvious 
disadvantage of this model. Several groups therefore demonstrated that this obstacle 
can be overcome by adoptive transfer of murine CLL cells from leukaemic TCL1 mice 
into healthy recipients, which leads to faster and less variable disease development214-
216. A similar approach uses a TCL1 leukaemia cell line established from the original 
TCL1 transgenic colony: 2x107 cells from a leukaemic TCL1 mouse with oligoclonal 
autoantigen phosphatidylcholine (PtC) reactive cells were injected into two severe 
combined immunodeficiency (SCID) mice, and serially transferred into other SCID mice 
for a total of 3 transfers217. This led to the outgrowth of cells expressing an autoantigen-
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specific B-cell receptor, superior autoantigen binding, and a more aggressive course of 
disease.  
 
1.2.1.2 Suitability to mirror the biology of human CLL 
Since its creation in 2002, the TCL1 model has been validated by several groups as an 
adequate tool to depict the biology of aggressive human CLL B cells. One of the 
earliest studies demonstrated that it replicates aspects of the molecular B-cell receptor 
V-region rearrangement characteristics of aggressive, unmutated human CLL218. This 
included minimal levels of IgVL and IgVH somatic hypermutation, biased VHDJH and 
VLJL rearrangements and CDR3 characteristics, as well as stereotypical BCR usage 
between sets of leukaemic clones. In addition, immunoglobulins from leukaemic mice 
were found to resemble auto-antibodies and antibodies reactive with microbial 
antigens, suggesting this might be driven by (auto)-antigens. Another study using 
extensive cross-species epigenetic analyses confirmed that epigenetic alterations seen 
in human CLL, such as the aberrant methylation of promoter sequences containing the 
binding sites for the transcription factor FOXD3, were recapitulated in CLL cells from 
TCL1 mice at various stages of disease progression219. More recently, CLL cells from 
TCL1 mice were found to mirror phenotypic and functional aspects of human CLL cells 
competent to produce IL-10, suggesting a similarity of human and murine CLL cells to 
regulatory B10 cells169.  
Work from our group also validated the appropriateness of the TCL1 model to mirror 
CLL-induced T-cell defects in humans216. With the development of CLL, TCL1 
transgenic mice exhibited various functional T-cell defects such as decreased in vivo 
antigen-specific activation, suppressed proliferation, and impaired induction of idiotype-
specific CD8+ cytotoxic T cells. Gene-expression profiling of CD4+ and CD8+ T cells 
from TCL1 mice with CLL, compared to young TCL1 mice without CLL and wild-type 
mice, revealed several differentially expressed genes in both CD4+ and CD8+ cells. 
With increasing tumour burden, the changes in gene-expression profiles in CD4+ and 
CD8+ cells became more evident and correlated well with findings in human CLL cells. 
A causal relationship between CLL and T-cell dysfunction was demonstrated by 
injecting CLL cells from leukaemic TCL1 mice into young transgenic mice without the 
disease. After just 7 days, gene-expression profile changes of CD4+ and CD8+ cells in 
mice receiving the leukaemic cell transfer were comparable to those seen in TCL1 
mice that developed CLL with age. Comparative analysis of gene-expression profiles of 
humans and mice using RESOURCERER, a database for annotating and linking 
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microarray resources within and across species, detected 50 overlapping differentially 
expressed genes, which were mainly involved in pathways of cell proliferation and 
activation, vesicle formation and protein trafficking, and actin cytoskeleton pathways. 
As in human CLL, these defects resulted in an impaired immune synapse formation. 
Another study examined CD4+ and CD8+ T-cell changes and subset compositions in 
lymph nodes and peripheral blood of TCL1 mice220. This work demonstrated that, as in 
human CLL, absolute T-cell numbers were increased in mice with manifest leukaemia 
compared to age-matched wild-type controls, that cells were shifted from naïve to 
antigen-experienced T cells, and that these cells were of a clonal character. The shift 
from naïve to antigen-experienced CD8+ T cells was recently confirmed by another 
study in the peritoneal cavity of 7 month old TCL1 mice with early stage leukaemia135.  
Finally, adoptive transfer studies indicated that the TCL1 model might also be suitable 
to study the tumour-promoting role of the microenvironment in vivo. Protein kinase C 
(PKC)-βII deficient mice were found to be insusceptible to adoptive transfer of CLL 
cells from leukaemic TCL1 mice, indicating that the expression of PKC-βII and the 
subsequent activation of NF-κB in bone marrow stromal cells are prerequisites to 
support the survival of malignant B cells221.  
In summary, a broad body of evidence supports the use of the TCL1 model and 
adoptive transfer of TCL1 leukaemia cells to wild-type mice to investigate the biology of 
CLL. However, immunological studies in mice generally must be interpreted within the 
context of age and genetic background strain, as both ageing222, 223 and genetics224, 225 
have been demonstrated to play a major role in shaping the immune response.  
 
1.2.1.3 Suitability as a preclinical tool to test in vivo efficacy of substances 
Several studies have demonstrated that the TCL1 model is very suitable to mirror 
clinical responses to therapy observed in human CLL patients, thus validating it as a 
preclinical tool to evaluate novel drugs and treatment combinations. An initial study 
confirmed that transformed murine lymphocytes express relevant therapeutic targets 
such as BCL-2, MCL-1, AKT, PDK1, and DNMT1, but have a wild-type p53 status215. In 
this work, treatment with low dose fludarabine led to a modest but significant survival 
advantage and reduced lymphocytosis, but mice became eventually completely 
resistant to fludarabine treatment. More recently, a direct comparison between 
treatment with fludarabine and actinomycin D, a p53-independent inducer of apoptosis 
targeting MCL-1 and BCL-2, indicated that actinomycin D was more effective than 
fludarabine in reducing tumour load and prolonging survival226. Other studies have 
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demonstrated responses of leukaemic mice to a variety of other substances such as 
agents targeting components of the BCR signalling pathway64, 65, 214, 227, 228, as well as 
agents targeting novel pathways or cellular mechanisms229-231. In addition, TCL1 mice 
are a suitable tool to investigate anti-tumour strategies targeted at the repair of the 
immune system. Our group has previously demonstrated that T-cell immune synapse 
deficiencies could be repaired by ex vivo treatment of murine cells with lenalidomide. In 
another study, anti-CD40 antibody and CpG oligonucleotide treatment increased anti-
tumour macrophage responses against T-cell depleted TCL1 donor cells and resulted 
in a significant retardation of tumour growth and prolonged survival of mice232.  
 
1.2.2 Alternative genetically engineered murine models of CLL 
Several alternative genetically engineered mouse models of CLL are described in the 
literature. These include models mimicking genetic lesions in CLL, as well as models 
with over-expression or targeted deletion of oncogenes or microRNAs. The most 
frequent genetic lesion in CLL associated with an indolent course of disease is 
del13q1413. Therefore, transgenic mouse models with targeted deletion of the minimal 
deleted region (MDR) including DLEU1, DLEU2 and the miR-15a/16-1 cluster233 and 
the common deleted region (CDR) of the corresponding murine 14qC3 locus have 
been created234. These mice developed a spectrum of lymphoproliferative disorders, 
including MBL and CD5- non-Hodgkin lymphoma (NHL), with the phenotype and 
severity of the developing disease being dependent on the size of the deleted region. 
While both MDR and CDR deleted mice first exhibited a leukaemic population at the 
age of 6 to 18 months and succumbed to disease after 12 to 18 months, similar to 
TCL1 mice, the percentage of CLL-like disease in relation to MBL or NHL was higher in 
CDR deleted mice.  
Additional genetically engineered models are based on the targeted deletion of TNF-
receptor family components, and include BCL-2/TRAF2DN235, APRIL236 and Myc/BAFF 
transgenic mice237. To provide insights into the in vivo biology of microRNAs, a plethora 
of mouse models based on the over-expression or targeted deletion of microRNAs 
have been described. This was pioneered by studies in the New Zealand Black strain, 
a model of sporadic late-onset CLL-like disease linked to a genetic abnormality in the 
microRNA miR-15a/16-1 locus238-240. The role of miR-15a/16-1 in CLL was further 
elucidated in the context of studies targeting murine 14qC3 described above233. 
Compared to MDR deleted mice, miR-15a/16-1 deleted mice had a longer time to CLL 
development and longer disease latency, with mice developing a similar spectrum of 
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lymphoproliferative disorders. In another model, miR-29a over-expression led to a 
markedly expanded CD5+ population detectable at 2 month of age in 85% of 
transgenic mice, but only 20% of mice developed frank leukaemia and died of disease 
at about 2 years of age241. Other microRNA-based models using miR-155242, the miR-
17-19 cluster243, 244, or miR-125b245 largely fail to mirror the course of disease or 
immunophenotype of CLL. A recently described murine model of CLL is based on the 
over-expression of ROR1, an oncoembryonic antigen found on CLL cells, but not on 
normal adult tissues246. However, only 5% of transgenic mice developed CLL. In 
contrast, CLL penetrance was significantly improved and reached 100% in models of 
IRF4-/-Vh11 deletion247 and simian virus 40 (SV40) T antigen transgenic mice248. Key 
characteristics of these models are summarized in Table 3.  
Most of these genetically engineered murine models of CLL are inferior to the TCL1 
model with regards to disease penetrance. This can likely be attributed to the strong 
oncogenic function of TCL1 on multiple cellular targets such as the serine/threonine 
kinase AKT pathway249, the NF-κB pathway250, 251, and the DNA methyltransferases 
DNMT3A and DNMT3B252. The high disease penetrance in IRF4-/-Vh11247 and Eµ-
SV40 T248 is most likely related to the presence of exogenous factors accelerating B-
cell transformation, but this leads to skewing of the IgVH repertoire, which is not 
representative of human CLL.  
 
model based on: 
time to 
leukaemia 
(months) 
age of death 
(months) 
% disease 
penetrance 
comments 
genetic lesions 
MDR 14qC3233 6-18 12-18 ~22 mice also developed 
MBL and NHL CDR 14qC3234 6-18 12-18 ~50 
TNFR family signalling 
Bcl-2xTRAF2 DN mice235 9-15 ~14 80  
APRIL Tg mice236 >9 12-15 40  
Myc/Baff Tg mice237 3 10 ~80 male gender bias 
microRNA 
miR15a/16-233 12-18 15-18 ~20 see above 
IgH-Eµ-miR-29241 12-24 24-26 20  
other 
Eµ-ROR1246 >15 >15 5  
IRF4-/-Vh11247 5-10 >9 100  
Eµ-SV40 T248 <5 <10 100  
Table 3: Summary of disease characteristics in alternative genetically engineered murine 
models of CLL.  
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1.2.3 TCL1 model-based crosses with other murine models 
To study the mechanisms of putative targets involved in CLL pathobiology and 
progression, the TCL1 model has been crossed with a variety of other genetically 
modified models. For examples, crosses between TCL1 and XID228, pkcβ-/- or pkcβ+/-
253, dnrag1 transgenic254, TIR8-/-255, IRE-1 XBP1256, TP53-/-257, ID4-/-258 and ROR1246 
mice have highlighted the effects of receptor signalling and tumour suppressors or 
oncogenes on disease onset and progression. Other crosses with transgenic APRIL259, 
BAFF260, MIF-/-200, CD44-/-261, fzd6-/-262, rhoH-/-263 and hs1-/- mice264 have significantly 
contributed to the understanding of microenvironmental interactions and cytoskeleton 
formation and cell trafficking. Figure 2 provides an overview of mouse models crossed 
with TCL1 mice.  
 
 
Figure 2: Summary of genetically engineered mouse models crossed with TCL1 mice to 
investigate effects of putative targets on disease development and progression. Adapted 
from Simonetti et al.265; Abbreviations: tg – transgenic. 
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1.2.4 Xenograft models of CLL 
A variety of xenograft models using primary CLL cells or CLL-like cell lines have been 
described266. In general, xenograft models using primary mature CLLs from peripheral 
blood are hampered by the observations that circulating CLL cells do not engraft well, 
that they are rejected by the host if recipients are immune competent mice, and that 
immune compromised mice such as SCID mice can develop CD5- EBV-driven B-cell 
tumours unrelated to human CLL267, 268. In addition, engraftment of human CLL cells 
appears to be influenced by T cells; early studies demonstrated that intraperitoneal 
(i.p.) injection of CLL cells into lethally irradiated BALB/c or beige/nude/Xid (BNX) mice 
which were radioprotected with bone marrow from NOD/SCID mice led to generally 
enhanced engraftment of CLL in the peritoneal cavity in the absence of T cells269, 270. 
Further studies improved the engraftment of human CLL cells by combinations of i.p. 
and intravenous (i.v.) injections, but confirmed that the expansion of CLL cells was 
influenced by T cells, suggesting a role for T cells in controlling the expansion of 
leukaemic B cells in vivo271, 272. In contrast, another study using completely lymphocyte 
deficient NSG mice (NOD/SCID x IL2rg-/-) observed engraftment and proliferation of 
CLL after co-transfer with autologous T cells and allogeneic antigen presenting cells. 
However, CLL disappeared after approximately 3 months, coincident with the onset of 
lethal T-cell mediated GvHD, indicating a dual functional role of T cells in this 
context273. Another study injected newborn NSG mice with immature CD34+CD38- 
stem cells from bone marrow from CLL patients274. CD34+ cells gave rise to a high 
number of polyclonal B-cell progenitors, but their maturation into B cells was restricted 
to monoclonal or oligoclonal CLL-like cells, which were independent from the original 
CLL clones as evidenced by different IGVH-DJ rearrangements. This indicates that the 
propensity to generate clonal B cells has already been acquired at the stem cell stage 
and is independent of oncogenic events. The NSG xenograft model has also been 
used for the preclinical testing of drug efficacy in vivo275. After i.v. transplantation of 
CLL peripheral blood mononuclear cells into NSG recipients pre-treated with busulfan, 
mice were treated with ibrutinib. This reduced CLL tumour burden by promoting the 
emigration of CLL cells from solid tissues and by blocking CLL cell proliferation.  
Altogether, xenograft models are appropriate tools to identify the genetic basis, 
development and evolution of CLL and to conduct rapid drug testing, while mostly 
falling short of depicting the complex associations and interactions between CLL cells 
and the microenvironment. The NSG xenograft model might be an exception to this, as 
a recently published study indicated that spleens from NSG xenografted mice are 
suitable to mirror the role of human lymph nodes in activating B-cell receptor and NFĸB 
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pathways in CLL cells, which leads to increased CLL cell proliferation and activation275. 
However, the complexity of long-term host immune responses in the context of 
developing disease can only be adequately modelled in immune competent mice. This 
makes the TCL1 model, along with the reasons discussed above (i.e. 100% 
penetrance of the disease and great biological similarity to human CLL) the most 
suitable model system currently available to investigate and explore potential strategies 
targeted at restoring anti-tumour immune responses. 
 
1.3 PD-L1/PD-1 immune checkpoint interactions 
1.3.1 PD-L1/ PD-1 in physiological immune responses 
The primary signal in T cells is generated after presentation of antigen by major 
histocompatibility complex molecules (MHC) and recognition by the T-cell receptor. In 
addition, accessory receptors are required during T-cell priming, activation, expansion, 
effector function and contraction to modulate T-cell signalling pathways and to prevent 
destructive autoimmune responses to self-tissues. Accessory T-cell molecules mostly 
belong to the immunoglobulin superfamily and include CD28 and CTLA-4, which are 
both receptors for CD80 and CD86276. CD28 is constitutively expressed by T cells and 
is essential for T-cell activation. Following co-ligation of CD28, the Src kinases Lck and 
Fyn phosphorylate a tyrosine within an ITAM in the cytoplasmic domain of CD28, 
allowing the latter to bind and to activate PI3K via its Src homology 2 (SH-2) domain. 
CD28 signalling also facilitates GTP/GDP exchange on Ras, resulting in activation of 
the MAP kinase pathway, activation of Akt kinase, and activation of the adapter protein 
Vav and the associated Rac pathway. These signals enhance the transcription of IL-2 
and the stability of IL-2 transcripts, thereby stimulating T-cell proliferation277. In 
contrast, CTLA-4 is only expressed by most T-cell types after activation, and transmits 
a negative signal276. Instead of an ITAM, CTLA-4 possesses an immunoreceptor 
tyrosine inhibitory motif (ITIM) in its cytoplasmic domain. Ligation of CTLA-4 induces 
tyrosine phosphorylation of the ITIM, which, in turn, recruits the tyrosine phosphatase 
SHP-2 that can deactivate the phosphorylated ITAMs of the ζ chains of the T-cell 
receptor complex. CTLA-4-/- mice develop a fatal lymphoproliferative disorder that is 
characterized by massive cell activation and infiltration into tissues, indicating that 
CTLA-4 serves as an essential brake on T-cell activation278. 
An important member of the CD28 family is CD279 (Programmed Death-1, PD-1). PD-
1 was first described in 1992 in apoptosis-induced murine cells279. The human PD-1 
gene was soon after mapped to chromosome 2q37.3 and was demonstrated to share 
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70% homology at the nucleotide level and 60% homology at the amino acid level with 
the murine PD-1 gene, translating into a 288 amino acid type I transmembrane protein 
containing an intracellular tyrosine domain280, 281. After expression of PD-1 mRNA was 
found to be restricted to thymus in adult mice, several studies examined the expression 
of PD-1 protein in lymphoid tissues. In thymus and normal murine lymphoid tissues PD-
1 was expressed at very low levels, while CD4-CD8- cells were enriched for PD-1-
expressing γδ T cells as well as PD-1-negative γδ T cells which upregulated PD-1 after 
stimulation with CD3 antibody. These observations indicate that PD-1 expression is 
restricted during T cell differentiation and can be induced at stages preceding clonal 
selection282. The notion of PD-1 as a marker of activated T cells was confirmed by 
further studies demonstrating increased PD-1 expression on mature T cells after in vivo 
stimulation with CD3 and in vitro stimulation with CD3, PHA and PMA/Ionomycin283. 
Moreover, PD-1 expression could also be induced on B cells by anti-IgM stimulation.  
The functional relevance of PD-1 was subsequently discovered in a number of studies 
using PD-1-/- mice. Initial studies indicated a role of PD-1 in increasing proliferative 
responses of B cells after anti-IgM stimulation in vitro284. In addition, PD-1-/- mice 
showed increased serum levels of IgG2b, IgA and IgG3, while IgM and IgG1 were 
comparable with control mice, indicating a role of PD-1 in B-cell differentiation and 
isotype class switching. The involvement of PD-1 in the maintenance of peripheral self-
tolerance as a negative regulator of immune responses was first suggested by the 
observation that aged C57BL/6 PD-1-/- mice spontaneously developed auto-immune 
diseases such as lupus-like proliferative arthritis and glomerulonephritis, and exhibited 
strong and ongoing T-cell receptor mediated proliferative responses to the stimulation 
with specific antigen-presenting cells285. The same group demonstrated autoimmune 
dilated cardiomyopathy in BALB/c PD-1-/- mice286.   
The PD-1 ligand PD-L1 (CD247, B7-H1) was first discovered as a member of the B7 
family with T-cell stimulatory effects after T-cell receptor engagement in the presence 
of IL-2287. In contrast, Freeman and colleagues found that engagement of PD-1 by PD-
L1 led to a dose-dependent inhibition of T-cell receptor-mediated proliferation and IFN-
γ and IL-10 cytokine secretion, which was not observed in T cells from PD-1-/- mice288. 
Interestingly, the outcome of PD-L1/PD-1 interactions was demonstrated to be 
dependent on the strength of the T-cell receptor and CD28 costimulation signals: under 
conditions of suboptimal T-cell receptor engagement, minimal proliferation was 
observed in the absence of costimulation, while the addition of increasing 
concentrations of soluble anti-CD28 antibody led to an up to 30-fold increase in 
proliferation. Under these conditions, activation of T cells in the presence of PD-L1 
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resulted in an 80% reduction in proliferation, and a maximal level of CD28 
costimulation was required to rescue the inhibition of proliferation mediated by PD-L1 
stimulation. In contrast, under saturating conditions of T-cell receptor activation, PD-
L1–mediated inhibition of T-cell proliferation was only observed in the absence of CD28 
costimulation, indicating that increasing levels of T-cell receptor or CD28 signalling can 
circumvent the inhibitory effects of PD-1 ligation at the activation stage. The same 
group later compared T-cell activation and cytokine production of PD-1-deficient versus 
PD-1/B7-1 (CD80) double-deficient T cells to PD-L1 ligation and of CD28/CTLA-4 
double-deficient versus CD28/CTLA-4/PD-L1 triple-deficient T cells to B7-1 (CD80) 
ligation289. These studies revealed a specific functionally relevant interaction between 
the two B7 family members CD80 and PD-L1, resulting in inhibitory signals, diminished 
expression of cell-surface activation markers, decreased T-cell proliferation and 
reduced cytokine production, therefore adding a new dimension to the 
immunoregulatory interactions within the B7:CD28 family of costimulatory molecules.  
PD-L1 mRNA expression follows very distinct patterns: in contrast to CD80 and CD86, 
PD-L1 mRNA was found to be constitutively expressed by non-lymphoid, parenchymal 
organs such as the heart, placenta, skeletal muscle, and lung, while mRNA expression 
could be induced in APCs, including human peripheral blood CD14+ monocytes, 
dendritic cells, activated B cells and to a certain extent by CD3+ T cells themselves 
after stimulation with IFN-γ287, 288. On a protein level, PD-L1 was detected in a variety of 
haematopoietic cell types, including a minor proportion of splenic T and B cells, the 
majority of pre-B cells and myeloid cells in bone marrow, and subsets of thymocytes290. 
In addition, a significant proportion of immature lineage-marker-negative and c-Kit-
positive bone marrow cells containing stem cells were found to express PD-L1. 
Following two-day mitogenic concanavalin A or LPS stimulation, PD-L1 surface 
expression could be detected in all lymphocyte subsets. Another study confirmed 
constitutive PD-L1 expression on freshly isolated murine splenic T cells, B cells, 
macrophages, and dendritic cells, and upregulation on T cells by anti-CD3 stimulation, 
on macrophages by LPS, IFN-γ, GM-CSF, or IL-4, and on dendritic cells by IFN-γ, GM-
CSF, or IL-4291.  
The second ligand for PD-1 is PD-L2 (CD273, B7-DC). Similar to PD-L1/PD-1, 
engagement of PD-1 by PD-L2 inhibited T-cell receptor mediated proliferation and 
cytokine production of CD4+ T cells292. At low antigen concentrations, PD-L2/PD-1 
interactions counteracted costimulatory CD28 signals, but reduced cytokine production 
only without inhibiting T-cell proliferation at high antigen concentrations. Compared with 
PD-L1, PD-L2 protein expression was found to be more restricted to subsets of 
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macrophages and dendritic cells stimulated with IFN-γ, GM-CSF, or IL-4291, whereas 
another study found PD-L2 expression to be absent in haematopoietic cells290. Early 
murine studies using PD-L1-/- and PD-L2-/-mice confirmed that PD-L1 and PD-L2 have 
largely overlapping functions in inhibiting IL-2 and IFN-γ production during T-cell 
activation, but that PD-L1 expression on parenchymal cells appears to be a more 
important mediator of tissue tolerance293. Other studies using PD-L1-/- mice observed a 
spontaneous accumulation of CD8+ T cells in the liver, leading to accelerated 
hepatocyte damage in experimental autoimmune hepatitis294, and confirmed the role of 
PD-L1 in negatively regulating both CD4+ and CD8+ T cells295. In a murine model of 
asthma, the severity of airway hyperreactivity and airway inflammation was significantly 
greater in PD-L2-/- mice compared with wild-type mice and increased IL-4 production 
by NKT cells, while PD-L1-/- mice showed significantly reduced airway hyperreactivity 
and enhanced production of IFN-γ by NKT cells, reflecting the expression of PD-L2 on 
lung dendritic cells296. In contrast, diminished IFN-γ immune responses suggesting a 
positive costimulatory function of PD-L2 were observed in another line of PD-L2-/- 
mice297.   
Several studies have contributed to elucidating the molecular mechanisms by which 
PD-L1/PD-L2/ PD-1 influence T-cell activation. Karwacz et al. demonstrated that PD-1 
ligation facilitates the down-modulation of the T-cell receptor by increasing expression 
of the E3 ubiquitin ligase Cbl-b, which is essential to downmodulate T-cell receptors as 
part of a normal immune response298. As early intracellular signalling pathways, PD-1 
ligation was found to attenuate T-cell receptor induced CD3ζ chain and ZAP-70 
phosphorylation, leading to impaired IL-2 production and T-cell proliferation via PKCθ 
signalling299. A key element in the mediation of PD-1 inhibition of T-cell receptor 
signalling is the binding and consecutive phosphorylation of SHP-2 to the cytoplasmic 
tail of PD-1, which contains both an ITIM and an immunoreceptor tyrosine-based 
switch motif (ITSM)292: SHP-2 phosphorylation after PD-1 engagement inactivates 
PI3K, which in turns inactivates Akt, a serine/threonine kinase that promotes T-cell 
activation, proliferation, and survival and induces IL-2 expression300. Mutation studies 
have demonstrated that this is mediated by binding of SHP-2 to ITSM301, and while 
either SHP-1or SHP-2 can function as mediators when artificially co-localized to T-cell 
receptor microclusters, only SHP-2 is recruited physiologically302. In addition, there are 
several mechanisms by which PD-1 engagement leads to impaired immune synapse 
formation. Firstly, SHP-2 can also inhibit integrin signalling, which may partially account 
for the destabilization of the immune synapse303. In addition, Src family kinases Csk 
and Lck can be recruited to ITSM and ITIM, which leads to PI3K/ Akt deactivation. As 
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LFA-1 mediated T cell/ B cell conjugation requires signalling through Lck304, Lck 
dephosphorylation after PD-1 ligation interferes with the formation of the immunological 
synapse. Planar bilayer systems demonstrated that physical co-localization of PD-1 to 
T-cell receptor microclusters was sufficient for destabilization of the immune synapse 
and efficient at inhibiting T-cell receptor signalling independent of PD-1 ITSM 
phosphorylation302: Following engagement of both T-cell receptor and PD-1, 98% of 
activated T-cell receptor microclusters contained PD-1, while in the absence of PD-L1 
ligation, PD-1 localized away from microclusters and allowed T-cell activation.  
Mechanisms of PD-1 concentration at the immunological synapse with dendritic cells 
were elucidated by another study305. Similarly to CD28 and CTLA-4, ligand binding led 
to the recruitment of PD-1 to the synapse of CD4+ T cells forming conjugates with 
peptide-pulsed activated splenic dendritic cells. It was suggested that PD-L2 was the 
preferred ligand for PD-1 recruitment to the immunological synapse in this context, but 
it is likely that this finding solely reflects the expression pattern of PD-L1 and PD-L2 on 
this cell type. However, another study describing the kinetics and relative affinities of 
the interactions between PD-L1, PD-L2 and PD-1 found a 2-6-fold higher affinity and 
different association/ dissociation kinetics for interaction of PD-L2 and PD-1 compared 
to interactions of PD-L1 and PD-1306.  
Both PD-L2/PD-1 and PD-L1/PD-1 signals inhibit T-cell proliferation by blocking cell 
cycle progression, as evidenced by an increased number of cells in the G0/G1 phase 
and a corresponding decrease in those in S/G2 phase292. This was more pronounced 
by the engagement of PD-1 by PD-L1 than by PD-L2. As the underlying molecular 
mechanism for PD-1 mediated cell cycle arrest, the suppression of SKP2 transcription 
via PI3K/Akt inhibition and impaired RAS/MEK/ERK signalling was identified307. SKP2 
encodes for a recognition component of the ubiquitin E3-ligase complex Skp, Cullin, F-
box containing complex (SCF), and PD-1 induced down-regulation of Skp2 prevents 
the ubiquitination and degradation of p27 (kip1) during the induction of cell cycle 
allowing cell cycle progression. In addition, PD-1 ligation prevented Smad3 
transcription factor phosphorylation, which increased the abundance of the G1 phase 
cell cycle inhibitor p15 (INK4) and repressed the CDK-activating phosphatase Cdc25A, 
resulting in inhibition of CDK2, CDK4, and CDK6 essential for progression through the 
G1 and S phases of the cell cycle308. Interestingly, exposure of cells to IL-2 restored 
activation of MEK/ERK signalling, but not Akt signalling, and only partially restored 
SKP2 expression307. In addition, p38 and JNK activation remained unaffected, 
indicating that PD-1 signalling selectively targets T-cell receptor signalling pathways 
rather than representing a global abrogation.  
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PD-1 was also described as having an effect on T-cell survival by impacting apoptotic 
genes. This is primarily mediated via PI3K inhibition, which attenuates expression of 
the antiapoptotic gene BCL-xL309. Another study found lower levels of the pro-apoptotic 
molecule Bim in antigen-primed CD8+ T cells in PD-L1 deficient mice, while the 
engagement of activated CD8+ T cells by a plate-bound PD-L1 fusion protein led to the 
upregulation of Bim and increased cell death310. As the Bim/Bcl-2 balance is critical for 
maintaining naive and memory T-cell homeostasis, PD-1 engagement might negatively 
regulate T-cell memory by enhancing the depletion of effector T cells through the 
upregulation of Bim. A simplified overview of intracellular targets in T cells affected by 
PD-1 ligation is depicted in Figure 3.  
 
 
Figure 3: Effect of PD-1 ligation on intracellular targets in T cells: The role of PD-1 is to 
guarantee T-cell homeostasis by limiting T-cell activation and proliferation. PD-1 co-localizes 
with the T-cell receptor (TCR) to microclusters following its ligation with PD-L1. PD-1 mediated 
Cbl-b activation increases the internalization of the TCR. PD-1 ligation directly inhibits proximal 
TCR signalling by blocking phosphorylation of the ZAP70/CD3ζ signallosome. As a key 
molecule, SHP-2 is recruited to the PD-1 intracytoplasmic ITSM domain, leading to the 
inactivation of PI3K, Akt and integrin, which results in impaired IL-2 production and T-cell 
proliferation. ITSM and ITIM also recruit the tyrosine kinases Csk and Lck, affecting PI3K/Akt 
signalling and destabilizing the immune synapse. Cell cycle arrest is mediated via Akt signalling, 
promoting accumulation of Smad3, and by SCF complex-mediated impaired degradation of p27. 
Apoptosis and impaired cell homeostasis is mediated via PI3K and Bcl-2 family proteins.  
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1.3.2 PD-L1 and PD-1 inhibitory signalling and adaptive immune resistance in 
cancer 
While the physiological role of PD-1 is to guarantee T-cell homeostasis and to prevent 
autoimmunity by limiting T-cell activation and proliferation, aberrant PD-L1 expression 
is often used by tumour cells to provide a pro-tumour microenvironment by suppressing 
T-cell effector functions. Soon after the discovery of PD-L1, several studies described 
aberrant PD-L1 expression on tumour cell lines and primary tumour cells. One of the 
earliest studies characterizing the protein expression found that a variety of murine 
leukaemic lines of T-, B-, and myeloid lineages expressed PD-L1290. Another study 
detected surface PD-L1 expression on human lung and ovarian carcinoma cell lines311. 
PD-L1 expression was also observed in both the cytoplasm and on the plasma 
membrane of a variety of primary solid tumours using immunohistochemistry311-314. Of 
note, considerable intra-tumour heterogeneity was found, and not all cells within a 
tumour expressed PD-L1.  
Aberrant PD-L1 expression is also utilized by haematological malignancies. For 
example, our group has demonstrated that PD-L1 is upregulated on primary tumour 
cells in patients with CLL, follicular lymphoma (FL) and diffuse large B cell lymphoma 
(DLBCL)79. Aberrant PD-L1 expression by tumour cells is also observed in mantle cell 
lymphoma315, Hodgkin Lymphoma (HL)316, primary mediastinal B-cell lymphoma 
(PMBL)317 and on CD34+ blasts cells from MDS318, CMML and AML patients319, 
especially patients with AML M5320, and multiple myeloma321. Of note, high PD-L1 
expression on tumour cells, along with increased PD-1 expression on tumour-specific 
CD8+ T cells, has also been described in patients with relapsed leukaemia after 
HSCT322.  
Immunohistochemistry-based studies also observed inverse correlations between PD-
L1 expression by solid tumour cells and tumour-infiltrating lymphocytes, particularly 
CD8+ T cells312, 314. This association, however, appears to be dependent on the tumour 
type, as another study in oesophageal cancer failed to recapitulate this correlation313. 
The functional relevance of PD-L1 expression by tumour cells was first demonstrated 
by the finding that cancer-associated PD-L1 increased the apoptosis of antigen-specific 
human T-cell clones in vitro311. Congruently, immunized PD-L1 deficient mice showed 
an increased expansion of effector CD8+ T cells and a delayed T-cell contraction 
followed by the emergence of a protective CD8+ T-cell memory capable of completely 
rejecting tumour metastases in the lung310. Similar observations have been made in 
haematological malignancies: in a PMBL cell line, both wild-type PD-L1 expression and 
a newly identified fusion product between the MHC class II transactivator CIITA and 
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PD-L1/ PD-L2 genes negatively regulated Jurkat T-cell activation317. In another study, 
the presence of PD-L1 blocking antibody and shRNA knockdown of PD-L1 in SP53 and 
Granta 519 cells significantly increased the proliferation of allogeneic T cells315. The in 
vivo relevance was demonstrated by the finding that in SCID mice with established 
mantle cell lymphoma, the downregulation of PD-L1 on lymphoma cells resulted in 
higher sensitivity to killing by lymphoma-specific cytotoxic effector memory T cells and 
led to improved survival. In HL, culturing bulk tumour cells in the presence of anti-PD-L 
blocking antibodies led to augmented IFN-γ production316. Blocking PD-1/PD-L1 
interactions also restored the proliferative activity of leukaemia-specific CD8+ memory 
T cells in patients who relapsed after HSCT322. 
Using a functional siRNA screening approach in the CLL-like cell line MEC-1, work 
from our group has demonstrated that knockdown of PD-L1, as well as silencing of 
CD200 (OX2), CD276 (B7-H3) and CD270 (TNF receptor, TNFR-superfamily 14), 
reverse impairment of T-cell actin dynamics via regulation of members of the Rho 
family of GTPases, including RhoA, Rac1 and Cdc4279. In primary CLL cells, 
neutralizing antibodies against these targets increased F-actin polymerization, 
measured by immune synapse formation assays, with the combination of antibodies 
against all four ligands yielding the largest effect on immune synapse repair. This 
translated into significantly improved normal donor CD8+ T cell killing function using 
third-party normal donor allogeneic B cells as antigen-presenting cells after primary 
coculture with CLL cells, which could be further improved by addition of lenalidomide to 
the coculture. Antibodies targeting co-receptors on T cells receiving the 
immunosuppressive signal from the tumour, namely against CD200R, CD272 and PD-
1, also improved synapse formation and T-cell effector function. This inhibitory ligand–
induced impairment of T-cell actin dynamics was also observed in FL and DLBCL, as 
well as in solid carcinoma cells, indicating that immunomodulating processes in CLL 
might serve as a model for other malignancies. 
Studies of tumour cell lines or primary tumour cells have also contributed considerably 
to elucidate the mechanisms leading to PD-L1 over-expression. For example, frequent 
cytogenetic alterations in PMBL and HL involve chromosome 9p323. This is also the 
coding region for PD-L1 and PD-L2 along with JAK2, which encodes a tyrosine kinase, 
and SMARCA2, which encodes a putative chromatin regulator. Rosenwald et al. 
demonstrated that elevated transcription of PD-L1 and PD-L2 were a characteristic 
feature of PMBL with chr 9p alterations324. This was confirmed by molecular studies in 
HL, which found PD-L1 and PD-L2 to be key targets at the 9p24.1 amplification peak in 
nodular sclerosing HL cell lines325. In classical HL, the extended 9p24.1 amplification 
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region included the JAK2 locus, leading to increased protein expression and activity, 
induction of PD-L1 transcription and enhanced sensitivity to JAK2 inhibition. In EBV 
positive HL, matrix protein 1 (MP1) and latent membrane protein 2A (LMP2A) 
enhanced the transcriptional activity of PD-L1 and PD-L2, indicating that the 
expression of PD-L genes is possibly caused by latent virus-associated membrane 
proteins316. PD-L1 was also found to be regulated by the oncogenic, chimeric 
nucleophosmin (NPM)/ anaplastic lymphoma kinase (ALK) in NPM+/ALK+ T-cell 
lymphoma via the STAT3 transcription factor, indicating a direct link between an 
oncoprotein and the immunosuppressive cell-surface protein PD-L1326. At the 
translational level, PD-L1 expression appears to be suppressed by the PTEN gene: 
mutated PTEN was found to activate S6K1, which shifts PD-L1 mRNA to polysomes, 
increasing the translation of PD-L1 mRNA and its plasma expression327. As another 
regulator at the translational level, miRNA513 was described, which is complementary 
to the 3’ UTR of PD-L1 and prevents PD-L1 mRNA translation328.  
Interestingly, several of these mechanisms lead to the increased production of IFN-γ. 
On the other hand, cancer-associated PD-L1 expression in response to IFN-γ has been 
described in several malignancies, for example in mantle cell lymphoma315, multiple 
myeloma321, AML329 and MDS blasts318, where this induction was associated with the 
activation of NF-κB and nearly completely blocked by an NF-κB inhibitor. Lee et al. 
demonstrated that interferon regulatory factor-1 (IRF-1) is primarily responsible for the 
constitutive PD-L1 expression as well as for the IFN-γ -mediated PD-L1 upregulation in 
a human lung cancer cell line A549, with AG490, a Janus activated kinase/signal 
transducer and activator of transcription inhibitor, greatly abolishing the responsiveness 
of A549 cells to IFN-γ by reducing the IRF-1 transcription330. However, PD-L1 induction 
on cancer cells was also observed in response to stimulation with IL-10 in mantle cell 
lymphoma315 and to toll-like receptors (TLR) ligands321, 329. In addition, as described in 
chapter 1.3.1, PD-L1 can be induced in various other non-tumour cell types of the 
microenvironment, whereas constitutive aberrant PD-L1 expression is a characteristic 
of certain cells of the tumour microenvironment such as MDSCs199, 331.  
These observations have prompted the formulation of the “adaptive immune 
resistance” hypothesis332 – under the pre-requisite of a tumour being immunogenic, 
immune and bystander cells produce cytokines such as TNF-α and IFN-γ as a result of 
activation by a tumour, which prompts the upregulation of PD-L1 by both the tumour 
and the tumour microenvironment. As a result, immune effector cells are suppressed, 
and the tumour is protected from anti-tumour immune responses and is able to 
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promote further immune suppression by additional immune escape mechanisms such 
as the downregulation of surface molecules or evasion into sanctuary and growth-
supporting niches. Moreover, other activated immune cells such as NKT cells333, B 
cells334 or dendritic cells335 also can express PD-1 and can hence be suppressed by 
PD-L1 ligation.  
 
1.4 Generating anticancer immunity harnessing T cell responses  
Hanahan and Weinberg famously proposed six hallmarks of cancer in 2000, which 
comprise biological capabilities acquired during tumour development due to genome 
instability336. Considering the rapidly building evidence of the central role of the immune 
system in tumour formation and progression, the authors since revisited these 
hallmarks337. Most if not all tumour types are now recognized to rely on immune 
suppression and evasion for their survival, and tumour cells in many cases actually 
subvert immune components to support their growth. In view of the cancer 
immunoediting hypothesis whereby an individual is protected from cancer through the 
elimination and immunogenic modification of cancer cells338, cancer immunotherapy is 
a very attractive approach. When properly established, anti-tumour immune 
surveillance is exquisitely capable of eliminating tumour cells, and in fact is probably 
the most likely route to achieving cures or at least long-term control of cancer. The 
ability of HSCT to produce cures in a subset of CLL patients, as described in chapter 
1.1.3, provides one illustration of the remarkable potential of the immune system. 
However, HSCT remains a risky option due to the immune-depleting conditioning 
regimens and GvHD, and thus alternative, safer methods of establishing anti-tumour 
immune responses are being aggressively pursued. 
An especially exciting new and active immunotherapy approach is chimeric antigen 
receptor (CAR) T-cell therapy. CAR technology has recently emerged as a promising 
strategy to specifically target malignant cells using precisely engineered T cells. The 
successful construction of a chimeric T-cell receptor was first described over 20 years 
ago339. Considerable progress has been made since then, to the point that at some 
centres the generation of CAR T-cells is nearly routine. CARs are generally made up of 
an antigen-recognizing receptor coupled to a signalling molecule or molecules that 
activate the T cell expressing the CAR340. The antigen receptors most commonly 
incorporated into CARs are single chain variable region moieties (scFv) that consist of 
the light chain and the heavy chain variable regions of a monoclonal antibody joined by 
a peptide linker. The scFv portion is linked to a transmembrane domain followed by a 
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tyrosine-based activation motif such as that from CD3ζ. In initial studies, CARs were 
designed to contain a single cytoplasmic signalling domain derived most commonly 
from the TCR-derived CD3ζ chain (first generation CARs). Second generation CARs 
contained additional cytoplasmic signalling domains, and third generation CARs now 
include more than one costimulatory signalling domain in addition to the CD3ζ chain to 
enhance T-cell proliferation and survival. As for monoclonal antibodies, attractive CAR 
targets in CLL include CD19, CD20 and ROR1. In part because of the uncertainty 
regarding antigen selection, the optimal clinical approach to treating patients with CAR-
T cells is not yet understood. Several Phase I/II clinical trials of anti-CD19 CAR-T cells 
have been initiated, and clinical activity is promising but not widespread (reviewed in 
341). One of the most impressive results was seen in a heavily pre-treated CLL patient 
with del17p and TP53 mutation, who entered a complete remission after receiving 
second-generation anti-CD19 CAR T cells after conditioning with pentostatin and 
cyclophosphamide, while experiencing no acute side effects342. 
Despite the promise of CAR T cells, there are several obstacles that must be 
overcome. First, as no single tumour-associated antigen is expressed by all tumour 
types, scFv encoded by CAR genes need to be constructed for each potential antigen. 
These target antigens must be carefully selected to avoid “on-target, off-organ” effects 
that can occur when the antigen is also expressed and recognized on non-malignant 
tissues and organs. Other issues include the paucity of such targets, the inability of 
current CARs to target more than one antigen which could promote the preferential 
growth of more aggressive antigen-negative tumour cells, manufacturing complexities 
and costs, and the inability to derive sufficient cells from some patients343, 344. In 
addition, CAR T-cell therapy can be associated with severe complications such as 
cytokine release syndrome, which is potentially lethal, and prolonged loss of normal B-
cells345, 346. It has also become clear that the success of CAR therapy is highly 
dependent on the inclusion of lympho-reducing conditioning chemotherapy as well as 
CAR design346-349.  
 
1.4.1 Potential of novel agents to correct immune defects in CLL 
As highlighted in Chapter 1.1.3, several novel agents have shown very promising 
activity even in high-risk CLL patients. In addition to eliminating malignant cells via 
inhibition of specific targets or tyrosine kinases, they partly appear to have the potential 
to correct CLL-associated immune defects. For example, the BTK inhibitor ibrutinib 
also affects BCR- and chemokine-controlled retention and homing of CLL cells in their 
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growth- and survival-supporting lymph node and bone marrow microenvironment64-66. 
Thus, malignant B cells are driven out of their protective niches and are more 
accessible to cytotoxic therapy and potentially other immune cells. Recently published 
preclinical data indicates that ibrutinib also irreversibly binds the BTK isoform ITK, 
which is expressed in T cells, and can therefore be potentially used to correct T-cell 
based immune responses350.  
Other novel agents that appear to affect signalling pathways involved in cell survival, 
clonal expansion and malignant cell retention in lymphoid tissues include idelalisib, an 
inhibitor of PI3Kδ, CXCR4 antagonists, as well as inhibitors of Syk protein kinase, 
RAF/MEK/ERK, and BCL2.  
A summary of key preclinical studies highlighting the effects of these substances on the 
immune system and the microenvironment in CLL is provided in Table 4. Especially 
lenalidomide has been demonstrated to have pleiotropic effects on several effector cell 
subsets of the immune system, probably accounting for the anti-tumour immune 
responses observed in CLL. This will be described in detail in Chapter 7.1. 
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target 
name of 
compound(s) 
published effects on the immune system/microenvironment in 
preclinical in vitro and in vivo models 
CXCR4/ 
CXCL12 
mediated 
chemotaxis 
T140, 
TC14012, 
TN14003, 
plerixafor 
(AMD3100) 
 antagonize the antiapoptotic effect of CXCL12 and stromal cell-
mediated protection of CLL cells351 
 combination with passive (i.e. monoclonal anti-CD20/CD52 
antibodies) but not active (i.e. activated T cells) immunotherapy as 
a promising potential treatment concept352 
SYK protein 
kinase 
R406, 
PRT318, 
P505-15 
 reduces CLL migration towards CXCL12 and adhesion to     
VCAM-1353 
 antagonizes CLL cell survival in NLC co-cultures, inhibits BCR-
dependent secretion of CCL3 and CCL4 by CLL cells, inhibits CLL 
migration towards CXCL12, CXCL13354 
TEC family 
kinases  
(BTK, ITK) 
ibrutinib  inhibits BCR-controlled signalling and integrin α(4)β(1)-mediated 
adhesion to fibronectin and VCAM-1, inhibits CXCL12-, CXCL13-, 
and CCL19-induced signalling, adhesion, and migration of primary 
CLL cells66  
 inhibits migration in response to tissue homing chemokines 
(CXCL12, CXCL13), down-regulates secretion of BCR-dependent 
chemokines (CCL3, CCL4) by CLL cells both in vitro and in vivo65 
 blocks survival signals provided from the microenvironment 
including soluble factors (CD40L, BAFF, IL-6, IL-4, and TNF-α), 
fibronectin engagement, and stromal cell contact64  
 ITK as an irreversible T-cell target of ibrutinib, driving a Th1-
selective pressure350 
PI3Kδ  idelalisib  
(GS-1101, 
CAL-101) 
 abrogates protection from spontaneous apoptosis induced by B 
cell-activating factors CD40L, TNF-α, and fibronectin, decreases 
activated T-cell production of various inflammatory and 
antiapoptotic cytokines355 
 inhibits CLL cell chemotaxis toward CXCL12 and CXCL13 and 
migration beneath stromal cells, down-regulates secretion of 
chemokines in stromal cocultures and after BCR triggering, 
reduces survival signals derived from the BCR or from NLC70 
RAF/MEK/ 
ERK 
sorafenib  inhibits RAF and ERK activation by NLC or stromal cells356 
 blocks migratory and microenvironmental survival signals in CLL 
cells357 
Bcl2 AT-101  induces similar extent of down-regulation of Mcl-1 and apoptosis in 
CLL lymphocytes cultured in suspension or on stroma358  
Table 4: Summary of key preclinical studies highlighting the effects of novel substances 
on the immune system and the microenvironment.  
 
1.4.2 PD-L1 and PD-1 blockade in cancer 
As discussed in Chapter 1.3.2, a variety of tumour types utilizes PD-L1/PD-1 immune 
checkpoints to their advantage to escape anti-tumour immune responses. Therefore, 
several clinical trials using PD-L1 or PD-1 antibody blockade have been initiated or are 
currently ongoing, mostly in heavily pre-treated or advanced disease stage patients. 
Key clinical trials using PD-L1 or PD-1 antibody blockade as a single therapy are 
summarized in Table 5 (PD-L1 blockade) and Table 6 (PD-1 blockade). Collectively, 
these trials have yielded very promising results: PD-L1/PD-1 antibodies were generally 
well tolerated and associated with a low incidence of serious adverse events (SAEs), 
while producing significant and in some cases durable responses in heavily pre-treated 
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patients with advanced stage cancers. Although a direct comparison has not been 
conducted yet, PD-1 blockade appears to be slightly superior to PD-L1 blockade based 
on objective response rates, while potentially being associated with a higher frequency 
of SAEs.  
Although preclinical data strongly suggest that inhibiting PD-L1/PD-1 interactions might 
also be effective in haematological malignancies (see Chapter 1.3.2), few clinical trials 
using PD-L1/PD-1 antibodies as single agents have been conducted. To date, anti-PD-
1 antibodies have been administered to patients with DLBCL after autologous 
haematopoietic stem-cell transplantation359, and to patients with relapsed FL in 
combination with rituximab360. These trials will be further discussed, with a focus on the 
effect of PD-1 blockade on immune effector cells, in Chapter 8.1.  
 
compound 
study 
design 
no of 
pts 
tumour types remarks key findings 
PD-L1 blockade 
BMS-
936559361 
Phase I 207 
 NSCLC 
 melanoma 
 colorectal cancer 
 RCC 
 ovarian cancer 
 pancreatic cancer 
 gastric cancer 
 breast cancer 
application 
until CR or 
confirmed 
disease 
progression 
 SAE grade 3/4 in 9% of 
pts 
 RR melanoma 9/52 pts 
 RR RCC 2/17 pts 
 RR NSCLC 5/49 pts 
 Response duration >1 
year in 8/16 pts with at 
least 1 year  follow-up 
Table 5: Summary of key findings of clinical trials using single agent PD-L1 blockade. 
Abbreviations: pts – patients; NSCLC - non–small-cell lung cancer; RCC - renal cell cancer; CR 
– complete response; SAE – serious adverse events; RR – response rate.  
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compound 
study 
design 
no  
pts 
tumour types remarks key findings 
PD-1 blockade 
CT-011 
(pidilizumab)362 
Phase I 
dose 
escalation 
17 
 AML 
 MDS 
 NHL (incl. 3 
CLL) 
first in-human 
study 
 well tolerated (DLT not 
reached) 
 stabilization of disease 
 cumulative survival at 
21 days 76% (95% CI 
48-90) 
 mean OS 25±27 weeks 
(range 1.7 to >77) 
 SD in ~⅓ of pts 
 1 CR 
MDX-1106 
(BMS-936558/ 
ONO-4538, 
nivolumu-
mab)363 
Phase I 
dose 
escalation 
39 
 metastatic 
melanoma 
 colorectal 
cancer 
 castrate-
resistant 
prostate 
cancer 
 NSCLC 
 RCC 
in n=9 pts, 
tumour PD-L1 
expression ~ 
likelihood of 
response to 
treatment 
 well tolerated (1 SAE: 
inflammatory colitis) 
 1 CR 
 2 PR 
 stabilisation of disease 
in 3 pts 
MDX-1106 
(BMS-936558/ 
ONO-4538, 
nivolumu-
mab)364 
multiple 
dose trial 
296 
 advanced 
melanoma 
 NSCLC 
 castrate-
resistant 
prostate 
cancer 
 RCC 
 colorectal 
cancer 
no objective 
response in pts 
with PD-L1 
negative 
tumours 
(n=17), but 
36% response 
in pts with PD-
L1 positive 
tumours (n=25) 
 SAE grade 3/4 (esp. 
pulmonary toxicity) in 
14% of pts 
 MTD not reached 
 RR NSCLC 18% 
 RR melanoma 28% 
 RR RCC 27% 
MDX-1106 
(BMS-936558/ 
ONO-4538, 
nivolumu-
mab)365 
update 
from364 
107 
 advanced 
melanoma 
 
OS outcomes 
in patients with 
melanoma 
 median OS 16.8 months 
 1-year OS 62% 
 2-year OS 43% 
 among pts with tumour 
regressions: median 
response duration 2 
years 
 71% maintained 
responses off-therapy 
for >16 weeks (range 
16 to >56) 
MK-3475 
(lambrolizu-
mab)366 
Phase I 135 
 advanced 
malignant 
melanoma 
responses 
regardless of 
pretreatment 
with CTLA-4 
antibody 
ipilimumab 
 well tolerated 
 objective clinical RR: 
38% (95% CI 25-44) 
 overall median PFS >7 
months 
MK-3475 
(lambrolizu-
mab, 
pembrolizu-
mab)367 
expansion 
cohort 
from366 
173 
 advanced 
melanoma with 
disease 
progression 
after ≥2 doses 
ipilimumab 
2 mg/kg (n=89) 
or 10 mg/kg 
(n=84) 
 well tolerated at both 
doses 
 overall RR 26% at both 
doses 
Table 6: Summary of key findings of clinical trials using single agent PD-1 blockade. 
Abbreviations: DLT – dose limiting toxicity; CI - confidence interval; OS – overall survival; SD – 
stable disease; CR – complete response; pts – patients; PR – partial response; NSCLC - non–
small-cell lung cancer; RCC - renal cell cancer; CR – complete response; SAE – serious 
adverse events; RR – response rate; MTD – maximum tolerated dose; PFS – progression-free 
survival.  
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1.5 Summary  
CLL is incurable using currently available standard immunochemotherapy approaches, 
but several novel agents show activity even in high-risk CLL patients. However, CLL-
associated immune dysfunction remains a very serious clinical problem. This is caused 
by a variety of humoral and cellular immune defects, the majority of which is 
responsible for providing a pro-tumour and immune-suppressive tumour 
microenvironment. As CLL is now understood as a disease that closely interacts with 
its microenvironment, targeting these interactions is a very attractive treatment 
approach. Novel target molecules in this context are immune checkpoints, which under 
physiological conditions regulate the activation of immune effector cells to maintain 
self-tolerance and prevent autoimmunity. PD-1 and its ligands PD-L1 and potentially 
PD-L2 constitute one of the most prominent immune checkpoint ligand/receptor axes 
mediating CLL-associated immune dysfunction. Establishing anti-tumour immune 
surveillance mechanisms via targeting of PD-L1/PD-1 is a novel and potentially 
powerful strategy to eliminate tumour cells, and in fact might be a route to achieving 
cures or at least long-term control of CLL. 
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2 Hypothesis and aims of the project 
The central hypothesis of this thesis project is that specific T-cell defects result from the 
interaction of malignant CLL cells with the immune system, and that repairing the 
defects in T-cell function will be required to activate an effective T-cell mediated anti-
tumour immune response. Using the TCL1 mouse model, the major aims are: 
1. To further characterize the nature of PD-L1/PD-1 mediated T-cell dysfunctions in 
the context of developing CLL and within different microenvironments 
Initial work on T-cell dysfunction in the TCL1 model has been conducted using TCL1 
mice on the B6C3H-F1 genetic background. As this potentially prevents crosses with 
other transgenic mice, which will be an essential component of future work of the 
group, we have backcrossed TCL1 mice to a pure C57BL/6 genetic background, 
greatly increasing the value of this model for immunological studies. However, the 
effects of CLL on T cells in this new strain require thorough assessment to confirm that 
this model remains valid. My first aim is therefore to compare T-cell dynamics and 
dysfunctions of TCL1 mice on the B6C3H-F1 background to TCL1 mice on the 
backcrossed C57BL/6 background at different stages of CLL to validate both 
backgrounds for the investigation of T-cell dysfunctions and to characterize T-cell 
defects in the direct context of advancing CLL. Additional aims are the characterization 
of T-cell subsets in different CLL-affected compartments to assess the impact of the 
microenvironment, and to explore changes in effector T-cell function alongside 
developing CLL. Considering the growing body of evidence suggesting a central role of 
PD-L1 and PD-1 in mediating immune defects, this will include markers and patterns of 
exhaustion to further characterize PD-L1/PD-1 mediated T-cell impairment in CLL. 
2. To investigate the effect of in vivo immune modulation on CLL/T-cell interactions 
As outlined in Chapters 1.1.3 and 1.3.2, several novel treatments have been shown to 
produce anti-tumour immune responses in preclinical and early clinical studies. Among 
those, lenalidomide probably provides the best evidence in CLL patients of functional 
immune enhancement, introducing the distinct possibility of reactivating the immune 
system to eliminate tumour cells. Although not yet explored clinically in CLL, PD-
L1/PD-1 blockade also holds the promise of restoring anti-tumour immunity. Despite 
the differences in these two strategies, immune modulation may in fact constitute the 
only safe route to long-term disease control or cure. Thus, investigating the in vivo 
potential of lenalidomide and PD-L1/PD-1 blockade using the TCL1 mouse model 
validated in Aim 1, and conducting detailed studies of their impact on effector T-cell 
responses, will be the second aim of this PhD project.   
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3 Materials and Methods 
3.1 Mice and animal procedures 
3.1.1 Ethical considerations relating to animal work 
To ensure the most ethical use of animals, to safeguard animal welfare, and to improve 
scientific quality, in vivo research is guided by the principle of the “Three Rs” (3Rs) – 
replacement, reduction and refinement368. Replacement refers to the preferred use of 
non-animal over animal methods whenever this is equivalent in achieving selected 
scientific aims. Reduction refers to the reduction of numbers of animals used in 
scientific experiments while producing statistically valid results to answer a scientific 
question. Refinement refers to all methods that alleviate or minimize animal pain, 
suffering and distress, and ensure animal welfare during experimental procedures. In 
EU countries and the US, these principles are now officially embraced in legislations 
and guidelines governing animal use369, 370.  
The research conducted in this project was also guided by the principles of the 3Rs. 
First, the lack of suitable CLL cell lines or in vitro model systems that mimic the 
complex dimensions of the natural CLL microenvironment justifies the use of an animal 
model to investigate the role of host immunity in the context of long-term cancer 
development (replacement). The number of animals was reduced by limiting 
experiments and procedures to interventions and repair strategies that have been 
demonstrated to be effective ex vivo. In addition, rigorous statistical calculations were 
performed for each experiment to determine the numbers of mice needed to obtain at 
least 80% power to detect significant changes in a Fisher exact test performed at the 
one-sided 0.05 significance level (reduction). The lymphocytosis, hepatosplenomegaly 
and lymphadenopathy associated with CLL development in mice are, just as in the 
majority of patients, generally painless. Adverse signs, which might present as 
impeded movement or dyspnoea, are generally rare. The interventions tested in this 
project were based on substances and application routes that are generally well-
tolerated or cause only minimal and transient discomfort. In addition, mice were 
inspected daily and underwent regular physical examinations and monitoring of 
disease status or impaired health (e.g. piloerection, sunken eyes, hunched posture, 
inactivity, reduced grip strength, weight loss). The combination of these follow-up 
procedures with the rigorous definition of disease endpoints minimised the probability 
of suffering from the disease or an intervention (refinement).  
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3.1.2 Breeding and standard maintenance of mice 
All animal work was carried out under Project Licence PPL 70/7531, in accordance to 
the Animals (Scientific Procedures) Act 1986. This licence was renewed in November 
2012 and amended in August 2013 to include treatment with additional novel 
substances that had demonstrated great efficacy in early clinical trials. Four TCL1 
breeding pairs on the B6C3H-F1 (abbreviated to C3H hereafter) and the backcrossed 
C57BL/6 (hereafter abbreviated to B6) background were provided by Dr. Carlo Croce, 
The Ohio State University, Columbus Ohio, who is one of our main collaborators within 
the CLL Research Consortium (CRC). Wild-type (WT) mice for breeding and 
experimental procedures were purchased from Charles River laboratories, UK, Harlan 
laboratories, UK, and Cancer Research UK laboratories. Mice were kept in suitable 
barrier systems in the Biological Services Unit (BSU) at Charterhouse Square, and all 
regulated in vivo procedures were carried out under sterile conditions in designated 
procedure rooms in the BSU. 
The colony was maintained and extended by breeding TCL1 transgenic males with a 
harem of WT syngeneic females. Breeders were paired at the age of 6 to 8 weeks and 
kept for a maximum of 10 months or until no new litters were produced for more than 2 
months. Litters were weaned at 3 to 4 weeks of age, ear-marked and genotyped and 
kept with a maximum of 5 littermates.  
Animals were observed daily for general signs of ill health, such as hunched posture, 
ruffled fur, separation from littermates, inactivity or weight loss. Disease status was 
monitored by physical examination of spleens and lymph nodes, and by haematology 
testing using blood smears and if necessary immunophenotyping. Mice were 
euthanized when they showed signs of ill health, or fulfilled one of the following criteria: 
white blood cell (WBC) count in blood smear >100 WBC/high power field (hpf, 40x 
objective), >90% of lymphocytes CD19+CD5+ CLL cells and/or spleen size >3cm in 
diameter compressing other organs. Endpoint definitions for experimental animals were 
in part adapted to the specific research question and are described in the respective 
materials and methods sections. Animals were euthanized using cardiac puncture 
under terminal anaesthesia and/or cervical dislocation.  
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3.1.3 Haematology testing 
The standard method of haematology testing was by blood smears, which routinely 
began at the age of 6 months in transgenic mice. Experimental animals, for which 
larger blood volumes were required, were subjected to repeated tail bleeding. For flow 
cytometry-based analyses, blood was stained in a total volume of 100μl FACS buffer 
[PBS with 2% fetal calf serum (FCS)] with fluorochrome-labelled antibodies at a ratio of 
1:100. Specific antibodies, clones and suppliers are listed in the respective chapters. 
Erythrocytes were then lysed in 5ml 1X ammonium-chloride-based RBC lysis buffer 
(NH4CL 8.3g/l, KHCO3 1g/l, EDTA 0.037g/l). After 10 minutes incubation, 2x volume 
PBS was added, cells were centrifuged at 300 x g for 10 minutes at 4°C and 
resuspended in 350μl FACS buffer. 300μl was transferred to polypropylene flow-
cytometry tubes. Cells were then recorded at a LSRII Fortessa cytometer (BD 
Biosciences, UK) and analysed using FlowJo and FACS Diva Software. Where 
appropriate, the remaining 50μl of cell suspension were analysed at a ViCell counter 
(Beckman-Coulter, UK) in a 1:10 dilution to obtain an automated estimate of total WBC 
count. 
 
3.1.4 Processing of mouse organs into single cell suspension 
Organectomy was performed under sterile conditions in the BSU immediately after the 
death of the animal by cervical dislocation and/or exsanguination. Lymphoid organs 
were kept in ice-cold PBS with 20% FCS and bones in ice-cold RPMI 160 medium 
supplemented with 10% FCS and 1% Penicillin/Streptomycin, and processed quickly 
under a class II biosafety cabinet. Spleen single cell suspensions were prepared using 
an automated tissue dissociator (Miltenyi, UK) following the manufacturer’s 
recommendations for mouse spleen without enzymatic treatment. Lymph nodes were 
dissociated by mashing through a 70μm strainer (Fisher Scientific, UK) with the rubber 
plunge of a 1ml tuberculin syringe (BD, UK). Bones were crushed with a sterile mortar 
and pestle, of flushed with ice-cold FACS buffer. Erythrocytes were lysed using an 
ammonium-chloride-based RBC lysis buffer (NH4CL 8.3g/l, KHCO3 1g/l, EDTA 
0.037g/l), and the reaction was stopped using 1.5-2x volume PBS. All centrifugation 
steps for mouse organs were performed at 300 x g for 10 minutes at 4°C. Cells were 
then either frozen at a maximum density of 200x106cells/ml in FCS/10% DMSO (Fisher 
Scientific, UK) and kept in liquid nitrogen for long-term storage without any further 
manipulation before the freezing process, or used directly in experiments and 
downstream applications.  
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3.1.5 Adoptive transfer of syngeneic mouse cells 
Based on available data in the literature214-216, 220 and previous experiences of the 
group, we adoptively transferred 4x107 previously frozen syngeneic mouse CLL cells 
from spleen by tail vein injection following standard protocols for mice371. Before the 
adoptive transfer, the percentage of CD19+CD5+ CLL cells of viable lymphocytes (CLL 
content) in donor cells was assessed by flow-cytometry. Control mice received an 
equal concentration of healthy mouse B cells from pooled WT donors by tail vein 
injection. Maximum volumes for all i.v. injections were 5ml/kg. Recipient mice were 
between 3 and 5 months of age, and both WT and TCL1 transgenic recipients were 
used. After adoptive transfer, mice were closely monitored, and haematology testing 
using blood smears and flow cytometry was conducted in regular intervals. Mice were 
euthanized when they showed signs of ill health, or fulfilled one of the following criteria: 
WBC count in blood smear >100 WBC/hpf (40x objective), >90% of lymphocytes 
CD19+CD5+ cells and/ or spleen size >3cm in diameter compressing other organs. 
Endpoint definitions for experimental animals were partly adapted to specific research 
questions and are described in the respective materials and methods sections. Animals 
were euthanized using cardiac puncture under terminal anaesthesia and/or cervical 
dislocation. 
 
3.1.6 Application of experimental substances  
Experimental substances tested for their potential to prevent or reverse T-cell defects 
were applied by i.p. injection or by oral gavage. Doses, application routes and 
treatment schedules were selected based on available data in the literature, or followed 
advice of our CRC collaborators who have conducted toxicity studies in WT and TCL1 
mice. Maximum volumes for all i.p. injections were 10ml/kg, and 20ml/kg for oral 
administration. Drugs were dissolved in sterile PBS, and a single stock was prepared 
under sterile conditions at the beginning of the experiment and used to treat all animals 
within one experiment. When indicated, the stability of the drug was confirmed by mass 
spectrometry. Control mice received equal concentrations or amounts of drug vehicle 
or isotype antibodies, and were kept under identical conditions. During treatment, mice 
were monitored daily and sacrificed at predefined endpoints.  
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3.2 Cell thawing procedures 
Cells were re-derived from cryopreservation by thawing them in a water bath set to 
37oC. Before opening the vials under a class II biosafety cabinet, they were disinfected 
with 70% IMS (Fisher Scientific, UK). Cells were carefully added into 10ml pre-warmed 
RPMI 1640 medium supplemented with 10% FCS, 1% Penicillin/Streptomycin (both 
from Sigma, UK), and 50μM β-mercaptoethanol (Gibco, UK). Cells were centrifuged at 
300 x g for 10 minutes at room temperature and resuspended at a volume adequate for 
the size of the cell pellet. Automated cell counting was performed on a Vi-cell XR 
haemocytometer (Beckman Coulter) at a 1:10 dilution.  
 
3.3 Cell separation procedures 
3.3.1 Positive selection of CLL and B cells 
Positive selection of murine CLL and B cells from spleen was performed using 
magnetic activated cell sorting (MACS®, Miltenyi Biotec, UK). Spleens were processed 
into single cell suspension or re-derived from cryopreservation. After cell counting, cells 
were centrifuged at 300 x g for 10 minutes at 4°C, and the supernatant was aspirated 
completely. Cells were resuspended in 90μl ice-cold MACS buffer (PBS, pH 7.2, 0.5% 
bovine serum albumin, 2mM EDTA) per 107 total cells, and 10μl of murine CD19 
conjugated MicroBeads per 107 total cells were added. The cell suspension was mixed 
and incubated for 15 minutes at 4oC, with repeated gentle shaking every 2 to 3 
minutes. Cells were then washed by adding 2ml MACS buffer, centrifuged as above, 
and resuspended in MACS buffer at a concentration of up to 108 cells in 500μl. MACS 
LS columns with a maximum capacity of 2x109 total cells were placed in a 
QuadroMACS magnet (both from Miltenyi) and rinsed with 3ml MACS buffer. The 
CD19 labelled cell suspension was applied to the column and washed through with 3 x 
3ml MACS buffer. The effluent representing the unlabelled cell fraction was collected in 
a 15ml Falcon tube and prepared for negative isolation or cell sorting as described 
below. To obtain the CD19 labelled cell fraction, LS columns were removed from the 
magnetic field and flushed through with 5ml MACS buffer and a provided plunger. 
Eluted cells were collected in a separate 15ml Falcon tube, and cells in both the 
positive and negative fraction were counted. During the whole isolation protocol, cells, 
buffers and reagents were kept on ice to prevent capping of antibodies on the cell 
surface and non-specific cell labelling.  
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3.3.2 Negative selection of T cells 
Negative selection was also performed following protocol developed by Miltenyi Biotec. 
After purification of CLL and B cells as described above, unlabelled cells in the 
negative fraction were counted, centrifuged at 300 x g for 10 minutes at 4°C, and the 
supernatant was aspirated completely. Cells were resuspended in 40μl MACS buffer 
per 107 total cells, and 10μl of biotin antibody cocktail from the murine pan T-cell 
isolation kit II (Miltenyi, UK) per 107 total cells was added. The cell suspension was 
mixed and incubated for 15 minutes at 4oC, with repeated gentle shaking every 2 to 3 
minutes. Subsequently 30μl buffer and 20μl anti-biotin microbeads per 107 total cells 
were added. The cell suspension was mixed and incubated for an additional 20 
minutes at 4oC with repeated gentle shaking every 2 to 3 minutes. Cells were then 
washed by adding 2ml MACS buffer and resuspended at a concentration of up to 1 x 
108 cells in 500μl buffer after centrifugation. MACS LS columns were placed in a 
QuadroMACS magnet and rinsed with 3ml MACS buffer. The labelled cell suspension 
was applied to the column and washed through with 3 x 3ml MACS buffer. The effluent 
representing the unlabelled T-cell fraction was collected in a 15ml Falcon tube, 
counted, and prepared for immune synapse assays or CFSE labelling. During the 
whole isolation protocol, cells, buffers and reagents were kept on ice to prevent 
capping of antibodies on the cell surface and non-specific cell labelling.  
 
3.4 Flow cytometry 
3.4.1 Surface staining 
Staining procedures using single-cell suspensions were generally performed at 2 to 
8oC to avoid antibody capping and internalisation. Surface molecules requiring different 
staining conditions or methods for experiments combining surface staining with 
intracellular/intranuclear staining are described in the specific methods and materials 
sections of the respective chapters. After cell counting, cells were transferred to 5ml 
polystyrene round-bottom tubes (BD, UK) or round-bottom 96-well plates (VWR, UK), 
washed with PBS/2% FCS, centrifuged at 300 x g for 10 minutes at 4oC and 
resuspended in 100μl PBS/2% FCS. Antibodies were generally used at a 1:100 dilution 
and prepared as a master mix to ensure consistency of staining. Cells were incubated 
for 30 minutes at 4oC in the dark, washed with PBS/2% FCS, centrifuged at 300 x g for 
10 minutes at 4oC and resuspended in 200-300μl PBS/2% FCS containing 250ng/ml 
4’6-diamidino-2-phenylindole (DAPI) to allow live/dead discrimination of cells. As the 
integrity of cell membranes is lost during cell death, DAPI enters the nucleus and binds 
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A-T rich regions of DNA, therefore labelling dead cells as DAPI-positive. All samples 
were kept on ice and in the dark until flow cytometry was performed. 
 
3.4.2 Intracytoplasmic and intranuclear staining 
In experiments using intracytoplasmic and intranuclear staining, fixable viability dyes 
instead of DAPI were used for live/dead discrimination, as the preparation of cells 
requires the permeabilisation of the cell membrane. Intracellular and intranuclear 
staining were performed in both 5ml polystyrene round-bottom tubes (BD, UK) and 
round-bottom 96-well plates (VWR, UK). After cell stimulation or short-time cell culture, 
cells were washed twice with 200μl (for 96 well plates) or 2ml (for 5ml tubes) azide-free 
and serum/protein-free PBS. Fixable Viability Dye 505 or 450 (eBioscience, UK) was 
prepared as a working stock solution in azide- and serum/protein-free PBS at a 
concentration of 1μl/ml. Cells were resuspended in 100μl or 1ml PBS/fixable viability 
dye stock solution, and the antibody cocktail for surface staining was added. Cells were 
then mixed well, incubated for 30 minutes at 4ºC in the dark, and washed twice with 
100μl or 1ml PBS/2%FCS. To prepare intracytoplasmic staining, cells were 
resuspended in 200μl or 2ml 1X fixation buffer (eBioscience, UK) and incubated in the 
dark at room temperature for 30 minutes. To prepare intranuclear staining, cells were 
resuspended in 200μl or 2ml Foxp3 fixation/permeabilisation working solution, which 
was prepared by diluting Foxp3 fixation/permeabilisation concentrate (1 part) with 
Foxp3 fixation/permeabilisation diluent (3 parts, eBioscience, UK), and incubated in the 
dark at room temperature for 30 minutes. To cells kept in 5ml tubes, 2ml of 1X 
permeabilisation buffer (eBioscience), which was prepared by diluting the 10X 
concentrate with distilled water prior to use, was added directly before centrifugation. 
Cells kept in 96 well plates were centrifuged first, and then resuspended in 200μl of 1X 
permeabilisation buffer. All cells were centrifuged again, and the washing step with 
200μl or 2ml 1X permeabilisation buffer was repeated. After centrifugation, cells were 
resuspended in 100μl 1X permeabilisation buffer for intracytoplasmic staining. 
Antibodies for intracellular cytokines were added as a cocktail at a 1:100 dilution, and 
cells were incubated for 1h at 4ºC in the dark. Cells were washed with 100μl or 1ml 1X 
permeabilisation buffer, centrifuged, and resuspended in 200-300μl PBS for analysis. 
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3.4.3 Absolute numbers 
Absolute numbers of cell populations were enumerated using CountBright™ absolute 
counting beads (Molecular Probes, UK), which are a calibrated suspension of 
fluorescent microspheres at a known concentration. A specific volume of the 
microsphere suspension is added to a specific volume of sample, so that the ratio of 
sample volume to microsphere volume is known. The volume of sample analysed can 
then be calculated from the number of microsphere events, and can be used with cell 
events to determine cell concentrations of population of interest.  
To enumerate absolute numbers in blood, the volume of sample available was 
recorded, and surface staining was performed in a total volume of 100μl FACS buffer. 
Cells were stained and red blood cells lysed as described in Chapters 3.1.3 and 3.4.1. 
To enumerate absolute numbers in bones and lymph nodes, organs were processed 
into single cell suspension in a standardized fashion (see Chapter 3.1.4) and 
resuspended consistently at a volume of 2ml (for bones) and 200μl (for lymph nodes), 
of which 100μl each were used for surface staining as described in Chapter 3.4.1. To 
enumerate absolute numbers in spleen, organs were processed into single cell 
suspension as described in Chapter 3.1.4, and the total number of cells were counted 
on a ViCell haemocytometer (Beckman-Coulter, UK). Throughout experiments, a 
consistent number of cells were used for surface staining as described in Chapter 
3.4.1. Specific antibodies, clones and suppliers are listed in the respective chapters. 
Counting beads were allowed to adjust to room temperature, gently vortexed for 30 
seconds, and 50μl were immediately added to stained and washed cells resuspended 
at 300μl FACS buffer/DAPI. The sample was then acquired on the flow cytometer, and 
beads were visualized on a plot depicting side scatter on a log scale versus R670/14 
on a linear scale. Gating was then performed as necessary for individual experiments. 
Cell concentrations were calculated by applying the following formula: (number of cell 
events in population of interest/ number of bead events)*(assigned bead count of the 
lot (beads/50μl)/volume of sample (μl)). For blood, this was normalized for the total 
volume used for staining, and reported as absolute number of population of interest per 
μl of blood. For lymph nodes and bone marrow, absolute numbers were reported per μl 
of cell suspension. For spleen, numbers were normalized for spleen weight. As an 
alternative method without counting beads, percentages of populations were multiplied 
by the total number of cells per spleen, which yielded very similar results to counting 
beads and has been reported as the method of choice by other groups195.  
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3.4.4 Flow cytometry based functional T-cell assays 
3.4.4.1 Cell stimulation for functional assays 
All functional assays were performed on fresh cells. For proliferation assays, cells were 
stimulated with Dynabeads® Mouse T-Activator CD3/CD28 beads (Gibco, UK). 
Dynabeads (25µl per 106 T cells) were first washed with full medium (RPMI 1640 with 
10% FCS, 1% Penicillin/Streptomycin, and 50μM β-mercaptoethanol), recovered by 
magnet, and resuspended at the original volume in full medium. T cells were 
resuspended in full medium at a concentration of 1x106/ml, and 200µl aliquots were 
added to 96 well round-bottom plates. Washed Dynabeads were added at a 1:1 
beads:cell ratio, and cells were cultured for 72 hours at 37ºC and 5% CO2. Beads were 
removed prior to staining by placing the tube on a magnet and transferring cells to a 
fresh tube. As controls, unstimulated cells cultured under the same conditions were 
used. For intracellular staining and the CD107a degranulation assay, cells were 
stimulated with 500X cell stimulation cocktail containing 40.5µM PMA (Phorbol 12-
Myristrate 13-Acetate) and 670µM ionomycin (eBioscience, UK) at a 1:500 dilution for 6 
hours at 37ºC/5%CO2. For the last 5 hours of culture, 500X protein transport inhibitor 
cocktail containing brefeldin A (5.3mM) and monensin (1mM), (eBioscience, UK) was 
added at a 1:500 dilution. Unstimulated cells and unstimulated cells cultured in the 
presence of brefeldin/monensin for the last 5 hours were included as controls. 
 
3.4.4.2 Proliferation assays 
3.4.4.2.1 CFSE labelling of lymphocyte for in vitro proliferation assay 
For selected experiments, T cells were labelled with carboxyfluorescein diacetate 
succinimidyl ester (CFSE) to assess ex vivo proliferation upon stimulation with 
CD3/CD28 following a staining protocol modified for mouse lymphocytes372. Up to 
5x107 purified T cells were resuspended in 1ml pre-warmed PBS/5% FCS and 
transferred to a fresh 15ml Falcon tube wrapped in aluminium foil. The tube was then 
inverted almost horizontally, 110µl of PBS was pipetted to a non-wetted portion of 
plastic at the inside top of the tube, and 1.1µl of 5mM CFSE stock (Molecular Probes, 
UK) was diluted into the drop of PBS to give a final concentration of 5µM in the cell 
suspension. After capping the tube, it was immediately inverted quickly several times 
and vortexed at low speed for 20 seconds. Cells were incubated at room temperature 
in the dark for exactly 5 minutes, and washed three times with 10ml pre-warmed 
PBS/5% FCS. Unlabelled cells were included as controls.  
Fabienne McClanahan                                                                                Materials and Methods 
Page 73 of 258 
 
3.4.4.2.2 Intranuclear ki67 
Intranuclear ki67 was assessed to measure T-cell proliferation ex vivo in selected 
experiments. Ki67 is present during all active phases of the cell cycle (i.e. G1, S, G2 
and M), but is absent from resting cells in G0 phase373. It can therefore be used to 
determine the growth fraction of a given population of cells. Fresh cells were cultured 
for six hours ex vivo alongside cells intended for intracellular cytokine assays, but in the 
absence of any stimulating agents. Cells were processed and prepared for intranuclear 
staining as described above.  
 
3.4.4.2.3 EdU incorporation 
In vivo proliferation was assessed by EdU (5-ethynyl-2´-deoxyuridine) incorporation. 
This is considered one of the most accurate methods to track DNA synthesis, and 
provides a good alternative to radioactive nucleoside based assays using 3H-
thymidine374. Similar to BrdU (bromo-deoxyuridine), EdU is a nucleoside analogue 
which is incorporated into DNA during active DNA synthesis. EdU detection is based 
on a “click” reaction, a copper catalysed, covalent, highly specific and stable reaction 
between an azide and an alkyne375, 376; the alkyne is found in the ethynyl moiety of 
EdU, while the azide is coupled to a fluorescent dye which can be detected by flow 
cytometry. The EdU assay can be multiplexed with additional antibodies against 
surface and intracellular markers, and is considered to be gentler than BrdU assays as 
it does not require the denaturation of DNA. Mice were injected i.p. with 100µg/g body 
weight EdU (Life Technologies, UK) 20 hours before they were sacrificed. EdU powder 
was dissolved in sterile PBS to a concentration of 1mg/100µl and kept at -20ºC. Spleen 
cells (2x106) in a single cell suspension were fixed in 4% paraformaldehyde (PFA) for 
15 minutes, washed once with PBS/1% bovine serum albumin (BSA) and 
permeabilised in PBS/0.1% Triton X-100 (Sigma, UK) for 30 minutes. After washing, 
cells were resuspended in 100µl Click-iT reaction cocktail containing 8.75µl 10X Click-
iT cell reaction buffer, 2µl CuSO4, 0.5µl fluorescent dye Alexa488 azide, 1µl 10X 
reaction buffer additive and 87.75µl H2O per reaction and incubated at room 
temperature in the dark for 30 minutes (all components from LifeTechnologies, UK). 
Control cells were incubated with the same cocktail without Alexa488 dye. Cells were 
then washed, and surface stained with for 20 minutes at room temperature, washed 
again and resuspended in 300µl FACS buffer.  
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3.4.4.3 CD107a degranulation assay 
Cell-mediated cytotoxicity was measured by flow-cytometry-based assays assessing 
effector cell degranulation as a non-radioactive alternative to chromium-release 
assays377. CD107a (LAMP-1) is a component of the lipid bilayer surrounding cytotoxic 
granules such as Granyzme B and perforin in T cells. Upon cell stimulation, granules 
are transported towards the immune synapse, their membrane fuses with the cell 
membrane, and the content of the granules is released into the synapse. As a 
consequence of the fusion of lysosomal and cellular membranes during the 
degranulation, CD107a is transiently expressed on the cell surface and can be 
detected with fluorescently labelled antibodies378. In our experiments, 5µg/ml CD107a 
antibody was added per well, and cells were stimulated as described above. Controls 
included wells with CD107a and protein transport inhibitor cocktail, but no cell 
stimulation cocktail.  
 
3.4.5 Flow Sorting 
Flow sorting was performed on a BD Aria II to isolate T-cell populations of interest. 
Frozen samples were debulked of CLL by magnetic separation and surface stained for 
flow cytometry as described above. Specific sorting strategies, gating and purities of 
sorted populations are described in specific methods and materials sections.  
 
3.4.6 Controls 
Unstained controls subjected to the same procedures as described above were 
included in all experiments to set photomultiplier tube (PMT) voltages on the flow 
cytometer. Isotype controls were used for surface staining experiments where a 
significant population of target antigen negative cells was not expected. For 
intracytoplasmic staining, stimulated and unstimulated cells prepared in the same way 
as described above but omitting the intracytoplasmic staining step, and unstimulated 
cells prepared as described above and stained with intracytoplasmic antibodies, were 
used. For intranuclear staining, unstimulated cells prepared in the same way as 
described above, but without the intranuclear staining step, were used. Each 
experiment included multiple internal controls such as healthy samples without 
aberrant expression of markers and Fluorescence-Minus-One (FMO) controls.  
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Compensation controls usually consisted of anti-rat immunoglobulin compensation 
beads (CompBeads; BD, UK). Compensation beads were prepared by adding one drop 
of negative control beads and anti-rat compensation beads to 80µl PBS/2% FCS in a 
5ml polystyrene round-bottom tube for each fluorochrome represented in a panel. 1µl 
Igκ rat anti-mouse fluorochrome-conjugated antibody was added to each tube, and 
incubated at 4oC for 30 minutes in the dark. The beads were then washed with 2ml 
PBS/2% FCS and resuspended in 300μl PBS for analysis. However, beads could not 
be used for fluorescently labelled markers with a hamster isotype and for DAPI. For 
these, single-stained cells were used.  
 
3.4.7 Data acquisition and analysis 
Data was acquired on a LSR Fortessa II (BD, UK) equipped with a four-laser optical 
system, integrated fluidics and the software package BD FACSDivaTM. The red laser 
emits at 640nm wavelength, yellow/green at 561nm, blue at 488nm, and violet at 
405nm. Beam shaping lenses and pinholes focus the combined laser light as a single 
beam into a cuvette, and emitted light is delivered through fibre optics to detector 
arrays arranged to maximise the signal detection using reflecting mirrors. Bandpass 
filters (for red lasers 670+/-14nm, 730+/-45nm, 780+/-60nm, for yellow/green 585+/-
15nm, 675+/-20nm and 780+/-60nm, for blue 695+/-40nm and for violet 525+/-50nm 
and 450+/-50nm) and PMTs improve spectral resolution, and are calibrated on a 
weekly basis using the FACS Comp software and Calibrite Beads (BD, UK) by a 
specialized technician.  
PMT voltages were adjusted for each experiment to ensure maximum signal:noise ratio 
and minimal spectral overlap in competing PMT detectors. Apart from the wavelength-
specific, bandpass-filtered fluorescence intensity arising from each fluorochrome as 
detected at the PMTs, data on light forward scatter (representing particle size) and side 
scatter (representing internal complexity of the particle) were collected. PMT voltages 
required for the amplification of signal from specific fluorescently-labelled antigens 
were determined in optimization experiments. To preserve experimental samples, 
compensation beads coated with antibody recognizing the appropriate isotype for each 
fluorochrome represented in a specific panel in combination with uncoated beads as 
the internal negative control were used. Compensation plots were produced using 
FACSDiva software which plotted the appropriate output channel on the x axis, against 
all other output channels under investigation in turn on the y axis. Compensation was 
adjusted until the ‘positive’ stained beads aligned horizontally with the ‘negative’ 
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stained beads by eye, and confirmed by calculating their Median Fluorescence 
Intensity (MFI). The compensation matrix was then applied to all samples and to 
cytometer setting.  
After compensation, cells were gated on the basis of DAPI/fixable viability dye and side 
scatter (SSC) to exclude dead cells from the analysis. A second gate was applied to 
viable (i.e. DAPI negative) cells, and cells were plotted as SSC-area (SSC-A) and 
SSC-width (SSC-W) to identify single cells. A third gate showing forward scatter (FSC) 
and side scatter (SSC) characteristics was then applied to viable single cells to exclude 
debris from the analysis. Lymphocytes/mononuclear cells (MNC) were identified based 
on specific FSC/SSC characteristics. Specific cell populations were evaluated based 
on whether they were expressing or not expressing a target antigen (i.e. positive or 
negative for a maker), expressed as a percentage of a defined parent population, or 
whether there were degrees to which they expressed an antigen, measured by MFI. 
However, MFI bears a non-linear relationship to the actual number of molecules 
expressed on each cell. Stopping gates and number of recorded events used in 
individual experiments are described in specific methods. Recorded data was exported 
as .FCS files, and analysed with FlowJo (Tree Star Inc.) software.  
 
3.5 Immune synapse formation assay 
3.5.1 Cell conjugation assays 
Up to 1.5x106 T cells were resuspended in 1ml full medium in 1.5ml Eppendorf tubes 
and rested in the incubator. Up to 1.5x106 healthy B or CLL cells were transferred into 
1.5ml Eppendorf tubes, washed twice in serum-free medium and resuspended in 500µl 
serum-free medium. A working stock of serum-free medium containing 2µg/ml 7-amino-
4-chloromethylcoumarin (CMAC) CellTracker Blue (LifeTechnologies, UK) was 
prepared and 500µl were added to the resuspended cells for a final CMAC 
concentration of 1µg/ml. Cells were incubated for 30 minutes at 37°C, centrifuged at 
4000rpm for 1 minute at room temperature in a table-top centrifuge, and resuspended 
in 1ml full medium containing 2μg/ml of staphylococcal superantigen cocktail (Sigma, 
UK). After a further 30 minutes incubation at 37°C, both B and T cells were centrifuged 
and the supernatant was aspirated completely. T cells were then resuspended in 150µl 
full medium, and transferred into the tube containing the activated B cells in a 1:1 ratio. 
After centrifugation at 1500rpm for 5 minutes, which allowed a cell pellet to form, 
resultant B cell/T cell conjugates were incubated at 37°C for 20 minutes, gently 
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resuspended in 150µl full medium, and transferred onto a Poly-l-lysine coated glass 
(Fisher Scientific, UK) slides using a 3-well cell concentrator and a cytofuge (Statspin).  
 
3.5.2 Staining for confocal microscopy 
While still in the cytofuge, cells transferred to slides were fixed in 150µl 3% methanol-
free formaldehyde in PBS (TAAB Laboratories Equipment Ltd., UK) for 15 minutes. 
After 3 washing steps (150µl PBS each), cells were permeabilised in 150µl 0.3% Triton 
X-100 (Sigma, UK) in PBS for 5 minutes. After 3 more PBS washing steps, cells were 
blocked 10 minutes with 0.1% BSA/PBS, again washed 3 times, and stained with 
rhodamine phalloidin in a goat serum buffer (Invitrogen, UK) 20 minutes at 4oC in the 
dark. After 3 final washing steps, the cytofuge unit was disassembled. Coverslips were 
mounted and slides kept at 4°C in the dark until analysis. 
 
3.5.3 Confocal microscopy and image analysis 
Confocal images were captured with a Zeiss 510 confocal laser-scanning microscope 
using a 63x/1.40 oil objective and LSM Version 3.2 SP2 imaging software (Zeiss, UK). 
A minimum of 10 images were acquired per condition. Images were exported as LSM 
files and analysed using AxioVision Version 4.8 image analysis software (Zeiss). The 
AxioVision outline tool was used to draw around each synapse between T cells and B 
cells, and all available interactions were scored in each condition. The synapse area 
was reported as the area of T-cell F-actin immune synapses (μm2) value, and exported 
into Prism Version 5 software (GraphPad) for statistical analysis.  
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3.6 Statistical considerations 
Data sets were subjected to normality testing using the Shapiro-Wilk normality test. 
Where all data sets could be accurately modelled by a Gaussian distribution an 
unpaired t test was used for analysis of differences between groups; where this was 
not the case the 2-sided Mann Whitney U test was used. For survival curves, shown by 
Kaplan-Meier plot, a log-rank (Mantel-Cox) test was performed and differences were 
expressed as Hazard Ratio with 95% confidence interval. Statistical dependence 
between two nonparametric variables was assessed by Spearman's rank correlation 
coefficient modeling. P values of less than.05 were considered statistically significant. 
Analyses were conducted using Prism Version 5 software (GraphPad). P values were 
visualized with the help of heatmap summaries in selected experiments, with blue 
colour indicating relative expansion and red colour indicating relative loss of cell 
subsets. Shades of blue and red were applied to express differences in significance 
(i.e. p<.05, p<.001, p<.0001). Values are reported as median and interquartile range, 
unless indicated otherwise.  
In treatment studies, mouse sample size calculations were based on the required 
number of mice per group needed to detect a 1.25 standard deviation difference in 
means of PD-1 expression on CD8+ T cells between mice without and with intervention 
(as expected from previous in vivo and in vitro experiments) in one-sided testing at a 
significance level α=0.05 with at least 80% power.  
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4 Breeding and maintenance of TCL1 mice and induction of disease by 
adoptive transfer 
4.1 Specific introduction 
The TCL1 model is a well-established murine model of CLL which closely mirrors the 
biology and therapeutic responses of aggressive human CLL212 (see Chapter 1.2.1). In 
general, mice become fully leukaemic after about 12 to 16 months, which makes the 
TCL1 model very time-consuming and cost-intensive. Therefore, it is crucial to 
implement optimized and reproducible standard procedures and protocols for 
genotyping and follow-up of mice in order to avoid ageing false-positive transgenic 
animals or to prematurely sacrifice transgenic mice in which the disease has not yet 
fully developed. We were the first group to demonstrate that this murine CLL is readily 
transplantable to healthy syngeneic mice by adoptive transfer (hereafter abbreviated to 
AT) of spleen cells from leukaemic donor mice. This finding has since been confirmed 
by others214-216, 220, and AT is now widely considered to be a reproducible strategy to 
study the pathomechanistic role of specific molecular targets as well as the efficacy 
and mechanism of action of novel therapies. However, considerable variability exists in 
the timing, dose, and application route of donor cells, which hampers the reproducibility 
of preclinical studies between experiments and different laboratories. It is also unclear 
whether donor cells should originate from individual mice or whether a pool of cells 
from several donors should be used. In addition, the biological course of disease after 
AT in the absence of treatment has not been well characterized. Relevant to this thesis, 
the generation and validation of standardized conditions for AT is particularly important 
to be able to rigorously investigate complex disease-related immune and 
microenvironmental interactions and how these are affected by novel therapeutic 
approaches.   
 
4.2 Goals and objectives 
My first goal for this part of my work was therefore to establish a TCL1 mouse colony in 
our centre from the breeding pairs we had received as a generous gift from our CRC 
collaborators. This included setting up protocols and procedures for breeding, 
genotyping and follow-up of transgenic mice. My second goal was to optimize the 
conditions for our in vivo preclinical studies by validating the AT model and by 
improving the transplantation conditions and the consistency of disease engraftment 
and development.  
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4.3 Specific methods 
4.3.1 Genotyping 
Material for genomic PCR was obtained from ear punches. DNA was extracted using 
alcohol precipitation after digestion at 55°C overnight with buffer consisting of 50mM 
TRIS pH 8.0 (Sigma, UK), 25mM EDTA pH 8.0 (Sigma, UK), 100mM NaCl (Fisher 
Scientific, UK), 1% SDS (Sigma, UK), and Proteinase K 20mg/ml (Roche Diagnostics, 
UK). DNA content was determined using a NanoDrop™ spectrophotometer (Thermo 
Scientific, UK). TCL1 primer sequences are: (TCL1 Forward) 5’-
GCCGAGTGCCCGACACTC-3’; (TCL1 Reverse) 5’-CATCTGGCAGCAGCTCGA-3’. 
The expected amplification product is 350 base pairs (bp). PCR products were 
confirmed by bidirectional sequencing using an ABI 3100 Genetic Analyser (Applied 
Biosystems, UK). Results were compared to the corresponding sequences for human 
TCL1 [accession number TCL1A: NM_001098725, TCL1B: NM_004918.3; National 
Center for Biotechnology Information (NCBI) GenBank database]. The endogenous 
mouse globin gene was used as an internal positive control. Mouse betaglobin (MBG) 
primer sequences are: (MBG Forward) 5’-
CCAATCTGCTCACACAGGATAGAGAGGGCAGG-3’ and (MBG Reverse) 5’-
CCTTGAGGCTGTCCAAGTGATTCAGGCCATCG-3’. The expected amplification 
product is 494 bp. All primers were purchased from Sigma UK. A negative no-template 
control (NTC) containing master mix and primers but no DNA was used for each primer 
pair. PCR conditions for TCL1 are activation at 95°C (5 min), then denaturation at 95°C 
(30 sec), annealing at 58°C (30 sec) and extension at 72°C (30 sec) for 35 cycles, and 
final extension at 72°C (5 min). PCR conditions for MBG are the same except for an 
annealing temperature of 70°C. ReddyMix Master Mix (Thermo Scientific, UK) was 
used for all PCR reactions at a total volume of 10μl. PCR products, controls and a 
100bp DNA ladder (Life Technologies, UK) were separated on a 2% agarose gel 
containing 20µl GelRed nucleic acid gel stain (VWR, UK), and visualized in a 
Transilluminator.  
 
4.3.2 Follow-up by haematology testing 
Mice were pre-warmed under a heat lamp, immobilized in a restrainer, and the lateral 
tail vein was punctured with a regular 19G needle (BD, UK). Blood smears were 
prepared, fixed with methanol, and stained with modified Romanowsky stain (Wright 
stain, Sigma, UK). A WBC count was estimated by counting 5 to 10 high power fields 
(hpf) using a 40x objective of a bright field microscope (Zeiss, UK) in an appropriate 
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area. When larger blood volumes were required, lidocaine-containing local anaesthetic 
ointment was applied to the tip of the tail and mice were warmed for 10 minutes in a 
heating chamber at 37°C. The tip of the tail was then cut with a sterile scalpel and 50μl 
of blood was collected in an EDTA-coated 1.5ml Eppendorf tube. To assess the 
proportion of CD19+CD5+ CLL cells in peripheral blood, whole blood was stained with 
1:100 CD45 APC (clone 30-F11), CD19 FITC or PE (clone eBio1D3) and CD5 PE or 
FITC (clone 53-7.3) (all eBiosciences, UK). CD19+CD5+ cells were gated on CD45+ 
cells after live/dead and singlet/doublet discrimination, and gates were confirmed by 
including samples from healthy controls.  
 
4.3.3 Adoptive transfer experiments 
Procedures for this are described in Section 3.1.5. Initial experiments used 2x107 cells 
in two separate injections three days apart, while later experiments used the same total 
cell number (4x107) in a single injection.  
 
4.4 Results 
4.4.1 Genomic PCR and TCL1 sequence analysis 
All TCL1 mice produced under licence PPL70/7531 were genotyped to confirm the 
presence of the TCL1 transgene. Copy number status and integration site were not 
examined. Sequence analysis carried out on genomic DNA from the first litter produced 
in our colony confirmed that the amplified product was identical with the coding region 
of human TCL1 (Figure 4 A). An example of a genomic PCR for four different litters is 
depicted in Figure 4 B. Bands at 494 bp for MBG as a housekeeping gene confirmed 
the quality of the extracted genomic DNA, while bands at 350 bp confirmed the TCL1 
transgene status of the animal. Breeding a transgenic male with WT females usually 
resulted in 50% TCL1 transgenic offspring, but some variation occurred, with less than 
half of some litters being transgenic. As transgene homozygosity is not lethal in TCL1 
mice, transgenic animals can also be bred with each other. However, we refrained from 
pursuing this breeding strategy to minimize the likelihood of the development of a TCL1 
sub-strain over time and to maintain better control of TCL1 lines derived from specific 
index animals, in accordance with good practise guidelines on the maintenance of 
transgenic mouse strains379. In addition, our breeding strategy allowed us to perform 
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specific experiments in age-matched WT littermates raised and kept in identical 
conditions as experimental animals.  
 
 
Figure 4: Validation of genotyping procedure and protocol to maintain the TCL1 colony. 
(A) TCL1 sequence confirmation was carried out by bidirectional sequencing and compared to 
the corresponding sequence for human TCL1 (accession number TCL1A: NM_001098725, 
TCL1B: NM_004918.3), confirming that the amplified product was identical. (B) Genomic DNA 
was amplified with TCL1 and mouse beta globin (MBG) primer pairs. MBG bands at 494bp 
confirmed the quality of the extracted DNA, while TCL1 bands at 350bp identified transgenic 
TCL1 offspring. No-template controls (NTC) demonstrate absence of PCR contamination.  
 
4.4.2 Haematology testing and anatomic sites of disease 
As seen in human CLL, blood smears from leukaemic mice showed an increase in 
circulating lymphocytes that were enlarged and displayed condensed nuclear 
chromatin. Also similar to the human disease, Gumprecht nuclear shadows (also 
known as smudge cells) as an artefact of the smear preparation were also present (see 
Figure 5 A). The immunophenotype of circulating lymphocytes also resembled human 
CLL, as murine leukaemia cells were CD19+CD5+. This population was absent in 
young transgenic mice and in age-matched WT controls (see Figure 5 B). 
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Figure 5: Results of routine haematology testing in TCL1 and WT mice. (A) Example of a 
blood smear of a leukaemic mouse. Smears were stained with a modified Romanowsky stain, 
and leukocytes were counted in 5-10 hpf using a 40x objective of a bright field microscope in an 
appropriate area. As in human CLL, mouse leukaemia cells were enlarged and had clumped 
nuclear chromatin, and Gumprecht nuclear shadows could be found. (B) Example of flow 
cytometry graphs in ageing TCL1 and age-matched WT mice. Whole blood was stained with 
CD45, CD19 and CD5. Cells were gated on CD45+ lymphocytes after live/dead and 
singlet/doublet discrimination. While young TCL1 and WT mice were free of CD19+CD5+ CLL 
cells, this population was found to consistently expand with ageing in transgenic mice.  
 
The morphology of CLL in TCL1 transgenic mice with fully developed disease is 
depicted in Figure 6 A. Just as is often the case in the human disease, mice with CLL 
exhibit hepatosplenomegaly and lymphadenopathy, which however are generally 
painless and cause only moderate impairment to the animals. Spleens are the major 
organs of disease, and are enlarged up to 5-fold compared to WT spleens (Figure 6 B). 
 
 
Figure 6: Anatomic sites of CLL in TCL1 transgenic mice. (A) Mice with CLL exhibit 
hepatomegaly (broken arrow), splenomegaly (solid arrow) and lymphadenopathy (*). (B) 
Differences in spleen sizes in organs taken from WT and TCL1 mice (m – male, f – female). 
Note differences in scale. 
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4.4.3 Adoptive transfer experiments 
A total of 12 consecutive AT experiments were conducted to optimize conditions for our 
in vivo preclinical studies (Table 7). With the exception of experiment 12, where mice 
were sacrificed at predefined endpoints, a previously determined maximum tolerable 
degree of splenomegaly assessed by physical examination along with predefined 
haematological parameters were used as endpoint definitions (see Chapter 3.1).  
 
aim exp. 
date of 
TPL 
no. 
of inj. 
recipients donors 
failed 
engraft-
ments 
weeks with 
CLL, 
median 
(range) 
spleen weight, 
median 
(range) 
testing i.v. 
TPL 
procedure 
1 17/01/12 2 1 C3H Tg 
several, 
inconsistent 
 
7.86 0.4g 
2 31/01/12 2 1 B6 Tg 
 
11.43 1g 
3 19/03/12 2 
2 C3H Tg 
4 C3H Tg 
several, 
consistent 
for individual 
mice 
1 C3H 
6.1 
(6-20) 
2.35g 
(1.8-5.6) 
establishing 
i.v. TPL 
procedure 
using 
uniform 
conditions 
4 11/05/13 2 
2 B6 Tg 
4 B6 Tg 
single donor 
 
4 
(4-5.6) 
0.8g 
(0.6-1.0) 
5 08/06/12 2 
5 B6 Tg 
4 B6 Tg 
single donor 
 
4.43 
(3.71-11.44) 
1.3g 
(0.7-2.8) 
6 02/07/12 2 
5 C3H Tg 
4 C3H Tg 
single donor 
 
7.71 
(7.71-11.57) 
1.8g 
(1.4-2.5) 
7 12/10/12 2 5 B6 Tg single donor 
 
9  
(no range, 
same 
endpoint for 
all mice) 
2.0g 
(1.6-2.6) 
comparing 
TPL in TCL1 
and WT 
recipients 
8 19/04/13 2 
5 B6 Tg 
5 B6 Tg 
5 B6 WT 
5 B6 WT 
donor pool 
1 B6 WT 
(censored 
day 60 with 
lympho-
cytosis) 
WT: 
5.8 (5-6.7) 
 
Tg: 
5 (4.7-5.9) 
WT: 
1.9g (1.9-2.8) 
 
Tg: 
1.9g (1.6-2.2) 
confirming 
TPL in WT 
recipients 
9 10/06/13 2 
3 B6 WT 
4 B6 WT 
single donor 
 
8.0 
(4.29-10.43) 
not assessed 
comparing 
2x i.v. TPL 
with 1x i.v. 
TPL 
10 01/10/13 1, 2 
10 B6 WT 
10 B6 WT 
donor pool 
 
1: 7.4 
(6.86-10.29) 
 
2: 8.0 
(6.86-10.29) 
1: 1.75g 
(1.3-2.2) 
 
2: 1.8g 
(1.3-2.4) 
confirming 
1x i.v. TPL 
11 11/02/14 1 16 B6 WT donor pool 
 
5.7 
(1.43-9) 
1.7g 
(0.5-2.2) 
confirming 
1x i.v. TPL, 
earlier 
endpoints 
12 07/04/14 1 15 B6 WT donor pool 
 
1.29 
(0.43-2.14) 
0.2g 
(0.1-0.5) 
Table 7: Overview of adoptive transfer experiments to validate and optimize the model for 
preclinical studies. Abbreviations: TPL – transplantation, i.v. – intravenous, inj. – injection(s), g 
– gram, C3H – C3HB6 background, B6 – C57Bl/6 background, Tg – transgenic, WT – wild type. 
Red font represents female recipients and blue font male recipients. 
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In the first three experiments, the aim of the AT was to test the i.v. transplantation 
procedure per se. Both TCL1 C3H and B6 recipients were used. Due to the limited 
availability of donors, cell doses and donors were often inconsistent within and 
between experiments. Therefore, the time between transplantation and culling based 
on previously defined splenomegaly and haematological parameters was quite variable 
in the initial experiments, and engraftment was not successful in one recipient. 
However, as the donor pool was greatly expanded after TCL1 mice in our colony had 
been successfully aged, we were able to examine the i.v. AT protocol under more 
uniform conditions. Using young male and female TCL1 recipients on both the C3H 
and the B6 backgrounds, we injected 2x107 cells each on d0 and d3 (total of 4x107 
cells per mouse) from single, syngeneic, leukaemic donors in four consecutive 
experiments (experiments 4 to 7 in Table 7). This led to median survivals of 4 to 9 
weeks after AT. Mice were sacrificed once they met previously defined criteria for 
spleen size and/or lymphocytosis. Examples of the development of lymphocytosis 
assessed by longitudinal blood smears are depicted in Figure 7. Although disease 
development appeared to be more aggressive in females, this difference was not 
statistically significant.  
 
 
Figure 7: Longitudinal follow-up of disease development in recipient mice after AT. 
Progression of lymphocytosis was assessed by blood smears. (A) 3 month old B6 TCL1 
transgenic males (n=5) and females (n=4) were injected with 4x107 cells from a single aged 
donor mouse with CLL, and bled every ten days. Non-transplanted transgenic female littermates 
were bled at the same time intervals as controls. Two males exhibited slower disease 
progression and were found dead on d24 (*) and d72 (**). Post-mortem examination showed 
clear signs of CLL (i.e. splenomegaly), indicating that AT was successful in all recipients. (B) 4 
month old C3H TCL1 transgenic males (n=5) and females (n=4) were injected with 4x107 cells 
from a single aged donor mouse with CLL, and bled in regular time intervals. Longitudinal blood 
smears demonstrated progressive lymphocytosis, indicating that CLL can be engrafted in both 
TCL1 backgrounds.  
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We next wanted to know if AT would lead to similar results in non-leukaemic TCL1 
transgenic and WT recipients. We therefore injected cells from a pool of aged, 
leukaemic B6 TCL1 mice into age- and sex-matched young, non-leukaemic transgenic 
mice and WT littermates, and followed disease development by blood smears and 
regular physical examination of spleen sizes. Control transgenic and WT littermates 
were injected with a pool of normal spleen B cells and sacrificed at identical time 
points. In mice that received CLL cells, there was no significant difference between WT 
and TCL1 recipients in the progression rate of lymphocytosis (Figure 8 A), spleen:body 
weight ratio (Figure 8 C) and percentage of CD19+CD5+ lymphocytes in spleen (Figure 
8 D). One WT recipient of CLL cells, in which the i.v. injection had been very 
challenging and likely led to the application of a lower cell dose, was censored from the 
study on day 60 with developing lymphocytosis, and sacrificed on day 90. Flow 
cytometry demonstrated a CLL content of 25% in the spleen, with beginning CLL-
typical T-cell phenotypic defects, with the healthy control mouse showing normal B- 
and T-cell subset distribution. This confirmed that engraftment had been successful, 
but that the longer latency was most likely related to the application of a suboptimal 
donor cell dose.  
Survival after AT was not statistically different between males and females (data not 
shown), and there was no difference in survival between WT and TCL1 recipients, 
although these comparisons are based on limited numbers of mice (Figure 8 B). After 
we confirmed successful engraftment in a second group of young WT recipients 
(experiment 9, Table 7), we concluded that WT mice can replace TCL1 mice as 
recipients in AT experiments. As B6 WT mice are readily available from commercial 
sources, this eliminates the need to breed and maintain a large stock of younger TCL1 
mice in addition to ageing mice.  
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Figure 8: Comparison of AT into young TCL1 transgenic and WT recipients. AT into 4 
month old transgenic and sex-matched WT littermates reliably induced CLL in all recipients. (A) 
Longitudinal blood smears performed every ten days demonstrated similar progression of 
lymphocytosis in WT and TCL1 recipients. (B) Leukaemic mice were sacrificed after a median 
time of 5.8 (WT recipients) and 5 (TCL1 recipients) weeks, with no difference between groups 
(HR .288, 95%CI .05-1.54, p=.1439). At the endpoint, spleen:body weight ratio (C) and 
%CD19+CD5+ lymphocytes in spleen (D) were comparable between WT and TCL1 recipients.   
 
We then sought to improve the AT procedure further by reducing the number of i.v. 
injections to a single injection, while maintaining the total dose of 4x107 cells. The goals 
were to reduce animal stress by eliminating a second invasive procedure while also 
reducing the likelihood of a potentially failed injection leading to the application of a 
suboptimal dose of cells. Male and female WT recipients were randomized to a single 
injection of 4x107 cells (1x), or to two injections of 2x107 cells each within 3 days of 
each other (2x), using the same donor pool for all recipients. As observed in previous 
experiments, females appeared to have a faster progression of lymphocytosis, but this 
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was not statistically significant. Both 1x and 2x injections produced reliable and similar 
rates of disease development (Figure 9 A). At the endpoint, there was no difference 
between 1x and 2x recipients in spleen:body weight ratio (p=.9705) and relative 
percentage of CD19+CD5+ lymphocytes in spleen (p=.9517) (Figure 9 B), thus 
validating the use of a single injection while maintaining a total dose of 4x107 cells. 
These findings were confirmed in a second group of young WT recipients (experiment 
11, Table 7). 
 
 
Figure 9: Improvement of AT model by reducing the number of i.v. injections to a single 
injection. (A) Longitudinal blood smears performed in regular intervals demonstrated very 
similar progression of lymphocytosis in all recipients. Females appeared to have a shorter time 
to lymphocytosis but this difference did not reach significance. (B) At the endpoint, spleen:body 
weight ratio and spleen CLL load were comparable between 1x and 2x recipients.  
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CLL was extremely reliably induced across all AT experiments, with only two out of 115 
transplanted animals failing engraftment. The median time between AT and fully 
developed CLL meeting predefined endpoint criteria as described in Chapter 3.1 was 7 
weeks (range 3.71-20, Figure 10 A). There were no differences in outcome between 
mice receiving cells from a single donor (n=36) and those receiving cells from a pool of 
donors (n=31) (HR .7842, 95% CI .4561-1.348, Figure 10 B). Splenic CLL load, defined 
as the percentage of CD19+CD5+ lymphocytes among spleen mononuclear cells and 
measured at the endpoint, was highly significantly correlated with spleen weight, 
indicating that the estimation of spleen size by palpation is an adequate parameter to 
determine the disease status of individual mice, with the caveat that inter-examiner 
heterogeneity might exist due to different levels of experience or interpretations 
(spearman r .7936, p<.0001, Figure 10 C). This can however be limited by setting up 
and following rigorous previously defined guidelines. In addition, increasing spleen 
weight and weeks after AT were significantly correlated (spearman r .7196, p<.0001, 
Figure 10 D), indicating that longer time with CLL translates into higher spleen weight 
as a surrogate for disease load. While some variability exists and is likely dependent on 
the biology of the transplanted disease as well as the gender of the recipient animal, 
this correlation allows reasonable estimation of when drug intervention should be 
initiated (i.e. early intervention at an earlier stage of disease versus later intervention at 
fully developed CLL). In sum, these experiments outline a reliable strategy for 
modelling CLL in mice by AT. 
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Figure 10: Reproducibility of and survival after AT: (A) Across consecutive experiments 
using different donors, AT led to consistent disease development in recipient mice (median 
survival 7 weeks, range 3.71-20). (B) Cells from a single donors (n=36 recipients) and cells 
pooled from several donors (n=31 recipients) produced comparable outcomes (HR .7842, 95% 
CI .4561-1.348). (C) The relative frequency of spleen CD19+CD5+ lymphocytes was highly 
significantly correlated with spleen weight. (D) Increasing spleen weight and weeks after AT 
were significantly correlated with each other. 
 
4.5 Discussion 
This fundamental optimization work has led to the establishment of an efficient and 
well-characterized TCL1 mouse colony and has allowed us to implement the necessary 
breeding, genotyping and ageing procedures in our centre. It has consolidated i.v. 
transplantation procedures, which previously were poorly defined, to reliably generate a 
CLL phenotype in previously disease-free transgenic mice on both the original C3H 
and the backcrossed B6 background. Furthermore, this work has optimized and 
standardized AT methodology by validating the use of young WT recipients and by 
reducing the number of required injections in controlled and randomized experiments. 
Together, these studies provide a reproducible and far more feasible approach for 
using the TCL1 mouse model in CLL preclinical research. This work will enormously 
facilitate the in vivo evaluation of novel agents as well as the investigation of immune 
defects in the context of developing disease, and approaches to repair them.  
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In contrast to the majority of published studies using AT in immunocompetent 
recipients, our transplantation strategy consists of higher cell doses and also uses a 
different application route. In initial reports, up to 106 and 107 spleen MNC were applied 
once by intraperitoneal (i.p.) injection214, 215. More recent publications administered 1.5 
to 2x107 MNC in up to 4 i.p. injections220, 227. Successful AT in SCID or TCL1 model 
variations using similar doses and application routes has been demonstrated by 
several other groups65, 231, 260, 261, although the specifics of these experiments vary 
substantially, and comparison of results between laboratories is therefore challenging. 
Similar to our strategy, Woyach et al. injected XID and B6 mice with 5x106 to 5x107 
cells i.v.228.  
In general, higher cell doses led to faster disease development and consequently 
shorter survival of animals. Animals that received 106 MNC had a median survival of 
166 days, while animals transplanted with 107 MNC in the same study survived for a 
median of 121 days214. Previous experiments from our group used a total of 1x108 cells 
injected i.v., which led to CLL-associated molecular T-cell defects after a latency of just 
8 days216. To achieve maximal experimental efficiency while being able to study the 
immune modulating effect of drug treatment, a short latency of disease that still leaves 
enough time for immune defects to develop is valuable. In view of these results, the 
dose and administration route selected and validated in this work balance these 
potentially conflicting experimental requirements and provide a solid basis for 
preclinical testing of immune modulating mechanisms of actions of novel drugs. 
In the current study, we demonstrate that virtually all mice exhibit fully developed CLL 
after a median of 7 weeks following AT. Although some mice had a later onset of 
disease (e.g. two males in experiment 6, and one male in experiment 8), all eventually 
succumbed to disease after showing signs of progressive CLL assessed by spleen size 
and lymphocytosis following previously defined criteria. This latency can most 
reasonably be explained by suboptimal injections leading to application of lower donor 
cell numbers. In general, CLL development was very consistent within single 
experiments. This was even further improved after reducing the number of injections, 
thus reducing the likelihood of suboptimal injections. However, variability between 
different experiments could also be due to the biology of the donor disease. Such 
differences in disease onset are common even within closely related TCL1 transgenic 
mice, suggesting that as-yet unidentified variables within individual animals influence 
the aggressiveness of leukaemia development. These experiments also frequently 
suggested a faster progression of disease in female mice; however, this difference was 
not statistically different even when combining data from all experiments. 
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5 Investigation of T-cell dysfunction in Eµ-TCL1 mice on the B6 background 
5.1 Specific introduction 
As described in Section 1.2.1, our group previously demonstrated that development of 
CLL in TCL1 mice is associated with global T-cell defects similar to those observed in 
human patients216. While expression of the TCL1 transgene in B cells had no effect on 
T cells before the development of CLL, with non-leukaemic mice exhibiting normal T-
cell numbers and function, development of CLL (i.e. expansion of CD5+CD19+ B cells) 
led to various T-cell defects. These included decreased in vivo antigen-specific T-cell 
activation, suppressed T-cell proliferation, and impaired induction of idiotype-specific 
CD8+ cytotoxic T-cells. T-cell lymphokine production was also dysfunctional and 
appeared Th2 preponderant. Gene-expression profiling of T cells from TCL1 mice with 
CLL revealed several differentially expressed genes in both CD4+ and CD8+ cells 
compared to those from WT or non-leukaemic transgenic mice. These were mostly 
involved in pathways of cell proliferation, differentiation, effector function, and actin 
cytoskeleton formation. With increasing tumour burden, these changes became more 
evident, again correlating with findings in human CLL. The causal relationship between 
leukaemia and induction of T-cell defects was demonstrated by the finding that AT of 
CLL cells into young disease-free mice rapidly induced the molecular T-cell changes 
observed in ageing TCL1 mice with CLL.  
In these original experiments, TCL1 mice on the original B6C3H-F1 background were 
used. B6C3H-F1 mice are hybrids produced by crossing mice of the two inbred strains 
C57Bl/6 (B6) and C3H [source: http://research.jax.org/grs/type/hybrid/index.html, 
accessed 17.10.11]. Although F1 hybrid mice are genetically and phenotypically 
uniform and possess great vigour, they are heterozygous at all loci for which their 
parents have different alleles. When mating F1 mice to produce F2 offspring, litters will 
therefore all have a unique random mixture of alleles from both parental strains, which 
will be further mixed in consecutive generations. To obtain a uniform genetic 
background, TCL1 mice on the B6C3H-F1 background were backcrossed over more 
than 10 generations to a pure B6 background. More important than eliminating the 
possibility that such genetic diversity might have an effect on immune responses, mice 
on a pure B6 background can more easily be crossed with other disease models, for 
example PD-L1 knockout mice, which will be an integral component of future 
experiments. Once the backcross was established, only a single study has examined 
T-cell dysfunction in B6 TCL1 mice by looking at T-cell subset composition changes in 
lymph nodes and peripheral blood220. In this report, TCL1 mice with manifest CLL had 
increased absolute T-cell numbers and exhibited a shift from naïve to antigen-
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experienced CD4+ and CD8+ T cells compared to age-matched WT controls, which 
was more pronounced in lymph nodes than in peripheral blood. These preclinical 
observations are largely in line with T-cell subset alterations in peripheral blood in 
human CLL, as described in Chapter 1.1.4. However, peripheral blood and secondary 
lymphoid organs and bone marrow have entirely different and distinct 
microenvironments based on their physiological roles in supporting lymphocyte 
maturation and differentiation. The importance of these tissue microenvironments for 
the interaction with CLL cells was recently explored by Mittal et al.380. The comparison 
of gene expression profiles of purified CLL cells from peripheral blood, bone marrow 
and lymph nodes revealed that gene signatures representing pathways critical for 
survival and activation of B cells were altered in different tissue compartments. Genes 
associated with the BCR, BAFF/APRIL and NF-κB pathway and immune suppression 
were enriched in lymph nodes, suggesting that they might be the primary site for 
tumour growth. In contrast, blood CLL cells overexpressed chemokine receptors, while 
their cognate ligands were enriched in secondary lymphoid organs and bone marrow. 
Bone marrow signatures were also enriched with antiapoptotic, cytoskeleton and 
adhesion molecules, and in TCL1 mice, a high percentage of leukaemic cells from the 
lymphoid compartment expressed key BCR and NF-κB molecules.  
The importance of different microenvironments on T-cell defects is however not well 
understood, and it is not clear to what extent T-cell defects described in the peripheral 
blood of CLL patients or TCL1 mice directly mirror the defects in other 
microenvironments. Moreover, it is possible that T-cell defects might be influenced by 
differences in CLL load in different compartments, or are subjected to dynamic 
changes while CLL develops or progresses. These questions have not been fully 
answered to date; Hofbauer et al.220 focused their characterization of T-cell subsets to 
peripheral blood and lymph nodes, but excluded spleen. However, the spleen is 
considered the major organ of disease in this model, and preclinical characterization 
studies such as the T-cell work from our group216, or studies investigating the effect of 
therapeutic interventions265, are generally done using splenocytes from TCL1 mice. In 
addition, this characterization was only done in a small number of moribund aged TCL1 
mice and in mice that became ill after a very long latency of 3 to 6 months after 
adoptive transfer, resulting in a large biological range of overall CLL disease load which 
might have biased the exploration of their effect on the T-cell compartment. In addition, 
a careful and thorough longitudinal investigation of the development of not only 
phenotypic T-cell subsets, but also functional T-cell defects alongside progressing 
disease has not been conducted.  
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5.2 Goals and objectives 
My next goal was therefore to fully validate the B6 TCL1 model for the investigation of 
global T-cell defects, to further characterize T-cell subsets in the context of advancing 
CLL in all CLL affected compartments, and to explore the impact of developing CLL on 
effector T-cell function. Specifically, I sought to address the following questions:  
 Do leukaemic B6 TCL1 mice recapitulate T-cell dysfunction previously observed in 
leukaemic B6C3H-F1 TCL1 mice? 
 Can AT into young TCL1 transgenic and WT B6 mice be used to model the T-cell 
dysfunction observed in leukaemic TCL1 mice?  
 How do T-cell defects develop in vivo in relation to CLL development? 
 Are T-cell defects observed in spleen representative of T-cell defects in other 
secondary lymphoid organs and in the peripheral blood?   
 
5.3 Specific methods and materials 
5.3.1 Mice and examined organs 
In addition to gene expression profile and effector function, T-cell subset composition 
appears to be quite similar in human patients and mice with CLL. We therefore used T-
cell subsets as a surrogate marker for global T-cell dysfunction to compare ageing 
TCL1 mice on the B6C3H-F1 background to ageing TCL1 B6 mice, and to validate the 
AT model to adequately mirror the defects seen in ageing CLL in both backgrounds. 
Three, 6 and 12 month old TCL1 mice on both backgrounds with confirmed presence 
of the TCL1 transgene by genomic PCR were selected from our colony. The mice 
selected were mostly littermates, with males and females being well balanced. To 
minimize the likelihood of a batch effect, experiments were repeated in a second group 
of 3, 6, and 12 month old B6 TCL1 mice and in 3 month old B6C3H-F1 TCL1 mice. 
Additional 6 and 12 month old B6C3H-F1 TCL1 mice were not examined as the 
breeding of this background was already terminated based on the clear findings of the 
first cohort. In collaboration with our Animal Technician Service (ATS), we 
cryopreserved sperm from young B6C3H-F1 TCL1 males before terminating the line. 
Sperm was confirmed to be viable and fertile after freezing/thawing as demonstrated by 
the ability to induce a two-cell stage embryo development, which will allow us to quickly 
recover the line should the need arise. The disease and T-cell phenotype in AT mice 
was examined using mice from experiments 5, 6, 7 and 11 (as described in Chapter 4). 
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Age- and sex-matched WT mice were purchased from commercial suppliers. Mice 
were sacrificed at the required age under protocol 19b2 of PIL 70/7531, and peripheral 
blood (PB), lymph nodes (LN), bone marrow (BM) and spleens were harvested and 
processed as described in Chapter 3.1.4.  
After optimization of functional T-cell assays, a third round of experiments confirming 
phenotypic changes, expanding the phenotype panel to include further subsets, and 
investigating T-cell function in spleen was conducted using 3, 6 and 12 month old B6 
TCL1 mice, AT mice, and age- and sex-matched WT controls from commercial 
suppliers. An overview of all cohorts of mice including numbers, as well as their usage 
and availability of organs for specific experiments is provided in Table 8.   
 
I. Available mice to assess T-cell phenotype in spleen alongside developing CLL 
 
CLL in spleen T-cell phenotype 
 
3mo 6mo 12mo AT 3mo 6mo 12mo AT 
B6 WT 
1
a
 n=6 2
a
 n=6 3
a
 n=4 4
a 
n=6 1
a
 n=6 2
a
 n=6 3
a
 n=4 4
a 
n=6 
1
b
 n=6 2
b
 n=6 3
b
 n=4 not repeated 1
b
 n=6 2
b
 n=6 3
b
 n=4 not repeated 
B6 TCL1 
5
a
 n=6 6
a
 n=6 7
a 
n=6 8
a 
n=6 5
a
 n=6 6
a
 n=6 7
a 
n=6 8
a 
n=6 
5
b
 n=6 6
b
 n=6 7
b
 n=6 8
b
 n=4 5
b
 n=6 6
b
 n=6 7
b
 n=6 8
b
 n=4 
C3H TCL1 
9
a 
n=6 10
a
 n=6 11 n=6 12 n=5 9a n=6 10a n=6 11 n=6 12 n=5 
9
b
 n=6 not repeated not repeated not repeated 9
b
 n=6 not repeated not repeated not repeated 
II. Available mice to assess T-cell function in spleen alongside developing CLL 
 
CLL in spleen T-cell function 
 
3mo 6mo 12mo AT 3mo 6mo 12mo AT 
B6 WT 1funct n=6 2funct n=6 3funct n=6 4funct n=10 1funct n=6 2funct n=6 3funct n=6 4funct n=10 
B6 TCL1 5funct n=6 6funct n=6 7funct n=6 not done 5funct n=6 6funct n=6 7funct n=6 not done 
III. Available mice to assess T-cell phenotype in organs alongside developing CLL 
 
CLL in BM, PB, LN T-cell phenotype 
 
3mo 6mo 12mo AT 3mo 6mo 12mo AT 
B6 WT 
1
a
 n=6 2
a
 n=6 3
a
 n=4 4
a 
n=5 1
a
 n=6 2
a
 n=6 3
a
 n=4 4
a 
n=5 
1
funct
 n=6 2
funct
 n=6 3
funct
 n=6 4
funct
 n=10 1
funct
 n=6 2
funct
 n=6 3
funct
 n=6 4
funct
 n=10 
B6 TCL1 
5
a
 n=6 6
a
 n=6 7
a 
n=6 8
a 
n=6 5
a
 n=6 6
a
 n=6 7
a 
n=6 8
a 
n=6 
5
funct
 n=6 6
funct
 n=6 7
funct
 n=6 not done 5
funct
 n=6 6
funct
 n=6 7
funct
 n=6 not done 
Table 8: Summary of all cohorts of mice used to validate and further characterize T-cell 
defects in spleen and other organs. Abbreviations: mo – months, AT – adoptive transfer, B6 – 
C57Bl6, WT – wild type, C3H – B6C3H-F1, BM – bone marrow, PB – peripheral blood, LN – 
lymph nodes. 
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5.3.2 Multicolour flow cytometry for cell surface markers 
As in humans, murine CD3ε expression is correlated with T-cell maturation, and the 
CD8+ and CD4+ molecules are used for identification of helper and cytotoxic T cells381. 
Antigen-experienced T-cell markers include CD44, CD62L, and CD45RB. CD62L (L-
selectin) is a peripheral lymph node homing receptor382. As a marker of T-cell 
development it is expressed on naive and memory T cells, while effector cells 
downregulate CD62L and can also express a diverse set of homing receptors to enable 
them to pass through non-lymphoid tissues383, 384. Murine CD44 and CD45RB 
correspond to human CD45RO as markers of antigen-experienced T cells, and are 
highly expressed on memory and effector T cells385-387. The concept of CM and EM 
cells was introduced in in 1999388. Both are functional subsets within CD45RO memory 
cells in humans, but show differences in their anatomical location, expression of cell 
surface markers and functional responses. Mice contain a comparable CD44+ cell 
population after clearance of acute viral infection, fitting the description of CM cells, and 
CD44RB-CD44+CCR7-CD62L- T cells, fitting the description of EM cells389. In our 
experiments, T-cell subsets were characterized based on the surface expression of 
CD3, CD4, CD8, CD62L, CD44 and CCR7, and CLL by CD19 and CD5. Information on 
antigens, fluorochromes, clones, concentrations and suppliers is listed in Table 9.  
 
 mouse antigen fluorochrome clone concentration host/isotype supplier 
T-cell 
phenotype 
CD3e APCCy7 17A2 0.2 mg/ml rat IgG2bκ Biolegend 
CD4 PerCPCy5.5 RM4-5 0.2 mg/ml rat IgG2aκ eBioscience 
CD8a FITC 53-6.7 0.5 mg/ml rat IgG2aκ eBioscience 
CD62L APC MEL-14 0.2 mg/ml rat IgG2aκ eBioscience 
CD44 PE IM7 0.2 mg/ml rat IgG2bκ eBioscience 
extended 
T-cell 
phenotype 
 
CD3e APCCy7 17A2 0.2 mg/ml rat IgG2bκ Biolegend 
CD4 PerCPCy5.5 RM4-5 0.2 mg/ml rat IgG2aκ eBioscience 
CD8a BV605 53-6.7 0.5 mg/ml rat IgG2aκ Biolegend 
CD62L FITC MEL-14 0.2 mg/ml rat IgG2aκ eBioscience 
CD44 AF700 IM7 0.2 mg/ml rat IgG2bκ eBioscience 
CCR7 PeCy7 4B12 0.2 mg/ml rat IgG2aκ eBioscience 
CLL 
CD5 APC 53-7.3 0.2 mg/ml rat IgG2aκ eBioscience 
CD19 FITC eBio1D3 0.5 mg/ml rat IgG2aκ eBioscience 
Table 9: Summary of antigens, fluorochromes, clones, concentrations and suppliers 
used to assess T-cell subsets in relation to CLL. 
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Cells were prepared for flow cytometry as described in Chapter 3.4, with the exception 
of CCR7, which required different conditions due to continuous recycling of chemokine 
receptors: cells were stained at 37ºC at 5% CO2 for 20 minutes, followed by staining 
with the remaining fluorochrome cocktail for 20 minutes at room temperature. Cells 
were then washed and processed as described in Chapter 3.4.1. Optimization 
experiments demonstrated that this resulted in better resolution between positive and 
negative populations, and that this could be achieved by using a 4:100 dilution (see 
Figure 11).  
 
 
Figure 11: Optimization of CCR7 4B.12 antibody. (A) TCL1 spleen cells were stained with a 
cocktail of anti-CD3, 4, 8, 44, 62L and CCR7 antibodies (full stain) for 20 minutes at room 
temperature (RT), at 37ºC, or with CCR7 for 20 minutes at 37ºC followed by 20 minutes staining 
at RT with the remaining cocktail. Fluorescence-minus-one (FMO) controls for CCR7 were 
included for all conditions. Incubation at 37ºC resulted in better resolution of positive and 
negative populations, and could be further improved by consecutive 37ºC/ RT staining. (B) WT 
and TCL1 spleen cells were then stained at 37ºC for 20 minutes followed by 20 minutes RT for 
the remaining cocktail using decreasing concentrations of CCR7. 3 to 5µl resulted in 
comparable resolution of CCR7+ populations, while brightness measured by median 
fluorescence intensity of CCR7-PeCy7 was not enhanced (C). 
 
Samples were acquired on a BD LSRII. Stopping gates were set to record at least 
12,000 CD3+CD8+ events. An example of the gating strategy to identify naive vs. 
antigen-experienced effector and memory, as well as CM and EM CD8 T cells, is 
depicted in Figure 12. Cells were gated on viable (i.e. DAPI-negative) single 
mononuclear cells (MNC) (Figure 12 B). CD4 and CD8 were gated on CD3+ 
lymphocytes (Figure 12 C), and CD8 subsets were gated on CD3+CD8+ MNC. Naïve 
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cells were identified as CD44low+CD62L+ and antigen-experienced cells as CD44+, 
with memory cells being CD62L+CD44high+ and effector cells being 
CD44medium/high+CD62low+. EM and CM cells were characterized based on 
CD62L/CCR7 expression. FMO controls for CD44 and CCR7 were included in all 
experiments (Figure 12 D).  
 
 
Figure 12: Gating strategy to identify naive vs. antigen-experienced effector, memory, 
central memory (CM) and effector memory (EM) CD8 T cells. (A) Summary of expression 
patterns and surface antigens to identify cell subsets. (B) Cells were gated on DAPI-negative 
single mononuclear cells (MNC). (C) CD4 and CD8 were gated on CD3+ MNC. (D) Naïve, 
antigen-experienced (Ag-exp.), EM and CM cells were gated on CD3+CD8+ MNC, and 
fluorescence-minus-one (FMO) controls for CD44 and CCR7 were included in all experiments. 
 
5.3.3 Multicolour flow cytometry for intracellular cytokines and effector 
function 
For these studies, T-cell subsets were characterized based on the surface expression 
of CD3, CD8 and CD44 to allow a basic discrimination between naïve CD44- and 
antigen-experienced CD44+ cells. Cytotoxicity was assessed by measuring CD107a 
effector cell degranulation and intracellular Granzyme B (GrB). Intracellular IFN-γ, IL-2 
and IL-4 were selected as representative Th1/Th2 cytokines and cytokines that our 
group has identified to be aberrantly produced by CD8+ T cells in humans133. Ex vivo 
proliferation was measured by intranuclear ki67. Information on antigens, 
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fluorochromes, clones, concentrations and suppliers is listed in Table 10. Up to 1x106 
fresh spleen cells were kept in 250µl RPMI 1640 with 10% FCS (Sigma), 1% 
Penicillin/Streptomycin, 1% Glutamine (both LifeTechnologies), and 500mM beta-
mercaptoethanol (Gibco) in round-bottom 96-well-plates (VWR). 5µg/ml CD107a was 
added to each well, and cells were stimulated with 500X PMA/Ionomycin cell 
stimulation cocktail (eBioscience, UK) for 6 hours at 37ºC/5% CO2, while 500X 
brefeldin A/monensin protein transport inhibitor cocktail (eBioscience, UK) was added 
for the last 5 hours of culture. Controls included wells with CD107a and protein 
transport inhibitor cocktail, but no cell stimulation cocktail, for each mouse. After the 
incubation, cells were harvested and processed as described in Chapter 3.4.2. Cells 
were then washed, and unstimulated wells were split for cytokine and ki67 stains. After 
fixation and permeabilisation as described in Chapter 3.4.2, cells were stained with 
intracellular and intranuclear antibodies for 1h at 4ºC at a 1:100 dilution. All steps were 
performed in a 96-well plate. 
 
 mouse antigen fluorochrome clone concentration 
host/ 
isotype 
supplier 
surface stain 
CD3e APCCy7 17A2 0.2 mg/ml rat IgG2bκ Biolegend 
CD8a BV605 53-6.7 0.5 mg/ml rat IgG2aκ Biolegend 
CD44 AF700 IM7 0.2 mg/ml rat IgG2bκ eBioscience 
cytotoxicity 
CD107a PE eBio1D4B 0.2 mg/ml rat IgG2aκ eBioscience 
GrB e450 NGZB 0.2 mg/ml rat IgG2aκ eBioscience 
intracellular 
cytokines 
IFN-γ AF488 XMG1.2 0.5 mg/ml rat IgG2aκ eBioscience 
IL-2 PeCy7 
JES6-
5H4 
0.2 mg/ml rat IgG2bκ eBioscience 
IL-4 PerCPefl 710 11B11 0.2 mg/ml rat IgG1κ eBioscience 
proliferation ki67 PeCy7 SolA15 0.2 mg/ml rat IgG2aκ eBioscience 
Table 10: Summary of antigens, fluorochromes, clones, concentrations and suppliers 
used to assess T-cell function in relation to CLL. 
 
IFN-γ, IL-2 and IL-4 were gated on CD3+ viable single MNC and plotted against CD8 
(Figure 13 A). CD107a, GrB and IFN-γ were gated on viable single CD3+CD8+ MNC 
and plotted against CD44 (Figure 13 B). Unstimulated cells were used as internal 
controls to determine correct gate positions. Ki67 was plotted against CD44 and gated 
on CD3+CD8+ viable single MNC, with FMO ki67 as control (Figure 13 C). CD44 was 
included as a marker to discriminate between naïve and antigen-experienced cells. 
Stopping gates were set to CD3+CD8+ cells to record at least 10,000 events, or until 
the sample had been fully aspirated, whichever occurred first. Differences in T-cell 
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function between mice with CLL and age-matched WT mice, and between mice of 
different age groups, were compared by calculating ratios between CD44+ antigen-
experienced cells positive for a cytokine/CD107a/GrB/ki67 and CD44+ antigen-
experienced cells negative for the same marker. Similar comparisons were made, 
where applicable, among CD44- naïve cells (Figure 13 D). Biologically, this describes 
differences and changes in cell subsets that maintain the ability to exert effector cell 
function compared to cells of the same subset that do not have this ability within one 
experimental group. In the context of shifting overall cell subsets with CLL compared to 
WT, direct comparisons of e.g. CD44+CD107a+ cells of leukaemic mice to 
CD44+CD107a+ cells of healthy mice might be less accurate, and are likely to not 
properly reflect the true biological impact of such changes.  
 
 
Figure 13: Gating strategy for functional T-cell assays. (A) Intracellular cytokines were 
gated on CD3+ viable single MNC, plotted against CD8, and compared between unstimulated 
and mitogen-stimulated cells for each animal. (B) Effector cell cytotoxicity was gated on 
CD3+CD8+ viable single MNC, plotted against CD44 and compared between unstimulated and 
mitogen-stimulated cells for each animal. (C) Intranuclear ki67 was gated on CD3+CD8+ viable 
single MNC and plotted against CD44. (D) Because of overall shifting cell subsets with CLL 
development and additional dynamics in the context of ageing (as depicted in the graph), 
changes in T-cell effector function were compared by calculating ratios between cytotoxic cells 
(CD107a+, selected as an example but representative for cytokines, GrB and ki67) and non-
cytotoxic cells (CD107a-) among CD44+ or CD44- subsets within one experimental group. The 
ratios of experimental groups were then compared to each other to describe changes in the 
ability of cells to exert certain effector functions.  
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5.3.4 Multicolour flow cytometry for in vivo proliferation 
In addition to intranuclear ki67, we measured in vivo proliferation by EdU incorporation. 
Preparation of EdU, injection of mice, and processing of samples and cells are 
described in Chapter 3.4.4.2.3. Cells were surface stained with CD19 v450 (clone 1D3, 
BD, UK), CD5 PE (clone 53-7.3, eBioscience, UK), CD8 BV605 (clone 53-6.7, 
Biolegend, UK) and PD-1 APC (clone RMPI1-30, eBioscience, UK) for 20 minutes at 
room temperature, washed again and resuspended in 300µl FACS buffer. Samples 
were acquired on a BD LSRII, cells were gated on single MNC, and stopping gates 
were set to CD5+ cells. CD5 was plotted against CD19 to discriminate between double 
positive CLL cells, CD19+ B cells, and CD5+ T cells. CD8+ and CD8- cells were then 
gated on CD5+ cells. An example of the gating strategy is shown in Figure 14. 
Proliferating cells were identified as Alexa488 positive populations, based on negative 
internal controls without Alexa488 in the Click-iT cocktail.  
 
 
Figure 14: Gating strategy for EdU in vivo proliferation. Fixed and permeabilised spleen 
cells were incubated with a Click-iT reaction cocktail with and without Alexa488 azide dye, 
followed by surface staining for CD5, 19 and 8. Cells were gated on single MNC, and B, T and 
CLL cells were identified based on CD19 and CD5 expression. B-cell and T-cell proliferation, as 
well as CLL proliferation (not shown in these plots as example is taken from 3 month old WT 
mouse without a CLL population) were assessed by Alexa 488 expression. Gates were 
determined based on samples without Alexa488 staining.  
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5.4 Results 
5.4.1 CLL progressively develops in transgenic TCL1 mice but shows 
considerable biological diversity, and can be consistently induced by AT in 
peripheral blood and secondary lymphoid organs 
While young TCL1 mice on both backgrounds were free of CLL, at the age of 6 
months, single cell suspensions from spleen, PB, and BM, but not LN started to be 
enriched for CD19+CD5+ cells. This progressed further with ageing in both the B6 and 
C3H backgrounds as expected, but considerable biological diversity was observed: 
among the 12 month old TCL1 cohorts examined, the median CLL load in spleen was 
16.5% in group 7a (see Table 8), 62.4% in group 7funct and 32.3% in group 11, with 
ranges of 8.4-25.8% (group 7a), 8.2-76.8% (group 7funct) and 9.8-77.8% (group 11). 
Similarly wide ranges were detected in other organs, but spleen and PB appeared to 
be the major compartments/organs of disease, exhibiting the highest median 
percentages of CD19+CD5+ cells. While these observations validate the backcrossed 
B6 background, they also underscore the differences in disease behaviour and indicate 
that even within littermates, some mice can already have late-stage CLL whereas 
others can still be found to have a relatively low burden of disease. In experiments 
using aged-matched WT mice, we routinely confirmed the absence of CLL in all 
examined organs.  
As described in Chapter 4, AT resulted in consistent CLL development in virtually all 
recipient mice. Uniformity of disease load was superior to ageing TCL1 mice, even 
when combining different AT experiments with different donors into the same analysis. 
The only exception were LNs, where the relative frequency of CD19+CD5+ 
lymphocytes was lower than in 12 month old leukaemic TCL1 mice (AT median 2.4%, 
range 0.3-21.9, versus 12 month TCL1 median 7.0%, range 1.6-16.6, p=.0083). 
However, LNs also appeared to have a longer disease latency and lagged behind other 
organs in ageing leukaemic TCL1 transgenic mice, as there was no difference in LN 
disease involvement between 3 month old (median 0.7%, range 0.3-1.8) and 6 month 
old (median 0.6%, range 0.4-4.8) transgenic mice (p=0.4023). Thus, although AT might 
not mirror the rate of leukaemic development in LNs observed in ageing TCL1 
transgenic mice, this model still appears more than adequate to model immune cell 
interactions with the LN microenvironment.  
We conducted all comparisons in individual ageing TCL1 transgenic mice and AT 
mouse cohorts separately. As the overall trend was found to be very similar within 
cohorts, making the existence of a batch effect unlikely, we combined cohorts for 
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statistical analyses to consolidate their statistical power. Figure 15 A depicts a 
summary of CLL development in combined cohorts of different age groups. Data is 
depicted as median with interquartile range. Figure 15 B summarizes statistical 
differences in the relative expansion of the CD19+CD5+ cell subset compared to 3 
month old TCL1 mice as baseline. 
 
 
Figure 15: CLL development in ageing TCL1 mice and after AT in peripheral blood (PB) 
and secondary lymphoid organs. PB and single cell suspensions from bone marrow (BM), 
lymph nodes (LN) and spleen (SP) of 3, 6 and 12 month old TCL1 mice and AT mice were 
stained for CD19 and 5 to determine disease load. (A) CLL progressively developed in TCL1 
mice but showed considerable biological diversity. Disease could be more consistently induced 
by AT, but CLL load in LN was lower than in ageing TCL1 mice. Graph depicts median with 
interquartile range (IQR). (B) Heatmap summary of p-values describing statistical differences in 
the organ CLL load. Groups were compared to the relative percentage of CD19+CD5+ cells in 3 
month old mice. Blue colour indicates relative expansion of cell subsets. ns = not-significant; 
*p<.05, **p<.001, ***p<.0001. Mann-Whitney test was used for non-normally distributed data 
and unpaired t-test for normally distributed data, as determined by Shapiro-Wilk normality test. 
 
5.4.2 Developing CLL is associated with significant changes in relative and 
absolute numbers of T-cell subsets in spleen 
We next examined changes in T-cell phenotype in organs from ageing TCL1 transgenic 
and AT mice. Groups of experimental animals are summarized in Table 8 under “I. 
Available mice to assess T-cell phenotype in spleen alongside developing CLL”. We 
first focused on the spleen in B6 and C3H TCL1 mice, and then compared B6 TCL1 
mice to age- and sex-matched B6 WT mice. C3H WT mice were not examined, as the 
primary focus of these experiments was to validate the B6 TCL1 by direct comparison 
of relative patterns to the C3H TCL1 model, and then compare relative and absolute 
changes between B6 TCL1 to WT mice in a second step. In addition, our colony did not 
produce sufficient numbers of C3H WT littermates to allow us to easily include them as 
controls, as we had received C3H TCL1 mice bred to homozygosity from our 
collaborators. Although we altered the breeding strategy for the B6 background by 
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breeding TCL1 mice with WT mice, as discussed in the previous chapter, we did not 
pursue this for the C3H background due to time and cost considerations. For the same 
reason, we decided against purchasing aged B6C3H-F1 WT mice from commercial 
suppliers, as we believed this would not have added significant information to further 
the project.  
In ageing transgenic mice of both backgrounds, we observed a loss in the percentage 
of CD3+ T cells among all lymphocytes with increasing CLL burden, with the greatest 
range at the age of 12 months (data not shown), which is in line with the biological 
diversity of CLL development described in Chapter 5.4.1. Within CD3+ cells, the 
CD4+/CD8+ ratio decreased with developing CLL (Figure 16 A) as a result of a 
combination between an expansion of CD3+CD8+ cells and a reduction of CD3+CD4+ 
cells (data for percentages of CD3+, CD4+ and CD8+ cells not shown). This was more 
clearly recapitulated in ageing B6 TCL1 than in C3H TCL1 mice, and could be induced 
by AT in young TCL1 mice as well as in young WT mice. In ageing WT mice, the 
relative frequencies of CD3+ and CD4+ cells were constant, but CD8+ cells were lost. 
This led to an increase of the CD4+/CD8+ ratio (Figure 16 A), which is in marked 
contrast to the CLL-driven inversion observed in TCL1 mice. In line with the CLL-
associated organomegaly, absolute numbers of CD3+, CD4+ and CD8+ cells 
increased in ageing B6 TCL1 and after AT in young WT mice, while remaining largely 
constant or being reduced in ageing WT mice (note: analysis of absolute numbers was 
only conducted for B6 TCL1 and WT mice but not for C3H TCL1 mice, Figure 16 B and 
Table 11).  
Within the CD3+CD8+ compartment, naïve T cells were lost (i.e. their percentage 
decreased), and shifted towards antigen-experienced cells (i.e. their percentage 
increased). In 12 month old B6 TCL1 mice, antigen-experienced CD3+CD8+ T cells 
appeared slightly shifted towards a memory phenotype (memory median 54.22% range 
34.16-61.65, effector median 41.56% range 30.88-57.36), but this was not-significant 
(p=.0931), while in 12 month old C3H TCL1 mice and all AT mice these cells were 
more skewed towards an effector phenotype (C3H memory median 23.87% range 
21.22-41.41, effector median 32.49% range 20.75-41.06; AT WT memory median 
10.92% range 7.96-15.69, effector median 54.84% range 51.77-70.88; AT B6 TCL1 
memory median 30.99% range 23.13-40.98, effector median 51.63% range 
29.82=57.94; AT C3H TCL1 memory median 21.99% range 9.08-32.72, effector 
median 53.5% range 51.87-64.46; Figure 16 C). In AT mice, however, the transgene 
status of the recipients (i.e. WT or TCL1) influenced if the relative number of memory 
cells was reduced or expanded. WT recipients appeared to lose memory cells 
Fabienne McClanahan                                                                                                     Chapter 5 
Page 105 of 258 
 
compared to 3 month old WT controls, showing a reduced frequency of 
CD44+CD62L+CD3+CD8+ cells; this population, however, was expanded in young 
TCL1 recipients compared to healthy young TCL1 controls, while 3 month old healthy 
TCL1 (median 17.56%, range 14.6-35.68) and WT (median 19.58%, range 11.58-
32.02) mice showed comparable percentages of memory cells. This observation 
indicates that the expression of the transgene itself might influence memory distribution 
in the context of adoptive transfer. Ageing WT mice also had decreased naïve cells and 
demonstrated a shift towards antigen-experienced cells, with memory and effector 
CD8+ cells being equally distributed (memory median 30.04%, range 15.02-28.35 vs. 
effector median 36.22%, range 27.2-64.66, p=.065, Figure 16 C). 
Similar to absolute numbers of CD3+, CD4+ and CD8+ cells, the absolute numbers of 
effector and memory cells increased in ageing B6 TCL1 and after AT in young WT 
mice, but decreased for naïve CD3+CD8+ T cells in ageing B6 TCL1 mice and 
increased after AT (Figure 16 D and Table 11). Comparing absolute numbers also 
demonstrated that although the relative naïve versus antigen-experienced shift was to 
a certain extent also observed in ageing WT mice, there were clear differences in the 
absolute expansion of effector and memory subsets.  
Statistical differences in the relative expansion of T-cell subsets compared to 3 month 
old mice as baseline are visualized in Figure 16 E. 
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Figure 16: T-cell subset changes in ageing TCL1 mice and after AT in spleen. Cohorts of 3, 
6 and 12 month old TCL1, WT and AT mice were sacrificed and single cell suspensions of 
spleen were stained for CD3, 4, 8, 62L and 44. Dead cells were excluded by DAPI. (A) With 
increasing CLL the CD4+/CD8+ ratio decreased, while age-matched WT mice showed an 
increase of the CD4+/CD8+ ratio. This was more clearly recapitulated in B6 TCL1 than in C3H 
TCL1 mice, but could be induced by AT in both young TCL1 and WT mice. (B) Absolute 
numbers (AN) increased, in line with CLL-associated organomegaly. (C) Within CD3+CD8+ 
cells, naïve cells were lost and shifted towards antigen-experienced cells. Naïve cells were also 
reduced and shifted towards antigen-experienced cells in WT mice. (D) AN of these subsets 
were significantly increased in TCL1 mice. (E) Heatmap summary of p-values describing 
statistical differences in T-cell subsets. Groups were compared to 3 month old mice. Blue colour 
indicates expansion, red colour indicates loss of cell subsets. ns = non-significant, *p<.05, 
**p<.001, ***p<.0001. Mann-Whitney test was used for non-normally distributed data and 
unpaired t-test for normally distributed data, as determined by Shapiro-Wilk normality test. 
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absolute 
numbers of 
cell subset 
B6 WT B6 TCL1 
 
3mo 6mo 12mo 3mo 6mo 12mo AT 
CD3+ 
med 1.56E+07 1.29E+07 9.34E+06 1.49E+07 1.36E+07 5.30E+07 4.31E+07 
min 1.07E+07 7.59E+06 8.01E+06 1.09E+07 1.09E+07 4.44E+07 1.77E+07 
max 1.91E+07 1.43E+07 1.28E+07 1.56E+07 1.83E+07 9.50E+07 5.74E+07 
CD3+ 
CD4+ 
med 3.58E+07 2.89E+07 2.75E+07 3.07E+07 3.00E+07 8.59E+07 3.92E+08 
min 3.30E+07 2.49E+07 2.22E+07 2.39E+07 2.66E+07 6.61E+07 2.92E+08 
max 4.25E+07 3.26E+07 3.52E+07 3.44E+07 4.07E+07 1.33E+08 5.83E+08 
CD3+ 
CD8+ 
med 2.33E+07 1.49E+07 1.29E+07 1.71E+07 2.28E+07 3.17E+08 4.12E+08 
min 1.62E+07 9.56E+06 1.06E+07 1.50E+07 1.91E+07 2.70E+08 3.32E+08 
max 2.88E+07 2.18E+07 1.31E+07 2.14E+07 2.77E+07 5.53E+08 6.86E+08 
CD3+ 
CD8+ 
effector 
cells 
med 6.97E+06 1.28E+07 2.08E+07 1.45E+07 1.97E+07 2.15E+08 5.37E+08 
min 3.58E+06 3.42E+06 1.09E+07 4.99E+06 8.11E+06 1.32E+08 1.40E+08 
max 1.69E+07 3.42E+07 3.10E+07 1.94E+07 3.63E+07 3.92E+08 1.45E+09 
CD3+ 
CD8+ 
memory 
cells 
med 1.65E+07 7.09E+06 1.41E+07 1.08E+07 2.23E+07 2.78E+08 1.96E+08 
min 5.69E+06 1.91E+06 7.21E+06 4.21E+06 1.30E+07 1.71E+08 8.09E+07 
max 3.71E+07 1.21E+07 1.85E+07 1.48E+07 2.95E+07 4.01E+08 9.34E+08 
CD3+ 
CD8+ 
naive 
med 1.74E+07 2.43E+07 7.48E+06 2.65E+07 1.89E+07 1.90E+07 1.19E+08 
min 9.67E+06 2.02E+07 1.11E+06 1.44E+07 9.86E+06 9.61E+06 6.42E+07 
max 3.03E+07 3.19E+07 3.18E+07 3.34E+07 3.70E+07 3.43E+07 1.89E+08 
Table 11: Summary of changes in absolute numbers of T-cell subsets in spleen. 
med=median, min=minimum, max=maximum. 
 
We confirmed that these patterns were recapitulated in an additional round of 
experiments (summarized in Table 8 as “III. Available mice to assess T-cell phenotype 
in organs alongside developing CLL”). As outlined in Chapter 5.3.1, these experiments 
consisted of a substantially larger multicolour panel for spleen, included CM and EM 
cells, used different fluorochromes/antigen conjugates, and were restricted to B6 TCL1 
and B6 WT mice. These experiments confirmed the previously observed changes, i.e. 
the decrease of the CD4+/CD8+ ratio with developing CLL and after AT in young WT 
mice, while this was stable and increased slightly in ageing WT mice (Figure 17 A), the 
increase of absolute numbers of CD3+, CD4+ and CD8+ T cells (Figure 17 B), the 
shifts in naive and antigen-experienced CD3+CD8+ T cells (Figure 17 C) and their 
increases in absolute numbers (Figure 17 D) in mice with CLL. In AT mice, which were 
WT recipients, the previously observed relative loss of CD3+CD8+ memory cells 
compared to age-matched healthy controls was confirmed.  
The most significant output of these experiments, however, was the additional 
information on CM and EM subsets, which revealed major differences between healthy 
and leukaemic mice: while both subsets showed relative expansion in ageing WT mice 
(CM 3 month median 2.89%, 6 month 2.86%, 12 month 7.78%; EM 3 month median 
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7.21%, 6 month 8.67%, 12 month 36.03%), CM were decreased in ageing TCL1 mice 
and after AT (3 month median 11.04%, 6 month 11.68%, 12 month 3.36%, AT 1.4%), 
and cells were shifted towards an expanded EM subset (3 month median 5.42%, 6 
month 10.9%, 12 month 14.23%, AT 55.26%; Figure 17 C). Absolute numbers of CM 
and especially EM CD3+CD8+ cells increased in mice with CLL (Figure 17 D and Table 
12).  
Statistical differences in the relative expansion of T-cell subsets compared to 3 month 
old mice as baseline are summarized in Figure 17 E. Absolute numbers of CD3+CD8+ 
CM and EM cells are summarized in Table 12. 
 
 
Figure 17: Confirmation of T-cell subset changes in ageing TCL1 and WT mice and after 
AT in spleen. (A) Confirmation of decreased CD4+/CD8+ ratio in mice with CLL and (B) 
increase of absolute CD3+, CD4+ and CD8+ T cells numbers (AN). (C) Confirmation of loss of 
CD3+CD8+ naïve cells and shift towards antigen-experienced cells. In WT mice, CM and EM 
subsets expanded with ageing, while CM were lost in ageing TCL1 mice and after AT and EM 
expanded. (D) AN of these cell subsets were significantly increased in mice with CLL. (E) 
Heatmap summary of p-values describing statistical differences in T-cell subsets. ns = non-
significant, *p<.05, **p<.001, ***p<.0001. 
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absolute 
numbers of 
cell subset 
B6 WT B6 TCL1 
 
3mo 6mo 12mo 3mo 6mo 12mo AT 
CM 
med 8.33E+05 1.25E+06 4.22E+06 5.61E+06 5.63E+06 6.20E+06 6.21E+06 
min 6.03E+05 8.68E+05 1.84E+06 2.93E+06 2.76E+06 3.70E+06 7.03E+05 
max 9.05E+05 1.95E+06 5.85E+06 6.73E+06 5.33E+07 4.44E+07 2.52E+07 
EM 
med 1.95E+06 3.37E+06 1.44E+07 2.37E+06 4.94E+06 2.72E+07 3.49E+08 
min 1.06E+06 2.13E+06 3.56E+06 1.57E+06 2.14E+06 8.66E+06 8.12E+07 
max 2.67E+06 8.04E+06 3.05E+07 3.80E+06 1.71E+08 5.48E+07 5.29E+08 
Table 12: Summary of changes in absolute numbers of T-cell subsets in spleen. 
med=median, min=minimum, max=maximum, CM=central memory, EM=effector memory. 
 
Altogether, these experiments suggested that some similarities in T-cell subset 
changes exist between ageing WT and ageing TCL1 mice. This implies that 
observations in ageing leukaemic mice might be confounded by the effects of ageing, 
as might be expected. However, clear patterns regarding T-cell subset shifts (i.e. 
CD4+/CD8+ ratio, effector, memory, CM and EM cells) and differences in absolute 
numbers appeared to be associated only with CLL and to develop alongside 
progressing disease. This was not only supported by the AT experiments, but also by 
the observation that CLL-specific T-cell patterns were recapitulated in a younger 
mouse in the 6 month old TCL1 cohort that already had advanced-stage CLL 
(CD19+CD5+ cells in spleen 57.4%). Together, these observations confirm that AT 
experiments allow the elimination of the confounding factor of ageing.  
 
5.4.3 CLL-specific T-cell subset changes are recapitulated in peripheral blood 
We next sought to determine if the phenotypic changes in spleen as the major organ of 
disease were recapitulated in other organs, where T cells are exposed to a different 
microenvironment. These experiments were repeated twice as described above for 
spleen, and the graphs depicted in the following chapters contain the combined data of 
these experiments, unless indicated otherwise. Just as in spleen, the CD4+/CD8+ ratio 
in PB decreased with increasing CLL tumour load and after AT (Figure 18 A) as a 
combined result of an expansion of CD3+CD8+ cells and a reduction of CD3+CD4+ 
cells (data for percentages of CD3+, CD4+ and CD8+ cells not shown). In ageing WT 
mice, the CD4+/CD8+ ratio also decreased, albeit not the degree observed in mice with 
CLL (12 month TCL1 median .09 range 0-.2 vs. 12 month WT median .59 range .11-
1.1; p<.0001). Absolute numbers of CD3+ T cells were largely constant in ageing WT 
mice (3 month median 2.9/µl blood, 6 month 3.4, 12 month 2.55) and increased in 
ageing TCL1 mice and moderately after AT (3 month median 3.5, 6 month 4.6, 12 
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month 17.3, AT 3.9). Absolute numbers of CD4+ were reduced in both ageing WT (3 
month median 1.62, 6 month 1.32, 12 month .96) and ageing TCL1 mice and after AT 
(3 month median 1.46, 6 month 2.08, 12 month .98, AT .70), while CD8+ T cells were 
largely constant in ageing WT mice (3 month median 1.34, 6 month .64, 12 month 
1.26) but increased in TCL1 and AT mice (3 month median 1.71, 6 month 2.14, 12 
month 11.87, AT 2.49; note: analysis of absolute numbers was only conducted in the 
first experiment; Figure 18 B).  
In mice with CLL, naïve CD3+CD8+ T cells were shifted towards antigen-experienced 
cells, which were generally skewed towards a memory phenotype in ageing TCL1 and 
in TCL1 mice with CLL after AT. In contrast, AT WT recipients were skewed towards an 
effector phenotype, as previously observed (Figure 18 C). Ageing WT mice also 
decreased naïve cells, however not to the same degree as ageing TCL1 mice (12 
month TCL1 median 4.32% range, 1.15-13.32 vs. 12 month WT median 30.07%, range 
1.17-60.09; p=.0024).  
Absolute numbers of naïve cells were largely stable in ageing WT mice (3 month .67, 6 
month .63, 12 month .69) but decreased in ageing TCL1 mice and after AT (3 month 
median 1.28, 6 month .96, 12 month .62, AT .11; Figure 18 D). Both effector (3 month 
median .06, 6 month .1, 12 month 1.01, AT .68) and memory (3 month median .29, 6 
month .76, 12 month 9.58, AT .94) CD3+CD8+ cells increased in ageing TCL1 mice 
and after AT.  
Statistical differences in the relative expansion of T-cell subsets compared to 3 month 
old mice as baseline are summarized in Figure 18 E. 
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Figure 18: Confirmation of T-cell subset changes in ageing TCL1 and WT mice and after 
AT in peripheral blood (PB). (A) Confirmation of decreased CD4+/CD8+ ratio in mice with CLL 
and (B) changes of absolute CD3+, CD4+ and CD8+ T cells numbers (AN). (C) Confirmation of 
loss of CD3+CD8+ naïve cells and shift towards antigen-experienced cells in mice with CLL, 
and (D) changes in AN. (E) Heatmap summary of p-values describing statistical differences in 
relative frequencies of T-cell subsets. ns = non-significant, *p<.05, **p<.001, ***p<.0001. 
 
5.4.4 CLL-specific T-cell subset changes are recapitulated in bone marrow 
Similar to spleen and PB, the CD4+/CD8+ ratio in BM decreased with increasing CLL 
tumour load and after AT (Figure 19 A), mainly due to an expansion of CD3+CD8+ 
cells while CD3+CD4+ cells remained largely stable. In WT mice, the CD4+/CD8+ ratio 
in 3 month old mice was relatively low due to a low percentage of CD4+ cells. This led 
to an increase of the ratio in ageing WT mice when compared to the 3 month old group, 
which however was consistent between 6 and 12 month old ageing WT mice. Absolute 
numbers of CD3+ cells increased in ageing TCL1 mice and after AT (3 month median 
2.45/µl cell suspension, 6 month 6.25, 12 month 5.2, AT 6.6), just as CD4+ (3 month 
median .52, 6 month .75, 12 month 1.12, AT 1.33) and CD8+ cells (3 month median 
.67, 6 month 2.15, 12 month 2.02, AT 2.85; note: analysis of absolute numbers was 
only conducted in the first experiment; Figure 19 B). 
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In mice with CLL, naïve CD3+CD8+ T cells were shifted towards antigen-experienced 
and especially effector cells (Figure 19 C). The BM of ageing WT mice, in accordance 
to other organs, decreased naïve cells, again not to the same extent as ageing TCL1 
mice with leukaemia (12 month TCL1 median 1.2%, range 0.07-3.74 vs. 12 month WT 
7.68%, range 1.17-60.09; p=.0197) and gained effector cells. However, the impact of 
CLL on T-cell subsets became again apparent when comparing absolute numbers in 
WT and leukaemic mice – absolute numbers of effector cells increased profoundly in 
mice with CLL (WT: 3 month median .12/µl cell suspension, 6 month .41, 12 month .66; 
TCL1: 3 month median .11, 6 month .66, 12 month 1.97, AT 2.53), while memory 
CD3+CD8+ cells only expanded moderately, as already indicated by the comparison of 
relative frequencies, in leukaemic TCL1 and AT mice compared to WT mice (WT 3 
month median .31, 6 month 1.05, 12 month .46; memory TCL1: 3 month .33, 6 month 
1.34, 12 month .88, AT .48; Figure 19 D).  
Statistical differences in the relative expansion of T-cell subsets compared to 3 month 
old mice as baseline are summarized in Figure 19 E. 
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Figure 19: T-cell subset changes in ageing TCL1 and WT mice and after AT in bone 
marrow (BM). (A) Confirmation of decreased CD4+/CD8+ ratio in mice with CLL and (B) 
changes of absolute CD3+, CD4+ and CD8+ T cell numbers (AN). (C) Confirmation of loss of 
CD3+CD8+ naïve cells and shift towards antigen-experienced cells in mice with CLL, and (D) 
changes in AN. (E) Heatmap summary of p-values describing statistical differences in T-cell 
subsets. ns = non-significant, *p<.05, **p<.001, ***p<.0001. 
 
5.4.5 T-cell subset changes exhibit particular patterns in lymph nodes 
Minor differences in CLL-induced T-cell subset changes were observed in LN. While 
the CD4+/CD8+ ratio generally decreased in ageing TCL1 mice with developing CLL 
(Figure 20 A), 3 month old TCL1 mice had a high CD4+/CD8+ ratio (median 1.86, 
range 1.63-3.78), which was caused by an accumulation of CD4+ T cells in this cohort 
of mice (data for percentages of CD3+, CD4+, CD8+ cells not shown). In mice with 
CLL after AT, the CD4+/CD8+ ratio only decreased in TCL1 but not in WT recipients. 
Absolute numbers of CD3+ (3 month median 15.1/µl cell suspension, 6 month 11.1, 12 
month 35.9, AT 51.1) and CD8+ (3 month median 3.68, 6 month 4.56, 12 month 28.81, 
AT 22.99) increased in leukaemic mice, but decreased in ageing WT mice (3 month 
CD3 median 20.15, CD8 6.8; 6 month CD3 21.8, CD8 9.35; 12 month CD3 3.5, CD8 
1.45). Absolute numbers of CD4+ cells were reduced in both ageing WT (3 month 
11.43, 6 month 11.32, 12 month 1.78) and ageing TCL1 mice (3 month 10.47, 6 month 
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5.74, 12 month 3.78), but not in AT mice (median 20.55, note: analysis of absolute 
numbers was only conducted in the first experiment; Figure 20 B).  
Shifts from CD3+CD8+ naive to antigen-experienced cells were recapitulated in 
leukaemic mice, with memory cells being the dominant cell type (Figure 20 C). These 
patterns, however, were less clear in AT mice, with TCL1 but not WT recipients, 
recapitulating the predominance of memory cells in ageing TCL1 mice. In ageing WT 
mice, absolute numbers of effector cells were found to be largely stable (3 month 
median .09/μl cell suspension, 6 month .32, 12 month .1), but increased in ageing 
TCL1 mice and after AT (3 month median .09, 6 month .21, 12 month 1.01, AT 1.55; 
Figure 20 D). Similarly, absolute numbers of memory cells increased in ageing 
leukaemic mice and after AT (3 month median .67, 6 month 1.27, 12 month 21.04, AT 
13.91), while being largely stable in WT mice (3 month median .88, 6 month 1.84, 12 
month .39). Statistical differences in the relative expansion of T-cell subsets compared 
to 3 month old mice are summarized in Figure 20 E.  
 
 
Figure 20: T-cell subset changes in ageing TCL1 and WT mice and after AT in lymph 
nodes (LN). (A) Confirmation of decreased CD4+/CD8+ ratio in ageing mice with CLL, and (B) 
changes of absolute CD3+, CD4+ and CD8+ cells numbers (AN). (C) Confirmation of loss of 
CD3+CD8+ naïve cells and shift towards antigen-experienced cells in ageing mice with CLL and 
partly after AT, and (D) increase in AN. (E) Heatmap summary of p-values describing statistical 
differences in T-cell subsets. ns = non-significant, *p<.05, **p<.001, ***p<.0001. 
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5.4.6 Developing CLL and CD3+, CD4+, CD8+ subset changes are significantly 
correlated with each other 
After characterizing the development of T-cell subset changes over time, we next 
sought to confirm the direct association between developing disease and T-cell 
phenotype. We therefore correlated the relative frequencies of CD19+CD5+ and CD3+, 
CD3+CD4+, and CD3+CD8+ cells, respectively, in all organs from TCL1 and AT mice, 
using the Spearman's rank correlation coefficient model to determine the statistical 
dependence between these variables. As indicated by the previous analyses, we found 
that developing CLL significantly associated with the loss of CD3+ and more 
importantly, among CD3+ cells, with the loss of CD4+ cells and the increase of CD8+ 
cells in spleen, PB, BM and LN, suggesting a causal and linear relationship between 
CLL and those T-cell defects (see Figure 21 A for spleens, B for PB, C for BM and D 
for LN, and Table 13). LN of AT mice were excluded from this analysis, as disease 
development is delayed in this compartment.  
 
 
Figure 21: Statistical correlations between CLL and T-cell subsets. Using nonparametric 
Spearman correlation coefficient modelling, the variables “developing CLL in all available TCL1 
and AT mice” and “changes in CD3, 4 and 8 subsets” were correlated with each other. Cells 
were gated on mononuclear cells (MNC). Each data point is representative of a single mouse, 
correlating the relative frequency of CD3, 4 or 8 (depicted in different shades of blue and plotted 
on the y-axes) with the corresponding relative frequency of CD19+CD5+ CLL cells (plotted on 
the x-axes). (A) In mice phenotyped in both experimental round 1 and 2, progressing CLL and 
the loss of CD3+ and CD3+CD4+ cells and the increase of CD3+CD8+ were significantly 
associated with each other. Associations with CD3+CD4+ and CD3+CD8+ cells were confirmed 
in (B) peripheral blood (PB), (C) bone marrow (BM) and (D) lymph nodes (LN), excluding the AT 
mice in LN correlation analyses.  
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spleen PB 
combined 
dataset 
BM 
combined 
dataset 
LN 
combined 
dataset exp. round 1 exp. round 2 
CD3 
spearman r -0.8155 -0.7759 -0.6436 0.4735 -0.3489 
95% CI 
-0.8836 to            
-0.7138 
-0.8951 to           
-0.5533 
-0.7852 to           
-0.4381 
0.2354 to  
0.6580 
-0.5840 to           
-0.05988 
p value          
(two-tailed) 
< 0.0001 < 0.0001 < 0.0001 0.0002 0.0162 
p value 
summary 
*** *** *** *** * 
CD4 
spearman r -0.3901 -0.5330 -0.5614 -0.03445 -0.6358 
95% CI 
-0.5786 to            
-0.1621 
-0.7642 to              
-0.1803 
-0.7303 to               
-0.3279 
-0.2996 to 
0.2357 
-0.7839 to             
-0.4193 
p value          
(two-tailed) 
0.0009 0.0042 < 0.0001 0.7992 < 0.0001 
p value 
summary 
*** ** *** ns *** 
CD8 
spearman r 0.3819 0.5061 0.6016 0.3645 0.6252 
95% CI 
0.1527 to    
0.5722 
0.1445 to   
0.7485 
0.3811 to   
0.7574 
0.1070 to   
0.5762 
0.4047 to   
0.7770 
p value          
(two-tailed) 
0.0012 0.0071 < 0.0001 0.0053 < 0.0001 
p value 
summary 
** ** *** ** *** 
Table 13: Summary of results of statistical Spearman correlation coefficient analyses for 
all examined organs according to CD3, 4 and 8 subset. Abbreviations: BM – bone marrow, 
PB – peripheral blood, LN – lymph nodes, CI – confidence interval, ns – not-significant. 
 
5.4.7 Developing CLL leads to characteristic functional changes in T-cell 
intracellular cytokines and effector cytotoxicity function 
After confirming the suitability of the B6 TCL1 model in general and the AT model 
specifically to mirror the T-cell defects previously described in the original C3H TCL1 
model, and that the spleen appears to be representative for the examined CLL-affected 
organs, we investigated changes in T-cell function in the context of developing CLL in 
splenocytes from 3, 6 and 12 month old ageing TCL1, WT and AT mice.  
In WT mice, intracellular IL-2 was predominantly produced by CD4+ cells, and showed 
a trend towards increased production with ageing, which was however not-significant 
(p=.09 for IL-2 levels at 3 vs. 12 months). In contrast, CD4+ cells from TCL1 mice 
demonstrated a significantly decreased production of IL-2 with developing CLL 
(p=.0043 for 3 vs. 12 months), but not after AT (p=.31 for AT mice vs. healthy, age-
matched WT mice, note: AT recipients were WT recipients). Interestingly, CD8+ cells 
Fabienne McClanahan                                                                                                     Chapter 5 
Page 117 of 258 
 
from TCL1 mice also started to produce more IL-2 with increasing CLL (p=.0043 for 3 
vs. 12 months), but not after AT (Figure 22 A). 
 
 
Figure 22: Intracellular cytokine production by CD4+ and CD8+ cell subsets. Fresh 
splenocytes from 3, 6 and 12 month WT and TCL1 mice and from mice with full CLL after AT 
were stimulated for 6 hours with PMA and ionomycin (P/I) in the presence of brefeldin/ 
monensin for the last 5 hours of culture. Cells were then harvested, surface stained, fixed, 
permeabilised and stained with antibodies against IL-2, IL-4 and IFN-γ. (A) Intracellular IL-2 was 
predominantly a CD4 cytokine, increased in ageing WT mice, but decreased with developing 
CLL. CD8+ cells increased IL-2 production with ageing CLL, but not after AT. (B) Intracellular 
IL-4 was also predominantly a CD4 cytokine, increased in ageing WT CD4+ cells but was stable 
in CD8 cells without and with mitogen. CD4+ cells from ageing TCL1 mice required mitogen to 
maintain production. AT mice had significantly increased IL-4 production. (C) CD8+ cells from 
ageing TCL1 mice had significantly increased IFN-γ production, which was not fully 
recapitulated in AT mice. In CD4+ cells from ageing leukaemic mice, IFN-γ production was lost 
while WT mice exhibited an increase just as in CD8+ cells. CD4+ cells from AT mice maintained 
increased IFN-γ production. All graphs show median with interquartile range (IQR). 
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Intracellular IL-4 was detected in both CD4+ and CD8+ cells, with a predominance in 
CD4+ cells (see Figure 22 B). Even without PMA/Ionomycin, CD4+ cells from ageing 
WT increasingly produced IL-4 (p=.0022 for CD4+ cells at 3 vs. 12 month), which was 
not further increased by mitogen. IL-4 production by WT CD8+ cells appeared relatively 
stable without and with mitogen. CD4+ cells from TCL1 mice showed no significantly 
altered IL-4 production without mitogen (p=.1255 at 3 vs. 12 months), and this could 
only be increased by PMA/Ionomycin in mice at 12 months compared to young TCL1 
mice (p=.008). Interestingly, both CD4+ and CD8+ cells from AT mice appeared to 
have significantly increased IL-4 production (CD4+ cells: p=.0002 without and with 
PMA/Ionomycin; CD8+ cells: p=.0079 without and p=.0002 with PMA/Ionomycin, both 
compared to age-matched healthy WT mice), indicating that this setting might 
predispose for IL-4 production.  
Both CD4+ and CD8+ cells appeared able to produce IFN-γ, but baseline production 
was negligible and mitogenic stimulation was required (see Figure 22 C). Differences 
were apparent between ageing WT and TCL1 mice: while CD8+ cells from ageing WT 
showed slightly increased IFN-γ production (p=.0152 at 3 vs. 12 months), this was 
significantly increased in ageing TCL1 mice (p=.0043), and 12 month old leukaemic 
mice showed almost twice the percentage of IFN-γ-producing CD8+ cells. In AT mice, 
this was only recapitulated in a few mice, with the overall group having no different 
CD8+ IFN-γ production compared to age-matched healthy mice. In contrast, IFN-γ 
production by CD4+ cells appeared lost in leukaemic mice, while WT mice exhibited an 
increase just as in CD8+ cells (p=.0022 at 3 vs. 12 months). CD4+ cells from AT mice, 
however, maintained increased IFN-γ production relative to healthy aged-matched WT 
controls (p=.0002). 
In the same experiment, we measured cytotoxicity by CD107a degranulation and 
intracellular GrB and attributed these effector functions, along with IFN-γ production, 
specifically to the antigen-experienced CD44+CD3+CD8+ subset. To describe CLL/ 
ageing-induced changes within antigen experienced CD44+ cells, we formed a ratio 
between cells expressing a certain effector marker and cells lacking this expression 
after stimulation with PMA/Ionomycin. A decreased ratio is therefore indicative of loss 
of cells able to act as effector cells, and vice versa. In ageing WT mice, 
CD44+CD3+CD8+ cells largely maintained their ability to localise CD107a to their 
surface and to produce IFN-γ. Intracellular GrB ratio also remained relatively constant, 
indicating that key effector functions were maintained. Some trends were observed 
over time, but none reached statistical significance (3 vs. 12 month CD107a ratio 
p=.1797; GrB ratio p=.2403; IFN-γ ratio p=.3095, Figures 23 A, B and C upper panels).  
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In contrast, with developing CLL both ageing TCL1 and AT mice showed a decreased 
CD107a ratio, demonstrating that within the CD44+ subset, cells without the ability to 
degranulate (i.e. functionally deficient cells) became predominant (p=.0173 for TCL1 
mice at 3 vs. 12 months; p=.0001 for AT vs. aged-matched healthy controls, Figure 23 
A ).  
Intracellular GrB ratio, however, remained constant, albeit at a generally lower level 
than in WT mice, and was even increased after AT (p=.0261), indicating that the 
production of lytic granule content is at least maintained to a certain extent in the 
presence of leukaemic cells (Figure 23 B). Interestingly, developing CLL in TCL1 mice 
was accompanied by an increase in the ratio of IFN-γ producing versus non-producing 
CD44+ cells (p=.0087 for mice at 3 vs. 12 months, Figure 23 C). However, this was 
not-significant in AT mice compared to age-matched healthy WT mice (p=.2119). In 
accordance to their differentiation status, these effector functions were restricted to 
antigen-experienced cells, and absent in naïve CD3+CD8+CD44- cells.  
 
 
Figure 23: Effector cell function in CD3+CD8+CD44+ antigen experienced cells. Key 
effector cell cytotoxic functions were measured after PMA/Ionomycin stimulation and expressed 
as a ratio between cells expressing CD107a, GrB and IFN-γ. (A) In contrast to ageing WT mice, 
developing CLL (i.e. ageing TCL1 mice and AT mice) led to significantly decreased CD107a 
ratio. (B) Intracellular GrB ratio remained constant in ageing TCL1 mice and increased after AT. 
(C) Developing CLL was accompanied by a highly significant increase in IFN-γ ratio in ageing 
TCL1 but not AT mice. 
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5.4.8 Developing CLL is accompanied by increasing T-cell proliferation 
As another marker of T-cell effector function, we determined ex vivo and in vivo 
proliferation by ki67 and EdU incorporation, respectively. In ageing WT mice, the 
proliferation of CD3+CD8+ T-cells, expressed by changes in the ki67 ratio, remained 
relatively constant but showed a trend towards decreased proliferation (p=.0632 at 3 
vs. 12 months; Figure 24 A). In ageing TCL1 mice with developing CLL, however, the 
ki67 ratio increased significantly, indicating that within the CD44+ subset, cells with the 
ability to proliferate became predominant (p=.0274 at 3 vs. 6 months; p=.0013 at 3 vs. 
12 months; Figure 24 A). This was also recapitulated after AT (p=.0016 for AT vs. age-
matched WT). These patterns were confirmed by measuring in vivo proliferation 
(Figure 24 B): T-cell proliferation, indicated by cells positive for AF488-coupled 
incorporated EdU, remained constant in WT T cells over time, but increased 
significantly with developing disease (p=.0043 at 3 vs. 6 months and p=.0002 at 3 vs. 
12 months for TCL1 mice; p=.0007 for AT vs. age-matched WT mice). This was 
observed in both CD8+ and non-CD8+ (i.e. largely CD4+) cells (CD8+: p=.0087 for 3 
vs. 6 months; p=.0007 for 3 vs. 12 months; p=.0002 for AT vs. WT; non-CD8+: p=.0173 
for 3 vs. 6 months; p=.0002 for 3 vs. 12 months; p=.0002 for AT vs. WT).   
 
 
Figure 24: Proliferation in T-cell subsets. Proliferation was measured ex vivo by intranuclear 
ki67 in CD3+CD8+ T cells and in vivo by EdU incorporation in all CD5+ T cells and CD8+ and 
CD8- T-cell subsets. (A) In contrast to ageing WT mice, developing CLL in TCL1 mice and AT 
led to significantly increased ki67 ratios in CD3+CD8+CD44+ cells, indicating increasing 
proliferation in the presence of CLL. (B) Confirmation of increased T-cell proliferation in vivo, 
both in CD8+ and in CD8- subsets.  
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As the EdU technique allows multiplexing with a variety of other markers, we also 
concurrently assessed B-cell proliferation in both ageing WT and TCL1 mice and after 
AT (see Figure 25). The proliferation of healthy CD19+CD5- B cells remained constant 
in ageing WT mice, but increased in CD19+CD5- B cells from 6 month old TCL1 mice 
and was similar to their CLL cell proliferation (i.e. CD19+CD5+ cells). This 6 month age 
group represents an early stage of CLL, where both a healthy B cell and a malignant 
CLL cell population exist and can be directly compared. With progressing CLL, the 
CD19+CD5+ population continued to proliferate, as expected. 
 
 
Figure 25: Proliferation of healthy 
B and CLL cells in vivo: 
Proliferation of healthy B cells 
remained constant in ageing WT 
mice, but CD5+CD19+ CLL cell 
proliferation continued to increase 
with developing disease.  
 
 
 
 
 
 
5.4.9 Developing CLL is accompanied by impaired ability of autologous B and T 
cells to form immunological synapses 
Our group has demonstrated that impaired immune synapse formation is an important 
feature of T-cell dysfunction in both human and murine CLL. To conclude the 
characterization of how T-cell defects develop alongside progressing CLL, we 
measured T-cell synapse formation between autologous B/CLL and T-cells in 3, 6 and 
12 month old TCL1 mice and in AT mice, and compared this to the synapse formation 
observed in autologous cells from 3 month old WT mice. While the ability to form 
immunological synapses was comparable in 3 month old TCL1 and WT mice, this was 
significantly impaired in 12 month TCL1 mice and after AT (p<.0001, respectively). 
Surprisingly, this did not appear to be a linear progressive loss, as 6 month old TCL1 
mice, i.e. at the early stage of CLL, exhibited superior synapse formation compared to 
3 month old TCL1 mice (Figure 26).  
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Figure 26: Development of 
immune synapse formation: The 
ability of autologous B and T cells 
to form immunological synapses 
was measured in 3, 6, 12 month 
old TCL1, 3 month old WT, and AT 
mice. Compared to young TCL1 
mice, this was significantly 
impaired in aged TCL1 and AT 
mice, but not 6 month old TCL1 
mice with early stage CLL.  
 
 
 
 
 
5.5 Summary of phenotypic and functional T-cell defects developing with 
progressing CLL 
In summary, we were able to demonstrate that developing CLL and phenotypic 
changes in T cell subsets were highly significantly correlated with each other, and that 
this is equally modelled in B6 TCL1 and C3H TCL1 mice. This included a decrease in 
CD4+/CD8+ ratio, which was recapitulated in spleen, PB, BM and LN. Within 
CD3+CD8+ cells, naïve cells were progressively lost and the population shifted 
towards antigen-experienced cells. The subset of antigen-experienced cells, however, 
appeared to be dependent on the microenvironment: effector cells progressively 
became the dominant cell type in BM, and memory cells in PB and LN. In spleens of 
B6 TCL1 mice, memory and effector cells were equally expanded, while C3H mice 
exhibited a more pronounced shift to effector cells. Regardless, the spleen memory 
pool of B6 TCL1 mice was further characterized by a shift towards EM and loss of CM 
cells. While some of these phenotypic T-cell changes, such as the progressive 
decrease of naïve cells and subset shifts among effector and memory cells, were also 
observed to a certain extent in ageing WT mice, they were considerably more 
pronounced in the presence of CLL. In addition, the extent of differences between 
healthy ageing T cells and ageing CLL T cells became apparent when comparing their 
absolute numbers, which were in general considerably higher in TCL1 mice. This 
allowed the identification of a CLL-specific T-cell phenotype, which included the CD8+ 
and EM subset expansions and the massive naïve cell loss. The AT model was 
confirmed to be a generally adequate tool to mirror the phenotypic T-cell changes of 
ageing CLL. However, the following differences became apparent: the disease load in 
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LN did not fully mirror 12 month old TCL1 mice, and as a consequence, the T-cell 
phenotype was not as clearly confined to CLL-typical changes in this compartment. In 
addition, minor differences were observed in effector versus memory subset 
distribution depending on whether AT recipients were WT or TCL1 mice. Functionally, 
typical cytokine T-cell defects that developed alongside CLL were a loss of IL-2 
producing CD4+ cells and aberrantly increased percentages of CD8+ cells producing 
IL-2, the loss of spontaneous IL-4 producing CD4+ cells, and significantly increased 
IFN-γ producing CD4+ and CD8+ cells. Cytokine profiles were only partly mirrored in 
AT mice, as they seemed to be enriched for IL-4 producing CD4+ and CD8+ cells while 
lacking a significant increase in IFN-γ producing cells. Antigen-experienced CLL T-cells 
appeared to lose their ability to localise CD107a to their surface progressively, which is 
indicative of impaired cytotoxicity function, but maintained the ability to produce 
cytolytic GrB, while increasing their IFN-γ production potential. Except for the latter 
change, this was mirrored in AT mice. Accordingly, immune synapse formation was 
significantly impaired in ageing TCL1 and AT mice, but this did not appear to be a 
linear development as 6 month old TCL1 mice exhibited an increased ability to form 
synapses relative to 3 month old TCL1 mice. Surprisingly, T-cell proliferation was found 
to increase with developing CLL and after AT. Statistical differences in the relative 
expansion or loss of functional T cell subsets compared to 3 month old mice as 
baseline are summarized in Figure 27. 
 
 
Figure 27: Heatmap summary of p-values describing statistical differences in functional 
T-cell subsets. Groups were compared to the relative percentage of functional subsets in 3 
month old mice. Blue colour indicates relative expansion, red colour indicates relative loss of 
cell subsets. ns = non-significant, *p<.05, **p<.001, ***p<.0001. 
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5.6 Discussion 
The goal of this part of the work was to validate the B6 TCL1 model for the 
investigation of global T-cell defects, to further characterize T-cell subsets in the 
context of advancing CLL in different CLL-affected compartments, and to explore the 
impact of developing CLL on T-cell effector function.  
Using T-cell phenotype as an established surrogate marker for global T-cell defects in 
human CLL and the TCL1 model118-120, 133, 220, we demonstrated that this can be 
adequately modelled in both the original C3H-F1 TCL1 and the backcrossed B6 TCL1 
model, therefore validating the latter for further studies on the characterization and 
repair of T-cell dysfunction. Previous work of our group on T-cell defects in mice has 
been done using C3H-F1 TCL1 mice, and the backcrossed B6 TCL1 model was been 
inadequately characterized so far. Therefore, in order to fully understand the underlying 
changes in the context of developing CLL, and in a second step, the impact of repairing 
our previously described T-cell defects in backcrossed B6 TCL1 mice, a thorough 
validation of this model was an essential first step. This comparison between C3H and 
B6 TCL1 mice was however restricted to splenic T-cell subsets, as the spleen is 
considered the major organ of disease in this model, but was excluded from the B6 
TCL1 characterization work of Hofbauer et al212, 220. In addition, preclinical 
characterization studies such as the T-cell work from our group216, or studies 
investigating the effect of therapeutic interventions265, are generally done using 
splenocytes from TCL1 mice, also in part because sufficient cell numbers are more 
easily obtained from an enlarged spleen than from LN or blood from a mouse. We were 
able to confirm that the T-cell phenotype in murine CLL cells from spleen mirrors that of 
human CLL121, 122, 133, 390, 391, and includes the fall in the CD4+/CD8+ ratio, and a shift 
from naïve to antigen-experienced CD3+CD8+ cells.  
However, this CLL-specific T-cell phenotype in human studies is largely based on the 
characterization of T cells from PB, while the only other murine study using 
backcrossed B6 TCL1 mice so far describing similar phenotypic alterations used T cells 
from PB and LN220. In contrast, an older study in CLL patients, which characterized T 
cells from LN and BM, reported increased numbers of CD4+ T cells in these 
compartments392. To directly compare differences in T-cell subsets in different organs 
from the same animals, we characterized CD3+, CD4+, CD8+ and CD3+CD8+ naïve 
and effector/memory cells in spleen, PB, LN and BM in ageing B6 TCL1 and age-
matched WT mice. We found that the major aspects of the CLL-specific T-cell 
phenotype were recapitulated in all organs, indicating that the described phenotypic T-
cell changes are induced by the presence of CLL regardless of the microenvironment. 
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It has been suggested that the relative reduction in numbers of PB CD4+ T cells is due 
to their increased susceptibility to FasL-mediated apoptosis126, and a recently 
published study using B cell-derived lymphoblastoid cell lines proposed that this could 
be mediated by constitutively produced MHCII(+)FasL(+) exosomes produced by B-
cells393. In addition, relatively reduced peripheral CD4+ cell numbers could also be a 
result of chemokine/cytokine driven migration into secondary lymphoid organs129. 
Studies in other disease entities associated with chronic inflammatory responses have 
also demonstrated that T-cell subpopulations differ between lymphoid organs and PB, 
and that this could be mediated by cytokines such as CCR4, CXCR3394, 395. Our 
findings support an accumulation of CD4+ T cells in the bone marrow and secondary 
lymphoid organs, probably as a result of migration, as in leukaemic mice, the 
CD4+/CD8+ ratio was generally higher in BM, LN and spleen than in PB. In line with 
previous reports in both human and mouse CLL, we largely found increased numbers 
of T-cell subsets due to leucocytosis and organomegaly in all examined compartments 
compared to age-matched WT mice.  
In all organs, naïve CD3+CD8+ cells were progressively lost and the population shifted 
towards antigen-experienced cells. The subset of antigen-experienced cells, however, 
appeared to be dependent on the microenvironment: effector cells progressively 
became the dominant cell type in BM, and memory cells in PB and LN. In spleens of 
B6 TCL1 mice, memory and effector cells were equally expanded, while C3H mice 
exhibited a more pronounced shift to effector cells. Regardless, the spleen CD8+ 
memory pool of leukaemic mice was further characterized by a shift towards EM and 
loss of CM cells, based on the coexpression of CCR7 and CD62L. A skewing towards 
CD8+ and CD4+ antigen-experienced cells in PB and LN has been previously 
described in murine CLL220. This paper, however, refers to these cells as memory cells 
and reports statistical values in the text for memory cells, but the corresponding figures 
and tables are consistently labelled “effector+memory” cells. It is therefore unclear 
based on the published information, which subset they found to be preferentially 
expanded. Another study using the original TCL1 C3H mice reported an expansion of 
CD8+ effector cells in the peritoneal cavity, but termed this population effector memory 
cells, although their panel did not include any markers such as CCR7 to allow such a 
discrimination135.  
Previous work from our group has found that human CLL CD8+ T cells in blood 
differentiate into CCR7- EM cells133. As this is very similar to our findings in spleen, this 
shift might be recapitulated regardless of microenvironment. Differences in human 
CD8+ lymphocyte subsets were originally thought to be potentially explained by the 
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presence of CMV144, but work from our group later confirmed that impaired T-cell 
function and altered subset composition were irrespective of CMV serostatus133. Based 
on the observation that CMV-reactivations are uncommon in untreated CLL, suggesting 
that antiviral responses are uncompromised, a recently published study suggested that 
CMV-specific CD8+ T cells were indeed functionally intact, while global T-cell defects 
were still present148. Therefore, changes in the T-cell compartment in CLL are likely to 
be very heterogeneous and potentially influenced by a variety of other factors. Murine 
studies allow us to at least control for the confounder of any underlying common 
infection, as mice are generally considered free of infection. This is ensured by the 
maintenance of mice in specific barrier-systems and rigorous infection screening, which 
were also conducted regularly and were confirmed negative in our colony. 
The AT model was confirmed to be a generally adequate tool to mirror the phenotypic 
T-cell changes of ageing CLL, while having the advantage of developing CLL more 
uniformly as a cohort than 12 month old TCL1 mice, where individual animals of the 
same age usually exhibit a wide range of stages of CLL development. The AT model 
therefore appears superior to ageing CLL in terms of more consistently modelling the 
full inhibitory effect of CLL on T-cells; therefore it can be argued that CLL-associated T-
cell changes are most adequately modelled in AT mice, while eliminating confounders 
such as underlying age. However, the TCL1 model per se has also been characterized 
to mirror the biological properties of aggressive human CLL, such as stereotyped B-cell 
receptors or epigenetic alterations (see Chapter 1.2.1.2). Due to its shorter disease 
latency, it is therefore possible that the AT model needs to be considered as even more 
aggressive than CLL that develops in ageing TCL1 mice. In addition, it is not known if 
serial leukaemia transfer in mice fosters clonal evolution of specific CLL sub-clones or 
mutations in BCR pathways, which have been described in human CLL. Therefore, our 
data on ageing TCL1 mice could be used to model the T-cell defects occurring in more 
indolent CLL, while AT mice mirror aggressive CLL. 
As spleen appeared to be representative for CLL-affected secondary lymphoid organs, 
we investigated changes in T-cell function in the context of developing CLL in 
splenocytes from TCL1, WT and AT mice. For a complete analysis of function in 
secondary lymphoid organs compared to blood, it would have been desirable to 
conduct these investigations in a direct comparison. However, functional assays in 
blood were not feasible given the very small volumes of blood retrieved by cardiac 
puncture. Regardless, we were able to identify typical cytokine T-cell defects that 
developed alongside CLL; these included the loss of IL-2 production in CD4+ cells and 
aberrantly increased production by CD8+ cells, the loss of spontaneous IL-4 production 
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by CD4+ cells, and significantly increased IFN-γ production by CD4+ and CD8+ cells. 
Cytokine profiles were only partly mirrored in AT mice, as they seemed to be enriched 
for IL-4 producing CD4+ and CD8+ cells while lacking a significant increase in IFN-γ 
production, which is however very similar to a pattern recently described by Brusa et al. 
in T cells from CLL patients134. Early studies in human CLL suggested that CLL was a 
CD4+ Th2-mediated disease, with increased numbers of both CD4+ and CD8+ T cells 
producing IL-4153, 396. However, a number of other reports have described increased 
production of IFN-γ and TNF-α by T cells from CLL patients, which also correlated with 
disease stage164, 397-400. In addition, IL-2 was shown to increase CLL cell proliferation401. 
Previous work from our group found that CD4+ T cells from CLL patients showed 
increased production of IFN-γ and IL-2, and no reduction in TNF-α, while CD8+ T cells 
had increased production of IFN-γ and TNF-α without any reduction in IL-2 when 
compared with healthy controls133. Our previous murine work suggested that T-cell 
cytokines were Th2 preponderant216. Assuming that the ageing TCL1 mouse model is 
more indolent and the AT models represents more aggressive disease, our present 
data indicate that CD4+ cells are IFN-γ/Th1 preponderant in more indolent stages, but 
become IL-4/Th2 preponderant in aggressive CLL. Similarly, indolent CLL would be 
associated with aberrant IL-2 and IFN-γ production by CD8+ T cells, and aggressive 
CLL with aberrant IL-4 and loss of IFN-γ production. However, these different cytokine 
secretion patterns between more and less aggressive CLL might also be biased by 
immune responses associated with the process of ageing. Although we were 
conducting all comparisons between leukaemic mice and age-matched WT mice (i.e. 
compared ageing TCL1 mice with ageing WT mice, and young AT mice with young 
age-matched WT), the cytokine-secretion potential of T cells has been demonstrated to 
undergo fundamental changes with ageing402. Therefore, the different cytokine 
repertoire in AT mice might also be explained by the fact that younger mice simply 
have a different repertoire of cytokine secretion potential than older mice.   
A more consistent picture between ageing TCL1 and AT mice was found regarding 
CD8 T-cell effector function: developing CLL led to a progressively lost ability of 
CD107a relocation to the cell surface, with was used as a measurement of cytotoxicity, 
but cells maintained the ability to produce cytolytic GrB. Accordingly, immune synapse 
formation was significantly impaired in ageing TCL1 and AT mice, but this did not 
appear to be a linear development as 6 month old TCL1 mice exhibited an increased 
ability to form synapses. We have previously described in both murine and human CLL 
that GrB mRNA levels were not impaired in CLL T cells, but that cells still had an 
impaired cytotoxicity function and poor immunological synapse formation77, 171, 216. 
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Impaired cytotoxicity was later found to be explained by an impaired ability of human 
CLL PB T-cells to focus CD107a and GrB polarisation into the immunological synapse, 
therefore preventing the targeted lysis of antigen-presenting cells133. In the present 
study, we have confirmed that all these functions were affected in T cells from spleen. 
This indicates that impaired effector function is a hallmark of CLL T cells regardless of 
the microenvironment, and that the defects are developing progressively alongside CLL 
from an early stage on. 
Somewhat surprisingly, T-cell proliferation was found to increase with developing CLL 
and after AT. This is a novel finding and is in marked contrast to our previous human 
work, which found a proliferative defect in PB CLL T cells due to a combination of a 
reduction in the proportion of cells able to divide upon polyclonal activation, and 
prolongation of the division time of the proliferating cells133. This, however, was 
measured by CFSE incorporation following 72h ex vivo stimulation with anti-CD3/CD28 
beads, whereas proliferation of murine T cells was measured both directly in vivo and 
ex vivo without any further antigen or mitogen stimulation. This can therefore be 
considered the most accurate measurement of actual T-cell proliferation in vivo. 
Interestingly, Roth et al. described significantly shorter average telomere lengths in 
naïve and memory T cells from ZAP-70+/CD38+ patients compared to ZAP-70-/CD38- 
patients and healthy controls, indicating increased proliferation of T cells in CLL 
patients with poorer risk disease. Therefore, increased proliferation of T cells in TCL1 
mice might be another indication of the aggressiveness of the disease.  
CLL B-cells themselves have long been viewed as non-proliferating cells; this was 
challenged by clinical studies using heavy water to label CLL cells in vivo, and more 
recently by murine studies demonstrating that CLL cells had higher proportions of 
proliferating cells than non-leukaemic lymphocytes, which is in line with our present 
observations comparing healthy B-cells and CLL cells260, 403. The same murine study 
also found that BrdU incorporation into T cells did not differ between TCL1 and WT 
mice, indicating that T-cell proliferation was at least maintained. The discrepancy to the 
increase in T-cell proliferation observed in our current work could be explained by the 
fact that Enzler et al. examined mice with a lower burden of disease, which are 
probably more similar to the 6 month old TCL1 mice we used in our study, and that 
increased proliferation might have become apparent had they used older mice with 
more progressed CLL as well.  
In sum, we have extensively validated the backcrossed B6 TCL1 model for the 
characterization and repair of T-cell defects in CLL, we have demonstrated the 
strengths and potential shortcomings of the AT model to mirror the T-cell defects seen 
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in ageing TCL1 mice, and we have shown for the first time how different 
microenvironments and compartments affect the T-cell phenotype in murine CLL. In 
addition, we have identified the dynamic alterations of T-cell phenotype and function in 
the context of developing CLL, and we have described novel mechanisms of T-cell 
dysfunction. Altogether, this work supports the understanding that, despite a typical 
CLL-induced T-cell phenotype, CLL T cells are at last partially functional and have 
developed several mechanisms that try to compensate increasing tumour load and 
maintain anti-tumour immune responses. The mechanisms of why these anti-tumour 
immune are not sufficient and do not lead to efficient anti-tumour control, and how the 
inhibitory effects of CLL cells are mediated, will be further investigated in the next 
chapter.  
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6 PD-L1/ PD-1 mediated T-cell dysfunction and T-cell exhaustion in TCL1 
mice on the B6 background 
6.1 Specific introduction 
Our group has previously identified the molecular signature of human CD4+ and CD8+ 
T cells in CLL, and confirmed that this is very closely mirrored in leukaemic TCL1 
mice171, 216. Dysregulated T-cell genes were mostly involved in pathways of cell 
proliferation, differentiation, effector function, and actin cytoskeleton formation. The 
functional impact of the latter was modelled in immune synapse formation assays 
between T cells and antigen presenting cells (APCs). These experiments confirmed 
that T cells from CLL patients inappropriately respond to APCs due to their inability to 
regulate actin modelling effectively, and to recruit key cytoskeletal signalling molecules 
to the immune synapse77. These defects could be induced in normal allogeneic T cells 
by co-culturing them in direct cell-cell contact with CLL cells, and were also 
recapitulated in synapses between autologous CLL and T cells from leukaemic TCL1 
mice. Using functional siRNA screening, aberrant surface expression of CD200, PD-L1, 
CD270 and CD276 on CLL cells were identified as the major mediators of impaired T-
cell actin dynamics, with a dominant role of PD-L179. Blocking these ligands in vitro led 
to a significant improvement of immune synapse formation, with the combined activity 
of all four molecules having the greatest effect.  
The corresponding binding partners of PD-L1 and CD270 - PD-1 and CD160 - have 
been demonstrated to be aberrantly expressed by CLL T cells, probably as a result of 
chronic antigenic stimulation133, 134. This has been extensively studied in the context of 
chronic viral infections with high viral replication, such as hepatitis B and C, human 
immunodeficiency virus (HIV), and simian immunodeficiency virus (SIV), where chronic 
antigenic stimulation leads to failed immune responses and persistence of viral 
antigens beyond the effector phase. The continued presence of viral antigen and 
inflammation drive the on-going replication of virus-specific effector T cells and lead to 
a number of progressive phenotypic and functional changes that have been termed “T-
cell exhaustion”. Of note, T-cell exhaustion is not limited to chronic viral infection, but 
also includes bacterial and parasitic infections. Exhaustion represents a state of 
functional hypo-responsiveness that occurs as a progressive process over a period of 
weeks or months, depending on the chronic stimulus, and has been characterized as a 
hierarchical loss of effector CD8+ T-cell function: first, proliferative capacity and 
production of IL-2 are lost, followed by the ability to produce TNF-α, and ultimately IFN-
γ147. Loss of function generally coincides with expression of inhibitory surface 
receptors, including PD-1, LAG-3, CD160, 2B4, TIM-3, BTLA, and CTLA-4404. PD-1 has 
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emerged as a major inhibitory receptor associated with T cell exhaustion405-407. Upon 
binding to its ligands PD-L1 and PD-L2, PD-1/PD-L1/PD-L2 mediated signalling 
represses T-cell receptor signalling and paralyses T-cell motility, probably in synergy 
with other inhibitory receptors285, 292, 408-410. In mice, T-cell exhaustion and the 
associated hierarchical loss of function can be modelled by infections with different 
strains of lymphocytic choriomeningitis virus (LCMV)411. Comparisons of gene 
expression profiles from naïve, effector, memory and exhausted CD8+ T cells from 
LCMV models have revealed that exhausted T cells harbour a unique and distinct 
molecular signature, with alterations in T-cell receptor and cytokine signalling 
pathways, metabolism, migration and actin-cytoskeleton formation412, 413. In addition, a 
number of transcription factors are differently expressed, such as BLIMP-1, BAT3, 
NFAT, TBET and EOMES414, 415.  
However, exhaustion is neither a fixed, irreversible, terminal differentiation state, nor an 
unresponsive T-cell state, and several studies have demonstrated that exhausted T 
cells represent a very heterogeneous population containing several subsets of cells 
that despite PD-1 expression are able to exert certain effector function. For example, T-
BEThiPD-1int cells represent a progenitor T-cell subset, which proliferate in response to 
persisting antigen, and give rise to EOMEShiPD-1hi subpopulations. The latter are 
considered the terminal progeny, express higher levels of other inhibitory receptors and 
do not replicate, but exhibit high levels of cytotoxic activity. Adoptive transfer 
experiments have demonstrated that during the early phase of chronic infection, 
exhausted virus-specific CD8+ T cells can continue their differentiation process and 
form functional T-cell memory upon transfer into healthy mice, but at the same time 
maintain an exhausted phenotype, including the surface expression of PD-1416. 
Exhausted T cells from established chronic infections in contrast were unable to 
differentiate when removed from antigen and did not restore effector functions. The 
heterogeneity of T-cell populations expressing PD-1 has been underscored by findings 
on the effect of antibody blockade, which could reverse exhaustion in PD-1int cells, but 
not in terminally differentiated PD-1hi T cells417.  
Several studies have demonstrated that tumour-infiltrating T cells share many 
phenotypic and functional characteristics of exhausted T cells in chronic infections: 
these include impaired production of IFN-γ, TNF-α, and IL-2, the expression of 
inhibitory receptors such as PD-1, LAG-3, 2B4, TIM-3, CD160 and CTLA-4, and altered 
signalling pathways described for exhausted T cells418-423 were demonstrated to be 
expressed in a substantial number of CD8+ cells in tumour-bearing mice.  
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Our group has demonstrated that T cells from CLL patients exhibit features of T-cell 
exhaustion, such as increased expression of surface exhaustion markers, impaired 
proliferation, and cytotoxic defects with a reduced ability to lyse target cells, while 
retaining the capacity to produce cytokines such as IFN-γ and TNF-α133. Another 
recently published study found that proliferating CD8 T cells from CLL patients had 
higher expression of PD-1 than non-proliferating T cells, and that T cells had impaired 
IFN-γ and IL-4 production after direct binding of PD-1 to PD-L1 ligand, with both of 
those patterns also being observed but at a lower degree after stimulation of T cells 
from healthy controls134, suggesting a somewhat contained physiological reaction in 
CLL T cells.  
Altogether, these observations emphasise the heterogeneity of PD-1 expressing T-cell 
populations in CLL. Despite the expression of typical exhaustion markers, certain 
effector functions appear to be maintained, but it is not clear how distinct states of 
dysfunction develop in the context of advancing CLL and what their functional 
characteristics are. Findings relating to PD-1 and exhaustion in human CLL are also 
likely to be biased by age: CLL is predominantly a disease of the elderly, but high PD-1 
expression is also found on functional effector memory T cells in healthy older 
humans424. This suggests that PD-1 should not be considered a definitive marker for T-
cell exhaustion and dysfunction. In addition, it is likely that factors such as antigen 
specificity, T-cell receptor affinity, level of tumour antigen, and T-cell differentiation 
state, as well as non-T-cell factors such as the microenvironment and metabolic 
conditions contribute to the functional state of not only CLL, but tumour-associated T 
cells in general.  
Understanding the associations between PD-L1 and PD-1 expression and T-cell 
function is however particularly important for immunotherapeutic interventions, as 
different subsets might require different strategies to restore cell function: it is possible 
that blockade of the PD-1/ PD-L1 pathway has distinct effects on T-cell subsets, such 
as promoting effector T-cell populations with physiological PD-1 expression, restoring 
impaired effector function of “early exhausted” populations, or rescuing some effector 
functions in even terminally differentiated T cells. To date, this has only been partly 
answered in CLL, and studies using human CLL samples are likely to be biased by not 
only age, but also potentially underlying infections other than CMV, and treatment. In 
addition, peripheral blood T cells might show different expression patterns than cells in 
secondary lymphoid organs. The majority of these questions can be answered in the 
TCL1 model. Our group has demonstrated the suitability of this model to mirror T-cell 
dysfunction and T-cell directed questions, which was confirmed and extended by 
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further in-depth work in this project. We therefore hypothesized that TCL1 mice are 
also an adequate preclinical model to mirror PD-L1/PD-1 mediated immune dysfunction 
and to further study the concept of exhaustion in the absence of confounders. This is 
also an essential step to fully understand the effect of in vivo antibody blockade of PD-
L1/PD-1 interactions.  
 
6.2 Goals and objectives 
My next goal was therefore to investigate the suitability of the B6 TCL1 model to mirror 
PD-L1/PD-1 interactions and their inhibitory effect on T-cell function, and to extend this 
to the second binding partner of PD-1, namely PD-L2. Specifically, I sought to address 
the following questions: 
 Are the inhibitory ligands CD200, CD270, CD274 (PD-L1), CD276 and CD273 (PD-
L2) differentially expressed on murine CLL cells? 
 Are the previously described corresponding receptors CD160 and PD-1 expressed 
on murine CD8+ T cells? 
 Can T-cell exhaustion be modelled in TCL1 mice, and if yes, what are the 
functional characteristics? 
 How do inhibitory ligands and typical exhaustion markers develop in the context of 
advancing CLL? 
 Can the TCL1 model be used to disentangle functional differences of the 
heterogeneous “exhausted” T-cell population using PD-1 as a marker?  
 
6.3 Specific methods and materials 
6.3.1 Mice and examined organs 
The surface expression of CD200, CD270, CD274 (PD-L1) and CD276 was initially 
characterized in aged TCL1 mice on both the original C3HB6-F1 and the backcrossed 
B6 background from our colony, and in AT mice from AT experiments 5 and 6 (see 
Chapter 4, Table 7). Aged WT mice were retired female breeders from our colony. Mice 
were sacrificed under protocol 19b2 of PIL 70/7531 once they met the endpoint criteria 
for established CLL (see general methods), and spleens were harvested and 
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processed as described in general methods. An overview of mice included in this 
experiment is depicted in Figure 28.  
 
 
Figure 28: Overview of mice to initially assess the expression of inhibitory ligands on 
spleen CLL and normal B cells. A total of 32 animals were phenotyped (20 TCL1 and 12 age-
matched WT mice). Both the original C3H and backcrossed B6 TCL1 mice were used, and 
leukaemic mice were aged TCL1 mice and young TCL1 mice that developed CLL after adoptive 
transfer (AT).  
 
The changes in PD-L1 expression in the context of developing CLL were assessed in a 
second round of experiments, which we conducted alongside the T-cell phenotyping 
and T-cell functional studies described in the previous chapter using 3, 6 and 12 month 
old TCL1 and WT and AT mice listed in Table 8 as “II. Available mice to assess T-cell 
function in spleen alongside developing CLL”. PD-L1 and PD-L2 expression were 
characterized in spleen, PB, BM and LN from mice listed as 1func through 7funct in “III. 
Available mice to assess T-cell phenotype in organs alongside developing CLL”.   
WT and AT mice, listed as 1b through 8b in Table 8 as “I. Available mice to assess T-
cell phenotype in spleen alongside developing CLL”, were used to characterize the 
expression and development of typical exhaustion markers in spleen. This was 
confirmed by a slightly modified panel excluding TIM-3 in spleen from mice listed as 
1func through 7funct in “III. Available mice to assess T-cell phenotype in organs alongside 
developing CLL”. These mice were also used to characterize expression of PD-1 in 
different organs. In the first experiment, AT recipients were young TCL1 mice, and in 
the second experiment, young WT recipients were used.  
To unmask the effect of ageing and to assess T-cell function, surface T-cell exhaustion 
markers and functional T-cell assays were conducted in mice from AT experiment 8, 
Chapter 4. Young TCL1 transgenic mice (n=10) and sex-matched WT littermates 
(n=10) were randomized to AT with 2x107 syngeneic CLL cells each, injected i.v. within 
three days of each other, or a pool of an equivalent number of spleen cells from healthy 
mice. Further information on AT procedures is provided in Chapter 4. Mice were bled 
regularly to assess the engraftment and development of CLL, and sacrificed once they 
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met the criteria for CLL defined in general methods. Matched recipients of normal 
spleen cells were sacrificed on the same day and served as controls in all experiments.  
 
6.3.2 Multicolour flow cytometry for inhibitory ligand expression on normal and 
malignant B cells 
CLL cells and normal B cells were characterized by CD19 and CD5 expression as 
previously described. Experiments were performed on both frozen and fresh samples. 
As controls, FMO and isotype controls for CD200, CD270, CD273 (PD-L2), CD274 
(PD-L1) and CD276 were prepared. Samples were acquired on a BD LSRII. Stopping 
gates were set to CD19+CD5+ cells in leukaemic mice and CD19+ in healthy mice to 
record 15,000 events. Information on antigens, fluorochromes, clones, concentrations 
and suppliers is listed in Table 14. 
 
 mouse antigen fluorochrome clone concentration host/isotype supplier 
inhibitory 
ligands 
CD200 PerCPe-fluor 710 OX90 0.2 mg/ml rat IgG2aκ eBioscience 
CD270 APC 
HMHV-
1B18 
0.2 mg/ml 
Armenian 
hamster IgG 
eBioscience 
CD273 PerCPe-fluor 710 122 0.2 mg/ml rat IgG2aκ eBioscience 
CD274 PeCy7 10F.962 0.2 mg/ml rat IgG2bκ Biolegend 
CD274 PE MIH5 0.2 mg/ml rat IgG2aλ eBioscience 
CD276 PE M3.2D7 0.2 mg/ml rat IgG2aκ eBioscience 
CLL 
CD5 FITC 53-7.3 0.5 mg/ml rat IgG2aκ eBioscience 
CD5 APC 53-7.3 0.2 mg/ml rat IgG2aκ eBioscience 
CD19 APC-Cy7 6D5 0.2 mg/ml rat IgG2aκ Biolegend 
CD19 FITC eBio1D3 0.5 mg/ml rat IgG2aκ eBioscience 
isotype 
controls 
 PE RTK2758 0.2 mg/ml rat IgG2aκ Biolegend 
 PeCy7 RTK4530 0.2 mg/ml rat IgG2bκ Biolegend 
 PerCPe-fluor 710 
eB149/ 
10H5 
0.2 mg/ml rat IgG2aκ eBioscience 
 APC HTK888 0.2 mg/ml 
Armenian 
hamster IgG 
Biolegend 
Table 14: Summary of antigens, fluorochromes, antibody clones, concentrations and 
suppliers used to assess inhibitory ligand expression. 
 
An example of the gating strategy to identify cell populations positive and negative for 
inhibitory ligands is depicted in Figure 29. Cells were gated on viable (i.e. DAPI-
negative) single MNC. Inhibitory ligands were gated on CD19+ B cells in WT mice and 
CD19+CD5+ CLL cells in TCL1 and AT mice. Gates were placed based on isotype and 
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FMO controls for inhibitory ligands and expressed as percentage of cells positive for a 
specific inhibitory marker (Figure 29 A, example shows gating on CLL cells from a 
representative TCL1 mouse). In addition, the median fluorescence intensity (MFI) was 
reported for each ligand, corrected for the MFI of the respective isotype control 
(specific MFI).  
 
 
Figure 29: Gating strategy to assess expression of inhibitory ligands on normal B cells 
and CLL cells in mice. Cells were gated on viable single mononuclear cells. CD200, CD270, 
CD274 and CD276 were gated on CD19+ B cells in WT mice and CD19+CD5+ CLL cells in 
leukaemic mice. (A) Cell populations positive and negative for inhibitory ligand expression were 
discriminated based on isotype and FMO controls. This graph shows a representative example 
from a TCL1 mouse, and combines FCS files from the full stain containing all fluorochromes-
labelled antibodies (black colour), and the isotype control for the respective marker (grey 
colour). (B) Corresponding histograms depicting the median fluorescence intensity (MFI) for 
each ligand (dark colour) and the isotype control (grey colour). 
 
6.3.3 Comparison of gene-expression profiles from T-cell subsets in deposited 
data 
To investigate the molecular mechanisms of T-cell exhaustion, the gene expression 
profile (GEP) of CD8+ T cells from leukaemic TCL1 mice published by our group (GEO 
accession number GSE8836)216 was compared to previously published GEP data of 
effector, memory, and exhausted T cells (GSM235537)412. The latter was a landmark 
publication characterizing differences in the molecular signature of exhausted, effector 
and memory CD8+ T cells from murine LCMV infection models compared to naïve 
CD8+ cells. This paper used infection with Armstrong strain of LCMV, which is usually 
cleared by day 10, followed by contraction and differentiation, to model acute infection 
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and the generation of functional effector and memory CD8+ T cells. Infection with clone 
13 of LCMV leading to chronic infection, accompanied by loss of effector function and 
ineffective viral control, was used to model T-cell exhaustion. The CLL T-cell dataset 
was reanalysed with Partek software, and following the criteria of the LCMV analysis, 
TCL1 genes that were at least 2-fold up-or downregulated were selected as aberrantly 
expressed and exported to Microsoft Excel for further analysis. This gene list was then 
manually compared to reported dysregulated genes in effector, memory and exhausted 
CD8+ T cells both by gene ID, alternative names, and accession number. Genes that 
were represented in both the TCL1 and any of the LCMV signatures were considered 
as overlapping genes, and attributed to specific LCMV subset signatures regardless of 
whether they were up- or downregulated.  
 
6.3.4 Multicolour flow cytometry for surface expression of T-cell exhaustion 
markers 
T-cell subsets were characterized based on the surface expression of CD3, CD4, CD8 
and CD44. PD-1, TIM-3, CD160, KLRG-1, 2B4 and LAG-3 were selected as typical 
exhaustion markers that have also been used to define exhaustion-like phenotypes in 
other murine cancer models. In experiments unmasking the effect of ageing by AT, the 
panel was extend by the cytokine receptors CD122 and CD127. CLL was routinely 
determined by CD19 and CD5 expression. Information on antigens, fluorochromes, 
clones, concentrations and suppliers is listed in Table 15.  
Cells were prepared for flow cytometry as described in Chapter 3.4.1. Stopping gates 
were set to CD3+CD8+ cells to record at least 12,000 events. Cells were gated on 
viable single MNC. CD4 and CD8 were gated on CD3+ lymphocytes. Naïve cells were 
identified as CD44low+ and antigen-experienced cells as CD44+ based on FMO 
controls for CD44. Exhaustion markers were gated on CD3+CD8+ MNC and plotted 
against CD44. Gates to discriminate cells positive and negative for a certain exhaustion 
marker were placed based on FMO controls for exhaustion markers and included in all 
experiments. 
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mouse 
antigen 
fluorochrome clone concentration 
host/ 
isotype 
supplier 
T-cell 
phenotype 
CD3e APCCy7 17A2 0.2 mg/ml rat IgG2bκ Biolegend 
CD4 PerCPCy5.5 RM4-5 0.2 mg/ml rat IgG2aκ eBioscience 
CD8a FITC 53-6.7 0.5 mg/ml rat IgG2aκ eBioscience 
CD44 PECy7 IM7 0.2 mg/ml rat IgG2bκ eBioscience 
CD44 PE IM7 0.2 mg/ml rat IgG2bκ eBioscience 
T-cell 
surface 
exhaustion 
markers 
 
PD-1 APC RMP1-30 0.2 mg/ml rat IgG2bκ eBioscience 
TIM3 PE 88.2C12 0.2 mg/ml rat IgG1κ eBioscience 
CD160 PE eBioCNX46-3 0.2 mg/ml rat IgG2aκ eBioscience 
LAG3 PE eBioC9B7W 0.2 mg/ml rat IgG1κ eBioscience 
LAG3 PerCP e-fluor710 eBioC9B7W 0.2 mg/ml rat IgG1κ eBioscience 
2B4 APC 244F4 0.2 mg/ml rat IgG2aκ eBioscience 
KLRG1 PE 2F1 0.2 mg/ml 
golden Syrian 
hamster IgG 
eBioscience 
KLRG1 PerCP e-fluor710 2F1 0.2 mg/ml 
golden Syrian 
hamster IgG 
eBioscience 
T-cell 
cytokine 
receptors 
CD122 PE 5H4 0.2 mg/ml rat IgG2aκ eBioscience 
CD127 APC A7R34 0.2 mg/ml rat IgG2aκ eBioscience 
CLL 
CD5 APC 53-7.3 0.2 mg/ml rat IgG2aκ eBioscience 
CD19 FITC eBio1D3 0.5 mg/ml rat IgG2aκ eBioscience 
Table 15: Summary of antigens, fluorochromes, antibody clones, concentrations and 
suppliers used to assess T-cell exhaustion markers in relation to CLL. 
 
6.3.5 Multicolour flow cytometry for intracellular cytokines and effector 
function in AT experiments unmasking the effect of ageing 
For these studies, T-cell subsets were characterized based on the surface expression 
of CD3, CD8 and CD44. PD-1 was included into this panel to allow discrimination of 
effector function based on PD-1 expression. Cytotoxicity was assessed by measuring 
CD107a effector cell degranulation. The cytokine panel was extended to include 
intracellular IFN-γ, IL-2, TNF-α, IL-4 and IL-5. Ex vivo proliferation was measured using 
CFSE. Table 16 shows information on antigens, fluorochromes, antibody clones, 
concentrations and suppliers. 10x106 fresh spleen cells from mice with CLL and 5x106 
fresh spleen cells from healthy mice were kept in RPMI 1640 with 10% FCS, 
1%Penicillin/Streptomycin, 1% Glutamine, and 500mM beta-mercaptoethanol in a flat 
bottom 12 well-plate. 5µg/ml CD107a was added to each well, and cells were 
stimulated and processed as described in Chapter 5.3.3. Controls included wells with 
CD107a antibody and protein transport inhibitor cocktail, but no cell stimulation 
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cocktail. After the incubation, cells were harvested, washed with PBS and prepared for 
flow cytometry as described before. 
For intracellular cytokine production, cells were set up using identical conditions in a 
separate 12 well plate, with the exception that 20x106 fresh spleen cells from mice with 
CLL were used. After the incubation, cells were harvested into Falcon tubes (BD, UK), 
stained with fixable viability dye 450 (eBioscience, UK) and surface stained 30 minutes 
on ice. Cells were washed, fixed and permeabilised as described before. Before 
intracellular staining, both stimulated and unstimulated wells were split equally to Th1 
and Th2 cytokine tubes, and cells were stained with intracellular antibody cocktails for 
30 minutes at room temperature.  
 
 mouse antigen fluorochrome clone concentration 
host/ 
isotype 
supplier 
surface 
stain 
CD3e PerCPefl 710 17A2 0.2 mg/ml rat IgG2bκ eBioscience 
CD8a BV605 53-6.7 0.5 mg/ml rat IgG2aκ Biolegend 
CD44 AF700 IM7 0.2 mg/ml rat IgG2bκ eBioscience 
PD-1 APC RMP1-30 0.2 mg/ml rat IgG2bκ eBioscience 
PD-1 PerCPefl 710 RMP1-30 0.2 mg/ml rat IgG2bκ eBioscience 
cytotoxicity CD107a PE eBio1D4B 0.2 mg/ml rat IgG2aκ eBioscience 
intracellular 
cytokines 
IFN-γ PE XMG1.2 0.2 mg/ml rat IgG1κ eBioscience 
IL-2 PeCy7 JES6-5H4 0.2 mg/ml rat IgG2bκ eBioscience 
TNF-α APC MP6-XT22 0.2 mg/ml rat IgG1κ eBioscience 
IL-4 APC 11B11 0.2 mg/ml rat IgG1κ eBioscience 
IL-5 PE TRFK5 0.2 mg/ml rat IgG1κ eBioscience 
Table 16: Summary of antigens, fluorochromes, antibody clones, concentrations and 
suppliers used to assess T-cell function in relation to CLL. 
 
CD107a and intracellular cytokines were gated as described before. In addition, 
cytokine production was plotted against CD44. Stopping gates were set to 
CD3+CD8+CD44+ cells to record at least 15,000 events, or until the sample had been 
fully aspirated, whichever occurred first. Differences in T-cell function between mice 
with CLL and healthy WT mice, and between PD-1high and PD-1low subsets were 
compared by calculating ratios between CD44+ antigen-experienced cells positive or 
negative for a cytokine or CD107a. This ratio was interpreted as cells with the ability to 
exert effector cell function compared to cells of the same subset that lack this ability. 
Changes of this ratio were interpreted as loss or gain of cells with effector cell function.  
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6.3.6 Flow sorting of PD-1 subsets for immune synapse formation assays 
To assess differences of PD-1 subsets in the ability to form immunological synapses 
with normal mouse B cells as APCs, spleens from 6 available mice with CLL after AT 
were flow-sorted based on PD-1 expression. A pool of normal frozen mouse 
splenocytes was used as controls and subjected to the same procedures, including 
flow sorting. Frozen splenocytes were thawed and debulked of CLL cells by positive 
magnetic selection as described in Chapter 3.3.1. Positive labelled normal B cells were 
used as APC and rested in the incubator until needed. Cells in the CD19- fractions 
were stained with CD8 FITC, CD44 PE and PD-1 APC. An example of the sorting 
strategy is shown in Figure 30 A. CLL T cells were sorted for PD-1high, PD-1low, and 
CD8+ T cells. Normal T cells were sorted for CD8+ only. Purities were confirmed to be 
>95% (Figure 30 B), and stopping gates were set to obtain a minimum of 500,000 T 
cells per subset for each condition in the synapse assay, which was performed as 
described in Chapter 3.5. 
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Figure 30: Flow sorting of CD8+ T cells according to PD-1 expression. Frozen splenocytes 
from WT mice and mice with CLL after AT were debulked of B cells by positive selection, and 
the remaining cells were stained with CD8, CD44 and PD-1. (A) Example of gating and sorting 
strategy. (B) Purities were confirmed to be >95% for all sorted populations.  
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6.4 Results 
6.4.1 Inhibitory ligands CD200, CD270, CD274 (PD-L1) and CD276 are expressed 
on murine CLL cells but only CD274 and CD276 are significantly upregulated 
compared to normal B cells 
To investigate if the TCL1 model is a suitable tool to mirror PD-L1/PD-1 interactions, 
we first compared the expression of the previously identified inhibitory ligands CD200, 
CD270, CD274 (PD-L1), and CD276 on spleen CLL cells from TCL1 and AT mice and 
compared this to the expression on CD19+ B cells from age-matched healthy WT mice. 
This first experiment was performed on frozen cells as mice had reached their 
individual CLL-defined endpoint at different times. To minimize the likelihood of a batch 
effect, samples were cryopreserved until a sufficient number of mice had been 
collected, and the phenotyping panel was performed on all previously frozen cells 
samples at the same time.  
The CLL load in spleen was very high, defined as the proportion of CD19+CD5+ cells 
after gating on viable single MNC in this cohort of leukaemic animals, with a median of 
92%, and a minimum of 64% in two animals. WT mice were confirmed to be free of 
CLL. PD-L1 was uniformly expressed on virtually all spleen CLL cells (median 99.2%, 
range 95.6-100). CD200 and CD270 were in general highly expressed but the 
percentage of expression on CD19+CD5+ spleen cells varied among animals (CD200 
median 84.8%, range 42.8-99.9; CD270 median 72.3%, range 46.7-96.7). In contrast, 
CD276 expression levels varied widely among leukaemic animals (median 51.9%, 
range 7.7-94.7)  
However, the comparison to normal spleen B cells from healthy WT mice revealed that 
in contrast to our human data, the percentage of CD200+ and CD270+ cells was 
significantly lower in TCL1 mice than in WT mice (CD200 p=.0216, CD270 p<.0001). 
Just as in human CLL, the percentages of PD-L1+ and CD276+ cells were higher in 
TCL1 than in WT mice (PD-L1 p=.0002; CD276 p=.0226, Figure 31 A). This pattern 
was also recapitulated when comparing the specific MFI (MFI corrected for the MFI of 
the FMO/isotype control: CD200 p<.0001; CD270 p=.0004; CD274 p<.0001; CD276 
p=.0008) (Figure 31 B). Both FMO conditions and isotypes were used as controls, 
which showed very similar results. In general, the expression of all ligands was 
relatively uniform on normal B cells from WT animals. Consistent with the 
organomegaly associated with CLL, the absolute numbers of spleen cells positive for 
CD200, CD270, PD-L1 and CD276 were all significantly increased in leukaemic mice 
(Figure 31 C). 
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In leukaemic mice, background (i.e. B6 TCL1 vs. C3H TCL1) appeared to have only a 
minor effect on expression of inhibitory ligands: similar patterns regarding CD270, PD-
L1 and CD276 were observed in B6 and C3H TCL1 mice, whereas CLL cells from C3H 
TCL1 mice showed a borderline significantly higher percentage of CD200 expression 
(Figure 31 D). This was also confirmed by comparing specific MFIs. No differences 
were found between aged TCL1 mice with CLL and AT mice, both in terms of relative 
expression and specific MFI (Figure 31 E). 
 
 
Figure 31: Expression of CD200, CD270, CD274 (PD-L1) and CD276 on CLL and normal B 
cells. Absolute number (AN) of cells positive for a marker, defined by gating on FMO and 
isotype controls, and specific MFI (Median Fluorescence Intensity, MFI corrected for the MFI of 
the FMO/ isotype control) were compared. (A) Percentage of CD200+ and CD270+ CLL/B cells 
was lower in TCL1 mice than in WT mice, while percentage of CD274+ and CD276+ cells was 
higher in TCL1 than in WT mice. (B) Similar patterns were found when comparing specific MFIs. 
(C) Consistent with the organomegaly associated with CLL, AN of spleen cells positive for 
CD200, CD270, CD274 and CD276 were significantly increased in leukaemic mice. (D) Similar 
expression patterns were found in TCL1 mice on both backgrounds (B6 TCL1 vs. C3H TCL1), 
with the exception of CD200. (E) No differences were found between aged TCL1 mice with CLL 
and AT mice. All graphs depict median with interquartile range (IQR). ns = non-significant, 
*p<.05, **p<.001, ***p<.0001.  
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6.4.2 Highly aberrant PD-L1 and PD-L2 expression are exclusive to malignant 
CLL cells and develop in the context of advancing disease regardless of 
microenvironment 
After we confirmed that aberrant PD-L1 expression on spleen CLL cells can be 
modelled in TCL1 mice and that it closely mirrors the expression of PD-L1 in human 
CLL, we sought to examine how this develops in the context of progressing CLL. In 
addition, characterization of PD-L1 expression in human CLL had been limited to flow 
cytometry in PB and immunohistochemistry in LN, while the mouse data described in 
Chapter 6.4.1 was derived from spleen single cell suspensions. Therefore, we sought 
to extend the mouse phenotyping panel to PB, BM and LN, and to also assess the 
expression of PD-L2 in 3, 6, and 12 month old TCL1 and WT mice and AT mice (WT 
recipients). As our first experiment demonstrated that percent positive cells and specific 
MFI provide effectively the same information, we restricted this analysis to comparison 
of MFIs.  
We routinely confirmed that WT and young TCL1 mice were free of CLL. As before, in 
mice without a detectable CLL population PD-L1/PD-L2 expression was assessed on 
CD19+ B cells, while in mice with CLL this was assessed on CD19+CD5+ CLL cells 
(Figure 32 C). As discussed in the previous chapter, 6 month old TCL1 mice represent 
an early stage of CLL, where malignant CD19+CD5+ CLL cells exist alongside normal 
CD19+ B cells, allowing these populations to be directly compared. We therefore 
assessed expression on both normal and malignant B cells in this age group to gain 
insight as to whether PD-L1/PD-L2 expression is exclusive to CLL cells.  
PD-L1 expression on normal spleen B-cells was relatively constant in healthy ageing 
WT mice, but increased in TCL1 mice developing CLL and after AT (Figure 32 A). This 
was recapitulated in BM and LN. In PB, PD-L1 expression in WT mice was significantly 
increased at 6 and decreased at 12 months, but this was most likely the result of a 
single outlier in this group of mice. In PB of TCL1 mice developing CLL and in AT mice, 
PD-L1 expression increased consistently. The direct comparison of normal and 
malignant B-cell populations in 6 month old TCL1 mice demonstrated that aberrant PD-
L1 expression appeared to be restricted to CLL cells in spleen and BM (for both 
organs, p=.0022 for MFI of PD-L1 in normal B cells vs. CLL cells). A similar, but not-
significant, trend was observed in PB (p=.09). Interestingly, PD-L1 expression was 
comparable (p=.2805) in normal and malignant B cells in LN in these 6 month old mice, 
and only became strongly upregulated at 12 months, and to a certain degree after AT. 
This is consistent with the longer latency of disease accumulation we observed in LN 
(see previous chapter). Confirming our previous findings, PD-L1 expression was 
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significantly upregulated in fully leukaemic mice compared to age-matched WT mice in 
all organs (p=.0043). PD-L2 expression appeared to be strongly dependent on the 
microenvironment in ageing WT mice, as it showed a slight upregulation in spleen, BM 
and LN, but not PB (Figure 32 B). In TCL1 mice, highly upregulated PD-L2 was 
restricted to CLL cells, as demonstrated by the direct comparison between normal and 
malignant B-cell populations in 6 month old TCL1 mice. In addition, PD-L2 expression 
was significantly higher on CLL cells from all organs from fully leukaemic mice 
compared to normal B cells from aged-matched healthy WT mice (p=.0043). Statistical 
differences of MFIs compared to 3 month old mice as baseline are summarized in 
Figure 32 D.  
 
 
Figure 32: Development of PD-L1/PD-L2 expression alongside advancing CLL in different 
organs. Organs from 3, 6, and 12 month old TCL1 and WT mice and AT mice (WT recipients) 
were phenotyped by flow cytometry and specific MFIs were compared. (A) PD-L1 expression 
increased progressively in TCL1 mice and after AT in all examined organs. Aberrant expression 
was restricted to CLL cells as evidenced by direct comparison between normal and malignant B 
cells in 6 month old TCL1 mice, and was significantly higher in fully leukaemic TCL1 than in 
healthy WT mice. (B) PD-L2 expression appeared to be dependent on the microenvironment in 
ageing WT mice, and increased progressively in TCL1 mice and after AT in all examined 
organs. Highly increased expression was exclusive to malignant B cells. (C) Examples of 
representative flow plots from spleen demonstrating the presence/absence/co-existence of 
normal and malignant B-cell populations. (D) Heatmap summary of p-values describing 
statistical differences in MFI. Groups were compared to specific MFIs in 3 month old mice. Blue 
colour indicates increase, red colour indicates decrease of MFI. ns = non-significant, *p<.05, 
**p<.001, ***p<.0001. 
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6.4.3 Molecular signature of exhausted T-cells from LCMV infection model is 
represented in murine CLL T cells but similarities to functional effector cells are 
maintained 
After confirming the suitability of TCL1 mice to model aberrant PD-L1/PD-L2 
expression, we focused on the further characterization of their binding partner PD-1 on 
CD8+ T cells. Aberrant PD-1 expression has been reported as having implications not 
only in human CLL, but also in chronic viral infection leading to T-cell exhaustion. In 
addition, the majority of dysregulated pathways identified in the molecular signature of 
CLL CD8+ T cells showed resemblance to dysregulated pathways reported in 
exhausted T cells in chronic viral infection. However, further studies have indicated that 
T cells in CLL show phenotypic similarities to exhausted T cells but maintain certain 
effector functions such as cytokine proliferation, indicating that they might not be “truly” 
exhausted. To investigate the molecular mechanisms of T-cell dysfunction and to 
determine if dysregulated CLL T cell genes are represented and/ or enriched in the 
molecular signature of exhausted, effector or memory cells, we compared the gene 
expression profile of CD8+ T cells from leukaemic TCL1 mice to previously published 
gene expression profile data of effector, memory, and exhausted T cells412.  
Between 690 dysregulated genes in the TCL1 and 680 dysregulated genes in the 
LCMV dataset, 73 genes were overlapping (Figure 33 A). A summary of overlapping 
genes can be found in Table 28 in the Appendix. Among LCMV genes, Wherry et al. 
confirmed that exhaustion represents a unique state of T-cell gene expression 
compared to other cell subsets, as it contains a large number of exclusively expressed 
dysregulated genes (Figure 33 B). In addition, they identified more similarities between 
exhausted and effector cells than between exhausted and memory cells. A remarkably 
similar distribution was observed in the overlapping genes from our dataset; over one 
third of CLL T-cell genes were represented in the exhaustion signature, indicating that 
this also represents a unique state of gene expression in CLL T cells (Figure 33 C). 
These genes were mostly involved in the regulation of signalling potential, transcription 
factors, metabolic/bioenergetic regulation, cytoskeleton regulation and vesicle 
trafficking. In addition, about 20% of overlapping dysregulated genes from our dataset 
were also represented in the effector signature, and 16% in the overlapping signature 
between exhausted and effector cells, which potentially explains the partly maintained 
effector function of CLL T cells described in the literature. 
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Figure 33: Comparison of gene expression profiles between deposited data. The 
molecular signature of CD8+ T cells from leukaemic TCL1 mice (Gorgun et al.216, GEO 
accession number GSE8836) was re-analysed with Partek software applying the criteria of 
Wherry et al.412 (GSM235537). (A) Overlap in gene expression profile for the TCL1 (Gorgun) 
and the Wherry dataset. (B) More similarities exist between exhausted and effector cells than 
between exhausted and memory cells (graph adapted from Wherry et al., shown here to 
illustrate the grouping of gene signatures). (C) Distributions in the overlapping genes from the 
TCL1 (Gorgun) and LCMV (Wherry) exhaustion (Ex), effector (Eff) and memory (Mem) 
signatures. 
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6.4.4 Typical exhaustion phenotype is modelled in TCL1 mice but is 
confounded by ageing 
After confirming that the molecular signature of CLL CD8+ T cells resembles that of 
exhausted T cells, we sought to determine the surface expression of exhaustion 
markers that had also been described in other murine cancer models. These included 
PD-1, TIM-3, CD160, KLRG-1, 2B4 and LAG-3. Here, we focused on PD-1 due to the 
prominent role of its ligands PD-L1 and PD-L2 in both human and murine CLL.  
Using CD44 expression to discriminate between naïve (CD44-) and antigen-
experienced (CD44+) CD3+CD8+ cells, we determined changes in the relative and 
absolute numbers of PD-1+ and PD-1- subsets in 3, 6 and 12 month old TCL1 and WT 
mice and after AT. Gates were defined based on PD-1 FMO controls (Figure 34 A). An 
example of how subsets were quantified in the context of the dynamic changes within 
CD3+CD8+ cells (i.e. loss of naïve cells and shift to antigen-experienced cells; see 
previous chapter) is depicted in Figure 34 B. With developing CLL, PD-1 was step-wise 
upregulated on antigen-experienced cells, and in line with the organomegaly, absolute 
numbers increased. This was to a certain extent also observed in ageing WT mice, 
confirming that the relative PD-1 expression is confounded by the effect of ageing. 
However, the upregulation of PD-1 could be induced in young mice after AT, 
suggesting a causal relationship between CLL and PD-1 expression. We confirmed 
these patterns in two independent experiments using different mice; the relative (left 
panel) and absolute numbers (right panel) of CD3+CD8+CD44+PD-1+ cells are shown 
in Figure 34 C for experiment 1, and in Figure 34 D for experiment 2.  
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Figure 34: Surface expression of PD-1 on naïve CD44- and antigen-experienced CD44+ 
CD3+CD8+ cells from spleen. Changes in relative and absolute numbers (AN) of PD-1+ and 
PD-1- subsets were compared in 3, 6 and 12 month old TCL1 and WT mice, and after AT. (A) 
Representative flow plots from TCL1 mice at different ages demonstrating the shifts of subsets. 
FMO controls were used to determine PD-1 gates. (B) Quantification of subsets in the context of 
CLL-induced T-cell subset changes. Stacked bar charts were used to visualize the loss of naïve 
(light grey) and shift to antigen-experienced cells (dark grey), along with the changing 
expression of PD-1. (C) With developing CLL and after AT, PD-1 expression increased on 
antigen-experienced cells, and to a certain extent also in WT mice. AN were significantly higher 
in TCL1 and AT mice. (D) Confirmation in second experimental round. All graphs in (C) and (D) 
show median with interquartile range. ns = non-significant, *p<.05, **p<.001, ***p<.0001. 
 
We observed very similar patterns for LAG-3 (Figure 35 A), 2B4 (Figure 35 B) and 
KLRG-1 (Figure 35 C), which were confirmed by two experimental rounds. TIM-3 
expression increased in ageing TCL1 mice but was generally expressed at very low 
levels (median in all age groups <2% CD3+CD8+CD44+TIM3+), and expression could 
not be induced by AT (Figure 35 D). As it cannot be assumed that expression changes 
at such low levels indicate true disease-related aberrations, we excluded this marker 
from the confirmation experiment.  
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Figure 35: Surface expression of other exhaustion markers on naïve CD44- and antigen-
experienced CD44+ CD3+CD8+ cells from spleen. Confirmation of increased expression of 
(A) LAG-3, (B) 2B4 and (C) KLRG-1 in ageing TCL1 mice and after AT. (D) TIM-3 was 
expressed at very low levels and could not be induced by AT. Stacked bar charts provide an 
overview of data from experiment 1 and are shown as a representative example for both 
experiments.  
 
A very different pattern was observed for CD160: in the first experiment, expression 
increased with developing CLL and after AT, in line with the other exhaustion markers. 
In the second experiment, however, expression was lost in ageing TCL1 mice and after 
AT, with absolute numbers still being significantly higher than in WT mice, while relative 
CD160 increased in WT mice (Figure 36 A and B). To rule out that this was caused by 
slight differences in the gating strategy or a batch effect by mice, data from both 
experiments was re-gated and re-analysed together, which yielded the same results. In 
addition, the characteristics of mice used in experiments were compared and no 
differences were detected (data not shown).  
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Figure 36: Surface expression of CD160 on naïve CD44- and antigen-experienced CD44+ 
CD3+CD8+ cells from spleen. Conflicting expression patterns were observed in the two 
experiments conducted. (A) The first experiment demonstrated increased expression with 
developing CLL and after AT and increased absolute numbers (AN). (B) In the second 
experiment, CD160 was lost with developing CLL and after AT, with AN increasing. (C) 
Representative flow plots from WT and TCL1 mice from the two experiments. Note: in first 
experiment, AT recipients were young TCL1 mice, and WT in the second experiment. Plots are 
overlaid graphs between FMO control for CD160 (black colour) and the full stain (grey colour). 
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A heatmap summary of relative (panel A) and absolute (panel B) changes of 
CD3+CD8+CD44+ cells expressing the investigated surface exhaustion markers in all 
experiments conducted is depicted in Figure 37. 
 
 
Figure 37: Heatmap summary of p-values describing statistical differences in relative and 
absolute changes of cell subsets expressing typical exhaustion markers. Groups were 
compared to (A) relative and (B) absolute numbers (AN) in 3 month old mice and experiments 
were conducted twice using different cohorts of mice. The first experiment is signified as (1), the 
second one as (2) in these tables. Blue colour indicates expansion, red colour loss of cell 
subsets. ns=non-significant, *p<.05, **p<.001, ***p<.0001. 
 
6.4.5 Aberrant PD-1 expression by CD3+CD8+ T cells develops largely 
regardless of microenvironment 
After demonstrating the step-wise upregulation of PD-1 on antigen-experienced 
CD3+CD8+ T cells from spleen, we compared this to PD-1 expression in PB, LN and 
BM from 3, 6 and 12 month old TCL1 mice and AT mice. As LNs have been 
demonstrated to show delayed disease development and model only some aspects of 
T-cell dysfunction after AT, LN from mice with CLL after AT were excluded from this 
comparison. With the exception of LN, the step-wise upregulation of PD-1 on antigen-
experienced CD3+CD8+ T cells was recapitulated in all organs, and could be induced 
by AT (Figure 38 A). A heatmap summary of p-values of the statistical comparison with 
3 month old mice is depicted in Figure 38 B. Spleen T cells had the highest PD-1 
expression (median 19.4%, range 12.3-28.8), followed by BM (median 14.6%, range 
10.0-27.9) and PB (median 8.7%, range 5.7-28.8).  
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Figure 38: Development of PD-1 expression on CD3+CD8+ T cells alongside advancing 
CLL in different organs. Cells from spleen, PB, BM and LN from 3, 6, and 12 month old TCL1 
and AT mice (WT recipients) were phenotyped by flow cytometry and percentages of 
CD3+CD8+CD44+PD1+ cells were compared. (A) PD-1 expression increased in ageing TCL1 
mice and after AT in all examined organs, with the highest percentage in spleen, followed by 
BM and PB. (B) Heatmap summary of p-values describing statistical differences. Groups were 
compared to expression in 3 month old mice. Blue colour indicates expansion, red colour 
indicates loss of cells expressing PD-1. ns = non-significant, *p<.05, **p<.001, ***p<.0001. 
 
6.4.6 Randomized AT experiments unmask the effect of ageing  
After we had confirmed that not only PD-L1/PD-L2 but also PD-1 and other exhaustion 
markers can be adequately modelled in TCL1 mice, but that the underlying 
mechanisms might be masked by ageing, we next conducted randomized AT 
experiments. The aim of these experiments was to eliminate ageing as a confounder 
by using young TCL1 and WT recipients, and to investigate functional differences 
between PD-1high and PD-1low T-cell subsets. Complementing other work in this project, 
additional aims were to directly compare T-cell phenotype changes in TCL1 and WT 
recipients using donor cells from the same pool. Before the AT, the purity of the donor 
pool was confirmed by flow cytometry to contain >95% CLL cells, while the WT pool 
was confirmed to be free of CLL. 
 
6.4.6.1 Confirmation of CLL-induced specific T-cell phenotype in both WT and 
TCL1 recipients 
For this experiment using mice from AT experiment 8 (see Table 7), CLL could be 
induced in both TCL1 and WT recipients by injecting them with cells from a pool from 
leukaemic TCL1 donors, without any significant differences in latency or disease 
characteristics (see Chapter 4.4.3, Figure 8). For mice receiving normal B cells, WT 
recipients did not develop any leukaemia, but TCL1 recipients had a slightly higher 
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percentage of CD19+CD5+ CLL cells in spleen (median 6.0%, range 3.9-11.9). This 
minor increase is in line with very early TCL1 transgene-driven CLL development 
expected at this age (recipients were 4 months old).  
The direct comparison between WT and TCL1 recipients confirmed that AT of CLL 
cells induced the previously defined disease-specific T-cell phenotype, namely the 
relative loss of CD3+ cells, the relative increase of CD3+CD8+ cells, the loss of naïve 
CD3+CD8+ cells, and the shift towards antigen-experienced cells (Figure 39 A and B 
left panel), and the increase of absolute numbers of all subsets in leukaemic mice 
(Figure 39 B right panel). This was observed regardless of whether animals were WT 
or transgenic (all differences for these subsets between WT and TCL1 recipients of 
CLL cells were not-significant). In line with the very early TCL1-driven CLL 
development, we observed slight differences in CD3+CD8+ T-cell subsets between WT 
and TCL1 recipients of normal B cells, namely a beginning loss of naïve and shift to 
antigen-experienced cells (p=.0182).  
 
 
Figure 39: Confirmation of CLL-specific T-cell phenotype in AT mice. Mice were injected 
with donor cells from a leukaemic TCL1 donor or normal B cells. (A) Correlation between 
increasing CLL and relative loss of CD3+ and relative increase of CD3+CD8+ cells were 
confirmed. Recipients of WT donor cells are clustered on the y-axis, with leukaemic mice 
exhibiting the CLL-induced phenotypic T-cell defects. (B) Confirmation of CLL-specific T-cell 
phenotype in relative (left panel) and absolute numbers (AN, right panel) of CD3+, CD8+, naïve 
and antigen-experienced CD3+CD8+ cells. Abbreviations: WT=wild-type; D=donor; R=recipient. 
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6.4.6.2 CLL induces aberrant expression of typical surface exhaustion markers 
We next compared PD-1 expression between WT and TCL1 recipients of CLL and 
normal B cells. In recipients of CLL cells, PD-1 was significantly upregulated compared 
to recipients of normal B cells, regardless of whether recipients were transgenic or not 
(Figure 40 A, all differences between PD-1+ and PD-1- subsets between WT and TCL1 
recipients were not-significant). The very early CLL development in young TCL1 mice 
did therefore not translate into induction of PD-1, indicating that WT and TCL1 
recipients can be analysed together. While eliminating the confounding effect of age, 
both relative PD-1 expression and absolute numbers (data for absolute numbers not 
depicted) were significantly higher in both CD44+ (Figure 40 B) and CD44- (Figure 40 
C) subsets in mice with CLL. The ratio between PD-1+ and PD-1- cells among CD44+ 
cells was also significantly higher in recipients of CLL, indicating that the antigen 
experienced CD3+CD8+ cell population was highly enriched for PD-1+ cells (Figure 40 
D, summary of p-values in Table 15).  
 
 
Figure 40: CLL-induced aberrant expression of PD-1 on CD3+CD8+ cells. (A) Antigen 
experienced and naïve CD3+CD8+ cells from mice with CLL showed increased PD-1 
expression and expanded numerically irrespective of transgene status of recipient mice. (B) 
Changes of relative PD-1 expression on CD44+ and (C) CD44- cells and (D) differences in PD-
1 subset ratios between mice injected with normal B cells from WT donors compared to mice 
injected with CLL cells from leukaemic TCL1 donors. WT=wild-type; D=donor; R=recipient. ns = 
non-significant, *p<.05, **p<.001, ***p<.0001. 
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Virtually identical patterns were observed for KLRG-1, 2B4, and LAG-3, regarding both 
changes in CD44 subsets and expression of exhaustion markers (summarized in 
Figure 41 A as stacked bar charts), increase in relative expression, and ratios (Figure 
41 B). Absolute numbers of cells expressing these exhaustion markers were also 
consistently significantly increased in mice with CLL (data not depicted). 
Representative flow plots are shown in Figure 41 C, and a summary of p-values is 
available in Table 17.   
 
 
Figure 41: CLL-induced aberrant expression of KLRG-1, 2B4 and LAG-3 on CD3+CD8+ 
cells. (A) Antigen experienced (dark grey) CD3+CD8+ cells from mice with CLL (TCL1 donor) 
upregulate exhaustion markers compared to normal mice (WT donor). Naïve cells are depicted 
in light grey. (B) Changes of relative numbers of CD44+ cells expressing exhaustion markers, 
and differences in ratios between mice injected with normal B cells from WT donors compared 
to mice injected with CLL cells from leukaemic TCL1 donors. (C) Representative flow plots. ns = 
non-significant, *p<.05, **p<.001, ***p<.0001. 
 
Interestingly, CD160 expression, which had shown conflicting expression patterns in 
previous experiments, was also increased in mice with CLL (p=.0115, Figure 42 A and 
B). However, the ratio between CD160+ and CD160- cells among CD44+ cells was not 
different between leukaemic and healthy mice, indicating that CLL does not lead to an 
enrichment of CD160+ cells in the antigen-experienced CD3+CD8+ cell population 
(Figure 42 B right panel). Representative flow plots are depicted in Figure 42 C. 
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A summary of all p-values of the comparisons between mice injected with normal B 
cells from WT donors compared to mice injected with CLL cells from leukaemic TCL1 
donors is provided in Table 17.  
 
 
Figure 42: CLL-induced expression of CD160 on CD3+CD8+ cells. (A) Antigen experienced 
CD3+CD8+ cells from mice with CLL (TCL1 donor) upregulate CD160 compared to healthy 
mice (WT donor). (B) Changes of relative numbers of CD160+CD44+ cells and differences in 
ratios between mice injected with normal B cells from WT donors compared to mice injected 
with CLL cells from leukaemic TCL1 donors. (C) Representative flow plots. ns = non-significant, 
*p<.05, **p<.001, ***p<.0001. 
 
 
absolute numbers of 
CD3+CD8+ cells 
relative numbers of 
CD3+CD8+ cells 
ratio of positive vs. 
negative cells in 
CD44+ subset marker CD44+ CD44- CD44+ CD44- 
PD-1 <.0001 .0006 <.0001 .0002 .0006 
KLRG-1 .0009 .0335 .0002 .02105 .0033 
2B4 .0006 .0006 <.0001 .0831 <.0001 
LAG-3 .0006 .0006 .0006 .8148 <.0001 
CD160 .001 .0047 .0115 .6065 .6806 
Table 17: Summary of p-values of comparisons between mice injected with normal B 
cells compared to mice injected with CLL cells for expression of exhaustion markers. For 
each marker, absolute and relative numbers, as well as ratios of cells positive and negative for 
exhaustion marker among antigen experienced CD3+CD8+CD44+ cells were compared. 
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6.4.6.3 CLL induces altered cellular survival cytokine profile indicating switch 
from IL-7 to IL-2 dependency 
In addition to surface exhaustion markers such as PD-1, KLRG-1, etc., aberrant 
expression of CD122 and CD127 cytokine receptors has been described as a 
characteristic of exhausted cells. CD122 is the β-chain of the receptor for IL-2, and 
CD127 the α-chain of the receptor for IL-7. CD127 is expressed by naïve and memory 
cells, and its selective expression in the effector phase identifies CD8+ T cells that give 
rise to long-lived memory T cells425. TBET has been shown to directly repress 
expression of the IL7R gene and to downregulate CD127 surface expression, thus 
promoting effector cell differentiation at the expense of memory cell formation. At the 
same time, it can upregulate CD122, switching the cellular survival cytokine profile from 
IL-7 to IL-2, resulting in hypo-responsiveness to homeostatic cytokines and becoming 
dependant on antigen stimulation for survival426.  
Antigen experienced CD3+CD8+ T cells from mice with CLL after AT significantly 
upregulated CD122 (p<.0001, Figure 43 A and B upper panels) while downregulating 
CD127 (p=.0025, Figure 43 A and B lower panels) compared to healthy controls, while 
expanding both subsets numerically (graphs not depicted, CD122 p=.0006, CD127 
p=.0006). In addition, the ratios between CD122+ and CD122- (p=.0002, Figure 43 B 
upper right panel), and CD127+ and CD127- cells (p<.0001, Figure 43 B lower right 
panel), respectively, demonstrated that antigen-experienced cells were enriched for 
CD122+ and depleted of CD127+ cells. This result indicates that the pool of cells 
committed to long-lived memory differentiation was very small. In addition, these 
patterns potentially reflect an altered dependency from IL-7 to IL-2. Representative flow 
plots are depicted in Figure 43 C. 
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Figure 43: CLL-induced expression of IL-2 and IL-7 cytokine receptors on CD3+CD8+ 
cells. CD122 (IL-2Rβ chain) and CD127 (IL-7Rα chain) expression was compared between 
mice injected with normal B cells compared to mice injected with CLL cells. (A) Antigen 
experienced CD3+CD8+ cells from mice with CLL (TCL1 donor) upregulate CD122 and 
downregulate CD127 expression compared to healthy mice (WT donor). (B) Changes of relative 
numbers of CD122+ and CD127+CD44+ cells, and differences in ratios. (C) Representative flow 
plots. ns = non-significant, *p<.05, **p<.001, ***p<.0001. 
 
6.4.6.4 CLL T-cells maintain certain effector functions such as cytokine 
production and degranulation despite PD-1 expression  
After the phenotypic characterization, we compared key CD3+CD8+ effector functions 
between mice injected with cells from CLL donors and a pool of WT donors and 
attributed these to PD-1high and PD-1low subsets in mice with CLL.  
Confirming the findings discussed in the previous chapter, the percentage of 
CD3+CD8+ cells producing IL-2 was comparable in mice with CLL and healthy mice 
(p=.1605, Figure 44 A left panel), while IL-4 (p=.0006, Figure 44 B left panel) and IFN-γ 
(p=.0104, Figure 44 C left panel) were significantly increased in mice with CLL. To 
attribute the ability to produce cytokines to specific cell subsets, we compared the 
ratios of cytokine producing and non-producing cells within CD44- naïve and CD44+ 
antigen experienced CD3+CD8+ cells between mice without and with CLL (Figure 44 
right panels). While IL-2 ratios were comparable between healthy and CLL mice 
(Figure 44 A), the increased IL-4 production in CLL T cells was found to be attributed to 
increased production by CD44- cells, as indicated by the significantly increased ratio in 
mice with CLL compared to healthy mice (p=.0006, Figure 44 B). Increased IFN-γ 
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production in mice with CLL could be attributed to both naive (p=.007) and antigen 
experienced (p=.0148, Figure 44 C) cells. Although no differences in the percentage of 
cells producing TNF-α was found when comparing CD3+CD8+ cells from mice without 
and with CLL (p=.5752, Figure 44 D left panel), a significantly reduced TNF-α ratio was 
found among antigen experienced cells, indicating that they were enriched for cells 
unable to produce TNF-α (p=.0011).  
In addition, we largely confirmed the previously observed differences in cytokine 
production by CD3+CD8- cells (note: CD4 antibody was not included in this panel, but 
as described in the previous chapter, gating CD3 against CD8 allows the identification 
of a CD3+CD8- population, which we previously found to be mostly CD4+ cells). CD4+ 
cells from mice with CLL had significantly higher IFN-γ (p=.0019), but lower TNF-α 
(p=.0002) production compared to healthy mice. In contrast to the previous experiment, 
IL-2 was not reduced in mice with CLL (p=.3823). In addition, there were trends 
towards increased IL-4 (p=.1605) and IL-5 (p=.083) production in mice with CLL 
(Figure 44 E).  
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Figure 44: Intracellular cytokine production by CD4+ and CD8+ subsets. Intracellular IL-2, 
IL-4, IFN-γ and TNF-α were compared between mice with CLL (TCL1 donor) and healthy mice 
(WT mice). Cytokines were first gated on CD3+CD8+ cells (left panel (A) to (D)), and then on 
CD44+ and CD44- subsets, and expressed as ratios (right panel (A) to (D)). (A) IL-2 production 
was not increased, and IL-2 ratios were comparable between healthy and CLL mice. (B) Mice 
with CLL had significantly increased IL-4 production, mostly due to an increased production 
within CD44- cells. (C) IFN-γ production was significantly increased in mice with CLL and could 
be attributed to both CD44- and CD44+ cells. (D) No difference in intracellular TNF-α was found 
when comparing CD3+CD8+ cells, but a significantly reduced TNF-α ratio became apparent in 
CD44+ cells. (E) CD4+ cells from mice with CLL had significantly higher intracellular IFN-γ, a 
trend towards increased IL-4 and IL-5, but lower TNF-α production. In contrast to previous 
findings, IL-2 was not reduced in CLL T cells. 
 
 
 
 
 
 
Fabienne McClanahan                                                                                                     Chapter 6 
Page 162 of 258 
 
We next compared cytokine production by CD3+CD8+ cells according to PD-1 
expression in mice with CLL. To rule out that mitogen stimulation would have an effect 
on PD-1 expression, the percentages of CD3+CD8+CD44+ cells positive for PD-1 
without and with PMA/Ionomycin treatment were compared, and no general increase of 
expression was found (Figure 45 E).  
In general, intracellular cytokines were detected in both PD-1high and PD-1low subsets 
(Figure 45 A). As a higher percentage of cells were PD-1low, leading to a substantially 
different distribution of cells between the PD-1high and the PD-1low pool, differences in 
cytokine production were described as ratios within PD-1high and PD-1low cells, 
respectively (Figure 45 B). There was no difference between PD-1high and PD-1low cells 
in the ratio of CD3+CD8+ cells able to produce IL-2 (p=.3939) and IL-4 (p=.2345) 
compared to those not producing any cytokine after PMA/Ionomycin treatment, 
indicating that despite PD-1 expression, comparable percentages of cells maintained 
IL-2 and IL-4 production.  
Albeit not significant, probably due to the large range between mice, the ratio of IFN-γ 
showed a trend to be increased in PD-1high cells (p=.38), indicating that those cells were 
enriched for IFN-γ producing cells. In contrast, PD-1high cells had a significantly lower 
TNF-α ratio (p=.026), indicating that they were depleted of cells producing TNF-α.  
Cytotoxic function, as measured by CD107a relocation to the cell surface after 
stimulation with PMA/Ionomycin, was maintained in both PD-1high and PD-1low 
CD3+CD8+ cells, indicating that cells were able to degranulate (Figure 45 C). When 
forming the ratio between CD107a+ and CD107a- cells within PD-1 subsets, we found 
a significantly increased ratio in PD-1high cells (p=.0104), indicating that cells with the 
ability to degranulate were enriched compared to the PD-1low subset.  
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Figure 45: Intracellular cytokine production and degranulation in PD-1 subsets. 
Intracellular IL-2, IL-4, IFN-γ, TNF-α and CD107a were gated on PD-1 subsets to compare 
differences in key effector functions. (A) Intracellular cytokines were detected in both PD-1high 
and PD-1low subsets. (B) Despite PD-1 expression, comparable percentages of cells were able 
to produce IL-2 and IL-4, while PD-1high cells showed a trend to be enriched for IFN-γ producing 
cells but depleted of cells producing TNF-α. (C) Both PD-1high and PD-1low CD3+CD8+ cells 
were able to degranulate, but cells with the ability to degranulate were enriched in the PD-1high 
subset (D). (E) PMA/Ionomycin stimulation had no effect on changes in PD-1 expression. 
 
We had intended to measure T-cell proliferation in this experiment ex vivo by CFSE 
dilution, after optimizing this assay beforehand using normal T cells from WT mice. 
Optimization included several experiments to determine the optimal number of cells, 
plates to be used, duration of stimulation and ratio between cells and CD3/CD28 
beads. We ultimately established that for mouse T cells, fresh cells needed to be used, 
that splenocytes had to be depleted of B cells by positive selection of CD19+ B cells 
with CD19 microbeads, and that 0.2x106 cells should be stimulated with CD3/CD28 
beads at a 1:1 cell:bead ratio and cultured for 72 hours in 96 well round-bottom plates. 
However, in the AT experiment described here, proliferation measured by CFSE 
dilution was very inconsistent in mice with CLL, and did not allow comparison of 
proliferation between CLL and normal T cells using conventional read-outs such as 
proliferation index. While T-cell proliferation was observed and could be quantified in 
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normal T cells, CLL T cells had in initial proliferation peak, and then diluted CFSE in “a 
bulk” instead of in an orderly fashion by cell cycle divisions, probably because CLL T 
cells were not quiescent at the time of labelling (see Figure 46 A and B). After this had 
been confirmed in three different mice with CLL, we did not pursue measurement of 
proliferation ex vivo by CFSE, but focused on methods using ki67 and EdU 
proliferation. Hence, this experiment did not yet yield the desired information on CLL 
induced proliferation defects and their association to PD-1 expression in T cells from 
mice with CLL.    
 
 
Figure 46: CD3+CD8+ T-cell proliferation by CFSE dilution. Fresh splenocytes were 
debulked of B and CLL cells, labelled with CFSE and cultured for 72h with CD3/CD28 
dynabeads. (A) Compared to normal T cells from mice injected with B cells from healthy WT 
donors (WTD), proliferation was not quantifiable using conventional tools such as proliferation 
index in T cells from mice with CLL after injection with cells from leukaemic TCL1 donors 
(TCL1D). (B) Representative histogram demonstrating proliferation peaks. All graphs show data 
gated on viable, single, CD3+CD8+ cells.  
 
6.4.6.5 The ability to form immunological synapses is significantly impaired in 
PD-1high compared to PD-1low cells 
As impaired immune synapse formation has been characterized as one of the major 
CD8+ effector cell defects, we compared the ability of PD-1high and PD-1low CD8+ T 
cells to form synapses with normal mouse B cells as APC. T cells from mice with CLL 
were flow-sorted for CD8, CD44+PD-1high and CD44+PD-1low, while normal T cells were 
flow-sorted for CD8, and their mean areas of T-cell F-actin immune synapses in µm2 
formed with CMAC-labelled normal B cells were compared. Compared to normal CD8+ 
T cells, the ability of CLL CD8+ T cells to form synapses with normal B cells was 
significantly impaired (p<.0001, Figure 47 A). However, PD-1low CD8+ T cells formed 
larger synapses than PD-1high CD8+ T cells (p<.0001). Compared to all CD8+ T cells, 
synapses between PD-1high T cells and APCs were significantly smaller (p<.0001), 
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while synapses between PD-1low T cells and APCs were significantly larger (p<.0001), 
indicating that the impaired ability of CD8+ T cells in general seems to be promoted by 
the PD-1high subset, probably via interference with Lck signalling. Representative 
confocal images are depicted in Figure 47 B. 
 
 
Figure 47: Immune synapse formation between normal B cells and T cells from healthy 
mice and mice with CLL. (A) Compared to normal B and CD8+ T cells (hBC-hTC), the ability 
of CLL T cells to form synapses with normal B cells as APCs was impaired (hBC-CLL TC), with 
PD-1low CD8+ T cells (hBC-PD-1low) forming larger synapses than PD-1high CD8+ T cells (hBC-
PD-1high). (B) Representative confocal images of synapses taken with a 63x objective between 
hBC-hTC, hBC- PD-1high and hBC-PD-1low cells. Blue = CMAC labelled B cells, red = Rhodamine 
Phalloidin.   
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6.4.7 PD-1 expressing normal T cells have markedly different effector functions 
than PD-1 expressing CLL T cells  
After the AT experiments had unmasked the effect of ageing and had demonstrated 
that effector functions such as cytokine production and degranulation appear to be 
maintained regardless of PD-1 expression of CLL T cells, we reinvestigated the cohort 
of ageing TCL1, WT, and AT mice described in Chapter 5.4. We had obtained 
functional data for these mice to elucidate how T-cell effector functions change in the 
context of developing CLL, and had also included PD-1 surface stain in these assays. 
As demonstrated in Chapter 5.4, PD-1 expression by CD3+CD8+CD44+ T cells could 
be detected in both TCL1 and WT mice from 6 months on. To investigate if PD-1 
expression might be associated with different effector functions in healthy mice than in 
mice with CLL, we attributed CD107a degranulation, intracellular GrB and IFN-γ, and 
EdU proliferation to PD-1high and PD-1low cells in both WT and TCL1 mice (Figure 48 A-
D). Three month old mice had no detectable PD-1 expression and effector function was 
therefore determined on PD-1low cells only.  
In ageing WT mice, both PD-1 subsets contributed to the overall patterns associated 
with ageing described in the previous chapter, i.e. maintenance of degranulation and 
intracellular GrB, reduction of proliferation, and increase of intracellular IFN-γ 
production. The effector ratios for CD107a (Figure 48 A left panel) and EdU 
proliferation (Figure 48 D left panel) were comparable in PD-1 subsets (PD-1high vs. 
PD-1low 6 and 12 month all p-values ns), indicating that both PD-1high and PD-1low 
contained comparable proportions of cells able to degranulate and to proliferate. 
Effector ratios for intracellular GrB (Figure 48 B left panel) and IFN-γ (Figure 48 C left 
panel), however, were 2 to 3 times higher in PD-1high than in PD-1low cells (GrB 6 month 
p=.0087, 12 month p=.0931; IFN-γ 6 month p=.026, 12 month p=.0043). The PD-1high 
subset therefore appeared to be enriched for cells positive for GrB and IFN-γ compared 
to the PD-1low subsets, making PD-1 expressing cells the main contributor to exerting 
these effector functions.  
In TCL1 mice developing CLL, effector ratios followed very different patterns: with the 
onset of CLL at 6 months, the CD107a effector ratios of PD-1high and PD-1low were very 
similar to each other (p=.5887), but about 2 fold higher than in age-matched WT mice, 
indicating that CLL T cells were highly enriched for cells able to degranulate at an early 
stage of disease (Figure 48 A right panel). With progressing CLL, both subsets lost 
cells with the ability to degranulate, leading to a significant decrease in ratios. However, 
no difference between PD-1high and PD-1low cells was observed (p=.0222), thus 
demonstrating that effector cells expressing PD-1 maintained the ability to degranulate.  
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GrB ratios were also found to be higher in mice with CLL compared to age-matched 
controls: the ratio of PD-1high cells was approximately 3 fold higher, and that of PD-1low 
cells was approximately 7 fold higher, than in WT mice (Figure 48 B right panel). These 
differences led to the predominance of PD-1high over PD-1low cells in being enriched for 
GrB-containing cells as it was observed in WT mice being abrogated in the context of 
developing CLL (GrB ratio PD-1high vs. PD-1low : 6 month p=.8726; 12 month p=.2948).  
TCL1 mice with CLL at 6 months had IFN-γ ratios comparable to age-matched WT 
mice, but the PD-1 subset ratios were not different in TCL1 mice (p=.3095), indicating 
that the physiological enrichment of PD-1high over PD-1low  cells observed in WT mice 
was lost with CLL (Figure 48 C right panel). The previously detected CLL-induced 
significant increase of IFN-γ could be attributed to both PD-1high and PD-1low cells, again 
with no difference between their ratios (p=1.0).  
CLL-induced increased T-cell proliferation was found to be attributed to both PD-1high 
and PD-1low, but the PD-1high ratio was significantly higher than the PD-1low ratio (6 
month p=.0087, 12 month p=.0317, Figure 48 D right panel). Increased T-cell 
proliferation therefore appears to be predominantly accounted for by PD-1high cells.  
Table 18 contains an overview of medians and ranges of effector cell ratios for ageing 
WT and TCL1 mice.  
In the AT mice in this cohort, we confirmed that PD-1high and PD-1low cells maintained 
comparable effector ratios for CD107a, and that PD-1high cells were enriched for IFN-γ 
containing cells compared to PD-1low cells. In addition, we added new information 
regarding GrB and proliferation: just as for IFN-γ, PD-1high cells were enriched for GrB 
containing and proliferating cells (graphs not shown, medians and ranges are 
summarized in Table 18).  
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Figure 48: Associations between PD-1 expression and effector functions in T cells from 
healthy mice and TCL1 mice with developing CLL. Ratios for CD107a degranulation, 
intracellular GrB and IFN-γ, and EdU proliferation were compared between PD-1high and PD-1low 
cells in WT and TCL1 mice. (A) In ageing WT mice, both PD-1high and PD-1low expressing cells 
contained comparable proportions of cells able to degranulate. In TCL1 mice with developing 
CLL, CD107a effector ratios were higher than in age-matched WT mice, but with progressing 
CLL both subsets similarly lost cells with the ability to degranulate. (B) In ageing WT mice, the 
PD-1high subset was enriched for GrB+ cells compared to the PD-1low subset. In TCL1 mice, GrB 
ratios were highly increased, but the predominance of PD-1high over PD-1low cells in being 
enriched for GrB+ cells was lost. (C) Ageing WT mice also exhibited an enrichment of the PD-
1high subset for IFN-γ+ cells, which was lost in TCL1 mice with developing CLL. Both PD-1 
subsets contributed to the CLL-induced significant increase of IFN-γ. (D) In ageing WT mice, 
both PD-1high and PD-1low expressing cells contained comparable proportions of proliferating 
cells. Increased T-cell proliferation in CLL T cells was predominantly driven by PD-1high cells. All 
graphs show median with IQR, and the percentage of PD-1+CD3+CD8+CD44+ cells is depicted 
for each age cohort on the right x-axis.  
 
 
   
WT Eµ-TCL1 
 
   
3 mo 6 mo 12 mo 3 mo 6 mo 12 mo AT 
CD107a PD1low minimum 1.17 0.02 1.23 3.96 3.66 2.05 1.03 
  
median 1.89 2.41 2.39 4.00 4.82 3.40 1.27 
  
maximum 2.68 2.74 5.14 4.42 6.61 6.23 1.79 
 
PD1high minimum 
 
0.19 1.52 
 
2.92 1.80 0.90 
  
median 
 
2.96 2.05 
 
4.26 2.54 1.48 
  
maximum 
 
4.33 4.63 
 
12.00 3.70 2.50 
GrB PD1low minimum 0.02 0.03 0.03 0.02 0.41 0.49 0.45 
  
median 0.04 0.06 0.05 0.03 0.45 0.54 0.59 
  
maximum 0.08 0.08 0.34 0.06 0.86 0.92 0.68 
 
PD1high minimum 
 
0.07 0.07 
 
0.16 0.40 1.68 
  
median 
 
0.19 0.14 
 
0.47 0.66 2.21 
  
maximum 
 
0.39 0.25 
 
3.24 2.42 3.22 
IFN-γ PD1low minimum 0.34 0.46 2.29 0.78 0.74 3.74 0.70 
  
median 0.64 0.97 3.13 1.20 1.14 6.31 1.25 
  
maximum 1.26 1.59 5.30 1.70 4.30 22.27 1.92 
 
PD1high minimum 
 
1.07 5.05 
 
0.20 0.49 2.82 
  
median 
 
1.67 6.74 
 
0.65 6.59 3.65 
  
maximum 
 
3.92 10.43 
 
3.00 16.67 4.96 
EdU PD1low minimum 0.00 0.01 0.02 0.02 0.01 0.04 0.12 
  
median 0.03 0.13 0.03 0.04 0.02 0.18 0.17 
  
maximum 0.08 0.33 0.05 0.07 0.16 0.27 0.24 
 
PD1high minimum 
 
0.01 0.03 
 
0.10 0.23 0.24 
  
median 
 
0.09 0.04 
 
0.18 0.28 0.30 
  
maximum 
 
0.27 0.11 
 
0.31 0.58 0.38 
Table 18: Medians and ranges of effector cell ratios for ageing WT, TCL1 and AT mice. 
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6.5 Summary of PD-L1/PD-1 mediated T-cell dysfunction and T-cell 
exhaustion in TCL1 mice 
In these experiments, we were able to demonstrate that all inhibitory ligands that have 
been identified as important mediators of impaired immune synapse formation, namely 
CD200, CD270, PD-L1 and CD276, were expressed on spleen CLL cells from TCL1 
mice with CLL, but that only PD-L1 and CD276 mirrored the aberrant over-expression 
of human CLL cells compared to normal B cells. This could be modelled in both the 
original C3H and backcrossed B6 TCL1 strains, as well as in ageing TCL1 mice with 
fully developed CLL and young mice with CLL after AT. In the context of developing 
CLL, both highly aberrant PD-L1 and PD-L2 expression were found to be exclusive to 
malignant CLL cells. This could be detected on CLL cells from PB, BM, LN and spleen, 
confirming the suitability of TCL1 mice to model aberrant PD-L1/PD-L2 expression of 
human CLL cells.  
The binding partner of PD-L1/PD-L2 on T cells, PD-1, is a major inhibitory receptor 
associated with T-cell exhaustion in chronic viral infections. As tumour-infiltrating T 
cells share many phenotypic and functional characteristics of exhausted T cells in 
chronic infections, we compared the molecular signatures of T cells from murine 
exhaustion models and murine CLL T cells. CLL CD8+ T cells genes were enriched in 
the unique molecular signature of exhausted CD8+ T cells, but were also represented 
in the signature of functional effector CD8+ T cells, indicating that CLL T cells are likely 
to be very heterogeneous populations with features of both exhaustion and functional 
effector cells. The surface expression of typical exhaustion markers, namely PD-1, 
KLRG-1, 2B4 and LAG-3 was found to be step-wise increased on CD44+ antigen-
experienced CD8+ T cells in mice with developing CLL. This was to a certain extent 
also observed in ageing WT mice, indicating that surface expression by itself might not 
be a definitive marker for T-cell exhaustion or dysfunction. PD-1, KLRG-1, 2B4 and 
LAG-3 expression could however be induced in young mice with CLL after AT, 
suggesting a causal relationship with disease. With the exception of LN, the step-wise 
upregulation of PD-1 on antigen-experienced CD3+CD8+ T cells and its induction by 
AT observed in spleen was recapitulated in cells taken from PB and BM, confirming 
that PD-1, along with other exhaustion markers, can be adequately modelled in TCL1 
mice.  
Randomized AT experiments injecting normal B cells and CLL cells into young, 
previously healthy TCL1 and WT mice confirmed that PD-1, KLRG-1, 2B4 and LAG-3 
expression could be induced by AT of CLL cells but not normal B cells. The previously 
defined disease-specific T-cell phenotype, namely the relative loss of CD3+ cells, the 
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relative increase of CD3+CD8+ cells, the loss of naïve CD3+CD8+ cells and the shift 
towards antigen-experienced cells, and the increase of absolute numbers of all subsets 
was recapitulated in both TCL1 and WT recipients, validating the use of WT mice for 
future AT experiments investigating CLL-induced T-cell dysfunction. Functionally, CLL 
was found to induce altered cellular survival cytokine profiles: antigen experienced 
CD44+CD3+CD8+ T cells from mice with CLL were enriched for CD122 (IL-2 cytokine 
receptor) and depleted of CD127 (IL-7 cytokine receptor), indicating altered 
dependency from IL-7 to IL-2. Confirming findings described in the previous chapter, 
the percentage of CD3+CD8+ cells expressing intracellular IL-2 was comparable 
between healthy and leukaemic mice. Similarly, CLL-associated increased IL-4 and 
IFN-γ production were confirmed, and this could be attributed to both CD44- naïve and 
CD44+ antigen experienced T cells. Although the percentage of CD3+CD8+ T cells 
positive for intracellular TNF-α appeared similar between normal and CLL T cells, 
CD44+ T cells from mice with CLL were enriched for cells unable to produce TNF-α. 
Significantly lower percentages of cells positive for TNF-α were also found in CD4+ T 
cells in mice with CLL.  
Randomized AT experiments also demonstrated that CLL-induced aberrant PD-1 
expression on CD3+CD8+ T cells could be associated with different abilities of cells to 
exert effector functions: in general, intracellular cytokines IL-2, IL-4, IFN-γ and TNF-α 
were detected in both PD-1high and PD-1low cells, and both PD-1high and PD-1low cells 
maintained their ability to degranulate, contrasting the notion that PD-1 expression 
would lead to a loss of these effector functions. While both PD-1 subsets contained 
comparable percentages of cells able to produce IL-2 and IL-4 compared to those that 
were not, PD-1high cells appeared to be enriched for IFN-γ producing cells but depleted 
of cells producing TNF-α compared to PD-1low cells. In addition, PD-1high cells were 
enriched for cells with the ability to degranulate compared to the PD-1low subset, but 
showed an impaired ability to form immunological synapses with normal B cells.  
Linking PD-1 expression with effector function of PD-1high cells in ageing WT mice and 
comparing this to effector function of PD-1high cells in ageing TCL1 mice developing 
CLL revealed the following differences: in ageing WT mice, both PD-1high and PD-1low 
cells contributed to the overall patterns associated with ageing described in the 
previous chapter, i.e. maintenance of degranulation and intracellular GrB, reduction of 
proliferation, and an increase of intracellular IFN-γ production. While both PD-1high and 
PD-1low subsets contained comparable proportions of cells able to degranulate and to 
proliferate, cells positive for GrB and IFN-γ appeared to be enriched in the PD-1high 
subset compared to the PD-1low subset, supporting the understanding that PD-1 
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expression in normal T cells contributes to the dynamic alterations of how effector 
functions are maintained in the context of ageing.  
CD8+ T cells from TCL1 mice developing CLL were initially highly enriched for 
degranulating cells in both the PD-1high and PD-1low subset, but both subsets lost these 
cells with progressing CLL, with degranulation being maintained in PD-1high cells even 
at later stages of disease. Similarly, GrB ratios were generally higher in mice with CLL 
compared to age-matched controls, but the predominance of PD-1high over PD-1low cells 
in being enriched for GrB containing cells that was observed in WT mice was 
abrogated in the context of developing CLL. Although IFN-γ ratios at early stages of 
CLL were roughly comparable to PD-1 subsets from age-matched WT mice, the 
physiological enrichment of PD-1high over PD-1low cells observed in WT mice was 
already lost at this stage. The previously detected CLL-induced significant overall 
increase of IFN-γ at advanced stages of CLL could be attributed to both PD-1high and 
PD-1low cells, but the enrichment of PD-1high over PD-1low cells observed in WT mice 
was continuously lost. CLL-induced increased T-cell proliferation could be attributed to 
both PD-1high and PD-1low cells, but this was predominantly accounted for by PD-1high 
cells. Altogether, these comparisons revealed that despite similar PD-1 expression 
patterns in healthy and leukaemic TCL1 mice, PD-1 expressing cells are markedly 
different in their composition of cells able to exert selected effector functions compared 
to cells that do not demonstrate this ability.  
 
6.6 Discussion 
The goal of this part of the project was to investigate the suitability of the B6 TCL1 
model to mirror PD-L1/PD-L2/PD-1 interactions, to investigate the effect of inhibitory 
signalling on T-cell exhaustion in the context of developing CLL and in different 
microenvironments, and to determine if PD-1 expression by CLL T cells can be 
correlated to specific T-cell effector functions. Using multicolour flow cytometry, we 
demonstrated that among the inhibitory ligands that have been identified as important 
mediators of impaired immune synapse formation in human CLL, PD-L1 and CD276 
mirrored the aberrant over-expression of CLL cells compared to normal B cells. This 
was established in single cell suspensions from mouse spleen cells, while previous 
experiments determining the expression of inhibitory ligands in human CLL patients 
were done by flow cytometry of peripheral blood cells, and by IHC of lymph nodes, thus 
representing different compartments where cells might be subjected to different 
microenvironmental stimuli79.  
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The functional relevance of human PD-L1 and CD276 expression was demonstrated 
by using ex vivo antibody blockade79. This augmented immune synapse formation and 
cytolytic effector function, and prevented the induction of T-cell Rho-GTPase signalling 
defects, with PD-L1 blockade having the most prominent effect. Aberrant PD-L1 
expression by tumour cells and the inhibitory effect on T cells has been shown in a 
number of other haematological malignancies, as introduced in Chapter 1.3.2, as well 
as in solid cancers312-314. In the current study, PD-L1 was also the most highly 
differentially upregulated ligand in CLL cells from TCL1 mice compared to B-cells from 
healthy mice. In contrast, CD200 and CD270 expression were significantly decreased 
on murine CLL cells compared to normal B cells. This is in marked contrast to human 
CLL, in which all four ligands were found to be aberrantly over-expressed. It is 
therefore possible that expression and function of CD200 and CD270 are regulated 
differentially in mice versus humans, and the great diversity of co-stimulatory and co-
inhibitory molecules in expression, structure and function, leading to a dual largely 
context-dependant role, has been described427. Therefore, the downregulation of 
CD200 and CD270 might be an adaptive mechanism by the tumour to counteract a 
potentially co-stimulatory function. While using ex vivo antibody blockade of CD200 
and CD276 might have elucidated the associations between expression and effect on 
T-cell effector function in the TCL1 model, we focused on aberrant PD-L1 expression 
as a major and clinically relevant mediator of T-cell dysfunction, which can be 
adequately modelled in TCL1 mice, and indeed our data support this contention.   
In addition, all ligands implicated in human CLL were discovered by siRNA screening of 
the CLL-like Mec-1 cell line, which might not translate to the complexity in vivo. 
Additional ligands or different combinations than those identified in vitro might play a 
role in mediating T-cell dysfunction in vivo. This assumption was supported by our 
findings that not only PD-L1, but also PD-L2 was aberrantly expressed on murine CLL 
cells, which has not been identified in the previously conducted siRNA screen. PD-L2 is 
a second ligand for PD-1 and inhibits T-cell activation, T-cell proliferation, cytokine 
production and cell adhesion, but exhibits a very distinct pattern of expression (see 
Chapter 1.3.1). Aberrant PD-L2 expression alongside aberrant PD-L1 expression by 
tumour cells has been described in a number of haematological malignancies317, 428. In 
solid malignancies, in contrast, PD-L1 appears to be the more dominant negative 
inhibitory molecule, with PD-L2 being expressed in only a minority of patients but still 
having some prognostic impact312-314.  
Expression of PD-L2 has not been well studied in CLL. Hence, our findings that murine 
CLL cells also aberrantly express PD-L2 compared to normal B cells are novel and 
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indicate that PD-L2 is likely to play a role in mediating T-cell defects in this disease. 
The use of this model also allowed us to attribute PD-L1 and PD-L2 overexpression 
specifically to malignant CLL cells by including 6 month old TCL1 mice, which 
represent an early stage of CLL where malignant CD19+CD5+ CLL cells exist next to 
normal CD19+ B cells and can be directly compared within the same animal. 
Interestingly, constitutive expression of PD-L2 was also found on up to 70% of mouse 
peritoneal CD5+ B1a cells, which share immunophenotypic similarities with CLL cells, 
with PD-L2 expression not being present on conventional B2-B cells429. Although we 
did not include peritoneal cavity into the current project, we demonstrated that both PD-
L1 and PD-L2 expression were also significantly higher on and exclusive to CLL cells 
from PB, BM and LN compared to normal B cells. This confirmed the suitability of TCL1 
mice to model PD-L1/PD-L2 overexpression and provided new insight into the 
modifying role of the tumour microenvironment   
The corresponding binding partner of PD-L1, PD-1, has been demonstrated to be 
aberrantly expressed by CLL T cells133, 134 and is also a major inhibitory receptor 
associated with T-cell exhaustion in chronic viral infections. Exhaustion represents a 
state of functional hypo-responsiveness that occurs as a progressive process in 
response to chronic antigenic viral stimulation. It has been characterized as a 
hierarchical loss of effector CD8+ T-cell function, which coincides with the expression of 
inhibitory surface receptors such as PD-1147,404. Interestingly, the gene expression 
profile of exhausted CD8+ T cells from murine infection models contained alterations in 
many pathways, including T-cell receptor and cytokine signalling pathways, migration 
and actin-cytoskeleton formation, that have also been identified in the molecular 
signature of CLL T cells216, 412, 413. Our comparison of deposited data on CLL T cells 
with exhausted and functional memory and effector CD8+ T cells demonstrated that 
CLL T-cell genes that were represented in the comparison dataset were enriched in the 
molecular signature of exhausted T cells, but were also somewhat represented in the 
signature of functional effector CD8+ T cells. This indicated that CLL T cells are likely 
to be a very heterogeneous population with features of both exhaustion and functional 
effector cells. Interestingly, this comparison also revealed that CLL T-cell genes 
enriched in the exhaustion signature appear to be also involved in pathways of T-cell 
metabolism and bioenergetics defects affecting ribosomal subunits, elongation factors, 
energy metabolism, citric-acid cycle, solute and ion channels and aquaporins. This is 
an interesting finding which underlines that defective T cells in CLL are a 
heterogeneous population, combining cells with many aspects of dysfunction. It also 
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identifies areas of how T-cell dysfunction in CLL can be further explored using new 
techniques such as CyTOF mass spectrometry in future studies.  
Our findings that the molecular signature of murine CLL T cells contains a mixture of 
genes that have implications in exhausted cells and in functional effector cells were 
recently mirrored in functional studies using T cells from CLL patients. Our group 
demonstrated that CLL T cells exhibit features of T-cell exhaustion, such as increased 
expression of surface exhaustion markers, including PD-1, impaired proliferation, and 
cytotoxic defects with a reduced ability to lyse target cells, but retain the capacity to 
produce cytokines such as IFN-γ and TNF-α133. In contrast, another recently published 
study found that proliferating CD8 T cells from CLL patients had higher expression of 
PD-1 than non-proliferating T cells, and that T cells had impaired IFN-γ and IL-4 
production after direct binding of PD-1 to PD-L1 ligand, which however was similar to 
the patterns in healthy controls134. These observations emphasise the functional 
relevance of the heterogeneity of CLL T cells and indicate that PD-1 expression might 
be linked to function in CLL as a more “physiological” marker than previously assumed, 
a notion that is clearly supported by our murine data. Several studies in the infection 
field have demonstrated that subsets of exhausted T cells are able to exert effector 
function despite PD-1 expression. For example, PD-1 expressing subsets have 
different abilities to continue their differentiation process and form functional T-cell 
memory upon transfer into healthy mice, while maintaining an exhausted phenotype, 
including the surface expression of PD-1416. In addition, T-cell populations expressing 
PD-1 have been demonstrated to react differently to antibody blockade. While this 
could reverse exhaustion and restore function in PD-1int cells, this was not possible in 
terminally differentiated PD-1hi T cells417. It is therefore likely that PD-1 expressing T 
cells in CLL are indeed a very heterogeneous population and probably consist of a 
larger proportion of functional effector cells despite or with PD-1 expression than 
previously assumed, while other PD-1 expressing cells might be truly dysfunctional.  
Our data demonstrated that the surface expression of typical exhaustion markers, 
namely PD-1, KLRG-1, 2B4 and LAG-3, was found to be step-wise increased on 
CD44+ antigen-experienced CD8+ T cells in mice with developing CLL. This was to a 
certain extent also observed in ageing WT mice, indicating that surface expression by 
itself cannot be considered a definitive marker for T-cell exhaustion or dysfunction. 
Indeed, high PD-1 expression is also found on functional effector memory T cells in 
healthy ageing humans424. However, we eliminated the confounding effect of ageing by 
using AT experiments, which demonstrated that PD-1, KLRG-1, 2B4 and LAG-3 
expression could be induced in young mice with CLL after AT, suggesting a causal 
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relationship with disease. With the exception of LN, the step-wise upregulation of PD-1 
on antigen-experienced CD3+CD8+ T cells and its induction by AT was recapitulated in 
cells taken from PB, BM and spleen, confirming that PD-1, along with other exhaustion 
markers, can be adequately modelled in TCL1 mice and is, similar to PD-L1/PD-L2 on 
CLL cells, independent of microenvironment.  
Functionally, CLL was found to induce altered cellular survival cytokine profiles that 
have also been implied in classical exhaustion, namely the enrichment for IL-2R+ and 
depletion of IL-7R+ CD8+ cells, which indicates an altered dependency from IL-7 to IL-
2. IL-7R is expressed by naïve and memory cells, and its selective expression in the 
effector phase identifies CD8+ T cells that give rise to long-lived memory T cells425. 
TBET has been shown to directly repress expression of the IL7R gene and to 
downregulate IL7R surface expression, thus promoting effector cell differentiation at 
the expense of memory cell formation. This is in line with the dominance of 
CD44+CD62L- effector cells over CD44+CD62L+ memory cells described in the 
previous chapter, which we have observed in mice with fully developed CLL after AT. 
At the same time, TBET can upregulate IL-2R, leading to the switch of the cellular 
survival cytokine profile from IL-7 to IL-2, resulting in hypo-responsiveness to 
homeostatic cytokines and becoming dependant on antigen stimulation for survival426. 
Although we did not examine transcription factors in this mouse model, increased 
TBET and EOMES were found in CD8+ T cells from human patients133. Interestingly, 
the percentage of both CD3+CD4+ and CD3+CD8+ cells expressing intracellular IL-2 
was comparable between healthy mice and leukaemic mice with CLL after AT, similar 
to human CLL T cells. IL-2 is predominantly produced by CD4+ T cells, and is 
important for peripheral T-cell expansion and cell survival430. In mice, the major role of 
IL-2 appears to be to promote the thymic development and peripheral expansion of 
CD4+CD25+ TRegs which regulate the size of the peripheral T-cell compartment. 
TRegs are also expanded in human CLL and correlate with progressive disease176, and 
in vitro IL-2 induces their expansion431. In a recently published in vivo study, low dose 
IL-2 administration enhanced CD8+ T-cell responses in chronically LCMV infected 
mice, decreased inhibitory receptor levels on virus-specific CD8+ T cells, and 
increased the expression of IL7R and CD44, shifting cells back to a memory-like 
phenotype432. The combination of IL-2 treatment with blockade of the PD-1 inhibitory 
pathway had synergistic effects in enhancing virus-specific CD8+ T-cell responses and 
decreasing viral load, despite increased numbers of TRegs. Increased IL-2R 
expression by CLL T cells might therefore be a compensation mechanism to account 
for increased requirement of IL-2 to maintain T-cell function in response to 
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immunological challenge by CLL cells, which is not met by increased production by T 
cells. IL-2 has also been indicated in being involved in aberrant PD-L1 and PD-1 
expression itself: common gamma-chain cytokines such as IL-2, IL-7, IL-15, and IL-21 
were found to up-regulate PD-1 and, with the exception of IL-21, PD-L1 on purified T 
cells in vitro, and to indirectly induce the expression of PD-L1 and PD-L2 on monocytes 
and macrophages in peripheral blood433. As described in the previous chapter, contrary 
to the AT model, IL-2 production by CD3+CD8+ T cells was found to aberrantly 
increase in ageing mice with CLL and was detected at early stages of CLL, coinciding 
with the beginning of aberrant expression of PD-L1/PD-L2 and PD-1. Hence, it could 
be involved in the induction of PD-L1/PD-L2 and PD-1 expression, or in the promotion 
of TRegs. If the AT model is interpreted as the aggressive form of CLL with high 
antigen load, IL-2 production in highly leukaemic mice that is not different to age-
matched WT mice might be the end-result of a previous dynamically increased 
production as indicated by the ageing TCL1 mice, with aberrant IL-2R expression 
representing the resulting “end-stage” compensation mechanism to maintain functions 
such as increased proliferation, which we have described in the previous chapter.   
Our randomized AT experiments also demonstrated that CLL-induced aberrant PD-1 
expression on CD3+CD8+ T cells could be associated with different abilities of cells to 
exert effector functions: in general, intracellular cytokines IL-2, IL-4, IFN-γ and TNF-α 
were detected in both PD-1high and PD-1low cells, and both PD-1high and PD-1low cells 
maintained their ability to degranulate, contrasting the notion that PD-1 expression 
would lead to a loss of these effector functions. In addition, we demonstrated that the 
increase in IFN-γ production frequently observed in CLL T cells appeared to be 
attributed to PD-1high cells, while this subset was depleted of cells producing TNF-α 
compared to PD-1low cells and showed an impaired ability to form immunological 
synapses with normal B cells.  
Lastly, the TCL1 model allowed us to better understand the functional difference of 
expression of PD-1 on CLL CD8+ T cells compared to the physiological expression on 
normal T cells. Linking PD-1 expression with effector function of PD-1high cells in ageing 
WT mice and comparing this to effector function of PD-1high cells in ageing TCL1 mice 
developing CLL revealed that in ageing WT mice, both PD-1high and PD-1low cells 
contributed to the overall patterns associated with ageing described in the previous 
chapter, i.e. maintenance of degranulation and intracellular GrB, reduction of 
proliferation, and increase of intracellular IFN-γ production. While both PD-1high and PD-
1low subsets contained comparable proportions of cells able to degranulate and to 
proliferate, cells positive for GrB and IFN-γ appeared to be enriched in the PD-1high 
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subset compared to the PD-1low subset, supporting the understanding that PD-1 
expression in normal T cells contributes to the dynamic alterations of how effector 
functions are maintained in the context of ageing. CD8+ T cells from TCL1 mice 
developing CLL were initially highly enriched for degranulating cells in both the PD-1high 
and PD-1low subset, probably as a result of beginning immunological challenge by CLL, 
but both subsets lost these effector cells with progressing CLL. Similarly, GrB ratios 
were generally higher in mice with CLL compared to age-matched controls, however 
the predominance of PD-1high over PD-1low cells in being enriched for GrB containing 
cells observed in WT mice was abrogated in the context of developing CLL. A similar 
observation was made for IFN-γ, indicating that PD-1 expressing cells indeed are likely 
to have a GrB and IFN-γ deficiency compared to non-PD-1 expressing cells, which 
however do not render them GrB or IFN-γ dysfunctional. In contrast, CLL-induced 
increased T-cell proliferation was predominantly driven by PD-1high cells. In this context, 
however, PD-1 expression and upregulation might also be a physiological reaction to 
increased T-cell proliferation in response to tumour antigen. Altogether, these data 
show that despite similar PD-1 expression patterns in ageing healthy and leukaemic 
TCL1 mice, PD-1 expressing cells are markedly different in their composition of cells 
able to exert selected effector functions, but that PD-1 expression in CLL T cells are 
largely functional T-cell effector cells.   
In sum, we have confirmed the suitability of the B6 TCL1 model to mirror PD-L1/PD-1 
interactions, we have extended this to the second binding partner of PD-1, PD-L2, and 
we have demonstrated that aberrant PD-L1/PD-L2/PD-1 expression is utilized by CLL 
and T cells regardless of their microenvironment. In addition, we have characterised 
the features of T-cell “exhaustion” in the context of different microenvironments, while 
unmasking the associations between CLL and ageing. Lastly, we have provided novel 
data on the associations between PD-1 expression and effector functions of T cells. 
Altogether, this work highlights the importance of PD-L1/PD-1 mediated inhibitory 
signalling on T-cell dysfunction in CLL. It supports the hypothesis that T cells in CLL 
might be rescued and reversed into a functional state able to effectively mount anti-
tumour responses by targeting PD-L1 and PD-1, and that the TCL1 model is a very 
suitable tool to study the effect of such treatment in vivo.  
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7 Potential of in vivo lenalidomide treatment to restore T-cell function in Eµ-
TCL1 mice 
7.1 Specific introduction 
A plethora of preclinical studies have demonstrated that second generation 
immunomodulatory drugs (IMiDs) such as lenalidomide and pomalidomide modulate 
the tumour microenvironment through the downregulation of pro-survival and 
inflammatory cytokines and the activation of immune effector cells. In addition to 
potently inhibiting TNF-α production in vitro434, 435, lenalidomide and pomalidomide 
increase IL-2 and IFN-γ production and cytotoxic capacities in T cells436-439. The latter 
most likely is a result of actin cytoskeleton activation. This hypothesis was further 
consolidated by work from our group showing that T cells from CLL patients exhibit 
multiple dysregulated genes and pathways involved in cytoskeleton formation and 
vesicle trafficking. This effect leads to an impaired ability to regulate F-actin 
polymerization and to polarize the cytoskeleton, therefore offering a unique platform to 
investigate the effect of IMiD treatment on cytoskeleton modelling77, 171. In vitro 
lenalidomide treatment of both APCs and T cells restored the ability of CD4+ and CD8+ 
T cells to polarize F-actin to the immunological synapse, increased the cytolytic 
capacity of CD8+ effector cells, and repaired defective integrin LFA-1-directed T-cell 
adhesion and migration77, 81. This was found to be mediated via activation of Rho 
GTPases RhoA, CdC42, and Rac179, which have been described as key signal 
transducer elements in morphological T-cell changes, cytoskeleton polarization and 
trans-endothelial migration in normal T cells, and also play a role in T-cell activation, 
thymocyte differentiation and transcription factor regulation440. The potential of in vivo 
lenalidomide treatment to restore defective immune synapse formation was recently 
confirmed in CLL patients treated within a Phase II trial with immunochemotherapy 
consisting of rituximab, pentostatin and cyclophosphamide (PCR), followed by 
lenalidomide maintenance80. Lenalidomide improved the depth of response in 24% of 
eligible patients, suggesting that it might prolong the time to re-treatment, and 
significantly improved immune synapse formation. However, immune synapses were 
already found to be enhanced after PCR compared to baseline prior to any treatment, 
indicating that cytoskeleton re-polarization can also partly be achieved by therapy with 
other substances or by removal of the CLL cells themselves as the patients respond to 
treatment.  
The addition of lenalidomide to co-cultures between CLL and normal allogeneic T cells, 
as well as treatment of autologous CLL/T-cell co-cultures, was recently demonstrated 
by our group to overcome the immunosuppressive effect of PD-L1, CD200, CD270 and 
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CD276 inhibitory signalling, as its effect on restoring the immune synapse and 
increasing CD8+ T cell cytolytic potential was comparable to the repair achieved by 
combined antibody blockade of all four inhibitory ligands79. In addition, lenalidomide 
downregulated the expression of PD-L1, CD200, CD270 and CD276 on CLL and 
tumour-infiltrated DLBCL and follicular lymphoma cells, and prevented the induction of 
aberrant expression of their receptors, including PD-1, on T cells. Similar effects were 
seen in a small number of samples from relapsed CLL patients treated with 
lenalidomide in a clinical trial79. Compared to baseline levels of expression prior to 
lenalidomide exposure, single agent lenalidomide treatment reduced the expression of 
both inhibitory ligands on CLL cells and the corresponding receptors on T cells, 
increased T-cell conjugation and synapse function with autologous tumour cells acting 
as APCs, and increased antigen-induced cytolytic effector activity. The modulation of 
levels of T cells expressing PD-1, 2B4, and CD57 were recently described in a cohort 
of 131 CLL patients441. Comparing 49 conventionally treated patients to 10 patients 
who had received a lenalidomide-containing regimen, the authors found that the 
percentage of CD4+ cells expressing either PD-1, 2B4 or CD57 alone, and all markers 
in combination, was significantly reduced after lenalidomide treatment, and was 
comparable to levels observed in healthy controls. Among CD8+ cells, the percentages 
of all subsets, with the exception of CD8+PD-1+ and CD8+PD-1+2B4+ cells, were 
similarly reduced in lenalidomide treated patients.  
Long term in vivo lenalidomide treatment also has the potential to normalize general T-
cell subsets in CLL442, 443. In 24 patients with untreated CLL enrolled in a Phase II 
clinical trial of lenalidomide, a significant reduction in percentages and absolute 
lymphocyte counts were observed after 3 cycles of therapy, with a relative increase of 
T cells, activated CD8+ T cells producing IFN-γ, and TRegs compared to baseline 
levels before treatment. After 15 cycles of treatment, activated IL-2/IFN-γ/TNF-α 
producing CD4+ T cells, TRegs and activated IFN-γ producing CD8+ T cells 
normalized to the range found in healthy subjects442. A long-term analysis of 60 CLL 
patients treated with lenalidomide (median follow up 4 years) identified a normalisation 
in the percentage of CD4+ and CD8+ cells and T-cell numbers in 48%, 71% and 99% 
of long-term responders, respectively87. Another immune cell subset that is affected by 
lenalidomide treatment, either directly or indirectly via T-cell activation, is NK cells444. 
Several preclinical studies demonstrate that IMiDs enhance NK cell mediated 
cytotoxicity439, 445, increase ADCC towards myeloma cells446, and reduce the expression 
of inhibitory ligands such as SOCS1447. In CLL, baseline NK cell numbers and 
activation status could be linked to clinical response to lenalidomide, with higher 
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numbers of NK cells, a greater capacity for NK cell proliferation in vitro, and higher 
baseline expression of NK cell activating ligands MIC-A/B on CLL cells predicting better 
outcome in a clinical trial448. Further evidence of in vivo immune activation stems from 
the observation of the occurrence of tumour-flare reactions in CLL patients treated with 
lenalidomide91. Tumour-flare reactions clinically manifests as acute and painful swelling 
of CLL-affected lymph nodes, hepatosplenomegaly, rash, and fever, which usually 
occur 8-72 hours after initial drug administration but generally respond well to steroid 
and non-steroid anti-inflammatory treatment. The clinical manifestations are associated 
with features of immune activation, with upregulation of costimulatory molecules such 
as CD40, CD80, and CD86 on CLL cells, upregulation of CD69 on T cells, and 
elevated serum levels of cytokines and chemokines78, 91, 448. As lenalidomide is not 
directly toxic to CLL cells in vitro, the anti-tumour effect of lenalidomide therefore 
appears to be mediated by activating T-cell and NK-cell anti-tumour immune responses 
rather than inducing direct tumour cell death. 
Extensive murine studies on the pharmacokinetics after oral, i.v. and i.p. application of 
lenalidomide and the resulting tissue distribution revealed that doses of 15 mg/kg i.v., 
22.5 mg/kg i.p., and 45 mg/kg orally are well tolerated in mice449. The administration of 
translationally relevant doses of 0.5 and 10 mg/kg led to systemic bioavailability ranges 
of 90–105% and 60–75% via i.p. and oral routes, respectively, with a dose-dependent 
tissue distribution. These findings demonstrate that the high oral bioavailability of 
lenalidomide in mice appears to be consistent with that in humans. Interestingly, 
studies on the effect of lenalidomide in the TCL1 mouse model are so far limited to in 
vitro studies: our group has demonstrated that the repair of immune synapse formation 
could be achieved by ex vivo treatment of autologous murine B and T cells, 
recapitulating the effect of lenalidomide in human CLL216. Work conducted in this 
dissertation project has confirmed that PD-L1/PD-1 mediated T-cell dysfunction 
observed in human CLL is adequately mirrored in TCL1 mice. In addition, we have 
demonstrated that TCL1 mice can be used to overcome the effect of confounding 
factors such as age, pre-treatment, or underlying chronic infections, which by 
themselves can influence the functional effect of PD-L1/PD-1 interactions. Although 
previous studies using CLL patient samples indicate that both in vivo and ex vivo 
lenalidomide treatment has an effect on modulating T-cell subsets and function442, 443, 
as well as PD-L1/PD-1-mediated inhibitory signalling79, 80, 441, a comprehensive analysis 
in vivo linking the effect of single agent lenalidomide to aberrant PD-L1/PD-1 
expression and functional T-cell defects has not been done.  
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7.2 Goals and objectives 
My next goal was therefore to investigate if in vivo lenalidomide treatment corrects 
CLL-induced T-cell dysfunction, with a focus on PD-L1/PD-L2/PD-1, and enhances 
anti-tumour T-cell responses in mice with CLL. Specifically, I sought to address the 
following questions: 
 Does in vivo lenalidomide treatment have the potential to effectively control disease 
development after adoptive transfer of murine CLL? 
 Does in vivo lenalidomide treatment prevent the development of the previously 
described aberrant T-cell phenotype? 
 Can in vivo lenalidomide treatment restore key T-cell effector functions? 
 Can in vivo lenalidomide treatment overcome functional T-cell defects relating to 
aberrant PD-1 expression? 
 
7.3 Specific methods and materials 
7.3.1 Mice and randomization procedure 
Three month old female B6 WT mice (n=42) were purchased from commercial 
suppliers (Charles River, UK), ear marked, and kept in cages containing a maximum of 
5 mice each for one week. Sample size was calculated based on the assumption that 
at least 17 mice per group would be needed to detect a 1.0 standard deviation 
difference in PD-1 means between treated and untreated mice in two-sided testing at a 
significance level α=0.05 with at least 80% power. For AT, mice were injected i.v. with 
4x107 syngeneic CLL cells in a single dose from the same pool of aged TCL1 mice. 
Twenty days after the i.v. injections, 50μl blood was obtained by tail bleeds from each 
mouse, and the percentage of CD19+CD5+ CLL cells among lymphocytes was 
determined by flow cytometry. Transplanted mice had a median CLL load of 26% 
(range 2-36%). Three mice did not show engraftment, and the CLL load could not be 
assessed in 1; these 4 animals were therefore excluded from the study. The remaining 
38 mice were distributed equally between treatment (n=19) and vehicle control (n=19) 
based on their individual CLL loads. The direct comparison between the intervention 
groups confirmed that mice with different CLL loads were equally balanced between 
the intervention groups (p=.6073, Figure 49). Lenalidomide (10mg/kg body weight in 
300μl PBS) or vehicle only (300μl PBS) was administered daily by oral gavage. 
Treatments were initiated on day 21 post AT, and mice were treated for 3 weeks. After 
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this time (total of 6 weeks after AT), mice were sacrificed under protocol 19b2 of PIL 
70/7531. Spleens and PB were processed as described in general methods. Healthy 
age-matched WT (hWT) mice were not included prospectively into this study. 
Differences between mice with CLL and healthy mice were depicted by historical 
comparison with data from hWT used in other experiments. 
 
Figure 49: CLL load in mice assigned to vehicle and 
lenalidomide treatment. Three weeks after AT, mice were 
bled and distributed equally between the vehicle and 
lenalidomide intervention group based on individual CLL 
loads, defined as the percentage of CD19+CD5+ 
lymphocytes. Statistical comparison confirmed that CLL loads 
were balanced between the intervention groups. Graph 
shows median with Interquartile Range (IQR). ns = non-
significant. 
 
 
 
7.3.2 Drug preparation and stability 
Lenalidomide was received as a kind gift from our collaborators at the Ohio State 
University (OSU). The drug was extracted from capsules donated by CLL patients no 
longer on treatment. Upon receipt of the powder, its content was confirmed by mass 
spectrometric analysis. The powder was diluted at 1:1000 in 30% acetonitrile solution 
containing 0.1% formic acid in LC-MS grade water (all from Fisher Scientific). Both high 
resolution Q-TOF MS1 and triple stage quadrupole Vantage mass spectrometry 
systems (Thermo Scientific, UK) with Agilent Jet Stream technology for electrospray 
ionization were used. All experiments were carried out in positive ionization mode. 
Spray voltage was set to 3500 volts, and the sheath gas (nitrogen) flow rate was 20 
arbitrary units. Argon was used as collision gas with a pressure of 1.5 mTorr. Data was 
acquired using Thermo Xcalibur software (version 2.1).  
Collecting total ion spectra over a mass range of 210 to 300 m/z, the received powder 
was confirmed as lenalidomide based on its molecular mass of 259.261 g/mol and 
published fragmentation patterns (Figure 50 A and B)450. Lenalidomide was then 
dissolved in sterile PBS, and kept in 6ml aliquots at -80°C to allow daily treatment of all 
mice from the same drug stock. Additional aliquots were kept for further mass 
spectrometry experiments. After all mice had been treated for 3 weeks, the ion count of 
the treatment compound was compared to a freshly reconstituted standard to 
document changes in drug stability. The ion count of the treatment compound was 
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1.05x107, which was lower than the ion count of the freshly reconstituted drug of 
2.03x107, indicating some degradation of the drug over the treatment period (Figure 50 
C).  
After the end of the study, 2 additional WT mice were treated with 10mg/kg body 
weight lenalidomide in 300μl PBS from the treatment compound stock or 300μl PBS 
vehicle control only. After 5 days of treatment, mice were sacrificed 24 hours after the 
last dose, and PB, spleen and brain were removed. A leukaemic untreated TCL1 
mouse was used as an additional control. Blood was collected in EDTA-coated 1.5ml 
Eppendorf tubes, centrifuged at 2,000 x g for 10 minutes at 4°C. Supernatant was then 
centrifuged at 2,000 x g for 15 minutes at 4°C to deplete platelets in the plasma 
sample. 150µl ice cold methanol containing 50ng/ml of the internal standard 
carbamazepine was added to the plasma, vortexed for one minute, kept on ice for 30 
minutes, and centrifuged at 10,000rpm for 10 minutes at 4°C. The supernatant was 
transferred to a fresh Eppendorf tube, and methanolic extracts were evaporated to 
dryness in a Savant Speedvac. Organs were weighed, and 50mg of each sample was 
homogenised in 1.5 ml of methanol/water (1:1) containing 50ng/ml of carbamazepine, 
using 5mm steel beads and a tissueLyser-II (Qiagen, UK) at 25 Hz for 5 minutes. 
Samples were then centrifuged at 16,000 x g for 10 minutes, and supernatants were 
transferred to fresh Eppendorf tubes and dried in a Savant Speedvac. All dried extracts 
were reconstituted in 10% acetonitrile, and 10µl of the reconstituted solutions were 
injected into an ultra-performance liquid chromatography system (Accela UPLC, 
Thermo Scientific, UK) equipped with an Acquity UPLC BEH C18, 1.7 µm, 100 × 2.1 
mm column (Waters, UK) and a mobile phase consisting of a mixture of water 
containing 0.1% formic acid (A), and acetonitrile containing 0.1% formic acid (B). The 
mobile phase gradient was employed, comprising buffer A = 90% at 0 - 1 min, from 90 
to 20% over 2 minutes, held at 20% for 2 minute, from 20 to 90% over 0.1 minutes, 
ending with 90% for 2.9 minutes, all at a flow rate of 250 µl/min. Eluting compounds 
were detected using the triple stage quadrupole Vantage mass spectrometry system 
(Thermo Scientific, UK). Samples were analysed in the Multiple Reaction Monitoring 
(MRM), positive ion modes at a spray voltage of 3500V. Nitrogen was used as sheath 
and auxiliary gas at a flow rate of 30 and 10 arbitrary units, respectively. Argon was 
used as collision gas with pressure of 1.5 mTorr. The optimum transitional daughter 
ions mass and collision energy of each analyst were as follows: Lenalidomide 260.0 → 
149.2 (collision energy 16V) and Carbamazepine 237.1 → 194.3 (collision energy 
20V). 
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Figure 50: Mass spectrometric analysis to confirm presence and stability of lenalidomide. 
Lenalidomide was extracted from capsules and purified by our collaborators. (A) High resolution 
Q-TOF MS1 confirmed the received compound as lenalidomide based on its molecular mass of 
259.261 g/mol and (B) principle fragmentation patterns of top 8 fragments. (C) After completion 
of the treatment period, the ion count of the treatment compound was 1.05x107, compared to 
the ion count of 2.03x107 of the freshly reconstituted drug. 
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7.3.3 Multicolour flow cytometry for cell surface markers  
T-cell subsets were characterized based on the surface expression of CD3, CD4, CD8, 
CD62L, CD44 and CCR7. Exhaustion markers included PD-1, KLRG-1, 2B4, CD160 
and LAG-3. Cytokine receptors included CD122 and CD127. CLL was assessed by 
CD19 and CD5 expression, and PD-L1 and PD-L2 were included into the CLL panel. 
Antigens, fluorochromes, clones, concentrations and suppliers are described in 
Chapters 5 and 6. Table 19 contains an overview of the flow panel combinations used 
in this experiment. Experiments were performed on fresh samples, and FMO controls 
for CD44, CCR7, exhaustion markers, cytokine receptors, PD-L1 and PD-L2 were 
included into all experiments. Cells were prepared for flow cytometry as described in 
the general methods section. The gating strategies have been described in Chapters 5 
and 6.  
 
1. spleen 
tube 1 tube 2 tube 3 tube 4 
T-cell subsets/ 
exhaustion 
T-cell exhaustion cytokine receptors B cells 
CD4 PerCPCy5.5 CD8 FITC CD8 FITC CD5 APC 
CD8 BV605 CD3 APCCy7 CD3 APCCy7 CD19 FITC 
CD3 APCCy7 CD44 AF700 CD44 AF700 CD45 APCCy7 
CD62L FITC 2B4 APC CD122 PE PDL1 PerCPefl710 
CD44 AF700 LAG3 PerCPefl710 CD127 APC PDL2 PE 
CCR7 PeCy7 CD160 PE viability dye DAPI viability dye DAPI 
KLRG1 PE viability dye DAPI   
  
PD1 APC 
  
  
  
viability dye DAPI 
  
  
  
2. peripheral blood 
tube 1 
 
tube 2 
T-cell subsets/ 
exhaustion 
B cells 
CD4 PerCPCy5.5 CD5 APC 
CD8 BV605 CD19 FITC 
CD3 APCCy7 CD45 APCCy7 
CD62L FITC PDL1 PE 
CD44 AF700 PDL2 PerCPefl710 
PD1 APC viability dye DAPI 
viability dye DAPI   
Table 19: Overview of flow panel to phenotype T-cell subsets, exhaustion markers, 
cytokine receptors, CLL and inhibitory ligands in spleen and peripheral blood.  
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7.3.4 Multicolour flow cytometry for intracellular cytokines and effector 
function 
Effector function and intracellular cytokines were evaluated as described in Chapter 6 
and included CD107a degranulation, intracellular IL-2, IL-4, and IFN-y, and intranuclear 
ki67. Differences in T-cell function between experimental groups were compared by 
calculating ratios between CD44+ cells positive for CD107a/IFN-γ/ki67, and CD44+ 
cells negative for these markers, to describe the ratio between effector cells within 
CD44+ cells compared to non-effector (i.e. negative) cells. Differences in ratios were 
interpreted as an increase of cells able to exert effector functions (increase of ratio), or 
decrease of cells able to exert effector functions (decrease of ratio), respectively. 
Similar comparisons were made between PD-1high and PD-1low ratios.  
 
7.3.5 Immune synapse formation assays 
CLL and B cells were purified from frozen splenocytes by manual magnetic separation 
using murine CD19 microbeads (Miltenyi, UK). The column effluent representing the 
CD19- fraction was further purified by negative selection using murine T-cell isolation 
kits (Miltenyi, UK). These T cells were used in synapse formation assays with CMAC 
labelled, sAg-pulsed autologous CLL and B cells as antigen-presenting cells at a 1:1 
ratio. Synapse assay, confocal microscopy, and image analysis were conducted as 
described in Chapter 3.5.   
 
7.3.6 Ex vivo lenalidomide treatment of autologous murine B and T cells 
The effect of ex vivo lenalidomide treatment on immune synapse formation between 
autologous mouse B and T cells was assessed following previously established 
protocols by our group77. After magnetic separation, 1x106 B and T cells were 
resuspended separately in 1ml RPMI 1640 with 10% FCS, 1% Penicillin/Streptomycin, 
1% Glutamine, and 500mM beta-mercaptoethanol, and transferred into a 24 well plate. 
Cells were then treated for 24 hours with 0.5μM lenalidomide in acidic PBS vehicle (1% 
HCl), or vehicle only, washed, and used in immune synapse formation assays as 
described in general methods. Optimization experiments using autologous B and T 
cells from three different fully leukaemic TCL1 mice confirmed that ex vivo treatment 
with lenalidomide increased the median area of F-actin immune synapses (Figure 51). 
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Cells from in vivo lenalidomide/vehicle treated mice were treated ex vivo following 
identical procedures. 
 
Figure 51: Ex vivo lenalidomide treatment 
of autologous murine B and T cells: Purified 
CLL and T cells from 3 different fully leukaemic 
TCL1 mice were treated separately for one 
hour with vehicle (white bars) or 0.5μM 
lenalidomide (grey bars), washed, and used in 
immune synapse formation assays. 
Lenalidomide treatment significantly improved 
the mean area of immune synapses compared 
to vehicle treated cells.  
 
 
 
7.3.7 Ex vivo PD-L1 and PD-1 blockade 
To assess the effect of additional ex vivo PD-L1 and PD-1 blockade, cells from in vivo 
lenalidomide or vehicle treated mice were pre-treated ex vivo with purified blocking 
antibodies against PD-L1 and PD-1, or isotype control blocking antibodies, before 
immune synapse formation assays. Optimal doses of PD-L1 and PD-1 blocking 
antibodies were established by flow cytometry based saturation assays. For this, 
previously frozen spleen cells from fully leukaemic TCL1 mice were thawed, washed, 
and counted following protocols described in general methods. Cells (1x106) were then 
resuspended in 0.1ml FACS buffer and pre-treated with 1, 5, 10, 15, 20, 30, or 40μg/ml 
purified LEAFTM (“Low Endotoxin, Azide-Free”) anti-mouse PD-L1 antibody (clone 
10F.9G2, rat IgG2bκ), 1, 5, 10, 15, 20, 30, or 40μg/ml purified anti-mouse PD-1 
antibody (clone RMP1-30, rat IgG2bκ), equivalent concentrations of purified isotype 
blocking antibodies, or were left untreated (all antibodies from Biolegend). After 1 hour, 
cells were washed to remove any unbound antibodies, and stained with PeCy7-labelled 
anti PD-L1 and APC-labelled PD-1 antibodies on the same clones (i.e. 10F.9G2 and 
RMP1-30, both from eBioscience, UK) at a constant 1:100 dilution. FMO controls for 
PD-L1 and PD-1 were included into all experiments. MFIs were compared among cells 
treated with increasing concentrations of blocking antibody, and a decrease in MFI was 
interpreted as the inability of fluorescently labelled antibody to bind to the PD-L1 or PD-
1 epitope because of pre-existing blockade by the purified antibody. Doses at which a 
plateau was reached, and no further decrease of MFI was observed by using higher 
concentrations of blocking antibody, were determined as optimal antibody doses to 
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achieve best possible blockade of PD-L1 and PD-1. For purified PD-L1 antibody, this 
was determined to be 10μg/ml (Figure 52 A), and for PD-1 20μg/ml (Figure 52 B). Cells 
from in vivo lenalidomide/vehicle treated mice were purified as described above, and 
treated ex vivo for 1 hour with 10μg/ml PD-L1, 20μg/ml PD-1, and blocking antibodies 
in 0.1ml FACS buffer. Cells were then washed, and used in immune synapse formation 
assays as described in Chapter 3.5. 
 
 
Figure 52: Saturation curves of blocking PD-L1 and PD-1 antibodies. To determine optimal 
doses of PD-L1 and PD-1 blocking antibodies in vitro, cells were pretreated for 1h with 
increasing concentrations of purified blocking PD-L1 (clone 10F.9G2), PD-1 (clone RMP1-30), 
and isotype blocking antibodies. After washing to remove unbound antibodies, cells were 
stained with PeCy7-labelled PD-L1 (clone 10F.9G2) and APC-labelled PD-1 (clone RMP1-30). 
(A) Pre-treatment with 10μg/ml anti-PD-L1 was found to sufficiently block the binding of 
fluorescently labelled PD-L1, determined by a plateau in decrease of Median Fluorescence 
Intensity (MFI). (B) Pre-treatment with 20μg/ml anti-PD-1 sufficiently blocked the binding of 
fluorescently labelled PD-1. Figure shows representative saturation curves from 3 different 
experiments. FMO = Fluorescence-Minus-One control.  
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7.4 Results 
7.4.1 In vivo lenalidomide treatment does not result in effective CLL control and 
has no effect on aberrant PD-L1 and PD-L2 expression 
To assess the effect of in vivo lenalidomide treatment in mice with CLL after AT of 
4x107 CLL cells from leukaemic Eµ-TCL1 donors, mice received daily lenalidomide or 
PBS vehicle control. Treatment was started 3 weeks after AT, and mice with different 
CLL loads were well balanced between intervention groups. After 3 weeks of treatment 
(a total of 6 weeks after AT), we found that in vivo lenalidomide did not result in 
effective CLL control. This was demonstrated by both spleen weights and CLL load in 
examined organs; no differences were observed in median spleen weights between 
lenalidomide (1.05g; range .85-1.24) and vehicle treated mice (1.0g; range .73-1.68, 
p=.7069, Figure 53 A), and the median percentages of CD19+CD5+ CLL lymphocytes 
were comparable in spleen (lenalidomide 71.3%, range 52.2-84.3; vehicle 68.1%, 
range 56.4-83.8, p=.6037, Figure 53 B) and PB (lenalidomide 69.7%, range 48.1-86.5; 
vehicle 70.5%, range 52.9-86.6, p=.4335, Figure 53 C).  
Similarly, in vivo lenalidomide had no effect on the surface expression of PD-L1 and 
PD-L2 on CLL cells from spleen and PB. In spleen, the specific MFI for PD-L1 was 
1,052 (range 610.9-1,414) in lenalidomide treated and 1,024 (range 675.2-1,227) in 
vehicle treated mice (p=.3981, Figure 53 D left panel). Specific MFIs for PD-L2 were 
2,338 (range 1,442-3,870) in lenalidomide treated and 2,463 (range 1,315-3,181) in 
vehicle treated mice (p=.900, Figure 53 D right panel). In PB, the specific MFI for PD-
L1 was 777.4 (range 508-987.5) in lenalidomide treated and 687.9 (range 511.1-1,087) 
in vehicle treated mice (p=.4389, Figure 53 E left panel). Specific MFIs for PD-L2 were 
1,826 (range 1,285-2,665) in lenalidomide treated and 1,726 (range 1,376-3, 148) in 
vehicle treated mice (p=.8043, Figure 53 E right panel). 
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Figure 53: Effect of in vivo lenalidomide treatment on CLL progression and PD-L1 and 
PD-L2 expression on CLL cells. Mice were treated with 10mg/kg body weight lenalidomide or 
vehicle control, started at 3 weeks after AT of 4x107 splenocytes from leukaemic TCL1 mice, 
and sacrificed after 3 weeks of treatment. (A) median spleen weights; (B) percentages of 
CD19+CD5+ lymphocytes in spleen and (C) peripheral blood (PB); (D) Median Fluorescence 
Intensity (MFI) of PD-L1 and PD-L2 in spleen and (E) PB CLL cells. All graphs show medians 
with IQR. ns = non-significant.  
 
7.4.2 Lack of CLL control is reflected by persistence of typical CLL-induced 
aberrant T-cell phenotype 
The ineffective CLL control by in vivo lenalidomide treatment was reflected by the 
persistence of typical CLL-induced T-cell phenotypic alterations. Both lenalidomide and 
vehicle treated mice exhibited comparable percentages of CD3+, CD3+CD4+ and 
CD3+CD8+ T cells in spleen (Figure 54 A) and PB (Figure 54 D), leading to non-
significantly different CD4+/CD8+ ratios in spleen (Figure 54 B) and PB (Figure 54 E). 
Among CD3+CD8+ cells, naive cells were lost and shifted towards antigen-
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experienced effector and EM cells. This was recapitulated in spleen (Figure 54 C) and 
PB (Figure 54 F, note: CM and EM cell subsets were not assessed in PB).  
 
 
Figure 54: T-cell phenotype in lenalidomide and vehicle control treated mice. In vivo 
lenalidomide did not correct the typical CLL-induced aberrant T-cell phenotype. Percentages of 
CLL cells and CD3+, CD4+, and CD8+ T cells in (A) spleen and (D) peripheral blood (PB), 
CD4+/CD8+ ratios in (B) spleen and (E) PB, and percentages of CD3+CD8+ T-cell subsets in 
(C) spleen and (F) PB without and with lenalidomide treatment.  
 
Table 20 summarizes the p-values of statistical comparisons of T-cell subsets between 
the experimental groups for all examined organs. 
 
 p-value 
T-cell subsets spleen peripheral blood 
%CD3 .0815 .7156 
%CD3+CD4+ .7639 .4459 
%CD3+CD8+ .4815 .0927 
CD4+/CD8+ ratio .7149 .1760 
%Naïve CD3+CD8+ .5022 .4808 
%Effector CD3+CD8+ .3353 .9856 
%Memory CD3+CD8+ .1348 .2438 
%EM CD3+CD8+ .5727 nd 
%CM CD3+CD8+ .5016 nd 
Table 20: Summary of p-values of statistical comparisons of T-cell subsets between 
lenalidomide and vehicle treated mice for spleen and peripheral blood. nd – not 
determined, EM – effector memory, CM – central memory  
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7.4.3 In vivo lenalidomide treatment prevents development of typical CLL-
induced exhaustion-like T-cell phenotype  
Despite the lack of CLL control and persistent T-cell subset alterations, in vivo 
lenalidomide treatment appeared to have an effect on the expression of previously 
described exhaustion-like markers on CD8+ T cells (Figure 55). Compared to vehicle 
control treated mice, the surface expression of PD-1 (p=.0368), KLRG-1 (p=.0039), 
LAG-3 (p=.0011) and 2B4 (p=.0157), but not CD160 (p=.0977) was significantly 
reduced on antigen-experienced CD3+CD8+CD44+ T cells from lenalidomide treated 
mice. The reduction of PD-1 was also observed in CD3+CD8+ T cells in PB (p=.0097).  
 
 
Figure 55: Exhaustion surface markers in lenalidomide and vehicle control treated mice. 
In vivo lenalidomide significantly reduced the surface expression of typical exhaustion markers 
on antigen experienced CD3+CD8+CD4+ cells. (A) Surface expression of PD-1, KLRG-1, LAG-
3, 2B4 and CD160 in spleen, and PD1 in peripheral blood (PB) on CD3+CD8+CD44+ T cells 
from lenalidomide treated mice. Samples from healthy WT mice (hWT) analysed with the same 
panel in a different experiment were retrospectively included to visualize expression levels in 
normal cells. (B) Representative flow plots for all examined markers from vehicle and 
lenalidomide treated mice, and respective fluorescence-minus-one (FMO) controls. All graphs 
show median with IQR. hWT are marked with an asterisk to emphasize that they were not 
prospectively included into the experiment. ns = non-significant.  
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7.4.4 In vivo lenalidomide treatment does not restore key T-cell effector 
functions 
In line with the persistence of CLL-typical aberrant T-cell subsets, effector function was 
not improved by in vivo lenalidomide treatment. There were no differences in the 
percentages of CD3+CD4+ lymphocytes positive for intracellular IL-4 (p=.8492), IFN-γ 
(p=.6120) or IL-2 (p=.5184) between vehicle and lenalidomide treated mice (Figure 56 
A). The retrospective comparison to healthy age-matched WT mice, which had been 
included into another study, revealed that both lenalidomide and vehicle treated mice 
maintained aberrantly increased intracellular IL-4 and IFN-γ, as well as decreased IL-2 
production.  
Among CD3+CD8+ cells, the CD107a ratio was equally impaired in lenalidomide and 
vehicle treated mice (p=.7513, Figure 56 B), indicating a maintained cytotoxic defect 
compared to cells from healthy WT mice, while IFN-γ (p=.3922, Figure 56 C) and ki67 
ratios (p=.8362, Figure 56 D) continued to be equally increased. Similarly, in vivo 
lenalidomide treatment had no effect on reducing aberrant intracellular IL-4 production 
in CD3+CD8+ T cells (p=.6678, data not shown). The expression of cytokine receptors 
CD122 and CD127 on CD3+CD8+ cells was also not different between lenalidomide 
treated and control mice (CD44- cells CD122 p=.347, CD127 p=.0643; CD44+ cells 
CD122 p=.1633, CD127 p=.1765, Figure 56 E).  
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Figure 56: T-cell effector function in lenalidomide and vehicle control treated mice. In vivo 
lenalidomide had no effect on key effector functions of CD8+ and CD4+ T cells. (A) Percentage 
of CD3+CD4+ lymphocytes positive for intracellular IL-4, IFN-γ, and IL-2 in vehicle and 
lenalidomide treated mice. (B) CD107a; (C) IFN-γ; and (D) ki67 ratios in CD44+CD3+CD8+ T 
cells from lenalidomide or vehicle treated mice. (E) Expression of cytokine receptors CD122 and 
CD127 on CD3+CD8+ cells from lenalidomide treated or control mice. All graphs show median 
with IQR. Healthy WT mice (hWT) are marked with an asterisk to emphasize that they were not 
prospectively included into the experiment. ns = non-significant. 
 
To assess if differences in PD-1 surface expression would translate into effector 
function of PD-1high and PD-1low CD3+CD8+ T cells, we compared CD107a and INF-γ 
ratios between lenalidomide and vehicle treated mice. Both in PD-1high and in PD-1low 
CD3+CD8+ T cells, there were no differences in CD107 ratio (PD-1high p=.5901, PD-1low 
p=.7274) or INF-γ ratio (PD-1high p=.2743, PD-1low p=.3418), indicating that 
lenalidomide treatment did not overcome effector defects associated with PD-1 
expression (Figure 57 A, B).  
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Figure 57: T-cell effector function in PD-1high and PD-1low CD8 T cells from lenalidomide 
and vehicle control treated mice. In vivo lenalidomide had no effect on effector functions in 
PD-1 cell subsets. (A) CD107 ratios and (B) INF-γ ratios in PD-1high and PD-1low CD3+CD8+ T 
cells from lenalidomide or vehicle treated mice. All graphs show median with IQR. ns = non-
significant. 
 
7.4.5 In vivo lenalidomide treatment improves immune synapse formation 
which can be further improved by additional ex vivo PD-L1 blockade 
After we had confirmed previously published findings on the effect of ex vivo 
lenalidomide treatment on murine B and T cells, we compared the abilities of 
autologous B and T cells to form immunological synapses between lenalidomide and 
vehicle treated mice. The mean area of T-cell F-actin synapse (μm2) was significantly 
larger in lenalidomide treated mice compared to vehicle treated mice, but was still 
impaired compared to normal autologous cells (Figure 58 A; p values are summarized 
in Table 19). Interestingly, additional lenalidomide treatment ex vivo restored the 
synapse area regardless of previous in vivo treatment, even above levels of normal 
cells, indicating that the repair of cytoskeletal defects is a very rapid and prominent ex 
vivo mechanism of action of this drug.  
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Figure 58: Immune synapse formation between autologous T and CLL/B cells. CLL and B 
cells and autologous T cells were purified from frozen splenocytes and used in immune synapse 
formation assays. (A) Effects of in vivo lenalidomide treatment on the ability of CLL T cells to 
form immunological synapses compared to cells from vehicle treated animals. Additional ex vivo 
lenalidomide treatment for 24hr restored the synapse area regardless of previous in vivo 
treatment. Graph shows mean with standard error of means (SEM). (B) Representative confocal 
images of synapses taken with a 63x objective between autologous WT B cells (hWT BC) and T 
cells (hWT TC), autologous CLL (CLL BC) and T cells (lena CLL TC) from in vivo lenalidomide 
treated mice, autologous CLL (CLL BC) and T cells from vehicle treated mice (veh CLL TC – all 
first row), and between autologous CLL (CLL BC) and lena CLL TC and veh CLL TC after 
additional ex vivo treatment with lenalidomide for 24h (second row). Blue = CMAC labelled B 
cells, red = Rhodamine Phalloidin.  
 
To establish the role of aberrant PD-L1 expression on CLL cells in mediating immune 
synapse formation defects in this experiment, CLL cells were pre-treated with PD-L1 or 
isotype blocking antibodies before immune synapse formation assays. While isotype 
had no effect, with the area of T-cell F-actin immune synapse being comparable to the 
levels of in vivo treated mice (in vivo lenalidomide treated mice p=.4482, in vivo vehicle 
treated mice p=.5916), additional ex vivo PD-L1 blockade significantly improved the 
area of immune synapses in both lenalidomide and vehicle treated mice (both p<.0001) 
and even restored immune synapses to normal levels (Figure 59 A).  
To quantify the effect of aberrant PD-1 expression on T cells on immune synapse 
formation, we next pre-treated T cells with PD-1 or isotype blocking antibodies before 
immune synapse formation assays. While ex vivo PD-1 blockage was unable to further 
increase the area of immune synapses in lenalidomide treated mice (p=.283), leaving 
synapses in those mice significantly smaller than in healthy mice (p<.0001), it 
significantly improved the area of immune synapses in vehicle treated mice (p<.0001) 
to levels comparable to lenalidomide treated mice (p=.977, Figure 59 B).  
The combined ex vivo blockade with both PD-1 and PD-L1 antibodies restored immune 
synapses in both lenalidomide and vehicle treated mice to normal levels, similar to PD-
L1 blockade alone (Figure 59 C). Table 21 summarizes the p-values of statistical 
comparisons of areas of immune synapses between different conditions.  
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Figure 59: Effect of ex vivo PD-L1 and PD-1 blockade on immune synapse formation 
between autologous T and CLL/B cells. Before synapse assays cells were pre-treated 1 hour 
with blocking antibodies at previously determined optimal concentrations. (A) PD-L1 blockade 
on CLL cells significantly improved the area of immune synapses in both lenalidomide and 
vehicle treated mice and restored immune synapses to sizes comparable to healthy WT (hWT) 
mice. (B) PD-1 blockade on T cells significantly improved the area of immune synapses in 
vehicle treated mice only but did not restore immune synapses to sizes observed in hWT mice. 
(C) Combined PD-L1 blockade on CLL cells and PD-1 blockade on T cells significantly 
improved the area of immune synapses in both lenalidomide and vehicle treated mice and 
restored immune synapses to sizes comparable to healthy WT (hWT) mice. 
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difference 
between 
lenalidomide 
and vehicle 
treatment 
effect of ex 
vivo 
treatment on 
lenalidomide-
treated mice 
effect of ex vivo 
treatment on 
vehicle-treated 
mice 
difference 
between 
healthy and     
lenalidomide-
treated mice 
difference 
between 
healthy and 
vehicle-treated 
mice 
in vivo treatment only < .0001 na na < .0001 < .0001 
24h ex vivo lenalidomide .2555 < .0001 < .0001 .532 < .0001 
ex vivo PD-L1 blockade 
PDL-1 blocking AB 
.1445 < .0001 < .0001 .9393 .1541 
isotype blocking AB < .0001 .4428 .5916 < .0001 .0009 
ex vivo PD-1 blockade 
PD-1 blocking AB 
.977 .283 < .0001 < .0001 .0001 
isotype blocking AB < .0001 .5476 .4959 .0002 < .0001 
ex vivo PD-L1/PD-1 
blockade 
PD-L1/PD-1 blocking AB 
.0176 < .0001 < .0001 .586 .0571 
isotype blocking AB .0293 .9278 .1683 .0037 < .0001 
Table 21: Summary of p-values of statistical comparisons between lenalidomide and 
vehicle treated mice and healthy WT mice with and without additional ex vivo 
lenalidomide treatment, ex vivo PD-L1/PD-1 antibody blockade, and isotype blocking 
antibodies (AB). na = not applicable. Statistically significant p-values are highlighted in bold.  
 
7.4.6 Lenalidomide is detectable in tissues and plasma of treated mice 
To confirm that the oral application of the selected dose of lenalidomide was sufficient 
to lead to detectable drug levels in plasma and CLL affected tissues, we treated WT 
mice with lenalidomide leftover from the stock administered to mice after AT, using 
identical doses and application routes. Mice received 5 days of oral application of 
10mg/kg lenalidomide in 300µl PBS or vehicle (PBS) only, were sacrificed 24 hours 
after the last dose, and tissues were collected. Lenalidomide concentrations in plasma 
as well as intracellular concentrations in spleen and brain (non-lymphoid tissue control) 
were measured by high-resolution mass spectrometry by an investigator blinded to the 
treatment of the mice. Tissues from an untreated leukaemic TCL1 mouse sacrificed at 
the same time as the treated mice were included as negative controls, and freshly 
constituted lenalidomide was included as a positive control. Lenalidomide could be 
detected in all tissues and plasma from treated mice, but not in tissues from untreated 
mice. These findings indicate that the drug concentration and stock used in this 
experiment was sufficient to lead to detectable drug levels in all tissues (Figure 60).  
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Figure 60: Confirmation of drug concentrations by mass spectrometry. High resolution 
mass spectrometry was used to confirm that treatment for 5 days with 10mg/kg body weight of 
the lenalidomide stock used in the in vivo study was sufficient to lead to detectable intracellular 
drug concentrations in lymphoid and non-lymphoid tissues, as well as in plasma. The drug could 
not be detected in tissues from healthy WT mice (hWT) or a leukaemic untreated TCL1 mouse. 
 
7.5 Summary of effect of in vivo lenalidomide treatment on T-cell dysfunction 
and T-cell exhaustion in TCL1 mice 
In summary, we found that in vivo lenalidomide did not result in effective CLL control if 
administered daily by oral gavage from three weeks after AT of 4x107 splenocytes from 
leukaemic TCL1 mice. Median spleen weights and the percentages of CD19+CD5+ 
CLL lymphocytes in spleen and peripheral blood were comparable in lenalidomide and 
vehicle treated mice. In addition, treatment had no effect on the expression of PD-L1 
and PD-L2 on CLL cells. The ineffective CLL control by in vivo lenalidomide treatment 
was reflected by the persistence of typical CLL-induced T-cell phenotypic alterations. 
Both lenalidomide and vehicle treated mice continued to exhibit a reduced CD4+/CD8+ 
ratio, and a loss of naive cells and shift towards antigen-experienced CD8+ effector 
and EM cells. This was recapitulated in spleen and PB. Accordingly, effector function 
was not improved by in vivo lenalidomide treatment. There were no differences in the 
percentages of CD3+CD4+ lymphocytes from spleen positive for intracellular IL-4, IFN-
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γ or IL-2 between vehicle and lenalidomide treated mice, and both groups continued to 
exhibit aberrantly increased intracellular IL-4 and IFN-γ, and decreased IL-2 production 
by CD4+ T cells compared to healthy WT mice. Among CD3+CD8+ cells, the CD107a 
ratio was equally impaired in lenalidomide and vehicle treated mice, indicating a 
maintained cytotoxic defect compared to cells from healthy WT mice, while IFN-γ and 
ki67 ratios continued to be equally increased, indicating persistent cytokine and 
proliferation defects. Similarly, in vivo lenalidomide treatment had no effect on reducing 
aberrant intracellular IL-4 production in CD3+CD8+ T cells, or on the expression of 
cytokine receptors CD122 and CD127. 
Despite the lack of CLL control and persistent T-cell subset alterations, in vivo 
lenalidomide treatment appeared to have an effect on the expression of previously 
described exhaustion-like markers, with the surface expression of PD-1, KLRG-1, LAG-
3 and 2B4, but not CD160 being significantly reduced on antigen-experienced CD44+ 
CD3+CD8+T cells from lenalidomide treated mice. The reduction of PD-1 was also 
observed in CD8+ T cells in peripheral blood. This however did not translate into 
improved effector function of PD-1high and PD-1low CD3+CD8 T cells, with CD107a and 
INF-γ ratios in PD-1 subsets being comparable between lenalidomide and vehicle 
treated mice.  
In contrast, in vivo lenalidomide treatment had a very strong effect on immune synapse 
formation between autologous T and CLL cells; the ability of CLL T cells to form 
immunological synapses was significantly improved compared to vehicle treatment, but 
synapses were not restored to normal levels. However, additional ex vivo lenalidomide 
treatment for 24 hours fully restored the synapse area regardless of previous in vivo 
treatment, underlining the strong ex vivo effect of the drug on cytoskeletal regulation. 
Ex vivo PD-L1 blockade on CLL cells significantly improved the area of immune 
synapses in both lenalidomide and vehicle treated mice and restored immune 
synapses to sizes comparable to healthy WT mice. Additional ex vivo PD-1 blockade 
on T cells significantly improved the area of immune synapses in vehicle treated mice 
only, but did not restore immune synapses to levels observed in WT mice. Combined 
ex vivo PD-L1 and PD-1 blockade significantly improved the area of immune synapses 
in both lenalidomide and vehicle treated mice and restored immune synapses to sizes 
comparable to healthy WT mice. 
 
 
Fabienne McClanahan                                                                                                     Chapter 7 
Page 202 of 258 
 
7.6 Discussion 
The goal of this part of the project was to investigate if in vivo lenalidomide treatment 
can correct CLL-induced PD-L1/PD-L2/PD-1 mediated T-cell dysfunction and enhance 
anti-tumour T-cell responses in mice with CLL after adoptive transfer. Despite 
promising early clinical trial data from human CLL, indicating that lenalidomide 
treatment normalizes general T-cell subsets and restores T-cell cytokine production441-
443, this was not observed in lenalidomide treated mice with CLL. In our experiments, in 
vivo lenalidomide did not result in the normalization of aberrant T-cell subsets and key 
T-cell effector functions such as CD4+ and CD8+ T-cell cytokine secretion, CD8+ T-cell 
proliferation, and CD107a degranulation.  
The most apparent explanation for our findings is the lack of effective CLL control by 
lenalidomide treatment in mice, allowing CLL cells to continuously exert their full 
immunosuppressive effect on immune cells. Several in vitro studies have demonstrated 
that lenalidomide is not directly toxic to CLL cells448, in contrast to multiple myeloma 
and MDS cells where it has a direct cytotoxic effect451. Instead, in vitro lenalidomide 
has been shown to increase the expression of costimulatory molecules, and to induce 
p-ERK signalling in CLL cells448. Other studies have implicated a role for the PI3-kinase 
pathway in lenalidomide-induced CLL cell activation71. The combination of PI3-kinase 
activation and induction of NFκB and NFAT signalling resulted in enhanced 
transcription and stabilisation of CD154 (CD40L) mRNA, leading to expression of 
CD154 on CLL cells452. CD154 positive CLL cells upregulated BID, DR5 and p73, 
became sensitised to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-
mediated apoptosis, and promoted the co-stimulatory activation of normal B cells, 
resulting in the production of polyclonal antibodies. A recently published study 
demonstrated that lenalidomide inhibited CLL proliferation via induction of the CDK 
inhibitor p21 regardless of functional p53453.  
In contrast, in our in vivo experiment the daily administration of lenalidomide (10mg/kg 
body weight by oral gavage) from three weeks after AT did not prevent CLL 
progression in treated mice, as evidenced by comparable spleen weights and CLL load 
in spleen and peripheral blood in lenalidomide and vehicle treated mice. This lack of 
CLL control could potentially be explained by insufficient drug application, such as 
inadequate doses or timing of treatment. According to current FDA guidelines454, 
human equivalent doses (HEDs) are calculated using the following formula: HED = 
animal dose in mg/kg x (animal weight in kg/human weight in kg). Assuming a 60kg 
human, the mouse dose of 10mg/kg selected in our studies corresponds to 48.8mg in a 
patient. This is considerably higher than the doses currently used in CLL patients; the 
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initial clinical study used a starting dose of 25mg/day in the majority of patients, which 
is the standard target dose for the treatment of multiple myeloma82. As this was 
associated with unacceptable toxicities in CLL patients, especially tumour flare 
reactions78, 91, reduced starting doses as low as 2.5mg were used in further clinical 
trials, and escalated to a maximum of 25mg80, 83-86, 90, 455. Therefore, the dose selected 
in our study clearly is translationally relevant. In addition, pharmacokinetics and 
pharmacodynamics studies in mice have demonstrated a high systemic bioavailability 
of 75% via oral routes and a dose-dependent tissue distribution, which is consistent 
with the high oral bioavailability in humans449. Moreover, we performed repeated mass 
spectrometry studies to rule out that the lack of CLL control was attributed to 
degradation of the dissolved drug stock over the treatment period of 3 weeks, as 
several studies have indicated that IMiDs are unstable in aqueous solutions456, 457. 
Indeed, comparing the PBS diluted treatment compound after three weeks storage at 
minus 80ºC to a freshly reconstituted standard demonstrated a two-fold lower ion count 
in the treatment compound, indicating some degradation of the drug over the duration 
of the treatment period. To assess if intracellular and plasma drug concentrations could 
still be achieved with this degraded compound, we treated additional healthy WT mice 
for 5 days with 10mg/kg per day, or PBS vehicle control, and sacrificed them 24 hours 
after the last dose. Despite the lower ion count and the 24 hour latency until the 
animals were sacrificed, lenalidomide could be detected in spleen, plasma, and non-
lymphoid tissues. It is therefore unlikely that the lack of disease control, either by direct 
or indirect mechanisms, can be attributed to insufficient dosing or degradation of the 
drug.  
It is possible that better CLL control could have been achieved by earlier initiation or 
longer duration of treatment. In our study, the median CLL load in peripheral blood, 
defined as the percentage of CD19+CD5+ lymphocytes, was 26% and therefore 
representative of an earlier stage of CLL. In addition, mice were well balanced between 
the intervention groups, ruling out that groups might have been enriched for mice with 
more or less advanced CLL. Initiation of treatment shortly after adoptive transfer might 
have resulted in the prevention of CLL-induced phenotypic and functional T-cell 
defects, as the drug would have been administered at a stage of low tumour volume. 
This hypothesis is supported by earlier findings from our groups, which demonstrated 
that T-cell defects are rapidly induced ex vivo by direct cell-cell contact with malignant 
cells after just 48 hours of co-culture77. However, this would have only insufficiently 
mirrored published studies using cells from human CLL patients, where a repair of T-
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cell phenotype and subsets was observed in patients with manifest disease and 
indication for treatment80, 441-443.  
More effective disease control in mice might have also been achieved by prolongation 
of the treatment period or by the combination with other substances. This hypothesis is 
supported by data from clinical trials in human CLL. Using lenalidomide monotherapy, 
ORR of up to 65% for first-line therapy and up to 47% for relapsed/refractory patients 
were reported, with most patients exhibiting PR82-85, 90. However, in these studies the 
median times to best response were 3 to 18 months in previously untreated and 6 to 9 
months in relapsed/refractory patients, with late responses being observed in some 
patients after more than one year. Combination therapy with monoclonal antibodies 
such as rituximab or ofatumumab increased ORR to up to 95% in previously untreated 
and up to 66% in relapsed/refractory patients, while largely increasing the proportion of 
patients with complete responses86, 88. Other studies have demonstrated an association 
between longer duration of treatment and normalization of T-cell subsets: in 24 patients 
with untreated CLL enrolled in a Phase II clinical trial of lenalidomide, a relative 
increase of T cells, activated CD8+ T cells producing IFN-γ, and TRegs compared to 
baseline levels before treatment were observed after 3 cycles of treatment. Only after 
15 cycles of treatment, activated IL-2/IFN-γ/TNF-α producing CD4+ T cells, TRegs and 
activated IFN-γ producing CD8+ T cells normalized to the range of healthy subjects442. 
Another long-term analysis of 60 CLL patients treated with lenalidomide with a median 
follow up 4 years showed normalization in the percentages of CD4+ and CD8+ cells 
and T-cell numbers respectively in 48%, 71% and 99% of long-term responders87. 
Therefore, the treatment duration of 3 weeks in our in vivo study might have been too 
short, and/or the single-agent application too weak to allow for effective disease control 
and modulation of T-cell subsets. Longer treatments, however, are not feasible in the 
AT model, as mice usually succumb to their disease after a median of 7 weeks (range 
3.7-20, see Figure 10 Chapter 4.4.3). Therefore, lenalidomide treatment of ageing 
TCL1 mice might be a more beneficial experimental model to study the long-term effect 
of lenalidomide on CLL and T cells in mice.  
There is reasonable concern that the lack of activity of lenalidomide in mice might be 
caused by species differences of molecular targets, as the first generation IMiD 
thalidomide has been found to have teratogenic activity in humans, rabbits, chicks, and 
zebrafish, but not in mice and rats. The molecular target of both thalidomide and 
second generation IMiDs essential for their activity is cereblon (CRBN), a 442 amino-
acid protein and a component of the E3 ubiquitin ligase complex that also contains 
DNA damage binding protein 1 (DDB1), regulator of cullins (Roc)-1 and Cullin 4 
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(Cul4)76, 458-460. CRBN was found to be largely evolutionarily conserved, and 
thalidomide was confirmed to bind to CRBN from humans, mice, chick, and 
zebrafish458. However, selected spots in the mouse ortholog of the human thalidomide 
binding domain (TBD) showed inter-species variability, raising the possibility that this 
might translate into functional differences. This was further explored by a recently 
published study describing the crystal structure of human and murine CRBN bound to 
DDB1 and different IMiDs461. The same conformations were found in both human and 
mouse TBDs, suggesting that any structural changes observed are not likely to be a 
consequence of species differences. In addition, CRBN orthologs were compared 
across different animal and plant kingdoms, and found to exhibit 100% sequence 
conservation in the essential tri-Trp binding pocket. However, due to two rodent 
polymorphisms proximal to the lenalidomide-binding site, mouse CRBN was unable to 
rescue the antiproliferative effects of pomalidomide in CRBN deficient DF15R cells and 
did not exhibit the pomalidomide-dependent degradation of transcription factors. These 
findings suggest that despite identical molecular targets and binding sites, it is likely 
that rodents do not respond to IMiD agents in the same way that humans do, which 
potentially explains the weak modulation of T-cell effector functions we observed.  
Two key substrates of the CRBN CRL4 E3 ligase are Aiolos (IKZF3) and Ikaros 
(IKZF1), which are members of a family of zinc finger transcription factors. It has been 
demonstrated that binding of lenalidomide and pomalidomide to CRBN in myeloma 
cells or T cells increased IKZF1 and IKZF3 binding to CRBN, inducing their 
ubiquitination and subsequent proteasomal degradation76, 462, 463. The resulting IKZF 
depletion led to loss of viability of IKZF-dependent myeloma cells, while simultaneously 
enhancing the production of IL-2 in T cells. Aiolos has also been described as playing a 
major role in promoting TH17 differentiation by directly silencing IL-2 expression464. In 
CLL, it was demonstrated by knockdown experiments using in vitro CD40L/IL-4/IL10 
stimulated CLL cells that p21-mediated reduction of CLL proliferation and degradation 
of IKZF 1 and 3 after lenalidomide treatment is dependent on CRBN453. Congruently, 
CLL cells from patients treated with lenalidomide within a clinical trial showed induced 
expression of p21 following lenalidomide therapy. Interestingly, Aiolos expression, but 
not Ikaros expression, was found to be upregulated in CLL cells465. This was later 
linked to being the result of NF-kB signalling, with enriched active chromatin marks of 
Aiolos having an effect on Bcl-2 family members466. The effect of lenalidomide on 
CRBN complex-mediated IKZF degradation in CLL T cells is not known. However, 
previous work from our group demonstrated that knockdown of CRBN significantly 
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reduced the ability of lenalidomide to modulate Rho GTPase-dependent T cell 
migration on CD54-coated slides81.  
Interestingly, despite the lack of disease control and the persistence of CLL-typical 
phenotypic and functional defects, we observed a reduction of the surface expression 
of typical exhaustion markers, namely PD-1, on CD8+ cells from lenalidomide treated 
mice. This is in line with observations in CLL patients treated with lenalidomide. The 
percentage of CD4+ cells expressing either PD-1, 2B4 or CD57 alone, and all markers 
in combination, was observed to be significantly reduced after lenalidomide treatment, 
and was comparable to levels observed in healthy controls441. Among CD8+ cells, the 
percentages of all subsets, with the exception of CD8+PD-1+ and CD8+PD-1+2B4+ 
cells, were similarly reduced in lenalidomide treated patients. This study, however, did 
not contain any information on the treatment duration. Our group has demonstrated on 
a small number of lenalidomide treated patients that aberrant expression of PD-1 was 
significantly reduced after 3 weeks of treatment79. During the same time, however, 
lenalidomide treatment also resulted in the reduced expression of PD-L1 on CLL cells, 
increased T-cell conjugation and synapse function with autologous tumour cells, and 
increased antigen-induced cytolytic effector activity. While the reduction of PD-1 
expression on mouse CD8+ T cells did not translate into improved effector function in 
PD-1 subsets, measured by cytokine secretion and CD107a degranulation, we were 
able to confirm previous findings on the restoration of the immune synapse; treatment 
of mice with lenalidomide significantly improved the ability of T cells to form 
immunological synapses with autologous CLL cells. However, it did not lead to a full 
restoration of synapses to levels observed in autologous cells from healthy mice. 
Interestingly, this was achieved by additional ex vivo lenalidomide treatment for 24 
hours, both in cells from mice treated with lenalidomide and vehicle. These findings 
underline the strong direct ex vivo effect of the drug on cytoskeletal regulation and 
demonstrate that cells from these animals are capable of synapse formation. 
Furthermore, these results support the hypothesis that our in vivo treatment did not 
attain sufficiently high lenalidomide levels for an adequate period and/or that the effects 
are readily reversible in vivo, rather than that lenalidomide solely fails to bind murine 
cereblon.  
The addition of lenalidomide to co-cultures between human CLL and normal allogeneic 
T cells, as well as treatment of autologous CLL/T-cell co-cultures, was able to 
overcome the immunosuppressive effect of PD-L1 inhibitory signalling, as its effect on 
restoring the immune synapse and increasing CD8+ T cell cytolytic potential was 
comparable to the repair achieved by antibody blockade of PD-L179. To assess the role 
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of PD-L1/PD-1 in inhibiting effective immune synapse formation in the context of in vivo 
lenalidomide treatment of mice, we added ex vivo blocking antibodies against PD-
L1/PD-1 before immune synapse assays. We found that additional ex vivo PD-L1 
blockade on CLL cells significantly improved the area of immune synapses in both 
lenalidomide and vehicle treated mice and restored immune synapses to sizes 
comparable to healthy WT mice. Interestingly, additional ex vivo PD-1 blockade on T 
cells only improved the area of immune synapses in vehicle treated mice and restored 
it to levels observed in lenalidomide treated mice. Combined ex vivo PD-L1 and PD-1 
blockade significantly improved the area of immune synapses in both lenalidomide and 
vehicle treated mice and restored immune synapses to sizes comparable to healthy 
WT mice. These findings highlight the importance of aberrant PD-L1 expression on 
CLL cells to mediate immune synapse formation defects of T cells. As immune 
synapse formation is an essential step to activate T cells upon the encounter of MHC-
presented antigen, it can be hypothesized that the repair of immune synapses by PD-
L1 blockade leads to a restoration of T-cell effector functions and overcomes the 
functional defects associated with aberrant T-cell phenotypes.   
In sum, our in vivo experiments using single agent and short term lenalidomide 
treatment have confirmed that the repair of cytoskeleton defects is a prominent 
mechanism of action that is recapitulated in mice with CLL, even though different 
therapeutic responses exist in mice with CLL versus human CLL patients. In addition, 
they have highlighted the role of aberrant PD-L1 expression by CLL cells in impairing 
T-cell function, and provided a strong rationale that this could be overcome using in 
vivo PD-L1 blockade. Therefore, the potential of in vivo PD-L1 blockage to correct CLL-
induced T-cell dysfunction and enhance anti-tumour T-cell responses in mice with CLL 
will be explored in the next chapter.  
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8 Potential of in vivo PD-L1 blockade to restore T-cell dysfunction 
8.1 Specific introduction 
In physiological settings, co-receptors essential for the activation of immune effector 
cells (so-called immune checkpoints) tightly regulate the amplitudes and qualities of T-
cell responses and thereby maintain self-tolerance, prevent autoimmunity, and protect 
healthy tissues from being damaged by limiting normal immune responses332. Many 
tumours utilize these checkpoints to their advantage to escape anti-tumour immune 
responses338. PD-L1 and PD-1 have emerged as one of the most prominent immune 
checkpoint ligand/receptor axes that contribute to maintaining an immunosuppressive 
tumour microenvironment, and several studies have demonstrated that aberrant PD-L1 
expression by tumour cells has an inhibitory effect on T cells, both in haematological 
malignancies (see Chapter 1.3.2) and in solid cancers312-314. Encouraging results from 
early clinical trials using PD-1/PD-L1 antibodies showed significant response rates, 
even in heavily pre-treated patients with solid tumours, thus validating PD-L1/PD-1 as 
key targets for immunotherapy approaches aiming to shift the balance back from a pro-
tumour to an anti-tumour microenvironment (see Chapter 1.4.2).  
One of the earliest clinical Phase I dose-escalation studies in patients with 
haematological malignancies using the PD-1 antibody pidilizumab showed a favourable 
safety profile and evidence of clinical activity in 6 of 18 patients, with no maximum 
tolerated dose defined362. In this cohort of patients, an increase of absolute numbers of 
peripheral blood CD4+ T cells was observed that was maintained up to 21 days after 
treatment. More recently, pidilizumab was administered to patients with DLBCL 30–60 
days after autologous haematopoietic stem-cell transplantation (auto-HSCT) at a 
dosing schedule of 1.5 mg/kg once every 6 weeks for three cycles359. The 16-month 
PFS from first treatment was 72%, and overall survival was 85%. Among 35 patients 
with measurable disease after auto-HSCT, the ORR after pidilizumab treatment was 
51%. Pidilizumab was well tolerated with the most common adverse events noted to be 
grade one to four neutropenia, fatigue, and diarrhoea. Notably, pidilizumab 
administration was associated with several changes in the absolute number of 
circulating lymphocyte subsets, and led to a sustained increase of PD-L1+CD25+CD4+ 
T cells, CD4+ CM T cells, CD8+ CM T cells, and PD-L1+ monocytes. In addition, the 
authors found an increase in CD127+ CM CD4+ and CD8+ T cells. In a recently 
published study, pidilizumab was combined with the anti-CD20 antibody rituximab in 
patients with relapsed follicular lymphoma360. This Phase II trial demonstrated that this 
combination was well-tolerated and produced overall and CRR of 66% and 52%, 
respectively, with tumour regression in 86% of patients. Within this trial, a number of 
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correlative studies were performed to assess the immunological effects of pidilizumab. 
The authors found that expression of PD-L1 (but not PD-1 or PD-L2) was significantly 
higher in peripheral blood CD4+, CD8+, and CD14+ cells of responders than non-
responders, but was not associated with PFS. The comparison of PB samples taken 14 
days after the first pidilizumab infusion with baseline samples demonstrated an 
increase in absolute lymphocyte count, CD3+ T cells and CD4+ T cells, but not in 
CD8+ T cells. Naive, EM, and CM CD4+ T cells were significantly increased after 
treatment. Among CD8+ T cells, terminally differentiated cells were decreased, but 
other subsets were not-significantly different. The comparison of gene expression 
profile data of paired core-needle biopsies demonstrated that the change in expression 
after treatment was correlated with outcome and tumour shrinkage, with increased 
expression of T-cell activation signatures after pidilizumab being associated with longer 
PFS. This however was not confirmed by flow cytometry or immunohistochemistry, and 
paired tissue and peripheral blood samples at diagnosis (i.e. from the same patient) 
could not be correlated with each other. In addition, it is possible that the co-
administered anti-CD20 antibody rituximab might have had a confounding effect on the 
amplitude and quality of T-cell responses; rituximab induces B-cell depletion and 
modulates immune-mediated cell killing via various degrees of complement-dependent 
cytotoxicity (CDC), ADCC and phagocytosis467, which might have had an effect on the 
T-cell signatures and phenotypes observed in this study. Ongoing Phase II studies are 
evaluating the safety and clinical efficacy of pidilizumab in patients with AML and 
multiple myeloma in combination with cell-based vaccines468, 469, and in patients with 
multiple myeloma in combination with lenalidomide470. Another PD-1 antibody currently 
under clinical evaluation in patients with MDS, multiple myeloma, HL, mediastinal large 
B cell lymphoma, and NHL is MK-3475 (pembrolizumab)471. 
Clinical data on anti-PD-L1 antibodies in patients with leukaemias and lymphomas is 
notably absent. The anti-PD-L1 antibody MPDL3280A is currently being tested in a 
Phase I dose escalation study in patients with solid and haematological 
malignancies472, but another study evaluating the anti-PD-L1 antibody BMS-936559 in 
patients with relapsed or refractory haematological malignancies was withdrawn prior 
to any patient enrolment473. Similarly, studies of the immunological effect of in vivo PD-
L1 blockade are rare, and information is currently limited to preclinical models. Data 
from murine solid cancer models indicate that in vivo PD-L1 blockade in combination 
with IL-15 administration, CTLA-4 blockade or IDO pathway blockade restores CD8+ T 
cell IL-2 production and proliferation within the tumour microenvironment474, increases 
the numbers and lytic activity of tumour antigen-specific CD8+ T cells, augments 
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antigen-specific IFN-γ release, and inhibits suppressive functions of regulatory T 
cells475, 476. However, it is becoming clear that PD-L1 is not only aberrantly expressed 
by tumour cells, but also by cells in the tumour microenvironment such as MDSCs, 
tumour-associated macrophages, and dendritic cells, which also has an effect on 
modulating T-cell function199, 298, 477, 478.  
Despite the increasing pre-clinical evidence pointing towards the importance of PD-1/ 
PD-L1 inhibitory signalling in CLL, neither PD-L1 nor PD-1 blockade has been clinically 
explored minimally in this disease. The study by Berger et al.362 included only 3 
patients with CLL/SLL, of which two showed stable disease with pidilizumab treatment. 
Future clinical trials on PD-1/PD-L1 blockade in CLL, however, could be supported by 
preclinical data from the TCL1 model. In-depth work performed in this project confirms 
that TCL1 mice are a valuable preclinical tool to mirror PD-L1/PD-1 mediated T-cell 
defects. In addition, our results highlight the significance of the PD-1/PD-L1 axis in 
suppressing specific T-cell effector functions in CLL, and identify T-cell subsets that are 
suitable candidates to be promoted to fully functional effector cells by blocking PD-
1/PD-L1 inhibitory signalling, as demonstrated in Chapter 7.3.7. TCL1 mice are 
therefore an ideal model to study if in vivo PD-1/PD-L1 blockade has the potential to 
add to effective disease control by restoring anti-tumour immune responses. Due to the 
similarity of our model to human CLL, output of these experiments is likely to provide a 
strong rationale for further clinical assessment of PD-L1/PD-1 immune checkpoint 
blockade. 
 
8.2 Goals and objectives 
Based on the data we generated thus far, my next goal was to investigate if in vivo PD-
L1 blockage corrects CLL-induced T-cell dysfunction and enhances anti-tumour T-cell 
responses in mice with CLL. Specifically, I sought to address the following questions: 
 Does early in vivo PD-L1 blockade have the potential to effectively control disease 
development after adoptive transfer (AT) of murine CLL? 
 Can early in vivo PD-L1 blockade prevent the development of the previously 
described aberrant T-cell phenotype? 
 Can early in vivo anti-PD-L1 treatment restore key T-cell effector functions? 
 Can early in vivo anti-PD-L1 treatment overcome functional T-cell defects relating 
to aberrant PD-1 expression? 
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8.3 Specific methods and materials 
8.3.1 Mice and in vivo treatment 
Three month old female B6 WT mice were purchased from Charles River, UK, 
randomized to “treatment” (n=15), “isotype” (n=10) or “no intervention” (n=6) groups, 
ear-tagged, and kept in cages containing 5 mice each (6 for “no intervention”) for one 
week without any further procedures. Sample size was calculated based on the 
assumption that at least 9 mice per group would be needed to detect a 1.25 standard 
deviation difference in PD-1 means between treated and untreated mice in one-sided 
testing at a significance level α=0.05 with at least 80% power. Mice randomized to 
“treatment” and “isotype” were then injected i.v. with 4x107 syngeneic CLL cells in a 
single dose from the same pool of aged TCL1 mice, followed by i.p. injection of 
10mg/kg anti-murine-PD-L1 in vivo monoclonal antibody (aPD-L1, clone 10F.9G2, rat 
IgG2b) or in vivo isotype monoclonal antibody (clone LTF-2, rat IgG2bκ, both BioXcell, 
USA) on day +1. Administrations of aPD-L1 or isotype antibodies were repeated every 
3 days, and mice were sacrificed 31 days later after having received a total of 11 
doses, along with the “no intervention” mice, under protocol 19b2 of PIL 70/7531. 
Spleens, PB, LN and BM were harvested and processed as described before. 
 
8.3.2 Multicolour flow cytometry for cell surface markers  
T-cell subsets were characterized based on the surface expression of CD3, CD4, CD8, 
CD62L, CD44 and CCR7. Exhaustion markers included PD-1, KLRG-1, 2B4, CD160 
and LAG-3. CLL was assessed by concurrent CD19 and CD5 expression, and PD-L1 
and PD-L2 were included into the CLL panel. Antigens, fluorochromes, clones, 
concentrations and suppliers are described in the previous chapters. For PD-L1, clone 
MIH5 was used, as the PD-L1 monoclonal antibody administered in vivo was clone 
10F.9G2. As demonstrated in the saturation experiments in the previous chapter, pre-
incubation with 10F.9G2 reduced consecutive binding of fluorochrome-labelled 
10F.9G2. To determine if 10F.9G2 would also block binding of fluorochrome-labelled 
MIH5, we incubated fresh MNC from the spleen of a leukaemic TCL1 mouse for 1 hour 
with the previously determined optimal dose of 10mg/ml LEAFTM purified 10F.9G2 
antibody, or LEAFTM isotype blocking antibody rat IgG2bκ (both Biolegend, UK). Cells 
were then washed and stained with fluorochrome-conjugated PD-L1 antibodies [clones 
10F.9G2 (PECy7) or MIH5 (PerCPeFluor710)] for flow cytometry. Fluorochrome-
conjugated isotype controls were also included. This experiment demonstrated that 
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pre-incubation with 10F.9G2 reduced the MFI of both PECy7 labelled 10F.9G2 and 
PerCPeFluor710 labelled MIH5, indicating that the in vivo antibody 10F.9G2 partially 
blocks the binding of MIH5, thereby influencing the correct assessment of PD-L1 
expression (Figure 61). 
 
Figure 61: In vitro blockade with PD-L1 clone 
10F.9G2 affects binding of PD-L1 clone MIH5: 
Fresh mouse spleen MNC were pre-incubated for 
1h with 10mg/ml purified anti-PD-L1 antibody clone 
10G.9G2 or isotype blocking antibody, and stained 
with PerCPefluor710 labelled PD-L1 antibody 
against clone MIH5. Cells stained with PeCy7 
10F.9G2 were used as positive control.  
 
 
 
Table 22 contains an overview of the flow panel combinations used in this experiment. 
Experiments were performed on fresh samples, and FMO controls for CD44, CCR7, 
exhaustion markers, PD-L1 and PD-L2 were included into all experiments. Cells were 
prepared for flow cytometry as described before. The gating strategies have been 
described in Chapters 5 and 6.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fabienne McClanahan                                                                                                     Chapter 8 
Page 213 of 258 
 
1. spleen 
tube 1 tube 2 tube 3 
T-cell subsets/exhaustion T-cell exhaustion B cells 
CD4 PerCPCy5.5 CD8 BV605 CD5 APC 
CD8 BV605 CD3 APCCy7 CD19 FITC 
CD3 APCCy7 CD44 AF700 CD45 APCCy7 
CD62L FITC 2B4 APC PDL1 PE 
CD44 AF700 LAG3 PerCPefl710 PDL2 PerCPefl710 
CCR7 PeCy7 CD160 PE viability dye DAPI 
KLRG1 PE viability dye DAPI 
  
PD1 APC 
    
viability dye DAPI 
    
2. peripheral blood 
tube 1 
 
tube 2 
T-cell subsets/exhaustion B cells 
CD4 PerCPCy5.5 CD5 APC 
CD8 BV605 CD19 FITC 
CD3 APCCy7 CD45 APCCy7 
CD62L FITC PDL1 PE 
CD44 AF700 PDL2 PerCPefl710 
PD1 APC viability dye DAPI 
viability dye DAPI   
3. bone marrow 
same as peripheral blood  same as peripheral blood 
4. lymph nodes 
same as peripheral blood  same as peripheral blood 
Table 22: Overview of flow panel used in this experiment to phenotype T-cell subsets, 
exhaustion markers, CLL and inhibitory ligands in mouse tissues.  
 
8.3.3 Multicolour flow cytometry for intracellular cytokines and effector 
function 
Effector function and intracellular cytokines were determined as described in Chapter 5 
and included CD107a degranulation, intracellular GrB, IL-2, IL-4, and IFN-y, 
intranuclear ki67, and in vivo EdU incorporation. Differences in T-cell function between 
experimental groups were compared by calculating ratios between CD44+ cells 
positive for CD107a/IFN-y/ki67, and CD44+ cells negative for these markers, to 
describe the ratio between effector cells within CD44+ cells compared to non-effector 
(i.e. negative) cells. Differences in ratios were interpreted as an increase of cells able 
to exert effector functions (increase of ratio), or decrease of cells able to exert effector 
functions (decrease of ratio), respectively. Similar comparisons were made between 
ratios within PD-1high and PD-1low subsets.  
 
Fabienne McClanahan                                                                                                     Chapter 8 
Page 214 of 258 
 
8.3.4 Immune synapse formation assays 
Frozen splenocytes were debulked of CLL and B cells by manual magnetic separation 
using murine CD19 microbeads, and the column effluent representing the CD19- 
fraction was further purified by negative selection using murine T-cell isolation kits as 
described in Chapter 3.3. These T cells were used in synapse formation assays with 
CMAC-labelled, sAg-pulsed healthy syngeneic B cells as antigen-presenting cells at a 
1:1 ratio. Synapse assays, confocal microscopy, and image analysis were conducted 
as described in Chapter 3.5.   
 
8.4 Results 
8.4.1 In vivo anti-PD-L1 treatment effectively controls CLL and prevents PD-L2 
expression on normal B cells 
Following AT of 4x107 CLL cells from leukaemic TCL1 donors, mice treated with 11 
doses of murine aPD-L1 showed effective control of CLL relative to mice receiving 
isotype antibody. Spleen sizes in aPD-L1 treated mice were remarkably reduced 
(Figure 62 A) and spleen weights were significantly lower compared to the isotype 
control group (median 0.2g vs. 0.9g, p<.0001, Figure 62 B). Dark focal pigmentations 
were apparent in spleens from aPD-L1 treated mice, although these are normal in 
young B6 mice and are caused by accumulation of melanin479. Compared to isotype, 
aPD-L1 treated mice had a significantly lower relative frequency of CD19+CD5+ CLL 
lymphocytes in spleens (1.6% vs. 71.7%, p<.0001), PB (10.5% vs. 63.5%, p.0019) and 
BM (.3% vs. 2.7%, p<.0001) as determined by flow cytometry of single-cell 
suspensions (Figure 62 C). In LN, no differences were detected. However, our work 
previously demonstrated that CLL involvement of LN is not well reflected in the AT 
model. Together, these results demonstrate very effective tumour control. Interestingly, 
mice treated with aPD-L1 appeared to have higher CLL loads in blood than in spleen, 
indicating that PD-L1 might have an effect on homing or migration into secondary 
lymphoid organs (Figure 62 D).  
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Figure 62: Effect of in vivo aPD-L1 treatment on disease development. Three month old B6 
WT mice transplanted with 4x107 splenocytes from leukaemic TCL1 mice were randomized to 
treatment with 10 mg/kg anti-murine-PD-L1 (aPD-L1, n=15) or isotype antibody (n=10), 
administered i.p. every 3 days starting one day after adoptive transfer, and sacrificed 31 days 
later. (A) Differences in spleen sizes between isotype and aPD-L1 treated mice. (B) Spleen 
weights in aPD-L1 treated and isotype treated mice. (C) Relative frequency of CD19+CD5+ CLL 
lymphocytes in all examined organs. (D) CLL loads in different organs in individual mice. All 
graphs shows median with interquartile range (IQR); (E) shows medians only.  
 
As expected, the specific MFI of PD-L1 was significantly reduced in all examined 
organs in aPD-L1treated mice compared to WT mice, reflecting the partial blockade of 
the binding site of the fluorochrome-labelled PD-L1 antibody used for flow cytometry 
(clone MIH5) by the in vivo PD-L1 antibody (clone 10F.9G2, Figure 63 A). Confirming 
previous findings, isotype treated mice showed significantly upregulated PD-L1 on CLL 
cells in all examined organs, as compared to normal B cells from WT mice. As the CLL 
population was notably absent in aPD-L1 treated mice compared to isotype treated 
mice (1.6% vs. 71.7% CLL cells), we compared the expression of PD-L2 on normal B 
cells in aPD-L1 treated mice to expression on CLL cells in isotype treated mice. 
Although we demonstrated in Chapter 6 that aberrant PD-L2 expression is exclusive to 
CLL cells, we hypothesized that B cells in aPD-L1 treated mice might still show 
upregulated PD-L2 as a result of the AT procedure or the immunological challenge by 
tumour. Interestingly, PD-L2 expression was comparable in aPD-L1 treated and 
healthy WT mice in all examined organs, and was significantly lower than in isotype 
treated mice (Figure 63 B). 
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Figure 63: Effect of in vivo aPD-L1 treatment on PD-L1 and PD-L2 expression. PD-L1 and 
PD-L2 were gated on CD19+CD5+ CLL cells in isotype treated mice, and on CD19+ B cells in 
aPD-L1 treated and healthy WT mice (hWT), as treatment had resulted in the significant 
reduction of the CLL population. (A) aPD-L1 treatment partially blocked binding of fluorochrome 
labelled PD-L1 on a different clone (MIH5), while PD-L1 expression was significantly increased 
on CLL cells from isotype treated mice compared to B cells from healthy mice. (B) PD-L2 
expression was comparable in normal B cells from aPD-L1 treated and WT mice, and was 
significantly increased in isotype treated mice. All graphs show median with IQR. ns = non-
significant, *p<.05, **p<.001, ***p<.0001.  
 
Table 23 summarizes the p-values of statistical comparisons of specific MFIs for PD-L1 
and PD-L2 between the experimental groups for all organs examined. 
 
    
aPD-L1 vs. 
isotype 
aPD-L1 vs. 
hWT 
isotype vs. 
hWT 
MFI PD-L1 spleen <.0001 .0005 .0002 
  peripheral blood <.0001 .0005 .0004 
  bone marrow <.0001 .0005 .0002 
  lymph node .0003 .0095 .0043 
MFI PD-L2 spleen <.0001 .0091 .0002 
  peripheral blood <.0001 .1990 .0004 
  bone marrow <.0001 .9578 .0002 
  lymph node .0009 .1143 .0043 
Table 23: Summary of p-values of statistical comparisons of specific MFIs for PD-L1 and 
PD-L2 between aPD-L1 and isotype treated mice and healthy WT mice (hWT). Significant 
p-values are highlighted in bold.  
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8.4.2 In vivo anti-PD-L1 treatment prevents development of the typical CLL-
induced aberrant T-cell phenotype 
The effective CLL control by in vivo aPD-L1 was reflected by significant changes in the 
T-cell phenotype. Compared to isotype treated mice, the relative frequencies of CD3+, 
CD3+CD4+ and CD3+CD8+ T cells in all examined organs were comparable in aPD-
L1 treated mice and in healthy WT mice (data for percentages of CD3+, CD4+ and 
CD8+ cells not shown). This was reflected in a normalization of the CD4+/CD8+ ratio in 
spleen (Figure 64 A), PB (Figure 64 B) and BM (Figure 64 C), indicating that aPD-L1 
treatment prevented typical CLL-induced broad phenotypic T-cell defects. Due to the 
shortcomings of the AT model to mirror LN involvement consistently, T-cell phenotype 
was not examined in LN. 
 
 
Figure 64: Prevention of typical CLL-induced aberrant T-cell phenotype in CD3+, CD4+ 
and CD8+ cells by in vivo anti-PD-L1 treatment. CD4 and CD8 were gated on CD3+ viable 
single MNC. aPD-L1 treatment led to a normalization of the CD4+/CD8+ ratio in (A) spleen, (B) 
PB and (C) BM. All graphs show median with IQR. ns = non-significant, *p<.05, **p<.001, 
***p<.0001. hWT=healthy WT mice. 
 
Similarly, the loss of naïve (CD44-) CD3+CD8+ cells in spleen, and shift to antigen-
experienced (CD44+) CD3+CD8+ cells with a relative expansion of effector and EM 
cells, was prevented by aPD-L1 treatment (Figure 65 A and B). However, aPD-L1 only 
moderately prevented the loss of CM cells. This was largely recapitulated in PB (Figure 
65 C) and BM (Figure 65 D), although the loss of naïve cells was more pronounced in 
these organs than in spleen (note: phenotyping in PB and BM excluded CM and EM 
cells). Memory cells appeared to be slightly promoted by aPD-L1 treatment in spleen, 
but this was not consistently observed in the other organs.  
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Figure 65: Prevention of typical CLL-induced aberrant T-cell phenotype in CD3+CD8+ 
naïve and antigen experienced cells by in vivo anti-PD-L1 treatment. Naïve (CD44-
CD62L+), effector (CD44+CD62L-), memory (CD44+CD62L+), effector memory (EM) 
(CD44+CD62L-CCR7-) and central memory (CM) (CD44+CD62L+CCR7+) cells were gated on 
CD3+CD8+ cells. FMO controls for CCR7 and CD44 were included in all experiments to 
discriminate positive and negative populations. (A) Changes in T-cell subsets in spleen 
lymphocytes with aPD-L1 treatment. (B) Data from (A) shown as stacked graph to depict shifts 
in cell subsets. (C) T-cell subset changes in PB. (D) T-cell subset changes in BM. All graphs 
except (B) show median with IQR. ns = non-significant, *p<.05, **p<.001, ***p<.0001. 
hWT=healthy WT mice. 
 
Table 24 summarizes the p-values of statistical comparisons of T-cell subsets between 
the experimental groups for all organs examined. 
 
 
 
 
 
 
 
 
 
 
Fabienne McClanahan                                                                                                     Chapter 8 
Page 219 of 258 
 
organ T-cell immunophenotype aPD-L1 vs. isotype aPD-L1 vs. hWT isotype vs. hWT 
spleen % CD3 .0002 .0322 .0002 
% CD3+CD4+ <.0001 .0565 .0002 
% CD3+CD8+ <.0001 .1713 .0002 
CD4+/CD8+ ratio <.0001 .0683 .0012 
% Naïve CD3+CD8+ <.0001 .0391 .0002 
% Effector CD3+CD8+ <.0001 .0005 .0002 
% Memory CD3+CD8+ <.0001 .0471 .0575 
% EM CD3+CD8+ <.0001 .0005 .0002 
% CM CD3+CD8+ .6492 .0005 .0002 
peripheral 
blood 
% CD3 .0244 .0265 .0008 
% CD3+CD4+ <.0001 .9070 .0004 
% CD3+CD8+ <.0001 .7853 .0004 
CD4+/CD8+ ratio <.0001 .9690 .0004 
% Naïve CD3+CD8+ .0548 .0007 .0004 
% Effector CD3+CD8+ .0018 .0005 .0004 
% Memory CD3+CD8+ .7366 .4137 .0987 
bone 
marrow 
% CD3 .6842 1.0 .5622 
% CD3+CD4+ .9118 .0110 .0005 
% CD3+CD8+ <.0001 .8749 .0002 
CD4+/CD8+ ratio .0002 .0569 .0013 
% Naïve CD3+CD8+ .0006 .0002 .0002 
% Effector CD3+CD8+ .0005 .0002 .0002 
% Memory CD3+CD8+ .1211 .0005 .0010 
Table 24: Summary of p-values for T-cell subset comparisons between aPD-L1 and 
isotype treated mice and healthy WT mice (hWT). Significant p-values are in bold. 
 
8.4.3 In vivo anti-PD-L1 treatment prevents development of typical CLL-induced 
exhaustion-like T-cell phenotype  
After confirming the ability of in vivo PD-L1 blockade to prevent the development of 
aberrant T-cell subset distributions, its effect on the expression of typical exhaustion-
like surface markers was determined. This experiment included the exhaustion markers 
we confirmed in previous experiments of this project to be aberrantly expressed by 
CD3CD8+CD44+ T cells, namely PD-1, CD160, KLRG-1, 2B4 and LAG-3. Compared 
to isotype treated mice, aPD-L1 treatment significantly reduced the aberrant expression 
of PD-1, KLRG-1, 2B4, and LAG-3, but not CD160, in spleen (Figure 66 A). With the 
exception of PD-1, expression levels were comparable between healthy WT and aPD-
L1 treated mice. The prevention of aberrant PD-1 expression was recapitulated in PB 
and BM, with other exhaustion markers not examined in these organs (Figure 66 B).  
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Figure 66: Prevention of typical CLL-induced exhaustion-like phenotype in 
CD3+CD8+CD44+ cells by in vivo anti-PD-L1 treatment. Exhaustion markers PD-1, KRLG-1, 
CD160, LAG-3 and 2B4 were gated on CD3+CD8+CD44+ cells. FMO controls for all exhaustion 
markers were included in all experiments to discriminate positive and negative populations. (A) 
aPD-L1 treatment prevented the aberrant expression of all exhaustion markers in aPD-L1 
treated mice compared to isotype treated mice, with the exception of CD160. (B) Similar 
patterns for PD-1 expression were observed in PB and in BM. All graphs show median with 
IQR. ns = non-significant, *p<.05, **p<.001, ***p<.0001. hWT=healthy WT mice.  
 
Table 25 summarizes the p-values of statistical comparisons of T-cell exhaustion 
markers between the experimental groups for all organs examined. 
 
organ T-cell immunophenotype 
aPD-L1 vs. 
isotype 
aPD-L1 vs. 
hWT 
isotype vs. 
hWT 
spleen %PD-1+CD3+CD8+CD44+ <.0001 .0005 .0002 
 
%KLRG-1+CD3+CD8+CD44+ <.0001 .3705 .0002 
 
%CD160+CD3+CD8+CD44+ .8185 .0007 .0014 
 
%2B4+CD3+CD8+CD44+ <.0001 .0565 .0002 
 
%LAG3+CD3+CD8+CD44+ <.0001 .4137 .0002 
peripheral blood %PD-1+CD3+CD8+CD44+ .0029 .0175 .0018 
bone marrow %PD-1+CD3+CD8+CD44+ <.0001 .0002 .0002 
Table 25: Summary of p-values for comparisons of T-cell surface exhaustion markers 
between aPD-L1 and isotype treated mice and healthy WT mice (hWT). Significant p-values 
are highlighted in bold font. 
 
8.4.4 In vivo anti-PD-L1 treatment corrects key T-cell effector functions 
After confirming that aPD-L1 treatment prevents the development of typical CLL-
induced T-cell phenotypic changes, we examined the effect on T-cell effector functions 
in spleen. In line with previous experiments in this project, CD107a degranulation, 
intracellular GrB, IL-2, IL-4 and IFN-γ production, in vivo and ex vivo proliferation and 
immune synapse formation were determined. In CD3+CD4+ T cells, aPD-L1 treatment 
reduced the typical CLL-induced loss of IL-2 (Figure 67 A) producing, and the increase 
of IL-4 (Figure 67 B) and IFN-γ (Figure 67 C) producing cells compared to isotype 
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treated mice. However, this was still markedly different compared to WT mice, probably 
indicating a cytokine reaction of CD3+CD4+ cells to CLL.  
 
 
Figure 67: Prevention of typical CLL-induced CD4+ cytokine production by in vivo anti-
PD-L1 treatment. Fresh splenocytes were stimulated for 6 hours with PMA/Ionomycin (P/I), in 
the presence of Brefeldin/Monensin for the last 5 hours of culture. Cells were then harvested, 
surface stained, fixed, permeabilised and stained with antibodies against IL-2, IL-4 and IFN-γ. 
Data show the effects of aPD-L1 treatment, compared to isotype treatment or healthy WT mice 
(hWT), on the percentage of CD3+CD4+ T cells producing (A) IL-2, (B) IL-4, and (C) IFN-γ. All 
graphs show median with IQR. ns = non-significant, *p<.05, **p<.001, ***p<.0001. 
 
In CD3+CD8+CD44+ T cells, aPD-L1 treatment prevented the loss of cells able to 
degranulate, as indicated by comparable CD107a ratios between healthy WT and aPD-
L1 treated mice (Figure 68 A). In contrast, no effect on changes in intracellular IFN-γ 
production was observed (Figure 68 B). However, work done in this project (Chapter 5) 
demonstrates that the CLL-induced increase of IFN-γ producing cells observed in 
ageing TCL1 mice and in CLL patients is inadequately modelled in mice after AT.  
aPD-L1 treatment also showed an effect on T-cell proliferation, as it significantly 
reduced the CLL-induced increased ki67 ratio (Figure 68 C) and the percentages of 
Alexa488-labelled EdU-positive CD4+ and CD8+ cells (Figure 68 D). In addition, the 
proliferation of normal CD19+CD5- B cells was comparable between healthy WT and 
aPD-1 treated mice, while it was significantly increased in CD19+CD5+ CLL cells from 
isotype treated mice (Figure 68 E). Importantly, aPD-L1 treatment restored the ability of 
CLL T cells to form immunological synapses with normal syngeneic B cells to the level 
of autologous cells from healthy WT mice (Figure 68 F). 
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Figure 68: Prevention of typical CLL-induced effector cell defects by in vivo anti-PD-L1 
treatment. Compared to isotype, aPD-L1 treatment corrected key CD3+CD8+CD44+ T-cell 
effector functions. (A) Ratio of CD107a+ to CD107a- cells, reflecting the ability to degranulate; 
(B) Ratio of IFN-γ+ to IFN-γ- cells; (C) Ratio ki67+ to ki67-, reflecting proliferation ex vivo;  (D) 
Percent EdU+ T cells, reflecting in vivo proliferation. (E) Percent EdU+ CLL and normal B cells. 
(F) Immune synapse formation of CLL T cells with normal syngeneic B cells, as assessed by F-
actin area. All graphs show median with IQR. ns = non-significant, *p<.05, **p<.001, ***p<.0001. 
 
Table 26 summarizes the p-values of statistical comparisons of key T-cell effector 
functions between the experimental groups. 
 
T-cell functional markers aPD-L1 vs. 
isotype 
aPD-L1 vs.  
hWT 
isotype vs.  
hWT 
% CD3+CD4+/IL-2+ .0091 .0265 .0005 
% CD3+CD4+/IL-4+ .0305 .0005 .0002 
% CD3+CD4+/IFN-γ+ .0002 .0007 .0002 
ratio CD107a+:CD107a-CD3+CD8+CD44+ <.0001 .199 .0005 
ratio IFN-γ+:IFN-γ- CD3+CD8+CD44+ .1539 .3281 .3283 
ratio ki67+:ki67-CD3+CD8+CD44+ <.0001 .0214 .0016 
% CD5+EdU+ <.0001 .0088 .0007 
% CD5+CD8+EdU+ .0213 .0194 .0002 
% CD5+CD8-EdU+ <.0001 .0057 .0002 
Immune synapse area <.0001 .7178 <.0001 
Table 26: Summary of p-values for comparisons of key T-cell effector functions between 
aPD-L1 and isotype treated mice and healthy WT mice (hWT). Significant p-values are in 
bold. 
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8.4.5 In vivo anti-PD-L1 treatment corrects key effector functions attributed to 
PD-1 expression 
Although PD-1 expression was significantly lower in aPD-L1 treated than in isotype 
control treated mice, they still had a higher percentage of CD3+CD8+CD44+PD-1+ T 
cells than healthy WT mice (see Chapter 8.4.3). To investigate the associations 
between PD-1 expression and T-cell effector function, we next compared effector 
function ratios between PD-1high and PD-1low cells in isotype versus aPD-L1 treated 
mice. The CD107a ratio was significantly higher in both PD-1high and PD-1low cells in 
aPD-L1 treated mice compared to isotype treated mice, indicating that in vivo PD-L1 
treatment increased the percentage of antigen experienced CD8+ cells with the ability 
to localize CD107a to their cell surface, also in cells with PD-1 expression (Figure 69 
A).  
The IFN-γ ratio was not different among PD-1high cells, but was significantly reduced 
among PD-1low cells in aPD-L1 treated mice compared to isotype (Figure 69 B). aPD-
L1 therefore appeared to correct the physiological predominance of the PD-1high over 
the PD-1low subset in being enriched for cells containing intracellular IFN-γ that we 
observed in ageing WT mice (see Chapter 6). In isotype treated mice, the median IFN-
γ ratio in PD-1high cells was 3.7 (range 2.8-5.0), and in PD-1low cells 1.3 (range .7-1.9), 
leading to an approximately 3-fold higher ratio in PD-1high cells. In aPD-L1 treated mice, 
the median IFN-γ ratio in PD-1high cells was 2.9 (range 1.4-7.8) versus .6 (range .4-1.8) 
in PD-1low cells, resulting in a 4.6-fold higher ratio in PD-1high cells. 
GrB ratios were significantly reduced in both PD-1high and PD-1low cells in aPD-L1 
treated mice compared to isotype treated mice (Figure 69 C). In addition, aPD-L1 
treatment also corrected the physiological predominance of the PD-1high over the PD-
1low subset in being enriched for cells containing intracellular GrB; in isotype treated 
mice, the median GrB ratio in PD-1high cells was 2.2 (range 1.7-3.2), and in PD-1low cells 
.6 (range .45-.68), leading to a 3.8-fold higher ratio in PD-1high cells. In aPD-L1 treated 
mice, the median GrB ratio in PD-1high cells was 1.1 (range .4-2.8) and in PD-1low cells 
.17 (range .09-.37), resulting in a 6-fold higher ratio in PD-1high cells.  
The EdU ratio was significantly lower in both PD-1high and PD-1low cells in aPD-L1 
treated mice compared to isotype treated mice, indicating that in vivo PD-L1 treatment 
abrogated the enrichment of proliferating cells, also in cells with PD-1 expression 
(Figure 69 D).  
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Figure 69: Differences in effector function between PD-1high and PD-1low cells in aPD-L1 
and isotype treated mice. To correlate PD-1 expression and T-cell effector function markers, 
ratios of key effector function markers between PD-1high and PD-1low cells in aPD-L1 treated 
versus isotype treated mice were compared. Graphs show percentages and ratios of antigen 
experienced (CD44+) CD8+ T cells expressing: (A) cell surface CD107a; (B) intracellular IFN-γ; 
and (C) intracellular GrB; as well as (D) EdU+ (proliferating) cells, among PD-1high and PD-1low 
subsets. 
 
Table 27 summarizes the p-values of statistical comparisons of key T-cell effector 
functions according to PD-1 expression between aPD-L1 and isotype treated mice. 
 
functional marker  
(ratio of positive vs. negative) 
p-value, aPD-L1 vs. isotype treatment 
PD-1high PD-1low 
CD107a .0002 .0003 
IFN-γ .07437 .0022 
GrB .0014 <.0001 
EdU <.0001 <.0001 
Table 27: Summary of p-values of statistical comparisons of key T-cell effector function 
markers according to PD-1 expression between aPD-L1 and isotype treated mice. 
Significant p-values are highlighted in bold. 
 
8.5 Summary of effect of in vivo PD-L1 blockade on T-cell dysfunction and T-
cell exhaustion in TCL1 mice 
In summary, we were able to demonstrate that in vivo anti-PD-L1 treatment led to very 
effective CLL control, while significantly improving the T-cell immune functional 
phenotype in mice adoptively transferred with CLL. Effective CLL control was 
demonstrated by remarkably reduced spleen sizes, significantly lower spleen weights, 
and a significantly lower relative frequency of CD19+CD5+ CLL lymphocytes in spleen, 
PB and BM in aPD-L1 treated mice compared to isotype control treated mice. PD-L1 
expression was significantly increased on CLL cells in isotype treated mice compared 
to B cells from healthy mice; however, this could not be accurately assessed in aPD-L1 
treated mice, as in vivo treatment partially blocked the binding of fluorochrome labelled 
PD-L1 on a different clone. Aberrant PD-L2 expression by normal B cells, however, 
was prevented in all examined organs by aPD-L1 treatment. 
The effective CLL control by in vivo aPD-L1 was reflected by remarkable corrections of 
the CLL-associated T-cell phenotype: aPD-L1 treatment prevented the reduction of the 
CD4+/CD8+ ratio. Similarly, the loss of naïve CD8+ cells and shift to antigen-
experienced cells, with a relative expansion of effector and EM cells, was reduced. This 
was recapitulated in spleen, PB and BM. Treatment with aPD-L1 also significantly 
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reduced the aberrant expression of PD-1, KLRG-1, 2B4, and LAG-3, but not CD160, in 
spleen CD8+ T cells. The effect on reducing aberrant PD-1 expression was also 
recapitulated in CD8+ T cells in PB and BM.  
Functionally, aPD-L1 treatment reduced the CLL-mediated reduction in IL-2 producing, 
and increase in IL-4 and IFN-γ producing, CD4+ T cells. In CD8+ cells, it prevented the 
loss of cells with the ability to degranulate, but had no effect on intracellular IFN-γ 
production. CLL-mediated increased ex vivo and in vivo proliferation was reduced both 
in CD4+ and CD8+ T-cell subsets, and the proliferation of normal CD19+CD5- B cells 
was comparable between aPD-L1 treated and hWT mice. Lastly, the ability of CLL T 
cells to form immunological synapses with normal syngeneic B cells was restored to 
normal levels by aPD-L1 treatment.  
The comparison of key effector functions in PD-1high and PD-1low cells from isotype and 
aPD-L1 treated mice demonstrated that in vivo PD-L1 treatment increased the 
percentage of antigen experienced CD8+ cells with the ability to localize CD107a to 
their cell surface even in cells with PD-1 expression, corrected the physiological 
predominance of the PD-1high over the PD-1low subset in being enriched for cells 
containing intracellular IFN-γ and GrB, and abrogated the enrichment of proliferating 
cells in both PD-1high and PD-1low cells. 
 
8.6 Discussion 
The goal of this part of the project was to provide a rationale for the clinical evaluation 
of targeted PD-L1/PD-1 blockade in human CLL by investigating if in vivo blockage in 
mice corrects CLL-induced T-cell dysfunction and enhances anti-tumour T-cell 
responses. The PD-L1/PD-1 pathway can be targeted from two directions: PD-1 
blockade inhibits binding of PD-1 to PD-L1 and PD-L2, but has no effect on binding of 
PD-L1 to the co-stimulatory molecule CD80, with CD80 having a greater affinity for PD-
L1 than for CD28 and about one third the affinity of PD-L1 for PD-1480. PD-L1 blockade 
inhibits binding of PD-L1 to CD80 and PD-1, while having no effect on binding of PD-1 
to PD-L2. As the PD-1-mediated inhibition of lymphocyte function is initiated upon 
binding to its ligands rather than by PD-1 expression per se, it is reasonable to 
counteract the aberrant expression of PD-L1 on tumour cells by blocking PD-L1, 
especially if it is hypothesized that PD-1 expression by T cells is important to maintain 
physiological T-cell homeostasis. In addition, several studies have now demonstrated 
that aberrant PD-L1 expression by MDSCs and TAMs in the tumour microenvironment 
also has an effect on T-cell effector function199, 298, 477, 478. Blocking PD-L1 therefore may 
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abrogate the inhibitory effects on T cells mediated not just by tumour cells, but also by 
non-malignant cells in the microenvironment. However, this approach still allows 
binding of PD-1 to PD-L2, which means that an immunosuppressive effect can be 
maintained via PD-1/PD-L2 signalling. While PD-L1 blockade has been clinically 
evaluated in a number of solid tumours361, experiences in haematological malignancies 
and especially CLL are still sparse. PD-1 blockade has recently been demonstrated to 
be well tolerated and effective in patients with DLBCL and relapsed FL, and correlative 
studies have provided some insights into the immunological effects of this treatment359, 
360. Without a randomized trial, however, no conclusive statements can be made 
regarding the safety and activity of agents targeting PD-1 versus those targeting PD-
L1.  
In the current study, mice were treated with murine anti-PD-L1 antibody from the day 
after CLL adoptive transfer to assess its ability to control disease and to normalize 
effector function. PD-L1 rather than PD-1 blockade was selected as we have 
demonstrated that aberrant PD-L1 expression is utilized by both human79 and mouse 
CLL cells (see Chapter 6), leading to impaired T-cell function. In addition, mouse 
experiments we conducted together with collaborators in Germany have shown that 
PD-L1 is also aberrantly expressed by myeloid cells and TAMs in this mouse model, 
and that this has an inhibitory effect on T-cell function in vitro [PhD work from B. 
Hanna, DKFZ Heidelberg, personal communication]. While both in vitro PD-L1 and PD-
1 blockade were able to restore T-cell effector function79, work produced in this project 
has demonstrated that subsets of CLL T cells are still functional effector cells despite 
PD-1 expression (see Chapter 6). To investigate the full potential of PD-L1/PD-1 
immune checkpoint blockade to repair defects and enhance T-cell subset functions, 
PD-L1 blockade appears to be a reasonable choice to counteract the inhibitory effect of 
PD-L1 expression by both tumour and myeloid cells without affecting T-cell receptor 
signalling itself, therefore allowing the investigation of the full potential of immune 
checkpoint blockade to influence T-cell function.  
The rationale to initiate treatment early after adoptive transfer was based on the 
hypothesis that this time point represents a state of low-volume disease, during which 
remodelling and corruption of the immune system are likely to start. Early PD-L1 
blockade was therefore hypothesized to protect the immune system from such 
inhibitory tumour-mediated effects. This assumption is supported by preclinical data 
from our group, which demonstrated that functional defects observed in T cells from 
patients with CLL could be induced in previously normal allogeneic T cells after just 48 
hours by co-culturing them in direct cell-cell contact with CLL cells77. Moreover, T-cell 
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defects that were very similar to the defects observed in T cells from ageing TCL1 mice 
with CLL could be induced by adoptive transfer after just 7 days on a molecular level in 
young previously healthy TCL1 mice216.  
Here we demonstrate that early PD-L1 blockade effectively controls CLL and prevents 
aberrant PD-L2 expression of normal B cells even after immunological challenge by 
CLL. However, we were not able to determine the effect on PD-L1 expression per se in 
aPD-L1 treated mice, as the in vivo treatment with 10F.9G2 partially blocked the 
binding site of fluorochrome labelled MIH5 PD-L1. 10F.9G2 and MIH5 were previously 
found to prevent binding of PD-L1 to both PD-1 and CD80, while 10F.2H11 prevented 
binding of PD-L1 to CD80 only480, 481. To assess whether these clones bound to 
overlapping epitopes on PD-L1, Paterson et al. pre-incubated 300.19-PD-L1 
transfectants with saturating concentrations of purified 10F.9G2, 10F.2H11 or isotype 
monoclonal antibody and then stained with fluorescently labelled 10F.9G2, 10F.2H11, 
or MIH5 antibodies481. They found that 10F.2H11 was not able to block 10F.9G2 
binding to PD-L1 and vice versa, suggesting that the 10F.2H11 and 10F.9G2 recognize 
distinct epitopes on PD-L1, and that pre-incubation with 10F.2H11 had no effect on 
MIH5 binding. In contrast, 10F.9G2 pre-incubation reduced the level of MIH5 binding, 
suggesting that the 10F.9G2 and MIH5 dual blockers bind to overlapping epitopes that 
are distinct from the epitope recognized by 10F.2H11. Based on these data, we 
attempted to obtain 10F.2H11 for our experiments, either in purified form or 
fluorescently labelled, to allow us to determine the effect of in vivo treatment on PD-L1 
expression. However, we were not successful, and this question remains open. 
As PD-L1 expression on tumour cells has been demonstrated to be linked with poor 
prognosis and tumour aggressiveness in a number of malignancies, it might serve as a 
useful predictive biomarker332, 482. Significantly increased PD-L1 expression on CLL 
cells was found in poor-prognosis patients with a median survival of 38 months 
compared with good-prognosis patients with a median survival of more than 10 years79. 
More recently, soluble PD-L1 (sPD-L1) has been explored as a biomarker, with 
elevated sPD-L1 being a predictive biomarker for poorer overall survival in patients with 
DLBCL483. Assessing PD-L1 expression changes might also be beneficial in the context 
of targeted PD-L1/PD-1 therapy. In a Phase I study of single agent anti-PD-1, tumour 
PD-L1 expression was found to be a predictive biomarker of response to treatment: 
while none of the PD-L1 negative patients achieved a tumour response, an overall 
response rate of 36% was observed in patients with PD-L1 positive tumours363.  
Although targeted PD-L1 blockade did not prevent binding of PD-1 to PD-L2, our data 
clearly demonstrate that the effective CLL control by in vivo aPD-L1 was reflected by 
Fabienne McClanahan                                                                                                     Chapter 8 
Page 229 of 258 
 
remarkable corrections of phenotypic and functional T-cell defects: in vivo anti-PD-L1 
treatment prevented the development of typical aberrant T-cell phenotypes and 
normalized key T-cell effector functions, even in less functional cells with PD-1 
expression. However, this was achieved by initiating treatment at an early stage of 
disease, and mice were only treated for a total of 31 days, with antibody being 
administered every three days. It is possible that this improved immune status might 
not be achieved with less intense or later treatment or be sustained over a longer 
period of treatment, especially if other immune-escape mechanisms are developed or 
cells become resistant to PD-L1 blockade and inhibitory signalling shifts towards (for 
example) PD-L2. Therefore, it is important to consider options for combination 
therapies. Several preclinical studies have indicated that the combination of PD-L1 
antibodies with blockade of other immune checkpoints may increase the quality of T-
cell responses474-476. This is supported by the observation that PD-1 positive T cells 
also express other inhibitory receptors such as CTLA-4, TIM-3, LAG-3, BTLA, CD160, 
and 2B4404. It is therefore likely that blocking of PD-L1/PD-1 mediated inhibitory 
signalling alone might not fully restore the function of anti-tumour T cells. In a mouse 
model of AML, CD8+ T cells co-expressing PD-1 and TIM-3 were found to be deficient 
in their ability to produce IFN-γ, TNF-α, and IL-2, with blocking the PD-1/PDL1 or Tim-
3/galectin-9 pathway alone being insufficient to rescue mice from AML lethality419. 
However, an additive effect was seen in reducing tumour burden and lethality when 
both pathways were blocked. Similarly, NY-ESO-1-specific CD8+ T cells from patients 
with epithelial ovarian cancer demonstrated impaired effector function, preferential 
usage of dominant T-cell receptors, and enriched co-expression of LAG-3 and PD-1484. 
CD8+LAG-3+PD-1+ T cells were more impaired in IFN-γ/TNF-α production compared 
with single positive subsets, and dual blockade of LAG-3 and PD-1 during T-cell 
priming efficiently augmented proliferation and cytokine production by NY-ESO-1-
specific CD8+ T cells. Co-expression of PD-1 and LAG-3 was also demonstrated on 
tumour-infiltrating CD4+ and CD8+ T cells in different transplantable tumours, with dual 
LAG-3/PD-1 blockade curing most mice of established tumours that were largely 
resistant to single antibody treatment420. Interestingly, dual PD-L1 and LAG-3 blockade 
also appears to have implications in other disease. For example, this approach was 
recently shown to rapidly clear established blood-stage Plasmodium infection in mice, 
to have an effect on the number of follicular helper T cells and germinal-centre B cells 
and plasmablasts, and to enhance protective antibodies485.  
CTLA-4 was the first immune checkpoint receptor to be clinically targeted, and CTLA-4 
antibodies were the first to achieve FDA approval486, 487. In a Phase I dose-escalation 
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trial of the anti-CTLA-4 antibody ipilimumab in patients with relapsed/refractory B-cell 
lymphoma, treatment was well tolerated and resulted in clinical response in two of 18 
patients, while in 31% of patients, T-cell proliferation to recall antigens was significantly 
increased488. The concept of enhanced efficacy by combination was recently supported 
by data from a clinical trial in which patients with melanoma were treated with 
ipilimumab and PD-1 antibody489. This combination produced durable tumour 
regression, with evidence of clinical activity being observed in 65% of patients. In 
preclinical carcinoma models, blockade of both PD-1 and CTLA-4 resulted in reversal 
of CD8+ T-cell dysfunction and led to tumour rejection in two thirds of mice. In 
physiological settings, CTLA-4 is critically required by TRegs to suppress immune 
responses by affecting the potency of antigen-presenting cells to activate other T 
cells181. The number of TRegs is increased and correlated with aggressive disease in 
CLL176, and could be significantly reduced by in vitro CD200 blockade, which also 
stimulated antigen-specific T cell responses towards the CLL-associated antigen 
fibromodulin490. Therefore, it is possible that the combination of CTLA-4 blockade with 
antibodies targeting PD-L1/PD-1 or CD200/CD200R might be especially beneficial in 
CLL.  
In DLBCL and FL, PD-L1/PD-1 blockade has been combined with other immune-
modulating strategies such as autologous haematopoietic stem cell transplantation and 
rituximab359, 360. Given the potential of novel substances targeting BCR signalling to 
also overcome CLL-induced immune dysfunction, the combination of PD-L1/PD-1 
blockade with agents such as the BTK inhibitor ibrutinib or the PI3kδ inhibitor idelalisib 
might represent attractive treatment strategies, especially in older or heavily pre-treated 
patients unable to tolerate aggressive therapy168. In addition, several pre-clinical and 
clinical studies have demonstrated that lenalidomide can correct typical PD-L1/PD-1 
mediated immune deficiencies in CLL77, 79-81. Our work supports and extends these 
findings, confirming that PD-L1 mediated defective immune synapse formation and 
some T-cell effector dysfunctions can be corrected by in vivo lenalidomide treatment. 
Other combinations could include immune stimulatory agents such as vaccines491, 492, 
cytokines432, or even soluble forms of co-stimulatory molecules such as soluble 
CD80493. 
In sum, our in vivo experiments have provided a strong rationale for the clinical 
assessment of PD-L1/PD-1 immune checkpoint blockade in CLL, and this could be 
promoted by further in vivo preclinical studies examining the combination of PD-L1 
antibodies with additional antibodies or novel agents.  
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9 Overall Discussion 
The central hypothesis of this thesis project was that specific T-cell defects result from 
the interaction of malignant CLL cells with the immune system, and that repairing the 
defects in T-cell function will be required to activate an effective T-cell mediated anti-
tumour immune response. As this was addressed using the TCL1 mouse model of 
CLL, it is important to first consider the limitations of this model.  
As outlined in Chapter 1.2, the TCL1 model is a well-established and widely used tool 
to mirror the biology and therapeutic responses of aggressive human CLL. A variety of 
alternative models have been created in which specific genes and gene products, 
transcription factors, or components of signalling pathways that drive CLL development 
and progression have been manipulated. However, all of these are inferior to TCL1 
mice with regards to disease penetrance and the ability to mirror biological properties 
of human CLL. Xenograft models of CLL allow the investigation of the direct effect of 
selected immune cell components and therapeutic interventions on the disease in its 
natural complexity, but these fall short in their ability to provide the host components of 
a complete tumour microenvironment. The TCL1 gene is now recognized as a clinically 
relevant oncogene in the vast majority of human CLL cases. For example, Herling et al. 
found TCL1 expression to be correlated with markers of poor prognosis and shorter 
PFS494, 495, while another group indicated that TCL1 expression serves, in addition to 
other clinical and genetic factors, as a predictor of OS496. Several studies have 
demonstrated that TCL1 acts on multiple cellular targets in CLL, such as the 
serine/threonine kinase AKT pathway249, the NF-κB pathway250, 251, the transcription 
factor AP-1250, the p53 modulator Atm497, and the methyltransferases DNMT3A and 
3B252.  
As CLL is a very heterogeneous and dynamic disease, however, genetically 
engineered mice driven by selected oncogenes such as TCL1 might be insufficient to 
mirror the genetic complexity and clonal evolution that is now recognized as a major 
hallmark of human CLL498. Early experiments demonstrated that transformed TCL1 
murine CLL cells have a wild-type p53 status215, which might render the TCL1 model 
inadequate to investigate p53-associated resistance mechanisms. The extent to which 
clonal evolution and novel mutations such as SF3B1 or NOTCH1 can be recapitulated 
in TCL1 mice is however not yet known. Despite these apparent limitations, our group 
pioneered studies highlighting the suitability of this model to mirror T-cell defects of 
human CLL, both on a molecular and functional level216. This was recently expanded to 
include defects in myeloid cells [PhD work from B. Hanna, DKFZ Heidelberg, personal 
communication], and several crosses, for example with MIF-/-200, CD44-/-261, rhoH-/-263 
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or hs1-/- mice264, have emphasized the suitability of TCL1-driven CLL in mice to depict 
and allow investigation of microenvironmental interactions observed in human CLL. 
However, with a disease latency of more than one year, the TCL1 model is very time- 
and cost-intensive. The fact that disease is readily transplantable and develops in 
healthy recipient mice is therefore a major benefit and enables the investigation of the 
pathomechanistic role of specific molecular targets as well as the efficacy and 
mechanism of action of novel therapies. Although the transplant of TCL1 leukaemia 
cells is now well-established and is utilized by groups worldwide, considerable 
variability exists in the timing, dose, and application route of donor cells. These 
variables impact the reproducibility of preclinical studies between experiments and 
between laboratories, hampering interpretation and comparison of results. An important 
contribution from this PhD project was therefore the characterization of adoptive 
transfer procedures and conditions, along with the biological course of disease after 
adoptive transfer in the absence of treatment. This work resulted in the generation and 
validation of standardized conditions that enable the investigation of complex disease-
related immune and microenvironmental interactions and how these are affected by 
therapeutic approaches such as lenalidomide and PD-L1 blockade. 
Early work from our group demonstrated the similarities between gene-expression 
profiles of T cells from leukaemic TCL1 mice and CLL patients, as well as the rapid 
reproduction of these profiles following adoptive transfer of TCL1 leukaemic cells into 
young disease-free mice216. Among the various defects of T cells in human CLL 
patients (see Chapter 1.1.4), aberrant subsets and phenotypes, such as a CD4+/CD8+ 
ratio inversion, a loss of naïve CD3+CD8+ T cells with a shift towards effector cells, 
and a similarity to exhausted T cells found in chronically infected patients have been 
described118-120, 133, 134. Although aspects of this are already published to be 
recapitulated in TCL1 mice backcrossed to the genetic B6 background220, no studies 
have been done regarding the effect of different microenvironments (i.e. peripheral 
blood, bone marrow and secondary lymphoid organs) on T-cell subsets and phenotype 
and how closely adoptive transfer mirrors those defects observed in ageing TCL1 mice. 
This is particularly interesting, as CLL is now understood as a disease that develops 
and is maintained due to complex interactions with the microenvironment499, indicating 
that T-cell defects themselves might undergo dynamic alterations depending on their 
site of contact with the disease. In addition, careful and thorough investigation of the 
dynamic development of phenotypic T-cell subsets and characterization of functional T-
cell defects alongside progressing disease have not been conducted before. This 
project demonstrated for the first time that the previously documented phenotypic 
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changes in T-cell subsets are equally modelled in backcrossed B6 TCL1 and C3H 
TCL1 mice, that the patterns regarding CD4+ and CD8+ (naïve and antigen-
experienced) T cells are observed regardless of microenvironment, and that this is 
recapitulated in young mice with CLL after adoptive transfer. Moreover, instead of 
“snapshot” characterizations of T-cell function in different patients with a certain 
disease stage, this work has produced for the first time a longitudinal characterization 
of the dynamic development of T-cell defects in the context of developing disease 
using a genetically uniform mouse model. This led to novel findings characterizing the 
stage of B-cell expansion in which T-cell defects emerge, how they evolve over the 
course of the disease, and how this is influenced by the different microenvironment that 
peripheral blood, bone marrow and secondary lymphoid organs provide. 
Previous work from our group identified PD-L1 as an important mediator of impaired T-
cell function in human CLL patients79. In addition, circulating T cells from CLL patients 
were found to exhibit features of T-cell exhaustion, with increased expression of 
exhaustion markers such as PD-1, a skew towards antigen experienced subsets, an 
altered transcription factor profile, and functional defects in proliferation and 
cytotoxicity133, highlighting the role of the PD-L1/PD-1 inhibitory signalling axis. 
However, several studies have indicated that the T-cell compartment in CLL might be 
very heterogeneous and is potentially influenced by a variety of other factors such as 
age and/or infection. Although differences in human CD8+ lymphocyte subsets were 
previously thought to be explained by the presence of CMV144, work from our group 
confirmed that impaired T-cell function and altered subset composition were 
irrespective of CMV serostatus133. This finding was further supported by a recently 
published study suggesting that CMV-specific CD8+ T cells were indeed functionally 
intact, while CLL-induced global T-cell defects were still present148. Moreover, data 
from “classical” exhaustion models indicated that the T-cell exhaustion state is neither 
a fixed, irreversible, terminal differentiation state, nor an unresponsive T-cell state, and 
several studies have demonstrated that exhausted T cells represent a very 
heterogeneous population containing several subsets of cells that, despite PD-1 
expression, are able to exert certain effector functions.  
Work from this PhD project highlighted that aberrant PD-L1 over-expression in human 
CLL is mirrored in the TCL1 model, and identified aberrant PD-L2 expression as an 
additional inhibitory ligand of potential functional relevance in CLL. The mechanisms of 
how these molecules are over-expressed require further investigation. Similar to T-cell 
defects, both ligands were characterized over the course of developing disease, and in 
the context of different microenvironments. The TCL1 model was further utilized to 
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identify ageing as a substantial confounding factor for PD-1 associated patterns of T-
cell defects, and this was fully unmasked by applying our rigorously characterized 
adoptive transfer methods. In addition, this project significantly adds to existing 
knowledge by the comparison of the molecular profiles of CLL T cells with exhausted 
and functional memory and effector CD8+ T cells. This work clearly demonstrated that 
CLL T cells are very heterogeneous, with features of both exhaustion and functional 
effector cells. Interestingly, this comparison also revealed that CLL T-cell genes 
enriched in the exhaustion signature appear to be also involved in pathways of T-cell 
metabolism and bioenergetics. These areas of T-cell defects have not been well 
studied in CLL, and our findings show that these pathways demand further 
investigation. 
Our randomized adoptive transfer experiments also demonstrated that CLL-induced 
aberrant PD-1 expression on CD3+CD8+ T cells could be associated with different 
abilities of cells to exert effector functions. In general, intracellular cytokines IL-2, IL-4, 
IFN-γ and TNF-α were detected in both PD-1high and PD-1low cells, and both PD-1high 
and PD-1low cells maintained their ability to degranulate and to proliferate, contradicting 
the notion that PD-1 expression would lead to a loss of these effector functions. In 
addition, we demonstrated that the increase in IFN-γ production frequently observed in 
CLL T cells appeared to be attributed to PD-1high cells, while this subset was depleted 
of cells producing TNF-α compared to PD-1low cells and showed an impaired ability to 
form immunological synapses with normal B cells. The TCL1 model also allowed us to 
better understand the functional impact of the difference in PD-1 expression on CLL 
CD8+ T cells compared to normal T cells. Linking PD-1 expression with effector 
function of PD-1high cells in ageing WT mice and comparing this to effector function of 
PD-1high cells in ageing TCL1 mice developing CLL demonstrated that despite similar 
PD-1 expression patterns, PD-1 expressing cells are markedly different in their 
composition of cells able to exert selected effector functions. 
After previous studies using CLL patient samples indicated that both in vivo and ex vivo 
lenalidomide treatment can modulate T-cell subsets and function442, 443, as well as PD-
L1/PD-1-mediated inhibitory signalling79, 80, 441, we conducted a comprehensive analysis 
in vivo linking the effect of single agent lenalidomide to aberrant PD-L1/PD-1 
expression and functional T-cell defects. Despite a lack of CLL control, resulting in the 
persistence of typical CLL-induced T-cell phenotypic alterations and T-cell effector 
dysfunction, we demonstrated that lenalidomide has an effect on the expression of PD-
1 and immune synapse formation between autologous T and CLL cells. This important 
observation highlights that the repair of cytoskeleton defects is a prominent mechanism 
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of action of lenalidomide that is recapitulated in mice with CLL. Additionally, we 
demonstrated that ex vivo PD-L1 blockade on CLL cells restores immune synapses to 
sizes comparable to those in cells from healthy WT mice, prompting us to investigate 
PD-L1 blockade in vivo. 
Given the lack of clinical studies exploring PD-L1/PD-1 blockade in CLL, our work 
provides both rationale and preclinical evidence for evaluating targeted PD-L1/PD-1 
blockade in patients with this disease. Our findings suggest that blocking PD-L1 in mice 
with CLL can re-activate the immune system by counteracting CLL-induced changes in 
T-cell populations and functions, resulting in very effective disease control and 
significant reduction of tumour load in disease-affected tissues. Consequently, further 
immune defects induced by chronic antigenic stimulation were resolved. It is tempting 
to speculate on the advantage of blocking PD-1 versus PD-L1, as PD-1 blockade 
would inhibit the binding of PD-1 both to PD-L1 and PD-L2 expressed by tumours and 
microenvironmental components. However, no conclusive statements can be made 
regarding the relative activity of these two approaches on the immune system in the 
absence of a direct head-to-head comparison. In addition, it is not clear how 
pronounced the effect of PD-L1/PD-1 blockade on re-activating immune effector cells 
would be in the context of more established disease. These questions clearly need to 
be addressed in further pre-clinical studies. Nevertheless, our in vivo findings confirm 
that PD-L1/PD-1 immune checkpoint blockade is a very promising clinical approach in 
CLL, potentially in combination with agents targeting BCR signaling. Based on 
experience to date with BCR inhibitory agents such as ibrutinib and idelalisib, these 
could be used to mobilize and clear tumour bulks, while residual disease could be 
eradicated and durable remission achieved by the re-activation and restoration of anti-
tumour immune responses via PD-1/PD-L1 blockade. Similarly, in patients undergoing 
HSCT or CAR therapy, PD-1/PD-L1 blockade could be administered in the setting of 
low tumour volume to re-activate immune responses. 
In collaboration with another group, the effect of PD-L1 blockade was also 
demonstrated in this project to abrogate the CLL-induced differentiation blockade of 
myeloid cells. This is particularly important in view of very recent findings highlighting 
that T-cell defects in CLL are not only induced by direct contact with the tumour cells, 
but that other components of the microenvironment such as TAMs and MDSCs also 
negatively regulate T-cell function, partly via PD-L1/PD-1 inhibitory signalling199. To 
fully understand the complexity of T-cell defects and their contribution to disease 
development and progression, it is important to further characterize the interactions 
between T cells and TAMs and/or MDSCs in vivo, to identify the stage(s) during 
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disease development at which they occur and what the underlying mechanisms are. In 
fact, we have already conducted preliminary experiments using in vivo macrophage 
depletion with liposomal clodronate after adoptive transfer of murine CLL to address 
those questions. We observed that in comparison to vehicle-treated mice, clodronate-
treated mice had significantly lower spleen weights and a lower percentage of CLL 
tumour cells in peripheral blood and secondary lymphoid organs, suggesting that 
macrophages are indeed important, albeit not vital, for disease development. Typical 
phenotypic and functional T-cell defects were still present in clodronate-treated mice, 
but were less pronounced than in vehicle-treated mice, confirming that T-cell defects 
are caused by malignant cells but might be magnified and/or promoted by interactions 
with macrophages and monocytes. In addition, it is possible that dynamic shifts 
towards immunosuppressive and tolerogenic phenotypes within myeloid cells 
determine the point at which CLL cells evade T-cell effector function, as observed in 
other entities500. Further studies will be needed to address the exact contributions of 
different components of the myeloid compartment, for example by adoptive transfer 
experiments into myeloid-deficient recipients such as the CX3CR1 mouse model, 
which is deficient for patrolling monocytes. Complementing our previous gene-
expression profiling studies, it would also be attractive to compare the molecular 
profiles of T cells from mice after adoptive transfer in the absence of macrophages 
(either from clodronate depletion or by the use CX3CR1 recipients) versus those from 
fully immune competent recipients as used throughout this project. 
An important question still to be addressed is the mechanism(s) underlying aberrant 
PD-L1 expression in CLL. In line with the adaptive immune resistance hypothesis, 
which is based on the observation that immune and bystander cells produce cytokines 
as a result of activation by a tumour, prompting the upregulation of PD-L1 by both the 
tumour and the tumour microenvironment, it is possible that additional signals might be 
involved in this process. Dr. Croce’s group recently reported that circulating miRNAs 
shed from tumours are a novel aspect of miRNA biology and play an important role in 
the interaction between cancer cells and the microenvironment501. Their work 
demonstrated that due to their structural similarity with natural ligands, circulating 
miRNAs bind to intracellular TLR7 in macrophages and induce pro-metastatic 
inflammatory responses. Given the established role of miRNAs in CLL pathogenesis 
and progression (see Chapter 1.2.2), aberrant TLR expression in CLL502, and published 
findings linking TLR stimulation in B cells to expression of PD-L1 in patients with 
seasonal allergic rhinitis503, it is tempting to speculate that aberrant PD-L1 expression 
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in CLL is the result of continuous TLR7 signalling mediated by specific circulating 
miRNAs shed by tumour cells at an early stage of disease.  
We tested this hypothesis using cells from young TCL1, age-matched WT and TLR7-/- 
mice, as well as primary human CLL and normal B cells, and DOTAP liposomal 
formulations of synthetic miRNAs reported to have an effect on immune cells and to be 
released by CLL cells. Indeed, we demonstrated that PD-L1 surface expression on 
murine and human B cells was strongly induced by miRs -21 and -29, and moderately 
by -150 and -155. The degree of PD-L1 upregulation by miRs -21 and -29 was 
comparable to that observed with direct TLR7 and TLR9 binding by specific agonists. 
Similar patterns were seen for CD69 and CD86 expression, and across treatment 
conditions, PD-L1 expression was highly correlated with the expression of CD69 and 
CD86. This observation strongly suggests that PD-L1 expression after TLR 
engagement is a marker of activation/costimulation, and therefore a physiological 
adaptive immune response to TLR binding in healthy B cells. Functionally, miRNA 
treatments resulted in increased IL-6, IL-10 and TNF-α. To elucidate when in the 
course of CLL development PD-L1 expression becomes aberrant and if it ceases to be 
inducible by miRNA treatment, we sacrificed mice at regular intervals following 
adoptive transfer to simulate tumour development. With increasing CLL the magnitude 
of the change of PD-L1 expression following miRNA treatment decreased substantially, 
and the baseline expression of PD-L1 in miRNA-untreated B cells increased 
consistently, until a median tumour load of about 70%. Importantly, miRNA treatment 
did not result in increased PD-L1, CD69 or CD86 expression in B cells from TLR7-/- 
mice, indicating that the miRNA/PD-L1 interactions are indeed mediated by TLR7. 
These findings therefore support the hypothesis that PD-L1 expression on B cells can 
be induced by specific miRNAs known to be produced by CLL cells, and that this effect 
is mediated via TLR7. Future work will focus on the molecular mechanisms of this 
effect, and the interactions between chronically active BCR signalling and TLR 
signalling.  
In conclusion, this dissertation project not only meaningfully improves our ability to 
make further discoveries by extensively characterising and validating the use of 
adoptive transfer to mimic CLL-induced T-cell defects in mice, but also provides 
substantial new and translationally relevant information to the field of CLL immunology. 
It is important to note that in CLL, as in other malignancies, immunotherapy is 
increasingly being recognised as the most likely route to long-term disease control, 
which results from our increasing understanding of the specificity and potency that can 
be achieved with proper immune education and activation. 
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10 Appendix 
genes represented in 
exhaustion signature 
genes represented in 
effector signature 
genes represented in 
memory signature 
gene function 
Alcam 
  
cell surface receptor/ligand 
Anxa2 Anxa2 Anxa2 apoptosis 
 
Apobec 
 
metabolism 
  
Aqp9 metabolism 
Ccnb1 Ccnb1 
 
cell cycle 
Ccnb2 Ccnb2 
 
cell cycle 
CD1d1 
  
cell surface receptor/ligand 
CD72 CD72 
 
cell surface receptor/ligand 
 
Cdc6 
 
cell cycle 
  
Ddit4 DNA repair 
Dnajb9 
  
regulating  ATPase activity of 
70 kDa heat shock proteins 
 
Dstn 
 
miscellaneous 
Egr2 
  
transcription factor 
 
Emp1 Emp1 miscellaneous 
 
Fcgr2b Fcgr2b cell surface receptor/ligand 
Fignl1 Fignl1 
 
miscellaneous 
Gzmb Gzmb Gzmb effector function 
  
Gzmm effector function 
 
H2-Aa H2-Aa MHC 
H2-D1 
  
histocompatibility antigen 
 
Hba-a1 
 
metabolism 
Hbb-b1 Hbb-b1 
 
metabolism 
Hist1h2ac Hist1h2ac 
 
transcription 
Ifrd1 
  
Interferon signalling 
IgK-V28 
 
IgK-V28 antigen receptors 
IL6st IL6st IL6st cytokine signalling 
 
Il18rap Il18rap cytokine signalling 
Irf4 
  
IFN response 
 
Itga4 
 
cell surface receptor/ligand 
 
Kctd12 
 
metabolism 
  
Klf4 transcription 
Lgals3 Lgals3 
 
  
Mad2l1 Mad2l1 
 
cell cycle 
Mox2 = CD200 
  
cell surface receptor/ligand 
 
Myo1f Myo1f cytoskeleton 
 
Nedd4l 
 
proteases 
Nedd4l 
  
transcription 
Nfatc1 
  
transcription 
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Nr1d2 
  
transcription 
Nr4a2 
  
transcription 
Nrp 
  
cell surface receptor/ligand 
Pglyrp1 
  
cell surface receptor/ligand 
Psmd13 
  
proteasome enzyme 
 
Racgab1 
 
signalling 
 
Rpa2 
 
DNA repair 
Rrm2 
  
metabolism 
S100a6 S100a6 S100a6 signalling 
Sema4a = kallikrein 
  
cell surface receptor/ligand 
Sesn1 Sesn1 Sesn1 miscellaneous 
Slc12a2 
  
ion  transporter 
 
Stard10 
 
miscellaneous 
St6gal1 St6gal1 St6gal1 glycosylation 
Stk38 
  
signalling 
TCRb-J 
  
signalling 
Tfdp1 
  
transcription 
 
Tm4SF13  
 
cell surface receptor/ligand 
Smarca2 Smarca2 
 
transcription 
Nusap1 Nusap1 
 
cell cycle 
 
clk1 
 
cell cycle 
  
kcnj8 metabolism 
Slc4a7 Slc4a7 
 
metabolism 
 
csda 
 
metabolism 
cmah 
  
metabolism 
ell2 ell2 ell2 translation 
 
Prpf39 
 
translation 
bach=acot7 bach=acot7 bach=acot7 miscellaneous 
Cst7 
  
miscellaneous 
Mcm3 
  
miscellaneous 
 
Birc5 
 
miscellaneous 
Tacc3 Tacc3 
 
miscellaneous 
Cxxc5 Cxxc5 Cxxc5 miscellaneous 
Spnb2 
  
miscellaneous 
Cnn3 Cnn3 Cnn3 miscellaneous 
Table 28: Gene list of overlapping genes in CLL T cell and exhausted/ effector/ memory T 
cell signature.  
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